18. Literaturverzeichnis – Supportive Therapie

1. Lind, M, Vernon, C, Cruickshank, D, Wilkinson, P, Littlewood, T, Stuart, N, et.al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life., Br J Cancer, 2002. 86 (8)(8): p. 1243-9., https://pubmed.ncbi.nlm.nih.gov/11953880/

2. Malyszko, J, Tesarova, P, Capasso, G, Capasso, A, The link between kidney disease and cancer: complications and treatment., Lancet, 2020. 396 (10246)(10246): p. 277-287., https://pubmed.ncbi.nlm.nih.gov/32711803 /

3. World Health Organization, Haemoglobin concentrations for the diagnosis of anaemia and assessment ofWorld Health Organization, 2011.

4. Gaskell, H, Derry, S, Andrew Moore, R, McQuay, HJ, Prevalence of anaemia in older persons: systematic review., BMC Geriatr, 2008. 8 (): p. 1., https://pubmed.ncbi.nlm.nih.gov/18194534/

5. Ganz, T, Anemia of Inflammation., N Engl J Med, 2019. 381 (12)(12): p. 1148-1157., https://pubmed.ncbi.nlm.nih.gov/31532961 /

6. Fleming, R. E., Bacon, B. R., Orchestration of iron homeostasis, N Engl J Med, 2005. 352: p. 1741-4.

7. Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D., Spivak, J. L., Decreased erythropoietin response in patients with the anemia of cancer, N Engl J Med, 1990. 322: p. 1689-92.

8. Ganz, T, Hepcidin and iron regulation, 10 years later., Blood, 2011. 117 (17)(17): p. 4425-33., https://pubmed.ncbi.nlm.nih.gov/21346250/

9. Kautz, L, Jung, G, Nemeth, E, Ganz, T, Erythroferrone contributes to recovery from anemia of inflammation., Blood, 2014. 124 (16)(16): p. 2569-74., https://pubmed.ncbi.nlm.nih.gov/25193872/

10. Knight, K., Wade, S., Balducci, L., Prevalence and outcomes of anemia in cancer: a systematic review of the literature, Am J Med, 2004. 116 Suppl 7A: p. 11S-26S.

11. Link, H., Schmitz, S., Treatment of cancer-associated anaemia: results from a two-day cross-sectional survey in Germany, Onkologie, 2013. 36: p. 266-72.

12. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., et.al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients, Eur J Cancer, 2004. 40: p. 2293-306.

13. Nitz, U, Gluz, O, Zuna, I, Oberhoff, C, Reimer, T, Schumacher, C, et.al. Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer., Ann Oncol, 2014. 25 (1)(1): p. 75-80., https://pubmed.ncbi.nlm.nih.gov/24356620/

14. Delarue, R., Haioun, C., Coiffier, B., Fornecker, L., Fournier, M., Mounier, N., et.al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study.Wolters Kluwer, Journal of Clinical Oncology, 2011. 29(15_suppl): p. 9048 - 9048., https://doi.org/10.1200/jco.2011.29.15_suppl.9048

15. Harrison, L. B., Shasha, D., White, C., Ramdeen, B., Radiotherapy-Associated Anemia: The Scope of the Problem, Oncologist, 2000. 5 Suppl 2: p. 1-7.

16. Griffiths, EA, Roy, V, Alwan, L, Bachiashvili, K, Baird, J, Cool, R, et.al. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022., J Natl Compr Canc Netw, 2022. 20 (5)(5): p. 436-442., https://pubmed.ncbi.nlm.nih.gov/35545171 /

17. Gattermann, N, Muckenthaler, MU, Kulozik, AE, Metzgeroth, G, Hastka, J, The Evaluation of Iron Deficiency and Iron Overload., Dtsch Arztebl Int, 2021. 118 (49)(49): p. 847-856., https://pubmed.ncbi.nlm.nih.gov/34755596/

18. Ostendorf, N, Referenzbereiche aktualisierenDtsch Arztebl Int, 2022. 119: p. 427.

19. Gattermann, N, SchlusswortDtsch Arztebl Int, Diskussion zu dem Beitrag Abklärung von Eisenmangel und Eisenüberladung von Gattermann et al 2021, 2022. 119: p. 428.

20. Alkhateeb, A. A., Connor, J. R., The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis, Biochim Biophys Acta, 2013. 1836: p. 245-54.

21. Ludwig, H, Evstatiev, R, Kornek, G, Aapro, M, Bauernhofer, T, Buxhofer-Ausch, V, et.al. Iron metabolism and iron supplementation in cancer patients., Wien Klin Wochenschr, 2015. 127 (23-24)(23-24): p. 907-19., https://pubmed.ncbi.nlm.nih.gov/26373748/

22. Hastka, J, Eisenmangel und EisenmangelanämieDeutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., Onkopedia Leitlinie, 2022., https://www.onkopedia.com/de/onkopedia/guidelines/eisenmangel-und-eisenmangelanaemie/@@guideline/html/index.html

23. Snook, J, Bhala, N, Beales, ILP, Cannings, D, Kightley, C, Logan, RP, et.al. British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults., Gut, 2021. 70 (11)(11): p. 2030-2051., https://pubmed.ncbi.nlm.nih.gov/34497146/

24. Thomas, D. W., Hinchliffe, R. F., Briggs, C., Macdougall, I. C., Littlewood, T., Cavill, I., Guideline for the laboratory diagnosis of functional iron deficiency, Br J Haematol, 2013. 161: p. 639-48.

25. Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., et.al. Erythropoietin or darbepoetin for patients with cancer, Cochrane Database Syst Rev, 2012. 12: p. CD003407.

26. Adams, A, Scheckel, B, Habsaoui, A, Haque, M, Kuhr, K, Monsef, I, et.al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis., Cochrane Database Syst Rev, 2022. 6 (): p. CD012633., https://pubmed.ncbi.nlm.nih.gov/35724934/

27. Debus, J., Drings, P., Baurecht, W., Angermund, R., Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa, Radiother Oncol, 2014.

28. Machtay, M., Zhang, Q., Suntharalingam, M., Hershock, D., Lustig, R., Nabid, A., Long-term outcomes from RTOG 99-03: Radiation therapy with or without erythropoietin for anemic head-and-neck cancer patients, International journal of radiation oncology, biology, physics, 2012. p. S21.

29. Moebus, V., Jackisch, C., Schneeweiss, A., Huober, J., Lueck, H. J., du Bois, A., et.al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial, J Natl Cancer Inst, 2013. 105: p. 1018-26.

30. Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., Merkel, D. E., Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales, J Pain Symptom Manage, 2002. 24: p. 547-61.

31. Tabernero, J, Vyas, M, Giuliani, R, Arnold, D, Cardoso, F, Casali, PG, et.al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers., ESMO Open, 2016. 1 (6)(6): p. e000142., https://pubmed.ncbi.nlm.nih.gov/28848668 /

32. Stebbing, J, Mainwaring, PN, Curigliano, G, Pegram, M, Latymer, M, Bair, AH, et.al. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars., J Clin Oncol, 2020. 38 (10)(10): p. 1070-1080., https://pubmed.ncbi.nlm.nih.gov/32058846/

33. Wolff-Holz E, Biosimilars in der Onkologie (Teil 1): Dank strenger Regulierung keine zweite WahlDtsch Arztebl International, 2019. 116: p. 35 - 36., https://www.aerzteblatt.de/archiv/209367/Biosimilars-in-der-Onkologie-(Teil-1)-Dank-strenger-Regulierung-keine-zweite-Wahl

34. Mhaskar, R, Wao, H, Miladinovic, B, Kumar, A, Djulbegovic, B, The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents., Cochrane Database Syst Rev, 2016. 2 (2)(2): p. CD009624., https://pubmed.ncbi.nlm.nih.gov/26845108/

35. Mafodda, A, Giuffrida, D, Prestifilippo, A, Azzarello, D, Giannicola, R, Mare, M, et.al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study., Support Care Cancer, 2017. 25 (9)(9): p. 2779-2786., https://pubmed.ncbi.nlm.nih.gov/28391437/

36. Maccio, A., Madeddu, C., Gramignano, G., Mulas, C., Sanna, E., Mantovani, G., Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study, Oncologist, 2010. 15: p. 894-902.

37. Steensma, D. P., Sloan, J. A., Dakhil, S. R., Dalton, R., Kahanic, S. P., Prager, D. J., et.al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia, J Clin Oncol, 2011. 29: p. 97-105.

38. Buchrits, S, Itzhaki, O, Avni, T, Raanani, P, Gafter-Gvili, A, Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., J Clin Med, 2022. 11 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/35887920/

39. Dangsuwan, P., Manchana, T., Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy, Gynecol Oncol, 2010. 116: p. 522-5.

40. Noronha, V, Joshi, A, Patil, VM, Banavali, SD, Gupta, S, Parikh, PM, et.al. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents., Asia Pac J Clin Oncol, 2018. 14 (2)(2): p. e129-e137., https://pubmed.ncbi.nlm.nih.gov/28849623/

41. Ansari Nejad, N, Abbasi, B, Fardad, F, Mehrara, M, Ramim, T, Comparing the effectiveness of ferric carboxymaltose and oral iron in treatment of chronic iron deficiency anemia in colon cancer patientsSupport Care Cancer, PS049, 2016. 24 (Suppl 1): p. 1 - 249.

42. Pasricha, SR, Tye-Din, J, Muckenthaler, MU, Swinkels, DW, Iron deficiency., Lancet, 2021. 397 (10270)(10270): p. 233-248., https://pubmed.ncbi.nlm.nih.gov/33285139/

43. Schaefer, B, Tobiasch, M, Wagner, S, Glodny, B, Tilg, H, Wolf, M, et.al. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management., Bone, 2022. 154 (): p. 116202., https://pubmed.ncbi.nlm.nih.gov/34534708/

44. Glaspy, JA, Lim-Watson, MZ, Libre, MA, Karkare, SS, Hadker, N, Bajic-Lucas, A, et.al. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review., Ther Clin Risk Manag, 2020. 16 (): p. 245-259., https://pubmed.ncbi.nlm.nih.gov/32308402/

45. McFarland, J. G., Perioperative blood transfusions: indications and options, Chest, 1999. 115: p. 113S-121S.

46. Carson, J. L., Sieber, F., Cook, D. R., Hoover, D. R., Noveck, H., Chaitman, B. R., et.al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial, Lancet, 2015. 385: p. 1183-9.

47. Murphy, G. J., Pike, K., Rogers, C. A., Wordsworth, S., Stokes, E. A., Angelini, G. D., et.al. Liberal or restrictive transfusion after cardiac surgery, N Engl J Med, 2015. 372: p. 997-1008.

48. Carson, J. L., Strair, R., Transfusion strategies in hematologic and nonhematologic disease, Hematology Am Soc Hematol Educ Program, 2014. 2014: p. 548-52.

49. Rohde, J. M., Dimcheff, D. E., Blumberg, N., Saint, S., Langa, K. M., Kuhn, L., et.al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis, JAMA, 2014. 311: p. 1317-26.

50. Salpeter, S. R., Buckley, J. S., Chatterjee, S., Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review, Am J Med, 2014. 127: p. 124-131 e3.

51. Holst, L. B., Petersen, M. W., Haase, N., Perner, A., Wetterslev, J., Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis, BMJ, 2015. 350: p. h1354.

52. Shah, A., Stanworth, S. J., McKechnie, S., Evidence and triggers for the transfusion of blood and blood products, Anaesthesia, 2015. 70 Suppl 1: p. 10-9, e3-5.

53. Mueller, MM, Van Remoortel, H, Meybohm, P, Aranko, K, Aubron, C, Burger, R, et.al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference., JAMA, 2019. 321 (10)(10): p. 983-997., https://pubmed.ncbi.nlm.nih.gov/30860564/

54. Carson, JL, Stanworth, SJ, Dennis, JA, Trivella, M, Roubinian, N, Fergusson, DA, et.al. Transfusion thresholds for guiding red blood cell transfusion., Cochrane Database Syst Rev, 2021. 12 (): p. CD002042., https://pubmed.ncbi.nlm.nih.gov/34932836/

55. Gregersen, M., Borris, L. C., Damsgaard, E. M., Blood Transfusion and Overall Quality of Life After Hip Fracture in Frail Elderly Patients-The Transfusion Requirements in Frail Elderly Randomized Controlled Trial, J Am Med Dir Assoc, 2015. 16: p. 762-6.

56. Hu, RT, Royse, AG, Royse, C, Scott, DA, Bowyer, A, Boggett, S, et.al. Health-related quality of life after restrictive versus liberal RBC transfusion for cardiac surgery: Sub-study from a randomized clinical trial., Transfusion, 2022. 62 (10)(10): p. 1973-1983., https://pubmed.ncbi.nlm.nih.gov/36066319/

57. Amato, A., Pescatori, M., Perioperative blood transfusions for the recurrence of colorectal cancer, Cochrane Database Syst Rev, 2006. p. CD005033.

58. Acheson, A. G., Brookes, M. J., Spahn, D. R., Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis, Ann Surg, 2012. 256: p. 235-44.

59. Schiergens, T. S., Rentsch, M., Kasparek, M. S., Frenes, K., Jauch, K. W., Thasler, W. E., Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases, Dis Colon Rectum, 2015. 58: p. 74-82.

60. Sun, C., Wang, Y., Yao, H. S., Hu, Z. Q., Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis, Int J Surg, 2015. 13: p. 102-10.

61. Estcourt, LJ, Malouf, R, Trivella, M, Fergusson, DA, Hopewell, S, Murphy, MF, Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support., Cochrane Database Syst Rev, 2017. 1 (): p. CD011305., https://pubmed.ncbi.nlm.nih.gov/28128441/

62. Hoeks, MPA, Kranenburg, FJ, Middelburg, RA, van Kraaij, MGJ, Zwaginga, JJ, Impact of red blood cell transfusion strategies in haemato-oncological patients: a systematic review and meta-analysis., Br J Haematol, 2017. 178 (1)(1): p. 137-151., https://pubmed.ncbi.nlm.nih.gov/28589623/

63. Prescott, LS, Taylor, JS, Lopez-Olivo, MA, Munsell, MF, VonVille, HM, Lairson, DR, et.al. How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology., Cancer Treat Rev, 2016. 46 (): p. 1-8., https://pubmed.ncbi.nlm.nih.gov/27046422/

64. Stanworth, SJ, Killick, S, McQuilten, ZK, Karakantza, M, Weinkove, R, Smethurst, H, et.al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial., Br J Haematol, 2020. 189 (2)(2): p. 279-290., https://pubmed.ncbi.nlm.nih.gov/31960409/

65. Tarantino, I., Ukegjini, K., Warschkow, R., Schmied, B. M., Steffen, T., Ulrich, A., et.al. Blood transfusion does not adversely affect survival after elective colon cancer resection: a propensity score analysis, Langenbecks Arch Surg, 2013. 398: p. 841-9.

66. Boehm, K., Beyer, B., Tennstedt, P., Schiffmann, J., Budaeus, L., Haese, A., et.al. No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer, World J Urol, 2015. 33: p. 801-6.

67. Dhanasekaran, R., Kooby, D. A., Staley, C. A., Kauh, J. S., Khanna, V., Kim, H. S., Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC), J Surg Oncol, 2010. 101(6): p. 476-80., https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jso.21522?download=true

68. World Health Organization, The urgent need to implement patient blood management: policy brief.World Health Organization, 2021., https://apps.who.int/iris/handle/10665/346655

69. Meybohm, P., Fischer, D., Schnitzbauer, A., Zierer, A., Schmitz-Rixen, T., Bartsch, G., et.al. [Patient blood management : Stand der aktuellen Literatur], Chirurg, 2016. 87: p. 40-6.

70. Carson, JL, Stanworth, SJ, Guyatt, G, Valentine, S, Dennis, J, Bakhtary, S, et.al. Red Blood Cell Transfusion: 2023 AABB International Guidelines., JAMA, 2023. 330 (19)(19): p. 1892-1902., https://pubmed.ncbi.nlm.nih.gov/37824153/

71. Retter, A., Wyncoll, D., Pearse, R., Carson, D., McKechnie, S., Stanworth, S., et.al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients, Br J Haematol, 2013. 160: p. 445-64.

72. Bundesaerztekammer, Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, Gesamtnovelle 2020, 2020. p. 1 - 287., https://www.bundesaerztekammer.de/themen/medizin-und-ethik/wissenschaftlicher-beirat/stellungnahmen-richtlinien-jahresberichte/haemotherapie-transfusionsmedizin/querschnitts-leitlinien-baek-zur-therapie-mit-blutkomponenten-und-plasmaderivaten-gesamtnovelle-2020

73. Berger, M. D., Gerber, B., Arn, K., Senn, O., Schanz, U., Stussi, G., Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation, Haematologica, 2012. 97: p. 116-22.

74. Yerrabothala, S., Desrosiers, K. P., Szczepiorkowski, Z. M., Dunbar, N. M., Significant reduction in red blood cell transfusions in a general hospital after successful implementation of a restrictive transfusion policy supported by prospective computerized order auditing, Transfusion, 2014. 54: p. 2640-5.

75. DeZern, AE, Williams, K, Zahurak, M, Hand, W, Stephens, RS, King, KE, et.al. Red blood cell transfusion triggers in acute leukemia: a randomized pilot study., Transfusion, 2016. 56 (7)(7): p. 1750-7., https://pubmed.ncbi.nlm.nih.gov/27198129/

76. Hicks, L. K., Bering, H., Carson, K. R., Kleinerman, J., Kukreti, V., Ma, A., et.al. The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question, Blood, 2013. 122: p. 3879-83.

77. Bracey, A. W., Radovancevic, R., Riggs, S. A., Houston, S., Cozart, H., Vaughn, W. K., et.al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome, Transfusion, 1999. 39: p. 1070-7.

78. Hajjar, L. A., Vincent, J. L., Galas, F. R., Nakamura, R. E., Silva, C. M., Santos, M. H., et.al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial, JAMA, 2010. 304: p. 1559-67.

79. Carson, J. L., Brooks, M. M., Abbott, J. D., Chaitman, B., Kelsey, S. F., Triulzi, D. J., et.al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease, Am Heart J, 2013. 165: p. 964-971 e1.

80. de Gast-Bakker, D. H., de Wilde, R. B., Hazekamp, M. G., Sojak, V., Zwaginga, J. J., Wolterbeek, R., et.al. Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial, Intensive Care Med, 2013. 39: p. 2011-9.

81. Hebert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., et.al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group, N Engl J Med, 1999. 340: p. 409-17.

82. Lacroix, J., Hebert, P. C., Hutchison, J. S., Hume, H. A., Tucci, M., Ducruet, T., et.al. Transfusion strategies for patients in pediatric intensive care units, N Engl J Med, 2007. 356: p. 1609-19.

83. Villanueva, C., Colomo, A., Bosch, A., Concepcion, M., Hernandez-Gea, V., Aracil, C., et.al. Transfusion strategies for acute upper gastrointestinal bleeding, N Engl J Med, 2013. 368: p. 11-21.

84. Kirpalani, H., Whyte, R. K., Andersen, C., Asztalos, E. V., Heddle, N., Blajchman, M. A., et.al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants, J Pediatr, 2006. 149: p. 301-307.

85. Grover, M., Talwalkar, S., Casbard, A., Boralessa, H., Contreras, M., Boralessa, H., et.al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty, Vox Sang, 2006. 90: p. 105-12.

86. Foss, N. B., Kristensen, M. T., Jensen, P. S., Palm, H., Krasheninnikoff, M., Kehlet, H., The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery, Transfusion, 2009. 49: p. 227-34.

87. So-Osman, C., Cicilia, J., Brand, A., Schipperus, M., Berning, B., Scherjon, S., Triggers and appropriateness of red blood cell transfusions in the postpartum patient--a retrospective audit, Vox Sang, 2010. 98: p. 65-9.

88. Carson, J. L., Terrin, M. L., Noveck, H., Sanders, D. W., Chaitman, B. R., Rhoads, G. G., et.al. Liberal or restrictive transfusion in high-risk patients after hip surgery, N Engl J Med, 2011. 365: p. 2453-62.

89. Prick, B. W., Jansen, A. J., Steegers, E. A., Hop, W. C., Essink-Bot, M. L., Uyl-de Groot, C. A., et.al. Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial, BJOG, 2014. 121: p. 1005-14.

90. Karam, O., Tucci, M., Ducruet, T., Hume, H. A., Lacroix, J., Gauvin, F., Red blood cell transfusion thresholds in pediatric patients with sepsis, Pediatr Crit Care Med, 2011. 12: p. 512-8.

91. Hoeg, RT, Leinoe, EB, Andersen, P, Klausen, TW, Birgens, HS, Measuring the impact of a restrictive transfusion guideline in patients with acute myeloid leukaemia., Vox Sang, 2013. 105 (1)(1): p. 81-4., https://pubmed.ncbi.nlm.nih.gov/23368963/

92. Jansen, AJ, Caljouw, MA, Hop, WC, van Rhenen, DJ, Schipperus, MR, Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia., Transfus Med, 2004. 14 (1)(1): p. 33-8., https://pubmed.ncbi.nlm.nih.gov/15043591/

93. Lightdale, JR, Randolph, AG, Tran, CM, Jiang, H, Colon, A, Houlahan, K, et.al. Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation., Biol Blood Marrow Transplant, 2012. 18 (5)(5): p. 813-7., https://pubmed.ncbi.nlm.nih.gov/22080050/

94. Webert, KE, Cook, RJ, Couban, S, Carruthers, J, Lee, KA, Blajchman, MA, et.al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation., Transfusion, 2008. 48 (1)(1): p. 81-91., https://pubmed.ncbi.nlm.nih.gov/17894791/

95. Froman, JP, Mathiason, MA, Kallies, KJ, Bottner, WA, Shapiro, SB, The impact of an integrated transfusion reduction initiative in patients undergoing resection for colorectal cancer., Am J Surg, 2012. 204 (6)(6): p. 944-50; discussion 950-1., https://pubmed.ncbi.nlm.nih.gov/23022253/

96. Wehry, J, Cannon, R, Scoggins, CR, Puffer, L, McMasters, KM, Martin, RC, Restrictive blood transfusion protocol in liver resection patients reduces blood transfusions with no increase in patient morbidity., Am J Surg, 2015. 209 (2)(2): p. 280-8., https://pubmed.ncbi.nlm.nih.gov/25305797/

97. de Almeida, JP, Vincent, JL, Galas, FR, de Almeida, EP, Fukushima, JT, Osawa, EA, et.al. Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial., Anesthesiology, 2015. 122 (1)(1): p. 29-38., https://pubmed.ncbi.nlm.nih.gov/25401417/

98. Park, SH, Nam, E, Bang, SM, Cho, EK, Shin, DB, Lee, JH, A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer., Cancer Chemother Pharmacol, 2008. 62 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/17690882/

99. Robitaille, N, Lacroix, J, Alexandrov, L, Clayton, L, Cortier, M, Schultz, KR, et.al. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation: a canadian blood and marrow transplant group trial., Biol Blood Marrow Transplant, 2013. 19 (3)(3): p. 468-73., https://pubmed.ncbi.nlm.nih.gov/23220014/

100. Tay, J, Allan, DS, Chatelain, E, Coyle, D, Elemary, M, Fulford, A, et.al. Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial., J Clin Oncol, 2020. 38 (13)(13): p. 1463-1473., https://pubmed.ncbi.nlm.nih.gov/32083994/

101. Vichinsky, E. P., Haberkern, C. M., Neumayr, L., Earles, A. N., Black, D., Koshy, M., et.al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group, N Engl J Med, 1995. 333: p. 206-13.

102. Jiang, HZ, Jiang, YL, Yang, B, Long, FX, Yang, Z, Tang, DX, Traditional Chinese medicines and capecitabine-based chemotherapy for colorectal cancer treatment: A meta-analysis., Cancer Med, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35650714/

103. Li, Y, Sui, X, Su, Z, Yu, C, Shi, X, Johnson, NL, et.al. Meta-Analysis of Paclitaxel-Based Chemotherapy Combined With Traditional Chinese Medicines for Gastric Cancer Treatment., Front Pharmacol, 2020. 11 (): p. 132., https://pubmed.ncbi.nlm.nih.gov/32174834/

104. Balducci, L, Falandry, C, List, A, New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology., Curr Oncol Rep, 2022. 24 (12)(12): p. 1695-1703., https://pubmed.ncbi.nlm.nih.gov/35986858/

105. Vaupel, P, Mayer, A, Höckel, M, Impact of hemoglobin levels on tumor oxygenation: the higher, the better?, Strahlenther Onkol, 2006. 182 (2)(2): p. 63-71., https://pubmed.ncbi.nlm.nih.gov/16447012/

106. Lee, WR, Berkey, B, Marcial, V, Fu, KK, Cooper, JS, Vikram, B, et.al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27., Int J Radiat Oncol Biol Phys, 1998. 42 (5)(5): p. 1069-75., https://pubmed.ncbi.nlm.nih.gov/9869231/

107. Varlotto, J, Stevenson, MA, Anemia, tumor hypoxemia, and the cancer patient., Int J Radiat Oncol Biol Phys, 2005. 63 (1)(1): p. 25-36., https://pubmed.ncbi.nlm.nih.gov/16111569/

108. Hoff, CM, Hansen, HS, Overgaard, M, Grau, C, Johansen, J, Bentzen, J, et.al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study., Radiother Oncol, 2011. 98 (1)(1): p. 28-33., https://pubmed.ncbi.nlm.nih.gov/20970213/

109. Hoff, CM, Lassen, P, Eriksen, JG, Hansen, HS, Specht, L, Overgaard, M, et.al. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - results from the randomized DAHANCA 5 and 7 trials., Acta Oncol, 2011. 50 (7)(7): p. 1006-14., https://pubmed.ncbi.nlm.nih.gov/21790306/

110. Bhide, SA, Ahmed, M, Rengarajan, V, Powell, C, Miah, A, Newbold, K, et.al. Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome., Int J Radiat Oncol Biol Phys, 2009. 73 (2)(2): p. 391-8., https://pubmed.ncbi.nlm.nih.gov/18692326/

111. Bush, RS, Jenkin, RD, Allt, WE, Beale, FA, Bean, H, Dembo, AJ, et.al. Definitive evidence for hypoxic cells influencing cure in cancer therapy., Br J Cancer Suppl, 1978. 3 (): p. 302-6., https://pubmed.ncbi.nlm.nih.gov/277250/

112. Fyles, AW, Milosevic, M, Pintilie, M, Syed, A, Hill, RP, Anemia, hypoxia and transfusion in patients with cervix cancer: a review., Radiother Oncol, 2000. 57 (1)(1): p. 13-9., https://pubmed.ncbi.nlm.nih.gov/11033184/

113. Grogan, M, Thomas, GM, Melamed, I, Wong, FL, Pearcey, RG, Joseph, PK, et.al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix., Cancer, 1999. 86 (8)(8): p. 1528-36., https://pubmed.ncbi.nlm.nih.gov/10526282/

114. Pedersen, D, Søgaard, H, Overgaard, J, Bentzen, SM, Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone., Acta Oncol, 1995. 34 (6)(6): p. 787-95., https://pubmed.ncbi.nlm.nih.gov/7576747/

115. Kapp, KS, Poschauko, J, Geyer, E, Berghold, A, Oechs, AC, Petru, E, et.al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy., Int J Radiat Oncol Biol Phys, 2002. 54 (1)(1): p. 58-66., https://pubmed.ncbi.nlm.nih.gov/12182975/

116. Bishop, AJ, Allen, PK, Klopp, AH, Meyer, LA, Eifel, PJ, Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?, Int J Radiat Oncol Biol Phys, 2015. 91 (1)(1): p. 196-205., https://pubmed.ncbi.nlm.nih.gov/25446609/

117. Harris, EE, Kasi, S, Hwang, WT, Vapiwala, N, Solin, LJ, Role of anemia prior to radiation treatment in local recurrence and survival after breast conservation treatment for early-stage breast cancer., Clin Breast Cancer, 2010. 10 (1)(1): p. 74-80., https://pubmed.ncbi.nlm.nih.gov/20133262/

118. Kader, AS, Lim, JT, Berthelet, E, Petersen, R, Ludgate, D, Truong, PT, Prognostic significance of blood transfusions in patients with esophageal cancer treated with combined chemoradiotherapy., Am J Clin Oncol, 2007. 30 (5)(5): p. 492-7., https://pubmed.ncbi.nlm.nih.gov/17921709/

119. Machtay, M, Pajak, TF, Suntharalingam, M, Shenouda, G, Hershock, D, Stripp, DC, et.al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03)., Int J Radiat Oncol Biol Phys, 2007. 69 (4)(4): p. 1008-17., https://pubmed.ncbi.nlm.nih.gov/17716826/

120. Henke, M, Laszig, R, Rübe, C, Schäfer, U, Haase, KD, Schilcher, B, et.al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial., Lancet, 2003. 362 (9392)(9392): p. 1255-60., https://pubmed.ncbi.nlm.nih.gov/14575968/

121. Dusenbery, KE, McGuire, WA, Holt, PJ, Carson, LF, Fowler, JM, Twiggs, LB, et.al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer., Int J Radiat Oncol Biol Phys, 1994. 29 (5)(5): p. 1079-84., https://pubmed.ncbi.nlm.nih.gov/8083076/

122. Aapro, M, Beguin, Y, Bokemeyer, C, Dicato, M, Gascón, P, Glaspy, J, et.al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines., Ann Oncol, 2018. 29 (Suppl 4)(Suppl 4): p. iv96-iv110., https://pubmed.ncbi.nlm.nih.gov/29471514/

123. Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E., Lyman, G. H., Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, 2006. 106: p. 2258-66.

124. Nielson, CM, Bylsma, LC, Fryzek, JP, Saad, HA, Crawford, J, Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-Analysis., Oncologist, 2021. 26 (9)(9): p. e1609-e1618., https://pubmed.ncbi.nlm.nih.gov/33973301/

125. Pettengell, R, Schwenkglenks, M, Bosly, A, Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy., Ann Hematol, 2008. 87 (5)(5): p. 429-30., https://pubmed.ncbi.nlm.nih.gov/18299833 /

126. Vehreschild, J. J., Bohme, A., Cornely, O. A., Kahl, C., Karthaus, M., Kreuzer, K. A., et.al. Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy--evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO), Ann Oncol, 2014.

127. Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., et.al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 2015. 33: p. 3199-212.

128. Lyman, G. H., Kuderer, N. M., Crawford, J., Wolff, D. A., Culakova, E., Poniewierski, M. S., et.al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy, Cancer, 2011. 117: p. 1917-27.

129. Mhaskar, R., Clark, O. A., Lyman, G., Engel Ayer Botrel, T., Morganti Paladini, L., Djulbegovic, B., Colony-stimulating factors for chemotherapy-induced febrile neutropenia, Cochrane Database Syst Rev, 2014. 10: p. CD003039.

130. Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., et.al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 2006. 24: p. 3187-205.

131. Hartmann, L. C., Tschetter, L. K., Habermann, T. M., Ebbert, L. P., Johnson, P. S., Mailliard, J. A., et.al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia, N Engl J Med, 1997. 336: p. 1776-80.

132. Gerhartz, HH, Stern, AC, Wolf-Hornung, B, Kazempour, M, Schmetzer, H, Gugerli, U, et.al. Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy., Leuk Res, 1993. 17 (2)(2): p. 175-85., https://pubmed.ncbi.nlm.nih.gov/8429694/

133. Fukuda, M, Nakano, M, Kinoshita, A, Watanabe, K, Itoh, N, Sakamoto, A, et.al. Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC), 1993. 12:

134. Lyman, G. H., Abella, E., Pettengell, R., Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review, Crit Rev Oncol Hematol, 2014. 90: p. 190-9.

135. Aapro, MS, Bohlius, J, Cameron, DA, Dal Lago, L, Donnelly, JP, Kearney, N, et.al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours., Eur J Cancer, 2011. 47 (1)(1): p. 8-32., https://pubmed.ncbi.nlm.nih.gov/21095116/

136. Crawford, J., Armitage, J., Balducci, L., Becker, P. S., Blayney, D. W., Cataland, S. R., et.al. Myeloid growth factors, J Natl Compr Canc Netw, 2013. 11: p. 1266-90.

137. Averin, A, Silvia, A, Lamerato, L, Richert-Boe, K, Kaur, M, Sundaresan, D, et.al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice., Support Care Cancer, 2021. 29 (4)(4): p. 2179-2186., https://pubmed.ncbi.nlm.nih.gov/32880732 /

138. Timmer-Bonte, J. N., de Boo, T. M., Smit, H. J., Biesma, B., Wilschut, F. A., Cheragwandi, S. A., et.al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study, J Clin Oncol, 2005. 23: p. 7974-84.

139. Lyman, G. H., Delgado, D. J., Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma, Cancer, 2003. 98: p. 2402-9.

140. Millward, M. J., Boyer, M. J., Lehnert, M., Clarke, S., Rischin, D., Goh, B. C., et.al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients, Ann Oncol, 2003. 14: p. 449-54.

141. Gianni, L., Munzone, E., Capri, G., Fulfaro, F., Tarenzi, E., Villani, F., et.al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study, J Clin Oncol, 1995. 13: p. 2688-99.

142. Fossa, S. D., Kaye, S. B., Mead, G. M., Cullen, M., de Wit, R., Bodrogi, I., et.al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom, J Clin Oncol, 1998. 16: p. 716-24.

143. Tjan-Heijnen, V. C., Postmus, P. E., Ardizzoni, A., Manegold, C. H., Burghouts, J., van Meerbeeck, J., et.al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study, Ann Oncol, 2001. 12: p. 1359-68.

144. Ravaud, A., Chevreau, C., Cany, L., Houyau, P., Dohollou, N., Roche, H., et.al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial, J Clin Oncol, 1998. 16: p. 2930-6.

145. Vellenga, E., Uyl-de Groot, C. A., de Wit, R., Keizer, H. J., Lowenberg, B., ten Haaft, M. A., et.al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia, J Clin Oncol, 1996. 14: p. 619-27.

146. Chao, C., Page, J. H., Yang, S. J., Rodriguez, R., Huynh, J., Chia, V. M., History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis, Ann Oncol, 2014. 25: p. 1821-9.

147. Lyman, GH, Poniewierski, MS, A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group., J Natl Compr Canc Netw, 2017. 15 (12)(12): p. 1543-1550., https://pubmed.ncbi.nlm.nih.gov/, 29223991 /

148. Agiro, A, Ma, Q, Acheson, AK, Wu, SJ, Patt, DA, Barron, JJ, et.al. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer., J Clin Oncol, 2016. 34 (32)(32): p. 3872-3879., https://pubmed.ncbi.nlm.nih.gov/, 27646945/

149. Lyman, Gary H., Lyman, Christopher H., Agboola, Olayemi, Group, for the Anc Study, Risk Models for Predicting Chemotherapy-Induced Neutropenia, The Oncologist, 2005. 10: p. 427-437.

150. Chrischilles, E., Delgado, D.J., Stolshek, B.S., Lawless, G., Fridman, M., Carter, W.B., Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma, Cancer Control., 2002. 9: p. 203-211.

151. Lyman, G. H., Michels, S. L., Reynolds, M. W., Barron, R., Tomic, K. S., Yu, J., Risk of mortality in patients with cancer who experience febrile neutropenia, Cancer, 2010. 116: p. 5555-63.

152. Dale, D. C., McCarter, G. C., Crawford, J., Lyman, G. H., Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials, J Natl Compr Canc Netw, 2003. 1: p. 440-54.

153. Crawford, J., NCCN® Practice Guidelines in Oncology - v.2.2014; Myeloid Growth Factors, National Comprehensive Cancer Network, 2014.

154. Lyman, G. H., Dale, D. C., Culakova, E., Poniewierski, M. S., Wolff, D. A., Kuderer, N. M., et.al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials, Ann Oncol, 2013. 24: p. 2475-84.

155. Pfeil, AM, Allcott, K, Pettengell, R, von Minckwitz, G, Schwenkglenks, M, Szabo, Z, Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review., Support Care Cancer, 2015. 23 (2)(2): p. 525-45., https://pubmed.ncbi.nlm.nih.gov/25284721/

156. Lyman, GH, Yau, L, Nakov, R, Krendyukov, A, Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support., Ann Oncol, 2018. 29 (9)(9): p. 1903-1910., https://pubmed.ncbi.nlm.nih.gov/30099478/

157. Lyman, GH, Dale, DC, Wolff, DA, Culakova, E, Poniewierski, MS, Kuderer, NM, et.al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review., J Clin Oncol, 2010. 28 (17)(17): p. 2914-24., https://pubmed.ncbi.nlm.nih.gov/20385991/

158. Early Breast Cancer Trialists Collaborative Group (EBCTCG), Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials., Lancet, 2019. 393 (10179)(10179): p. 1440-1452., https://pubmed.ncbi.nlm.nih.gov/30739743/

159. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., et.al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 2011. 364: p. 1817-25.

160. Peddi, P. F., Lubner, S., McWilliams, R., Tan, B. R., Picus, J., Sorscher, S. M., et.al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma, JOP, 2012. 13: p. 497-501.

161. Lowery MA, Yu KH, Adel NG, Apollo AJ, Boyar MS, Caron P, et.al. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC)., ASCO Meeting Abstracts, 2012. 30(15 suppl):4057:

162. Marsh Rde, W., Talamonti, M. S., Katz, M. H., Herman, J. M., Pancreatic cancer and FOLFIRINOX: a new era and new questions, Cancer Med, 2015. 4: p. 853-63.

163. Truong, J., Lee, E. K., Trudeau, M. E., Chan, K. K., Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis, Ann Oncol, 2016. 27: p. 608-18.

164. Klastersky, J, de Naurois, J, Rolston, K, Rapoport, B, Maschmeyer, G, Aapro, M, et.al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines., Ann Oncol, 2016. 27 (suppl 5)(suppl 5): p. v111-v118., https://pubmed.ncbi.nlm.nih.gov/27664247/

165. Cooper, KL, Madan, J, Whyte, S, Stevenson, MD, Akehurst, RL, Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis., BMC Cancer, 2011. 11 (): p. 404., https://pubmed.ncbi.nlm.nih.gov/21943360/

166. Kuderer, NM, Dale, DC, Crawford, J, Lyman, GH, Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review., J Clin Oncol, 2007. 25 (21)(21): p. 3158-67., https://pubmed.ncbi.nlm.nih.gov/17634496/

167. Kosaka, Y, Rai, Y, Masuda, N, Takano, T, Saeki, T, Nakamura, S, et.al. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy., Support Care Cancer, 2015. 23 (4)(4): p. 1137-43., https://pubmed.ncbi.nlm.nih.gov/25576433/

168. Hidalgo, M, Mendiola, C, López-Vega, JM, Castellano, D, Mendez, M, Batiste-Alenton, E, et.al. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain., Cancer, 1998. 83 (4)(4): p. 719-25., https://pubmed.ncbi.nlm.nih.gov/9708936/

169. Papaldo, P., Lopez, M., Cortesi, E., Cammilluzzi, E., Antimi, M., Terzoli, E., et.al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide, J Clin Oncol, 2003. 21: p. 3462-8.

170. Lyman, G. H., Kuderer, N. M., Djulbegovic, B., Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis, Am J Med, 2002. 112: p. 406-11.

171. Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., et.al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer, N Engl J Med, 1991. 325: p. 164-70.

172. Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., et.al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Eur J Cancer, 1993. 29A: p. 319-24.

173. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R., Wilkinson, P. M., et.al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial, Blood, 1992. 80: p. 1430-6.

174. Bui, B. N., Chevallier, B., Chevreau, C., Krakowski, I., Peny, A. M., Thyss, A., et.al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity, J Clin Oncol, 1995. 13: p. 2629-36.

175. Fukuoka, M., Masuda, N., Negoro, S., Matsui, K., Yana, T., Kudoh, S., et.al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer, Br J Cancer, 1997. 75: p. 306-9.

176. Gatzemeier, U., Kleisbauer, J. P., Drings, P., Kaukel, E., Samaras, N., Melo, M. J., et.al. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study, Am J Clin Oncol, 2000. 23: p. 393-400.

177. Masuda, N., Fukuoka, M., Furuse, K., CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer, Oncology, 1992. 49 Suppl 1: p. 19-24.

178. Negoro, S., Masuda, N., Furuse, K., Saijo, N., Fukuoka, M., Dose-intensive chemotherapy in extensive-stage small-cell lung cancer, Cancer Chemother Pharmacol, 1997. 40 Suppl: p. S70-3.

179. Trillet-Lenoir, V., Green, J. A., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., et.al. Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up, Eur J Cancer, 1995. 31A: p. 2115-6.

180. Woll, P. J., Hodgetts, J., Lomax, L., Bildet, F., Cour-Chabernaud, V., Thatcher, N., Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer, J Clin Oncol, 1995. 13: p. 652-9.

181. Chevallier, B., Chollet, P., Merrouche, Y., Roche, H., Fumoleau, P., Kerbrat, P., et.al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer, J Clin Oncol, 1995. 13: p. 1564-71.

182. del Giglio, A., Eniu, A., Ganea-Motan, D., Topuzov, E., Lubenau, H., XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy, BMC Cancer, 2008. 8: p. 332.

183. Glaspy, J, Bondarenko, I, Burdaeva, O, Chen, J, Rutty, D, Li, R, et.al. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial., Support Care Cancer, 2023. 32 (1)(1): p. 34., https://pubmed.ncbi.nlm.nih.gov/38103088/

184. Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., et.al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors, J Clin Oncol, 2007. 25: p. 247-56.

185. Nichols, C. R., Catalano, P. J., Crawford, E. D., Vogelzang, N. J., Einhorn, L. H., Loehrer, P. J., Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study, J Clin Oncol, 1998. 16: p. 1287-93.

186. National Comprehensive Cancer Network ® (NCCN ®), NCCN Guidelines Version 1.2024 Hematopoietic Growth Factors, 2023.

187. Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H., Cavallin-Stahl, E., et.al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial, Blood, 2003. 101: p. 3840-8.

188. Zinzani, P. L., Pavone, E., Storti, S., Moretti, L., Fattori, P. P., Guardigni, L., et.al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma, Blood, 1997. 89: p. 3974-9.

189. Bohlius, J, Herbst, C, Reiser, M, Schwarzer, G, Engert, A, Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma., Cochrane Database Syst Rev, 2008. 2008 (4)(4): p. CD003189., https://pubmed.ncbi.nlm.nih.gov/18843642/

190. Gisselbrecht, C., Haioun, C., Lepage, E., Bastion, Y., Tilly, H., Bosly, A., et.al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte, Leuk Lymphoma, 1997. 25: p. 289-300.

191. Fridrik, M. A., Greil, R., Hausmaninger, H., Krieger, O., Oppitz, P., Stoger, M., et.al. Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy, Ann Hematol, 1997. 75: p. 135-40.

192. Doordujin, J., Van der Holt, B., Van Der Kem, F., Randomized trial of colony-stimulating factor (G-CSF) added to CHOP in elderly patients with aggressive non-Hodgkin’s lymphoma., Blood, 2000.

193. Aviles, A., Diaz-Maqueo, J. C., Talavera, A., Nambo, M. J., Garcia, E. L., Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy, Leuk Lymphoma, 1994. 15: p. 153-7.

194. Harousseau, J. L., Witz, B., Lioure, B., Hunault-Berger, M., Desablens, B., Delain, M., et.al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques, J Clin Oncol, 2000. 18: p. 780-7.

195. Jaramillo, S, Benner, A, Krauter, J, Martin, H, Kindler, T, Bentz, M, et.al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia., Blood Cancer J, 2017. 7 (5)(5): p. e564., https://pubmed.ncbi.nlm.nih.gov/28548643/

196. Burnett, AK, Russell, NH, Hills, RK, Hunter, AE, Kjeldsen, L, Yin, J, et.al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial., J Clin Oncol, 2013. 31 (27)(27): p. 3360-8., https://pubmed.ncbi.nlm.nih.gov/23940227/

197. Dombret, H, Chastang, C, Fenaux, P, Reiffers, J, Bordessoule, D, Bouabdallah, R, et.al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group., N Engl J Med, 1995. 332 (25)(25): p. 1678-83., https://pubmed.ncbi.nlm.nih.gov/7539109/

198. Gurion, R, Belnik-Plitman, Y, Gafter-Gvili, A, Paul, M, Vidal, L, Ben-Bassat, I, et.al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia., Cochrane Database Syst Rev, 2012. (6)(6): p. CD008238., https://pubmed.ncbi.nlm.nih.gov/22696376/

199. Ohno, R, Tomonaga, M, Kobayashi, T, Kanamaru, A, Shirakawa, S, Masaoka, T, et.al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia., N Engl J Med, 1990. 323 (13)(13): p. 871-7., https://pubmed.ncbi.nlm.nih.gov/1697646/

200. Feng, X, Lan, H, Ruan, Y, Li, C, Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis., Hematology, 2018. 23 (9)(9): p. 581-589., https://pubmed.ncbi.nlm.nih.gov/29516766/

201. DiNardo, C., Pratz, K., Panayiotidis, P., Wei, X., Vorobyev, V., Illés, Á., et.al. THE IMPACT OF POST-REMISSION GRANULOCYTE COLONY-STIMULATING FACTOR USE IN THE PHASE 3 STUDIES OF VENETOCLAX COMBINATION TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA, 2022. 6:, https://journals.lww.com/hemasphere/Fulltext/2022/06003/P510__THE_IMPACT_OF_POST_REMISSION_GRANULOCYTE.409.aspx

202. Heil, G., Hoelzer, D., Sanz, M. A., Lechner, K., Liu Yin, J. A., Papa, G., et.al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group, Blood, 1997. 90: p. 4710-8.

203. Link, H, G-CSF (lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial.Blood, 1996. 88 (10):

204. Döhner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, et.al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN., Blood, 2022. 140 (12)(12): p. 1345-1377., https://pubmed.ncbi.nlm.nih.gov/35797463/

205. Dale, DC, Crawford, J, Klippel, Z, Reiner, M, Osslund, T, Fan, E, et.al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim., Support Care Cancer, 2018. 26 (1)(1): p. 7-20., https://pubmed.ncbi.nlm.nih.gov/28939926/

206. Geissler, K., Koller, E., Hubmann, E., Niederwieser, D., Hinterberger, W., Geissler, D., et.al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study, Blood, 1997. 90: p. 590-6.

207. Holowiecki, J., Giebel, S., Krzemien, S., Krawczyk-Kulis, M., Jagoda, K., Kopera, M., et.al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study, Leuk Lymphoma, 2002. 43: p. 315-25.

208. Ottmann, O. G., Hoelzer, D., Gracien, E., Ganser, A., Kelly, K., Reutzel, R., et.al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial, Blood, 1995. 86: p. 444-50.

209. Thomas, X., Boiron, J. M., Huguet, F., Reman, O., Sutton, L., Turlure, P., et.al. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study, Hematol J, 2004. 5: p. 384-94.

210. Larson, R. A., Dodge, R. K., Linker, C. A., Stone, R. M., Powell, B. L., Lee, E. J., et.al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111, Blood, 1998. 92: p. 1556-64.

211. Bassan, R., Lerede, T., Di Bona, E., Rossi, G., Pogliani, E., Rambaldi, A., et.al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs, Leuk Lymphoma, 1997. 26: p. 153-61.

212. Lyman, Gary H., Yau, Lillian, Nakov, Roumen, Krendyukov, Andriy, A Systematic Literature Review of Overall Survival and Delivered Dose Intensity in Cancer Patients Receiving Chemotherapy and G-CSF in Randomized Control Trials, 2017. 130: p. 3424., https://www.sciencedirect.com/science/article/pii/S000649711983940X

213. Glaspy, John, Daley, William, Bondarenko, Igor, Rutty, Dean, Chen, Jianmin, A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy, 2021. 138(Supplement 1): p. 4290 - 4290., https://doi.org/10.1182/blood-2021-145760

214. Glaspy, J, Bondarenko, I, Krasnozhon, D, Rutty, D, Chen, J, Fu, Y, et.al. Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial., Support Care Cancer, 2024. 32 (2)(2): p. 91., https://pubmed.ncbi.nlm.nih.gov/38194162/

215. Zhang, Q, Wang, Z, Yao, W, Wang, S, Zhang, G, Chen, J, et.al. A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer., BMC Cancer, 2024. 24 (1)(1): p. 1143., https://pubmed.ncbi.nlm.nih.gov/39272058/

216. Crawford, J., Kreisman, H., Garewal, H., Jones, S. E., Shoemaker, D., Pupa, M. R., et.al. The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy, Ann Oncol, 1997. 8: p. 1117-24.

217. Soda, H., Oka, M., Fukuda, M., Kinoshita, A., Sakamoto, A., Araki, J., et.al. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer, Cancer Chemother Pharmacol, 1996. 38: p. 9-12.

218. Itamochi, H., Irie, T., Okada, M., al., et, An optimal regimen of G-CSF (granulocyte colony-stimulating factor) treatment after anticancer chemotherapy for patients with gynecologic malignancy., J Jpn Soc Cancer Ther, 1995. 30: p. 776-780.

219. Katakami, N., Hasegawa, T., Umeda, B., Adachi, S., Ishii, N., Takada, Y., et.al. [Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study], Nihon Kyobu Shikkan Gakkai Zasshi, 1996. 34: p. 520-8.

220. Hofmann, W. K., Seipelt, G., Langenhan, S., Reutzel, R., Schott, D., Schoeffski, O., et.al. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia, Ann Hematol, 2002. 81: p. 570-4.

221. Kish, MA, Guide to development of practice guidelines., clin infect dis, 2001. 32: p. 851-854.

222. Loibl, S., Mueller, V., von Minckwitz, G., Conrad, B., Koehne, C. H., Kremers, S., et.al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33), Support Care Cancer, 2011. 19: p. 1789-95.

223. Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., et.al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study, J Clin Oncol, 2005. 23: p. 1178-84.

224. Lyman, GH, Allcott, K, Garcia, J, Stryker, S, Li, Y, Reiner, MT, et.al. The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review., Support Care Cancer, 2017. 25 (8)(8): p. 2619-2629., https://pubmed.ncbi.nlm.nih.gov/28484882/

225. Weycker, D, Barron, R, Edelsberg, J, Kartashov, A, Legg, J, Glass, AG, Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis., BMC Health Serv Res, 2014. 14 (): p. 189., https://pubmed.ncbi.nlm.nih.gov/24767095/

226. Rajan, SS, Lyman, GH, Stearns, SC, Carpenter, WR, Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy., Med Care, 2011. 49 (7)(7): p. 649-57., https://pubmed.ncbi.nlm.nih.gov/21478779/

227. Scott, SD, Chrischilles, EA, Link, BK, Delgado, DJ, Fridman, M, Stolshek, BS, Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy., J Manag Care Pharm, 2003. 9 (2 Suppl)(2 Suppl): p. 15-21., https://pubmed.ncbi.nlm.nih.gov/14613340/

228. Clemons, M, Fergusson, D, Simos, D, Mates, M, Robinson, A, Califaretti, N, et.al. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer., Ann Oncol, 2020. 31 (7)(7): p. 951-957., https://pubmed.ncbi.nlm.nih.gov/32325257/

229. Weycker, D, Li, X, Tzivelekis, S, Atwood, M, Garcia, J, Li, Y, et.al. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor., Support Care Cancer, 2017. 25 (2)(2): p. 439-447., https://pubmed.ncbi.nlm.nih.gov/27734153/

230. Weycker, D, Hackett, J, Edelsberg, JS, Oster, G, Glass, AG, Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?, Ann Pharmacother, 2006. 40 (3)(3): p. 402-7., https://pubmed.ncbi.nlm.nih.gov/16492793 /

231. Kochanek, M, Schalk, E, von Bergwelt-Baildon, M, Beutel, G, Buchheidt, D, Hentrich, M, et.al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO)., Ann Hematol, 2019. 98 (5)(5): p. 1051-1069., https://pubmed.ncbi.nlm.nih.gov/30796468/

232. Clark, O. A., Lyman, G. H., Castro, A. A., Clark, L. G., Djulbegovic, B., Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials, J Clin Oncol, 2005. 23: p. 4198-214.

233. Berghmans, T., Paesmans, M., Lafitte, J. J., Mascaux, C., Meert, A. P., Jacquy, C., et.al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis, Support Care Cancer, 2002. 10: p. 181-8.

234. Talcott, J. A., Siegel, R. D., Finberg, R., Goldman, L., Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule, J Clin Oncol, 1992. 10: p. 316-22.

235. Garcia-Carbonero, R., Mayordomo, J. I., Tornamira, M. V., Lopez-Brea, M., Rueda, A., Guillem, V., et.al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial, J Natl Cancer Inst, 2001. 93: p. 31-8.

236. Sun, HL, Atenafu, EG, Yeboah, E, Reece, DE, Trudel, S, Kukreti, V, et.al. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone., Leuk Lymphoma, 2015. 56 (2)(2): p. 407-14., https://pubmed.ncbi.nlm.nih.gov/24738975 /

237. Wierda, WG, Tambaro, FP, How I manage CLL with venetoclax-based treatments., Blood, 2020. 135 (17)(17): p. 1421-1427., https://pubmed.ncbi.nlm.nih.gov/32076705 /

238. Fischer, K, Al-Sawaf, O, Bahlo, J, Fink, AM, Tandon, M, Dixon, M, et.al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions., N Engl J Med, 2019. 380 (23)(23): p. 2225-2236., https://pubmed.ncbi.nlm.nih.gov/31166681 /

239. Maschmeyer, G, De Greef, J, Mellinghoff, SC, Nosari, A, Thiebaut-Bertrand, A, Bergeron, A, et.al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)., Leukemia, 2019. 33 (4)(4): p. 844-862., https://pubmed.ncbi.nlm.nih.gov/30700842/

240. Palumbo, A, Bladé, J, Boccadoro, M, Palladino, C, Davies, F, Dimopoulos, M, et.al. How to manage neutropenia in multiple myeloma., Clin Lymphoma Myeloma Leuk, 2012. 12 (1)(1): p. 5-11., https://pubmed.ncbi.nlm.nih.gov/22178143/

241. Hu, W, Sung, T, Jessen, BA, Thibault, S, Finkelstein, MB, Khan, NK, et.al. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies., Clin Cancer Res, 2016. 22 (8)(8): p. 2000-8., https://pubmed.ncbi.nlm.nih.gov/26631614 /

242. Ettl, J, Management of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors., Breast Care (Basel), 2019. 14 (2)(2): p. 86-92., https://pubmed.ncbi.nlm.nih.gov/31798379/

243. Spring, LM, Zangardi, ML, Moy, B, Bardia, A, Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations., Oncologist, 2017. 22 (9)(9): p. 1039-1048., https://pubmed.ncbi.nlm.nih.gov/, 28706010/

244. Bas, O, Erul, E, Guven, DC, Aksoy, S, Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis., Support Care Cancer, 2022. 30 (11)(11): p. 9071-9078., https://pubmed.ncbi.nlm.nih.gov/35972646/

245. Du, R, Hu, P, Liu, Q, Zhang, J, Deng, G, Hu, D, et.al. Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer., Technol Cancer Res Treat, 2018. 17 (): p. 1533033818816076., https://pubmed.ncbi.nlm.nih.gov/31122176/

246. Gomes, F, Faivre-Finn, C, Mistry, H, Bezjak, A, Pourel, N, Fournel, P, et.al. Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial., Lung Cancer, 2021. 153 (): p. 165-170., https://pubmed.ncbi.nlm.nih.gov/33545577/

247. Wang, C, Zhu, S, Miao, C, Wang, Y, Chen, J, Yuan, S, et.al. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial., BMC Cancer, 2022. 22 (1)(1): p. 542., https://pubmed.ncbi.nlm.nih.gov/35562713/

248. Zou, D, Guo, M, Zhou, Q, A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer., BMC Cancer, 2021. 21 (1)(1): p. 661., https://pubmed.ncbi.nlm.nih.gov/34078317/

249. Aupérin, A, Le Péchoux, C, Rolland, E, Curran, WJ, Furuse, K, Fournel, P, et.al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer., J Clin Oncol, 2010. 28 (13)(13): p. 2181-90., https://pubmed.ncbi.nlm.nih.gov/20351327/

250. Byhardt, RW, Scott, C, Sause, WT, Emami, B, Komaki, R, Fisher, B, et.al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung., Int J Radiat Oncol Biol Phys, 1998. 42 (3)(3): p. 469-78., https://pubmed.ncbi.nlm.nih.gov/9806503/

251. Bunn, PA, Crowley, J, Kelly, K, Hazuka, MB, Beasley, K, Upchurch, C, et.al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group., J Clin Oncol, 1995. 13 (7)(7): p. 1632-41., https://pubmed.ncbi.nlm.nih.gov/7602352/

252. Sheikh, H, Colaco, R, Lorigan, P, Blackhall, F, Califano, R, Ashcroft, L, et.al. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial., Lung Cancer, 2011. 74 (1)(1): p. 75-9., https://pubmed.ncbi.nlm.nih.gov/21353720/

253. Jahn, F, Wörmann, B, Brandt, J, Freidank, A, Feyer, P, Jordan, K, The Prevention and Treatment of Nausea and Vomiting During Tumor Therapy., Dtsch Arztebl Int, 2022., https://pubmed.ncbi.nlm.nih.gov/35140010/

254. Jordan, K., Jahn, F., Aapro, M., Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review, Ann Oncol, 2015. 26: p. 1081-1090.

255. Dranitsaris, G, Molassiotis, A, Clemons, M, Roeland, E, Schwartzberg, L, Dielenseger, P, et.al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting., Ann Oncol, 2017. 28 (6)(6): p. 1260-1267., https://pubmed.ncbi.nlm.nih.gov/28398530/

256. Warr, D., Prognostic factors for chemotherapy induced nausea and vomiting, Eur J Pharmacol, 2014. 722: p. 192-6.

257. Jordan, K, Chan, A, Gralla, RJ, Jahn, F, Rapoport, B, Warr, D, et.al. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents., Support Care Cancer, 2017. 25 (1)(1): p. 271-275., https://pubmed.ncbi.nlm.nih.gov/27501965/

258. Hesketh, PJ, Kris, MG, Basch, E, Bohlke, K, Barbour, SY, Clark-Snow, RA, et.al. Antiemetics: ASCO Guideline Update., J Clin Oncol, 2020. 38 (24)(24): p. 2782-2797., https://pubmed.ncbi.nlm.nih.gov/32658626/

259. Jordan, K, Chan, A, Gralla, RJ, Jahn, F, Rapoport, B, Ruhlmann, CH, et.al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation., Support Care Cancer, 2023. 32 (1)(1): p. 53., https://pubmed.ncbi.nlm.nih.gov/38129530/

260. Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I., et.al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy, Ann Oncol, 2014. 25: p. 1328-33.

261. Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., de Wit, R., et.al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group, J Clin Oncol, 2003. 21: p. 4112-9.

262. Poli-Bigelli, S., Rodrigues-Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K., Hipple, A., et.al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America, Cancer, 2003. 97: p. 3090-8.

263. Schmoll, H. J., Aapro, M. S., Poli-Bigelli, S., Kim, H. K., Park, K., Jordan, K., et.al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment, Ann Oncol, 2006. 17: p. 1000-6.

264. Warr, D. G., Hesketh, P. J., Gralla, R. J., Muss, H. B., Herrstedt, J., Eisenberg, P. D., et.al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy, J Clin Oncol, 2005. 23: p. 2822-30.

265. Grunberg, S., Chua, D., Maru, A., Dinis, J., DeVandry, S., Boice, J. A., et.al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE, J Clin Oncol, 2011. 29: p. 1495-501.

266. Hata, A, Okamoto, I, Inui, N, Okada, M, Morise, M, Akiyoshi, K, et.al. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE., J Clin Oncol, 2022. 40 (2)(2): p. 180-188., https://pubmed.ncbi.nlm.nih.gov/34793245/

267. Matsuura, K, Tsurutani, J, Inoue, K, Tanabe, Y, Taira, T, Kubota, K, et.al. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC., Cancer, 2022. 128 (8)(8): p. 1692-1698., https://pubmed.ncbi.nlm.nih.gov/35045185/

268. Abe, M, Hirashima, Y, Kasamatsu, Y, Kado, N, Komeda, S, Kuji, S, et.al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial., Support Care Cancer, 2016. 24 (2)(2): p. 675-682., https://pubmed.ncbi.nlm.nih.gov/26130365/

269. Navari, RM, Qin, R, Ruddy, KJ, Liu, H, Powell, SF, Bajaj, M, et.al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting., N Engl J Med, 2016. 375 (2)(2): p. 134-42., https://pubmed.ncbi.nlm.nih.gov/27410922/

270. Zhou, JG, Huang, L, Jin, SH, Xu, C, Frey, B, Ma, H, et.al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials., ESMO Open, 2020. 5 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/32079622/

271. Wang, DY, Chen, Y, Zhang, Y, Shen, YQ, The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis., Front Oncol, 2021. 11 (): p. 705866., https://pubmed.ncbi.nlm.nih.gov/34660273/

272. Chow, R, Navari, RM, Terry, B, DeAngelis, C, Prsic, EH, Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis., Support Care Cancer, 2022. 30 (2)(2): p. 1015-1018., https://pubmed.ncbi.nlm.nih.gov/34613472/

273. Jantunen, I. T., Kataja, V. V., Muhonen, T. T., An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting, Eur J Cancer, 1997. 33: p. 66-74.

274. Hesketh, P. J., Sanz-Altamira, P., Bushey, J., Hesketh, A. M., Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy, Support Care Cancer, 2012. 20: p. 1043-7.

275. Jordan, K, Blättermann, L, Hinke, A, Müller-Tidow, C, Jahn, F, Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis., Support Care Cancer, 2018. 26 (1)(1): p. 21-32., https://pubmed.ncbi.nlm.nih.gov/28861627/

276. Piechotta, V, Adams, A, Haque, M, Scheckel, B, Kreuzberger, N, Monsef, I, et.al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis., Cochrane Database Syst Rev, 2021. 11 (): p. CD012775., https://pubmed.ncbi.nlm.nih.gov/34784425/

277. Gralla, R., Jordan, K., Rapoport, B., Street, J. C., Carides, A., Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: Analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs), J Clin Oncol, 2010. 28: p. 9057.

278. Hesketh, P. J., Schwartzberg, L., Modiano, M., Arora, S., Poma, A., Schnading, I., Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC), J Clin Oncol Suppl: #9622, 2015.

279. Ito, Y., Karayama, M., Inui, N., Kuroishi, S., Nakano, H., Nakamura, Y., et.al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy, Lung Cancer, 2014. 84: p. 259-64.

280. Tanioka, M., Kitao, A., Matsumoto, K., Shibata, N., Yamaguchi, S., Fujiwara, K., et.al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy, Br J Cancer, 2013. 109: p. 859-65.

281. Yahata, H., Kobayashi, H., Sonoda, K., Shimokawa, M., Ohgami, T., Saito, T., et.al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin, Int J Clin Oncol, 2015.

282. Weinstein, C., Jordan, K., Green, S. A., Camacho, E., Khanani, S., Beckford-Brathwaite, E., et.al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial, Ann Oncol, 2016. 27: p. 172-8.

283. Hesketh, P. J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., et.al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study, Ann Oncol, 2014. 25: p. 1340-6.

284. Hesketh, P. J., Bohlke, K., Lyman, G. H., Basch, E., Chesney, M., Clark-Snow, R. A., et.al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update, J Clin Oncol, 2016. 34: p. 381-6.

285. Herrstedt, J, Roila, F, Warr, D, Celio, L, Navari, RM, Hesketh, PJ, et.al. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy., Support Care Cancer, 2017. 25 (1)(1): p. 277-288., https://pubmed.ncbi.nlm.nih.gov/27443154/

286. Hashimoto, H, Abe, M, Tokuyama, O, Mizutani, H, Uchitomi, Y, Yamaguchi, T, et.al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial., Lancet Oncol, 2020. 21 (2)(2): p. 242-249., https://pubmed.ncbi.nlm.nih.gov/31838011/

287. Rapoport, B. L., Jordan, K., Boice, J. A., Taylor, A., Brown, C., Hardwick, J. S., et.al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study, Support Care Cancer, 2010. 18: p. 423-31.

288. Swenerton, K., Jeffrey, J., Stuart, G., Roy, M., Krepart, G., Carmichael, J., et.al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 1992. 10: p. 718-26.

289. Hannigan, E. V., Green, S., Alberts, D. S., O'Toole, R., Surwit, E., Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer, Oncology, 1993. 50 Suppl 2: p. 2-9.

290. Yahata, H., Sonoda, K., Kobayashi, H., Shimokawa, M., Ohgami, T., Saito, T., et.al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy: A multicenter, placebo-controlled, double-blind, randomized study in Japanese gynecologic patients receiving paclitaxel and carboplatin, Ann Oncol, 2014. p. 25 (4): iv518.

291. Scotté, F, Schwartzberg, L, Iihara, H, Aapro, M, Gralla, R, Hesketh, PJ, et.al. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents., Support Care Cancer, 2023. 32 (1)(1): p. 45., https://pubmed.ncbi.nlm.nih.gov/38114821/

292. Spring, LM, Nakajima, E, Hutchinson, J, Viscosi, E, Blouin, G, Weekes, C, et.al. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities., Oncologist, 2021. 26 (10)(10): p. 827-834., https://pubmed.ncbi.nlm.nih.gov/34176192/

293. Bardia, A, Hurvitz, SA, Tolaney, SM, Loirat, D, Punie, K, Oliveira, M, et.al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer., N Engl J Med, 2021. 384 (16)(16): p. 1529-1541., https://pubmed.ncbi.nlm.nih.gov/33882206/

294. Hesketh, P. J., Wright, O., Rosati, G., Russo, M., Levin, J., Lane, S., et.al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study, Support Care Cancer, 2012. 20: p. 1471-8.

295. Nishimura, J., Satoh, T., Fukunaga, M., Takemoto, H., Nakata, K., Ide, Y., et.al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial, Eur J Cancer, 2015. 51: p. 1274-82.

296. Italian Group for Antiemetic Research, Is an antiemetic prophylactic treatment needed for patients submitted to consecutive days of 5-fluorouracil? An observational study., Tumori, 2001. 87 (6)(6): p. 379-82., https://pubmed.ncbi.nlm.nih.gov/11989589/

297. Olver, I, Clark-Snow, R, Ruhlmann, CH, Garcia-Del-Barrio, MA, Schwartzberg, L, Rapoport, BL, et.al. 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential., Support Care Cancer, 2023. 32 (1)(1): p. 37., https://pubmed.ncbi.nlm.nih.gov/38110581/

298. Albany, C., Brames, M. J., Fausel, C., Johnson, C. S., Picus, J., Einhorn, L. H., Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study, J Clin Oncol, 2012. 30: p. 3998-4003.

299. Jordan, K., Kinitz, I., Voigt, W., Behlendorf, T., Wolf, H. H., Schmoll, H. J., Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy, Eur J Cancer, 2009. 45: p. 1184-7.

300. Olver, I. N., Grimison, P., Chatfield, M., Stockler, M. R., Toner, G. C., Gebski, V., et.al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy, Support Care Cancer, 2013. 21: p. 1561-8.

301. Einhorn, L. H., Brames, M. J., Dreicer, R., Nichols, C. R., Cullen, M. T., Jr., Bubalo, J., Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer, Support Care Cancer, 2007. 15: p. 1293-300.

302. Rapoport, BL, Herrstedt, J, Snow, RC, Radhakrishnan, V, Saito, M, Navari, RM, et.al. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting., Support Care Cancer, 2023. 32 (1)(1): p. 36., https://pubmed.ncbi.nlm.nih.gov/38105286/

303. Zhao, Yuanyuan, Yang, Yunpeng, Gao, Fangfang, Hu, Changlu, Zhong, Diansheng, Lu, Miaozhen, et.al. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study), 2022. p. 101771., https://www.sciencedirect.com/science/article/pii/S2589537022005004

304. Schmitt, T., Goldschmidt, H., Neben, K., Freiberger, A., Husing, J., Gronkowski, M., et.al. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial, J Clin Oncol, 2014.

305. Stiff, P. J., Fox-Geiman, M. P., Kiley, K., Rychlik, K., Parthasarathy, M., Fletcher-Gonzalez, D., et.al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens, Biol Blood Marrow Transplant, 2013. 19: p. 49-55 e1.

306. Clemmons, AB, Orr, J, Andrick, B, Gandhi, A, Sportes, C, DeRemer, D, Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial., Biol Blood Marrow Transplant, 2018. 24 (10)(10): p. 2065-2071., https://pubmed.ncbi.nlm.nih.gov/29906570/

307. Trifilio, S, Welles, C, Seeger, K, Mehta, S, Fishman, M, McGowan, K, et.al. Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study., Clin Lymphoma Myeloma Leuk, 2017. 17 (9)(9): p. 584-589., https://pubmed.ncbi.nlm.nih.gov/28694084/

308. Morrow, G. R., Roscoe, J. A., Hynes, H. E., Flynn, P. J., Pierce, H. I., Burish, T., Progress in reducing anticipatory nausea and vomiting: a study of community practice, Support Care Cancer, 1998. 6: p. 46-50.

309. Aapro, M. S., Molassiotis, A., Olver, I., Anticipatory nausea and vomiting, Support Care Cancer, 2005. 13: p. 117-21.

310. Klein, J, Griffiths, P, Acupressure for nausea and vomiting in cancer patients receiving chemotherapy., Br J Community Nurs, 2004. 9 (9)(9): p. 383-8., https://pubmed.ncbi.nlm.nih.gov/15389150/

311. Konno, R, Cochrane review summary for cancer nursing: acupuncture-point stimulation for chemotherapy-induced nausea or vomiting., Cancer Nurs, 2010. 33 (6)(6): p. 479-80., https://pubmed.ncbi.nlm.nih.gov/20975347/

312. Aapro, M, 5-HT3 receptor antagonists: are they all the same? Management of nausea and vomiting: revisiting the role of the 5-HT3 receptor antagonists, Cancer Today, 2002. p. 3-15.

313. Hesketh, P. J., Younger, J., Sanz-Altamira, P., Hayden, M., Bushey, J., Trainor, B., et.al. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide, Support Care Cancer, 2009. 17: p. 1065-70.

314. Navari, R. M., Nagy, C. K., Gray, S. E., The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Support Care Cancer, 2013. 21: p. 1655-63.

315. Chanthawong, S., Subongkot, S., Sookprasert, A., Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting, J Med Assoc Thai, 2014. 97: p. 349-55.

316. Hocking, C. M., Kichenadasse, G., Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review, Support Care Cancer, 2014. 22: p. 1143-51.

317. Chow, R, Herrstedt, J, Aapro, M, Chiu, L, Lam, H, Prsic, E, et.al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature., Support Care Cancer, 2021. 29 (7)(7): p. 3439-3459., https://pubmed.ncbi.nlm.nih.gov/33442782/

318. Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., et.al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology, J Clin Oncol, 1999. 17: p. 2971-94.

319. Eisenberg, P., Figueroa-Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., et.al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron, Cancer, 2003. 98: p. 2473-82.

320. Gralla, R., Lichinitser, M., Van Der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., et.al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron, Ann Oncol, 2003. 14: p. 1570-7.

321. Saito, M., Aogi, K., Sekine, I., Yoshizawa, H., Yanagita, Y., Sakai, H., et.al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial, Lancet Oncol, 2009. 10: p. 115-24.

322. Morganroth, J., Flaharty, K. K., Parisi, S., Moresino, C., Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers, Support Care Cancer, 2015.

323. Piraccini, E, Dima, V, Maitan, S, Persistent hiccups after cervical facet dexamethasone injections., Minerva Anestesiol, 2019. 85 (11)(11): p. 1246-1247., https://pubmed.ncbi.nlm.nih.gov/31238643 /

324. Natale, JJ, Spinelli, T, Calcagnile, S, Lanzarotti, C, Rossi, G, Cox, D, et.al. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data., J Oncol Pharm Pract, 2016. 22 (3)(3): p. 485-95., https://pubmed.ncbi.nlm.nih.gov/25998320 /

325. Loos, W. J., de Wit, R., Freedman, S. J., Van Dyck, K., Gambale, J. J., Li, S., et.al. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients, Cancer Chemother Pharmacol, 2007. 59: p. 407-12.

326. Aapro, M. S., Walko, C. M., Aprepitant: drug-drug interactions in perspective, Ann Oncol, 2010. 21: p. 2316-23.

327. Ioannidis, J. P., Hesketh, P. J., Lau, J., Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence, J Clin Oncol, 2000. 18: p. 3409-22.

328. Grunberg, S. M., Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis, Ann Oncol, 2007. 18: p. 233-40.

329. Roila, F., Tonato, M., Cognetti, F., Cortesi, E., Favalli, G., Marangolo, M., et.al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone, J Clin Oncol, 1991. 9: p. 675-8.

330. Vardy, J., Chiew, K. S., Galica, J., Pond, G. R., Tannock, I. F., Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy, Br J Cancer, 2006. 94: p. 1011-5.

331. Lee, Gyeong‐Won, Oh, Sung Yong, Kang, Myoung Hee, Kang, Jung Hun, Park, Se Hoon, Hwang, In Gyu, et.al. Treatment of Dexamethasone‐Induced Hiccup in Chemotherapy Patients by Methylprednisolone Rotation, 2013. 18(11): p. 1229 - 1234., https://doi.org/10.1634/theoncologist.2013-0224

332. Go, Se‐Il, Koo, Dong‐Hoe, Kim, Seung Tae, Song, Haa‐Na, Kim, Rock Bum, Jang, Joung‐Soon, et.al. Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone‐Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single‐Blind, Crossover Phase III Trial, 2017. 22(11): p. 1354 - 1361., https://doi.org/10.1634/theoncologist.2017-0129

333. Schubert, ML, Schmitt, M, Wang, L, Ramos, CA, Jordan, K, Müller-Tidow, C, et.al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy., Ann Oncol, 2021. 32 (1)(1): p. 34-48., https://pubmed.ncbi.nlm.nih.gov/33098993/

334. Celio, L, Cortinovis, D, Cogoni, AA, Cavanna, L, Martelli, O, Carnio, S, et.al. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study., Oncologist, 2021. 26 (10)(10): p. e1854-e1861., https://pubmed.ncbi.nlm.nih.gov/34101934/

335. Climent, M. A., Palau, J., Ruiz, A., Soriano, V., Aznar, E., Olmos, T., et.al. The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support, Support Care Cancer, 1998. 6: p. 287-90.

336. Gralla, R. J., Itri, L. M., Pisko, S. E., Squillante, A. E., Kelsen, D. P., Braun, D. W., Jr., et.al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting, N Engl J Med, 1981. 305: p. 905-9.

337. Isola, Sasank, Hussain, Azhar, Dua, Anterpreet, Singh, Karampal, Adams, Ninos, Metoclopramide, in StatPearls, 2022, StatPearls Publishing: Treasure Island (FL)., https://www.ncbi.nlm.nih.gov/pubmed/30137802

338. Alderman, B, Hui, D, Mukhopadhyay, S, Bouleuc, C, Case, AA, Amano, K, et.al. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer., Support Care Cancer, 2022. 31 (1)(1): p. 39., https://pubmed.ncbi.nlm.nih.gov/36525085/

339. Tramer, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J., Moore, R. A., McQuay, H. J., Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review, BMJ, 2001. 323: p. 16-21.

340. Whiting, PF, Wolff, RF, Deshpande, S, Di Nisio, M, Duffy, S, Hernandez, AV, et.al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis., JAMA, 2015. 313 (24)(24): p. 2456-73., https://pubmed.ncbi.nlm.nih.gov/26103030/

341. Meiri, E, Jhangiani, H, Vredenburgh, JJ, Barbato, LM, Carter, FJ, Yang, HM, et.al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting., Curr Med Res Opin, 2007. 23 (3)(3): p. 533-43., https://pubmed.ncbi.nlm.nih.gov/17355735/

342. Grimison, P, Mersiades, A, Kirby, A, Lintzeris, N, Morton, R, Haber, P, et.al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial., Ann Oncol, 2020. 31 (11)(11): p. 1553-1560., https://pubmed.ncbi.nlm.nih.gov/32801017/

343. Warr, D, Hesketh, P, Cannabinoids as antiemetics: everything that's old is new again., Ann Oncol, 2020. 31 (11)(11): p. 1425-1426., https://pubmed.ncbi.nlm.nih.gov/32860877 /

344. Herdegen T., Cannabis – Die PharmakologieDeutscher Apotheker Verlag Dr. Roland Schmiedel GmbH & Co. KG, 2020. 160: p. 58 - 66.

345. Abdel-Aziz, H., Windeck, T., Ploch, M., Verspohl, E. J., Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum, Eur J Pharmacol, 2006. 530: p. 136-43.

346. Walstab, J., Kruger, D., Stark, T., Hofmann, T., Demir, I. E., Ceyhan, G. O., et.al. Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT3 receptors of enteric neurons, Neurogastroenterol Motil, 2013. 25: p. 439-47, e302.

347. Patel, P, Robinson, PD, Devine, KA, Positano, K, Cohen, M, Gibson, P, et.al. Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update., Pediatr Blood Cancer, 2021. 68 (5)(5): p. e28947., https://pubmed.ncbi.nlm.nih.gov/33686754/

348. Patel, P, Robinson, PD, Thackray, J, Flank, J, Holdsworth, MT, Gibson, P, et.al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update., Pediatr Blood Cancer, 2017. 64 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/28453189/

349. Patel, P, Paw Cho Sing, E, Dupuis, LL, Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis., Expert Opin Drug Saf, 2019. 18 (2)(2): p. 97-110., https://pubmed.ncbi.nlm.nih.gov/30640557/

350. Dupuis, LL, Boodhan, S, Sung, L, Portwine, C, Hain, R, McCarthy, P, et.al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients., Pediatr Blood Cancer, 2011. 57 (2)(2): p. 191-8., https://pubmed.ncbi.nlm.nih.gov/21465637/

351. Nava, T, Ansari, M, Dalle, JH, de Heredia, CD, Güngör, T, Trigoso, E, et.al. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT)., Bone Marrow Transplant, 2020. 55 (6)(6): p. 1126-1136., https://pubmed.ncbi.nlm.nih.gov/32029909/

352. Keefe, D., Anthony, L., Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care, Curr Opin Support Palliat Care, 2008. 2: p. 19-21.

353. Schmidt-Hieber, M, Bierwirth, J, Buchheidt, D, Cornely, OA, Hentrich, M, Maschmeyer, G, et.al. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)., Ann Hematol, 2018. 97 (1)(1): p. 31-49., https://pubmed.ncbi.nlm.nih.gov/29177551/

354. Kist, Manfred, Mauch, Harald, Podbielski, Andreas, Herrmann, Mathias, Kniehl, Eberhard, MIQ 09: Gastrointestinale Infektionen, 2013.

355. Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., et.al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA), Infect Control Hosp Epidemiol, 2010. 31: p. 431-55.

356. Debast, S. B., Bauer, M. P., Kuijper, E. J., European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection, Clin Microbiol Infect, 2014. 20 Suppl 2: p. 1-26.

357. Baron, E. J., Miller, J. M., Weinstein, M. P., Richter, S. S., Gilligan, P. H., Thomson, R. B., Jr., et.al. Executive summary: a guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a), Clin Infect Dis, 2013. 57: p. 485-8.

358. Saltz, L. B., Douillard, J. Y., Pirotta, N., Alakl, M., Gruia, G., Awad, L., et.al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard, Oncologist, 2001. 6: p. 81-91.

359. O'Shaughnessy, J, Miles, D, Vukelja, S, Moiseyenko, V, Ayoub, JP, Cervantes, G, et.al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results., J Clin Oncol, 2002. 20 (12)(12): p. 2812-23., https://pubmed.ncbi.nlm.nih.gov/12065558/

360. Chau, I, Norman, AR, Cunningham, D, Tait, D, Ross, PJ, Iveson, T, et.al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer., Ann Oncol, 2005. 16 (4)(4): p. 549-57., https://pubmed.ncbi.nlm.nih.gov/15695501/

361. Falcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., et.al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, 2007. 25: p. 1670-6.

362. Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., et.al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. 25: p. 4779-86.

363. Wang-Gillam, A, Li, CP, Bodoky, G, Dean, A, Shan, YS, Jameson, G, et.al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial., Lancet, 2016. 387 (10018)(10018): p. 545-557., https://pubmed.ncbi.nlm.nih.gov/26615328/

364. Cassidy, J, Clarke, S, Díaz-Rubio, E, Scheithauer, W, Figer, A, Wong, R, et.al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer., J Clin Oncol, 2008. 26 (12)(12): p. 2006-12., https://pubmed.ncbi.nlm.nih.gov/18421053/

365. Al-Batran, SE, Homann, N, Pauligk, C, Goetze, TO, Meiler, J, Kasper, S, et.al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial., Lancet, 2019. 393 (10184)(10184): p. 1948-1957., https://pubmed.ncbi.nlm.nih.gov/30982686/

366. Johnston, SRD, Harbeck, N, Hegg, R, Toi, M, Martin, M, Shao, ZM, et.al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)., J Clin Oncol, 2020. 38 (34)(34): p. 3987-3998., https://pubmed.ncbi.nlm.nih.gov/32954927/

367. Dickler, MN, Tolaney, SM, Rugo, HS, Cortés, J, Diéras, V, Patt, D, et.al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR, Clin Cancer Res, 2017. 23 (17)(17): p. 5218-5224., https://pubmed.ncbi.nlm.nih.gov/28533223/

368. Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., et.al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 2013. 31: p. 3327-34.

369. Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., et.al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 2011. 378: p. 1931-9.

370. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., et.al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial, Lancet, 2007. 370: p. 2103-11.

371. Miles, D. W., Chan, A., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., et.al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer, J Clin Oncol, 2010. 28: p. 3239-47.

372. Dimopoulos, MA, Goldschmidt, H, Niesvizky, R, Joshua, D, Chng, WJ, Oriol, A, et.al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial., Lancet Oncol, 2017. 18 (10)(10): p. 1327-1337., https://pubmed.ncbi.nlm.nih.gov/28843768/

373. Brummendorf, T. H., Cortes, J. E., de Souza, C. A., Guilhot, F., Duvillie, L., Pavlov, D., et.al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial, Br J Haematol, 2015. 168: p. 69-81.

374. Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., et.al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J Clin Oncol, 2013. 31: p. 412-9.

375. Vaishampayan, U., Cabozantinib as a novel therapy for renal cell carcinoma, Curr Oncol Rep, 2013. 15: p. 76-82.

376. Shaw, A. T., Engelman, J. A., Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 2014. 370: p. 2537-9.

377. Van Cutsem, E., Kohne, C. H., Lang, I., Folprecht, G., Nowacki, M. P., Cascinu, S., et.al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 2011. 29: p. 2011-9.

378. Ellis, PM, Shepherd, FA, Millward, M, Perrone, F, Seymour, L, Liu, G, et.al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial., Lancet Oncol, 2014. 15 (12)(12): p. 1379-88., https://pubmed.ncbi.nlm.nih.gov/25439692/

379. Flinn, IW, Hillmen, P, Montillo, M, Nagy, Z, Illés, Á, Etienne, G, et.al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL., Blood, 2018. 132 (23)(23): p. 2446-2455., https://pubmed.ncbi.nlm.nih.gov/30287523/

380. Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., et.al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, 2013. 369: p. 507-16.

381. Flinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., et.al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma, Blood, 2014. 123: p. 3406-13.

382. Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., et.al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma, N Engl J Med, 2014. 370: p. 1008-18.

383. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et.al. Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 2010. 363: p. 711-23.

384. Andrews, S., Holden, R., Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma, Cancer Manag Res, 2012. 4: p. 299-307.

385. Cameron, D., Casey, M., Press, M., Lindquist, D., Pienkowski, T., Romieu, C. G., et.al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses, Breast Cancer Res Treat, 2008. 112: p. 533-43.

386. Schlumberger, M, Tahara, M, Wirth, LJ, Robinson, B, Brose, MS, Elisei, R, et.al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer., N Engl J Med, 2015. 372 (7)(7): p. 621-30., https://pubmed.ncbi.nlm.nih.gov/25671254/

387. Saura, C, Oliveira, M, Feng, YH, Dai, MS, Chen, SW, Hurvitz, SA, et.al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial., J Clin Oncol, 2020. 38 (27)(27): p. 3138-3149., https://pubmed.ncbi.nlm.nih.gov/32678716/

388. Cottin, V, Martinez, FJ, Jenkins, RG, Belperio, JA, Kitamura, H, Molina-Molina, M, et.al. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial., Respir Res, 2022. 23 (1)(1): p. 85., https://pubmed.ncbi.nlm.nih.gov/35392908/

389. Peeters, M, Price, TJ, Cervantes, A, Sobrero, AF, Ducreux, M, Hotko, Y, et.al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer., J Clin Oncol, 2010. 28 (31)(31): p. 4706-13., https://pubmed.ncbi.nlm.nih.gov/20921462/

390. Modest, DP, Martens, UM, Riera-Knorrenschild, J, Greeve, J, Florschütz, A, Wessendorf, S, et.al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of , J Clin Oncol, 2019. 37 (35)(35): p. 3401-3411., https://pubmed.ncbi.nlm.nih.gov/31609637/

391. von Minckwitz, G, Procter, M, de Azambuja, E, Zardavas, D, Benyunes, M, Viale, G, et.al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer., N Engl J Med, 2017. 377 (2)(2): p. 122-131., https://pubmed.ncbi.nlm.nih.gov/28581356/

392. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et.al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 2013. 381: p. 303-12.

393. Escudier, B., Lassau, N., Angevin, E., Soria, J. C., Chami, L., Lamuraglia, M., et.al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma, Clin Cancer Res, 2007. 13: p. 1801-9.

394. Beck, J., Procopio, G., Bajetta, E., Keilholz, U., Negrier, S., Szczylik, C., et.al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings, Ann Oncol, 2011. 22: p. 1812-23.

395. Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., et.al. Sorafenib for the treatment of advanced renal cell carcinoma, Clinical Cancer Research, 2006. 12: p. 7271-8.

396. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et.al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, The New England journal of medicine, 2007. 356: p. 115-24.

397. Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., et.al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial, Lancet Oncol, 2009. 10: p. 757-63.

398. Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., et.al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial, Lancet Oncol, 2012. 13: p. 897-905.

399. Campbell, M. J., Seib, C. D., Gosnell, J., Vandetanib and the management of advanced medullary thyroid cancer, Curr Opin Oncol, 2013. 25: p. 39-43.

400. Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausova, J., Macarulla, T., et.al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 2012. 30: p. 3499-506.

401. Stingl, J. C., Bartels, H., Viviani, R., Lehmann, M. L., Brockmoller, J., Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review, Pharmacol Ther, 2014. 141: p. 92-116.

402. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F., Mahjoubi, M., et.al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports, Ann Oncol, 1997. 8: p. 1049-51.

403. Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., Chowdhury, N. R., Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype, Hum Mutat, 2000. 16: p. 297-306.

404. Karas, S, Innocenti, F, All You Need to Know About , JCO Oncol Pract, 2022. 18 (4)(4): p. 270-277., https://pubmed.ncbi.nlm.nih.gov/34860573/

405. Morel, A., Boisdron-Celle, M., Fey, L., Soulie, P., Craipeau, M. C., Traore, S., et.al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance, Mol Cancer Ther, 2006. 5: p. 2895-904.

406. Offer, S. M., Fossum, C. C., Wegner, N. J., Stuflesser, A. J., Butterfield, G. L., Diasio, R. B., Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity, Cancer Res, 2014. 74: p. 2545-54.

407. van Kuilenburg, A. B., Meinsma, R., Zonnenberg, B. A., Zoetekouw, L., Baas, F., Matsuda, K., et.al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity, Clin Cancer Res, 2003. 9: p. 4363-7.

408. Amstutz, U., Offer, S. M., Sistonen, J., Joerger, M., Diasio, R. B., Largiader, C. R., Polymorphisms in MIR27A associated with early-onset toxicity in fluoropyrimidine-based chemotherapy, Clin Cancer Res, 2015.

409. Pullarkat, S. T., Stoehlmacher, J., Ghaderi, V., Xiong, Y. P., Ingles, S. A., Sherrod, A., et.al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy, Pharmacogenomics J, 2001. 1: p. 65-70.

410. Lecomte, T., Ferraz, J. M., Zinzindohoue, F., Loriot, M. A., Tregouet, D. A., Landi, B., et.al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy, Clin Cancer Res, 2004. 10: p. 5880-8.

411. Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., et.al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 2015. 16: p. 1639-50.

412. Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., et.al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis, J Clin Oncol, 2016. 34: p. 227-34.

413. Launay, M., Dahan, L., Duval, M., Rodallec, A., Milano, G., Duluc, M., et.al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer, Br J Clin Pharmacol, 2016. 81: p. 124-30.

414. Henricks, LM, Lunenburg, CATC, de Man, FM, Meulendijks, D, Frederix, GWJ, Kienhuis, E, et.al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis., Lancet Oncol, 2018. 19 (11)(11): p. 1459-1467., https://pubmed.ncbi.nlm.nih.gov/30348537/

415. Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens, JHM, Swen, JJ, et.al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update., Clin Pharmacol Ther, 2018. 103 (2)(2): p. 210-216., https://pubmed.ncbi.nlm.nih.gov/29152729/

416. Antoun, S., Boige, V., Ducreux, M., Paintain, M., Martin van't Hof Enslen, M., Steenhout, P., et.al. Protective effect of an enteral formula containing TGF-beta2 in the prevention of chemotherapy-induced diarrhoea: a pilot study, e-SPEN, 2009. 4: p. e348-50.

417. Bozzetti, F., Biganzoli, L., Gavazzi, C., Cappuzzo, F., Carnaghi, C., Buzzoni, R., et.al. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study, Nutrition, 1997. 13: p. 748-51.

418. Coghlin Dickson, T., Wong, R., offrin, R., Shizuru, J., Johnston, L., Hu, W., et.al. Effect of oral glutamine supplementation during bone marrow transplantation, Journal of Parenteral and Enteral Nutrition, 2000. 24: p. 61-66.

419. Coyle, V. M., Lungulescu, D., Toganel, C., Niculescu, A., Pop, S., Ciuleanu, T., et.al. A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea, Br J Cancer, 2013. 108: p. 1027-33.

420. Daniele, B., Perrone, F., Gallo, C., Pignata, S., De Martino, S., De Vivo, R., et.al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial, Gut, 2001. 48: p. 28-33.

421. de Jong, F. A., Kehrer, D. F., Mathijssen, R. H., Creemers, G. J., de Bruijn, P., van Schaik, R. H., et.al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study, Oncologist, 2006. 11: p. 944-54.

422. Hoff, P. M., Saragiotto, D. F., Barrios, C. H., Del Giglio, A., Coutinho, A. K., Andrade, A. C., et.al. Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial, J Clin Oncol, 2014.

423. Jebb, S. A., Marcus, R., Elia, M., A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants, Clin Nutr, 1995. 14: p. 162-5.

424. Jebb, S. A., Osborne, R. J., Maughan, T. S., Mohideen, N., Mack, P., Mort, D., et.al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation, British journal of cancer, 1994. 70: p. 732-5.

425. Karthaus, M., Ballo, H., Abenhardt, W., Steinmetz, T., Geer, T., Schimke, J., et.al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer, Oncology, 2005. 68: p. 326-32.

426. Li, Y., Ping, X., Yu, B., Liu, F., Ni, X., Li, J., Clinical trial: pophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy: a randomised crossover trial, Aliment Pharmacol Ther, 2009.

427. Middleton, G., Brown, S., Lowe, C., Maughan, T., Gwyther, S., Oliver, A., et.al. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO), Eur J Cancer, 2013. 49: p. 3507-16.

428. Osterlund, P., Ruotsalainen, T., Korpela, R., Saxelin, M., Ollus, A., Valta, P., et.al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study, Br J Cancer, 2007. 97: p. 1028-34.

429. Pytlik, R., Benes, P., Patorkova, M., Chocenska, E., Gregora, E., Prochazka, B., et.al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study, Bone Marrow Transplant, 2002. 30: p. 953-61.

430. Sornsuvit, C., Komindr, S., Chuncharunee, S., Wanikiat, P., Archararit, N., Santanirand, P., Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients, J Int Med Res, 2008. 36: p. 1383-91.

431. Tamura, T., Yasutake, K., Nishisaki, H., Nakashima, T., Horita, K., Hirohata, S., et.al. Prevention of irinotecan-induced diarrhea by oral sodium bicarbonate and influence on pharmacokinetics, Oncology, 2004. 67: p. 327-37.

432. Ychou, M., Douillard, J. Y., Rougier, P., Adenis, A., Mousseau, M., Dufour, P., et.al. Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study, Am J Clin Oncol, 2000. 23: p. 143-8.

433. Barcenas, CH, Hurvitz, SA, Di Palma, JA, Bose, R, Chien, AJ, Iannotti, N, et.al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial., Ann Oncol, 2020. 31 (9)(9): p. 1223-1230., https://pubmed.ncbi.nlm.nih.gov/32464281/

434. Kee, B. K., Morris, J. S., Slack, R. S., Crocenzi, T., Wong, L., Esparaz, B., et.al. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan, Support Care Cancer, 2014.

435. Qin, Y, Wang, N, Chen, F, Han, X, Zhu, Y, Rang, Y, et.al. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1 , Pharmazie, 2020. 75 (5)(5): p. 186-190., https://pubmed.ncbi.nlm.nih.gov/32393425/

436. Rotovnik Kozjek, N, Kompan, L, Soeters, P, Oblak, I, Mlakar Mastnak, D, Možina, B, et.al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study., Clin Nutr, 2011. 30 (5)(5): p. 567-70., https://pubmed.ncbi.nlm.nih.gov/21733605/

437. Sabry, NM, Naguib, TM, Kabel, AM, Khafagy, ES, Arab, HH, Almorsy, WA, Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial., Medicina (Kaunas), 2022. 58 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/35334570/

438. Altman, BJ, Stine, ZE, Dang, CV, From Krebs to clinic: glutamine metabolism to cancer therapy., Nat Rev Cancer, 2016. 16 (10)(10): p. 619-34., https://pubmed.ncbi.nlm.nih.gov/27492215/

439. Rubin, J. S., Osada, H., Finch, P. W., Taylor, W. G., Rudikoff, S., Aaronson, S. A., Purification and characterization of a newly identified growth factor specific for epithelial cells, Proc Natl Acad Sci U S A, 1989. 86: p. 802-6.

440. Bradstock, K. F., Link, E., Collins, M., Di Iulio, J., Lewis, I. D., Schwarer, A., et.al. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia, Br J Haematol, 2014. 167: p. 618-25.

441. Namikawa, T, Munekage, E, Maeda, H, Kitagawa, H, Kobayashi, M, Hanazaki, K, Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer., Anticancer Res, 2014. 34 (12)(12): p. 7297-301., https://pubmed.ncbi.nlm.nih.gov/25503163/

442. Gupta, E., Safa, A. R., Wang, X., Ratain, M. J., Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A, Cancer Res, 1996. 56: p. 1309-14.

443. Sun, J., Wang, H., Hu, H., Glutamine for chemotherapy induced diarrhea: a meta-analysis, Asia Pac J Clin Nutr, 2012. 21: p. 380-5.

444. Takeda, Y., Kobayashi, K., Akiyama, Y., Soma, T., Handa, S., Kudoh, S., et.al. Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 2001. 92: p. 269-75.

445. Donnet-Hughes, A., Duc, N., Serrant, P., Vidal, K., Schiffrin, E. J., Bioactive molecules in milk and their role in health and disease: the role of transforming growth factor-beta, Immunol Cell Biol, 2000. 78: p. 74-9.

446. Heuschkel, R., Salvestrini, C., Beattie, R. M., Hildebrand, H., Walters, T., Griffiths, A., Guidelines for the management of growth failure in childhood inflammatory bowel disease, Inflamm Bowel Dis, 2008. 14: p. 839-49.

447. Pox, C. P., Schmiegel, W., [German S3-guideline colorectal carcinoma], Dtsch Med Wochenschr, 2013. 138: p. 2545.

448. Mego, M, Chovanec, J, Vochyanova-Andrezalova, I, Konkolovsky, P, Mikulova, M, Reckova, M, et.al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study., Complement Ther Med, 2015. 23 (3)(3): p. 356-62., https://pubmed.ncbi.nlm.nih.gov/26051570/

449. Wardill, HR, Van Sebille, YZA, Ciorba, MA, Bowen, JM, Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis., Curr Opin Support Palliat Care, 2018. 12 (2)(2): p. 187-197., https://pubmed.ncbi.nlm.nih.gov/29547491/

450. Huang, J. S., Bousvaros, A., Lee, J. W., Diaz, A., Davidson, E. J., Efficacy of probiotic use in acute diarrhea in children: a meta-analysis, Dig Dis Sci, 2002. 47: p. 2625-34.

451. Szajewska, H., Mrukowicz, J. Z., Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials, J Pediatr Gastroenterol Nutr, 2001. 33 Suppl 2: p. S17-25.

452. Alam, N. H., Meier, R., Schneider, H., Sarker, S. A., Bardhan, P. K., Mahalanabis, D., et.al. Partially hydrolyzed guar gum-supplemented oral rehydration solution in the treatment of acute diarrhea in children, J Pediatr Gastroenterol Nutr, 2000. 31: p. 503-7.

453. Redman, MG, Ward, EJ, Phillips, RS, The efficacy and safety of probiotics in people with cancer: a systematic review., Ann Oncol, 2014. 25 (10)(10): p. 1919-1929., https://pubmed.ncbi.nlm.nih.gov/24618152/

454. Hempel, S., Newberry, S. J., Maher, A. R., Wang, Z., Miles, J. N., Shanman, R., et.al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis, JAMA, 2012. 307: p. 1959-69.

455. Johnston, B. C., Ma, S. S., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., et.al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis, Ann Intern Med, 2012. 157: p. 878-88.

456. Allen, S. J., Wareham, K., Wang, D., Bradley, C., Hutchings, H., Harris, W., et.al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 2013. 382: p. 1249-57.

457. Benson, A. B., 3rd, Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., Jr., et.al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea, J Clin Oncol, 2004. 22: p. 2918-26.

458. Bossi, P, Antonuzzo, A, Cherny, NI, Rosengarten, O, Pernot, S, Trippa, F, et.al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines., Ann Oncol, 2018. 29 (Suppl 4)(Suppl 4): p. iv126-iv142., https://pubmed.ncbi.nlm.nih.gov/29931177/

459. Riaz, IB, Khan, MS, Kamal, MU, Sipra, QR, Riaz, A, Zahid, U, et.al. Cardiac Dysrhythmias Associated With Substitutive Use of Loperamide: A Systematic Review., Am J Ther, 2019. 26 (1)(1): p. e170-e182., https://pubmed.ncbi.nlm.nih.gov/28594339/

460. Ruskone, A., Rene, E., Chayvialle, J. A., Bonin, N., Pignal, F., Kremer, M., et.al. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera, Dig Dis Sci, 1982. 27: p. 459-66.

461. Cascinu, S., Fedeli, A., Fedeli, S. L., Catalano, G., Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial, J Clin Oncol, 1993. 11: p. 148-51.

462. Gebbia, V., Carreca, I., Testa, A., Valenza, R., Curto, G., Cannata, G., et.al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy, Anticancer Drugs, 1993. 4: p. 443-5.

463. Nikou, G. C., Polyzos, A., Kostalas, G., Avramopoulos, H., Nikolopoulos, A., Kitsou, E., et.al. Octreotide administration and gut hormone levels in patients with chemotherapy-induced diarrhea, Hell J Gastroenterol, 1994. 7: p. 111-114.

464. Geller, R. B., Gilmore, C. E., Dix, S. P., Lin, L. S., Topping, D. L., Davidson, T. G., et.al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients, Am J Hematol, 1995. 50: p. 167-72.

465. Cascinu, S., Fedeli, A., Fedeli, S. L., Catalano, G., Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin, Oncology, 1994. 51: p. 70-3.

466. Rougier, P., Bugat, R., Douillard, J. Y., Culine, S., Suc, E., Brunet, P., et.al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy, J Clin Oncol, 1997. 15: p. 251-60.

467. Coutré, SE, Barrientos, JC, Brown, JR, de Vos, S, Furman, RR, Keating, MJ, et.al. Management of adverse events associated with idelalisib treatment: expert panel opinion., Leuk Lymphoma, 2015. 56 (10)(10): p. 2779-86., https://pubmed.ncbi.nlm.nih.gov/25726955/

468. Ianiro, G, Rossi, E, Thomas, AM, Schinzari, G, Masucci, L, Quaranta, G, et.al. Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma., Nat Commun, 2020. 11 (1)(1): p. 4333., https://pubmed.ncbi.nlm.nih.gov/32859933/

469. Al-Rudayni, AHM, Gopinath, D, Maharajan, MK, Menon, RK, Impact of oral mucositis on quality of life in patients undergoing oncological treatment: a systematic review., Transl Cancer Res, 2020. 9 (4)(4): p. 3126-3134., https://pubmed.ncbi.nlm.nih.gov/35117676/

470. Al-Dasooqi, N., Sonis, S. T., Bowen, J. M., Bateman, E., Blijlevens, N., Gibson, R. J., et.al. Emerging evidence on the pathobiology of mucositis, Support Care Cancer, 2013. 21: p. 3233-41.

471. Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., et.al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients, Cancer, 2004. 100: p. 1995-2025.

472. Avritscher, E. B., Cooksley, C. D., Elting, L. S., Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis, Semin Oncol Nurs, 2004. 20: p. 3-10.

473. Wagner, AD, Grothey, A, Andre, T, Dixon, JG, Wolmark, N, Haller, DG, et.al. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database., J Natl Cancer Inst, 2021. 113 (4)(4): p. 400-407., https://pubmed.ncbi.nlm.nih.gov/32835356/

474. Gebri, E, Kiss, A, Tóth, F, Hortobágyi, T, Female sex as an independent prognostic factor in the development of oral mucositis during autologous peripheral stem cell transplantation., Sci Rep, 2020. 10 (1)(1): p. 15898., https://pubmed.ncbi.nlm.nih.gov/32985512/

475. Nakagaki, M, Kennedy, GA, Gavin, NC, Clavarino, A, Whitfield, K, The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation., Support Care Cancer, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/36008731/

476. Vokurka, S, Bystrická, E, Koza, V, Scudlová, J, Pavlicová, V, Valentová, D, et.al. Higher incidence of chemotherapy induced oral mucositis in females: a supplement of multivariate analysis to a randomized multicentre study., Support Care Cancer, 2006. 14 (9)(9): p. 974-6., https://pubmed.ncbi.nlm.nih.gov/16502004/

477. Brioli, A, Nägler, TM, Yomade, O, Rüthrich, MM, Scholl, S, Frietsch, JJ, et.al. Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort., Oncol Res Treat, 2022. 45 (9)(9): p. 494-503., https://pubmed.ncbi.nlm.nih.gov/35705004/

478. Blijlevens, N, Schwenkglenks, M, Bacon, P, D'Addio, A, Einsele, H, Maertens, J, et.al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group., J Clin Oncol, 2008. 26 (9)(9): p. 1519-25., https://pubmed.ncbi.nlm.nih.gov/18268357/

479. McGuire, D. B., Fulton, J. S., Park, J., Brown, C. G., Correa, M. E., Eilers, J., et.al. Systematic review of basic oral care for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 3165-77.

480. Hong, CHL, Gueiros, LA, Fulton, JS, Cheng, KKF, Kandwal, A, Galiti, D, et.al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2019. 27 (10)(10): p. 3949-3967., https://pubmed.ncbi.nlm.nih.gov/31286232/

481. Sonis, S. T., Eilers, J. P., Epstein, J. B., LeVeque, F. G., Liggett, W. H., Jr., Mulagha, M. T., et.al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group, Cancer, 1999. 85: p. 2103-13.

482. Eilers, J., Berger, A. M., Petersen, M. C., Development, testing, and application of the oral assessment guide, Oncol Nurs Forum, 1988. 15: p. 325-30.

483. Stiff, P. J., Erder, H., Bensinger, W. I., Emmanouilides, C., Gentile, T., Isitt, J., et.al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT), Bone Marrow Transplant, 2006. 37: p. 393-401.

484. Eilers, J, Epstein, JB, Assessment and measurement of oral mucositis., Semin Oncol Nurs, 2004. 20 (1)(1): p. 22-9., https://pubmed.ncbi.nlm.nih.gov/15038514/

485. Feber, T., Management of mucositis in oral irradiation, Clin Oncol (R Coll Radiol), 1996. 8: p. 106-11.

486. Vokurka, S., Bystricka, E., Koza, V., Scudlova, J., Pavlicova, V., Valentova, D., et.al. The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study, Support Care Cancer, 2005. 13: p. 554-8.

487. Choi, S. E., Kim, H. S., Sodium Bicarbonate Solution versus Chlorhexidine Mouthwash in Oral Care of Acute Leukemia Patients Undergoing Induction Chemotherapy: A Randomized Controlled Trial, Asian Nurs Res (Korean Soc Nurs Sci), 2012. 6: p. 60-6.

488. Dudjak, LA, Mouth care for mucositis due to radiation therapy., Cancer Nurs, 1987. 10 (3)(3): p. 131-40., https://pubmed.ncbi.nlm.nih.gov/2844390/

489. Correa, MEP, Cheng, KKF, Chiang, K, Kandwal, A, Loprinzi, CL, Mori, T, et.al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2020. 28 (5)(5): p. 2449-2456., https://pubmed.ncbi.nlm.nih.gov/31836937/

490. Park, SH, Lee, HS, Meta-analysis of oral cryotherapy in preventing oral mucositis associated with cancer therapy., Int J Nurs Pract, 2019. 25 (5)(5): p. e12759., https://pubmed.ncbi.nlm.nih.gov/31290244/

491. Wilairat, P, Kengkla, K, Kaewpanan, T, Kaewthong, J, Ruankon, S, Subthaweesin, C, et.al. Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis., Eur J Hosp Pharm, 2020. 27 (2)(2): p. 103-110., https://pubmed.ncbi.nlm.nih.gov/32133137 /

492. López-González, Á, García-Quintanilla, M, Guerrero-Agenjo, CM, Tendero, JL, Guisado-Requena, IM, Rabanales-Sotos, J, Eficacy of Cryotherapy in the Prevention of Oral Mucosistis in Adult Patients with Chemotherapy., Int J Environ Res Public Health, 2021. 18 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/33498628/

493. Katranci, N., Ovayolu, N., Ovayolu, O., Sevinc, A., Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial, Eur J Oncol Nurs, 2012. 16: p. 339-44.

494. Peterson, D. E., Ohrn, K., Bowen, J., Fliedner, M., Lees, J., Loprinzi, C., et.al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy, Support Care Cancer, 2013. 21: p. 327-32.

495. Al-Rudayni, AHM, Gopinath, D, Maharajan, MK, Veettil, SK, Menon, RK, Efficacy of Photobiomodulation in the Treatment of Cancer Chemotherapy-Induced Oral Mucositis: A Meta-Analysis with Trial Sequential Analysis., Int J Environ Res Public Health, 2021. 18 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/34299869 /

496. Rocke, LK, Loprinzi, CL, Lee, JK, Kunselman, SJ, Iverson, RK, Finck, G, et.al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis., Cancer, 1993. 72 (7)(7): p. 2234-8., https://pubmed.ncbi.nlm.nih.gov/8374882/

497. Zadik, Y, Arany, PR, Fregnani, ER, Bossi, P, Antunes, HS, Bensadoun, RJ, et.al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2019. 27 (10)(10): p. 3969-3983., https://pubmed.ncbi.nlm.nih.gov/31286228/

498. Elad, S, Arany, P, Bensadoun, RJ, Epstein, JB, Barasch, A, Raber-Durlacher, J, Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters., Support Care Cancer, 2018. 26 (10)(10): p. 3319-3321., https://pubmed.ncbi.nlm.nih.gov/29789949/

499. Malta, CEN, Carlos, ACAM, de Alencar, MCM, Alves E Silva, EF, Nogueira, VBC, Alves, APNN, et.al. Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial., Support Care Cancer, 2022. 30 (3)(3): p. 2569-2580., https://pubmed.ncbi.nlm.nih.gov/34799776/

500. Rozza-de-Menezes, R, Souza, PHC, Westphalen, FH, Ignácio, SA, Moysés, ST, Sarmento, VA, Behaviour and Prevention of 5'Fluorouracil and Doxorubicin-induced Oral Mucositis in Immunocompetent Patients with Solid Tumors: A Randomised Trial, Oral Health Prev Dent, 2018. 16 (6)(6): p. 549-555., https://pubmed.ncbi.nlm.nih.gov/30574609/

501. Zecha, JA, Raber-Durlacher, JE, Nair, RG, Epstein, JB, Sonis, ST, Elad, S, et.al. Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations., Support Care Cancer, 2016. 24 (6)(6): p. 2781-92., https://pubmed.ncbi.nlm.nih.gov/26984240/

502. Lai, CC, Chen, SY, Tu, YK, Ding, YW, Lin, JJ, Effectiveness of low level laser therapy versus cryotherapy in cancer patients with oral mucositis: Systematic review and network meta-analysis., Crit Rev Oncol Hematol, 2021. 160 (): p. 103276., https://pubmed.ncbi.nlm.nih.gov/33716203/

503. Anschau, F, Webster, J, Capra, MEZ, de Azeredo da Silva, ALF, Stein, AT, Efficacy of low-level laser for treatment of cancer oral mucositis: a systematic review and meta-analysis., Lasers Med Sci, 2019. 34 (6)(6): p. 1053-1062., https://pubmed.ncbi.nlm.nih.gov/30729351/

504. Saunders, DP, Rouleau, T, Cheng, K, Yarom, N, Kandwal, A, Joy, J, et.al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2020. 28 (5)(5): p. 2473-2484., https://pubmed.ncbi.nlm.nih.gov/32052137/

505. Ala, S, Saeedi, M, Janbabai, G, Ganji, R, Azhdari, E, Shiva, A, Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial., Nutr Cancer, 2016. 68 (3)(3): p. 456-63., https://pubmed.ncbi.nlm.nih.gov/27007594/

506. Nottage, M., McLachlan, S. A., Brittain, M. A., Oza, A., Hedley, D., Feld, R., et.al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial, Support Care Cancer, 2003. 11: p. 41-7.

507. Pfeiffer, P, Hansen, O, Madsen, EL, May, O, A prospective pilot study on the effect of sucralfate mouth-swishing in reducing stomatitis during radiotherapy of the oral cavity., Acta Oncol, 1990. 29 (4)(4): p. 471-3., https://pubmed.ncbi.nlm.nih.gov/2390274/

508. Pfeiffer, P., Madsen, E. L., Hansen, O., May, O., Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study, Acta Oncol, 1990. 29: p. 171-3.

509. Sayles, C, Hickerson, SC, Bhat, RR, Hall, J, Garey, KW, Trivedi, MV, Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review., Nutr Clin Pract, 2016. 31 (2)(2): p. 171-9., https://pubmed.ncbi.nlm.nih.gov/26507188/

510. Tang, G, Huang, W, Zhang, L, Wei, Z, Role of Glutamine in the Management of Oral Mucositis in Patients with Cancer: A Meta-Analysis of Randomized Controlled Trials., Nutr Cancer, 2022. 74 (2)(2): p. 482-495., https://pubmed.ncbi.nlm.nih.gov/33605813/

511. Jensen, S. B., Jarvis, V., Zadik, Y., Barasch, A., Ariyawardana, A., Hovan, A., et.al. Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 3223-32.

512. Yarom, N., Ariyawardana, A., Hovan, A., Barasch, A., Jarvis, V., Jensen, S. B., et.al. Systematic review of natural agents for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 3209-21.

513. Logan, RM, Al-Azri, AR, Bossi, P, Stringer, AM, Joy, JK, Soga, Y, et.al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2020. 28 (5)(5): p. 2485-2498., https://pubmed.ncbi.nlm.nih.gov/32080767/

514. Yarom, N, Hovan, A, Bossi, P, Ariyawardana, A, Jensen, SB, Gobbo, M, et.al. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements., Support Care Cancer, 2019. 27 (10)(10): p. 3997-4010., https://pubmed.ncbi.nlm.nih.gov/31286229/

515. Yarom, N, Hovan, A, Bossi, P, Ariyawardana, A, Jensen, SB, Gobbo, M, et.al. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents., Support Care Cancer, 2020. 28 (5)(5): p. 2457-2472., https://pubmed.ncbi.nlm.nih.gov/32056010/

516. Hasheminasab, FS, Hashemi, SM, Dehghan, A, Sharififar, F, Setayesh, M, Sasanpour, P, et.al. Effects of a Plantago ovata-based herbal compound in prevention and treatment of oral mucositis in patients with breast cancer receiving chemotherapy: A double-blind, randomized, controlled crossover trial., J Integr Med, 2020. 18 (3)(3): p. 214-221., https://pubmed.ncbi.nlm.nih.gov/32268991/

517. Münstedt, K, Männle, H, Using Bee Products for the Prevention and Treatment of Oral Mucositis Induced by Cancer Treatment., Molecules, 2019. 24 (17)(17):, https://pubmed.ncbi.nlm.nih.gov/31438508/

518. Toyomasu, Y, Mochiki, E, Yanai, M, Suzuki, M, Yanoma, T, Kimura, A, et.al. A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer., Surg Oncol, 2019. 29 (): p. 97-101., https://pubmed.ncbi.nlm.nih.gov/31196501/

519. Yokomizo, H, Yoshimatsu, K, Hashimoto, M, Ishibashi, K, Umehara, A, Yoshida, K, et.al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis., Anticancer Res, 2004. 24 (2C)(2C): p. 1131-4., https://pubmed.ncbi.nlm.nih.gov/15154636/

520. Howell, SB, Wung, WE, Taetle, R, Hussain, F, Romine, JS, Modulation of 5-fluorouracil toxicity by allopurinol in man., Cancer, 1981. 48 (6)(6): p. 1281-9., https://pubmed.ncbi.nlm.nih.gov/7023652/

521. Kroener, JF, Saleh, F, Howell, SB, 5-FU and allopurinol: toxicity modulation and phase II results in colon cancer., Cancer Treat Rep, 1982. 66 (5)(5): p. 1133-7., https://pubmed.ncbi.nlm.nih.gov/7083215/

522. Howell, SB, Pfeifle, CE, Wung, WE, Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection., Cancer, 1983. 51 (2)(2): p. 220-5., https://pubmed.ncbi.nlm.nih.gov/6336975/

523. Panahi, Y, Ala, S, Saeedi, M, Okhovatian, A, Bazzaz, N, Naghizadeh, MM, Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis., Eur J Cancer Care (Engl), 2010. 19 (3)(3): p. 308-12., https://pubmed.ncbi.nlm.nih.gov/19659665/

524. Loprinzi, CL, Cianflone, SG, Dose, AM, Etzell, PS, Burnham, NL, Therneau, TM, et.al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis., Cancer, 1990. 65 (8)(8): p. 1879-82., https://pubmed.ncbi.nlm.nih.gov/2180557/

525. Clark, PI, Slevin, ML, Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity., Eur J Surg Oncol, 1985. 11 (3)(3): p. 267-8., https://pubmed.ncbi.nlm.nih.gov/4029407/

526. Tsavaris, N, Caragiauris, P, Kosmidis, P, Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes., Eur J Surg Oncol, 1988. 14 (5)(5): p. 405-6., https://pubmed.ncbi.nlm.nih.gov/3181443/

527. Tsavaris, NB, Komitsopoulou, P, Tzannou, I, Loucatou, P, Tsaroucha-Noutsou, A, Kilafis, G, et.al. Decreased oral toxicity with the local use of allopurinol in patients who received high dose 5-fluorouracil., Sel Cancer Ther, 1991. 7 (3)(3): p. 113-7., https://pubmed.ncbi.nlm.nih.gov/1771297/

528. Elzawawy, A, Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes., Oncology, 1991. 48 (4)(4): p. 282-4., https://pubmed.ncbi.nlm.nih.gov/1891169/

529. Van der Vliet, W, Erlichman, C, Elhakim, T, Allopurinol mouthwash for prevention of fluorouracil-induced stomatitis., Clin Pharm, 1989. 8 (9)(9): p. 655-8., https://pubmed.ncbi.nlm.nih.gov/2791481/

530. McGaw, WT, Belch, A, Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen., Oral Surg Oral Med Oral Pathol, 1985. 60 (3)(3): p. 275-80., https://pubmed.ncbi.nlm.nih.gov/3862040/

531. Ferretti, GA, Raybould, TP, Brown, AT, Macdonald, JS, Greenwood, M, Maruyama, Y, et.al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial., Oral Surg Oral Med Oral Pathol, 1990. 69 (3)(3): p. 331-8., https://pubmed.ncbi.nlm.nih.gov/2179802/

532. Rutkauskas, JS, Davis, JW, Effects of chlorhexidine during immunosuppressive chemotherapy. A preliminary report., Oral Surg Oral Med Oral Pathol, 1993. 76 (4)(4): p. 441-8., https://pubmed.ncbi.nlm.nih.gov/8233423/

533. Dodd, M. J., Larson, P. J., Dibble, S. L., Miaskowski, C., Greenspan, D., MacPhail, L., et.al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy, Oncol Nurs Forum, 1996. 23: p. 921-7.

534. Sorensen, J. B., Skovsgaard, T., Bork, E., Damstrup, L., Ingeberg, S., Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies, Cancer, 2008. 112: p. 1600-6.

535. Pitten, FA, Kiefer, T, Buth, C, Doelken, G, Kramer, A, Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study., J Hosp Infect, 2003. 53 (4)(4): p. 283-91., https://pubmed.ncbi.nlm.nih.gov/12660125/

536. Cheng, KK, Chang, AM, Yuen, MP, Prevention of oral mucositis in paediatric patients treated with chemotherapy; a randomised crossover trial comparing two protocols of oral care., Eur J Cancer, 2004. 40 (8)(8): p. 1208-16., https://pubmed.ncbi.nlm.nih.gov/15110885/

537. Mehdipour, M, Taghavi Zenoz, A, Asvadi Kermani, I, Hosseinpour, A, A comparison between zinc sulfate and chlorhexidine gluconate mouthwashes in the prevention of chemotherapy-induced oral mucositis., Daru, 2011. 19 (1)(1): p. 71-3., https://pubmed.ncbi.nlm.nih.gov/22615642/

538. Crawford, J, Tomita, DK, Mazanet, R, Glaspy, J, Ozer, H, Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy., Cytokines Cell Mol Ther, 1999. 5 (4)(4): p. 187-93., https://pubmed.ncbi.nlm.nih.gov/10850381/

539. Karthaus, M, Rosenthal, C, Huebner, G, Paul, H, Elser, C, Hertenstein, B, et.al. Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial., Bone Marrow Transplant, 1998. 22 (8)(8): p. 781-5., https://pubmed.ncbi.nlm.nih.gov/9827976/

540. Patte, C, Laplanche, A, Bertozzi, AI, Baruchel, A, Frappaz, D, Schmitt, C, et.al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology., J Clin Oncol, 2002. 20 (2)(2): p. 441-8., https://pubmed.ncbi.nlm.nih.gov/11786572/

541. Mohamed, Salwa A, Shebl, A, Weheida, SM, The effect of topical application of honey on management of chemotherapy induced oral stomatitis, 2012. 9(4): p. 5128 - 5134.

542. Dos Reis, PE, Ciol, MA, de Melo, NS, Figueiredo, PT, Leite, AF, Manzi, Nde M, Chamomile infusion cryotherapy to prevent oral mucositis induced by chemotherapy: a pilot study., Support Care Cancer, 2016. 24 (10)(10): p. 4393-8., https://pubmed.ncbi.nlm.nih.gov/27189615/

543. Fidler, P, Loprinzi, CL, O'Fallon, JR, Leitch, JM, Lee, JK, Hayes, DL, et.al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis., Cancer, 1996. 77 (3)(3): p. 522-5., https://pubmed.ncbi.nlm.nih.gov/8630960/

544. Eghbali, A, Taherkhanchi, B, Bagheri, B, Sadeghi Sedeh, B, Effect of Chewing Gum on Oral Mucositis in Children Undergoing Chemotherapy: A Randomized Controlled Study., Iran J Ped Hematol Oncol, 2016. 6 (1)(1): p. 9-14., https://pubmed.ncbi.nlm.nih.gov/27222697/

545. Gandemer, V, Le Deley, MC, Dollfus, C, Auvrignon, A, Bonnaure-Mallet, M, Duval, M, et.al. Multicenter randomized trial of chewing gum for preventing oral mucositis in children receiving chemotherapy., J Pediatr Hematol Oncol, 2007. 29 (2)(2): p. 86-94., https://pubmed.ncbi.nlm.nih.gov/17279004/

546. Saunders, D. P., Epstein, J. B., Elad, S., Allemano, J., Bossi, P., van de Wetering, M. D., et.al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 3191-207.

547. Topuz, E, Derin, D, Can, G, Kürklü, E, Cinar, S, Aykan, F, et.al. Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer., Invest New Drugs, 2008. 26 (6)(6): p. 567-72., https://pubmed.ncbi.nlm.nih.gov/18762864/

548. Ariyawardana, A, Cheng, KKF, Kandwal, A, Tilly, V, Al-Azri, AR, Galiti, D, et.al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines., Support Care Cancer, 2019. 27 (10)(10): p. 3985-3995., https://pubmed.ncbi.nlm.nih.gov/31286230/

549. Lalla, RV, Gordon, GB, Schubert, M, Silverman, S, Hutten, M, Sonis, ST, et.al. A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy., Support Care Cancer, 2012. 20 (8)(8): p. 1797-804., https://pubmed.ncbi.nlm.nih.gov/21964618/

550. Dueñas-Gonzalez, A, Sobrevilla-Calvo, P, Frias-Mendivil, M, Gallardo-Rincon, D, Lara-Medina, F, Aguilar-Ponce, L, et.al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study., Bone Marrow Transplant, 1996. 17 (5)(5): p. 809-12., https://pubmed.ncbi.nlm.nih.gov/8733702/

551. Epstein, J. B., Vickars, L., Spinelli, J., Reece, D., Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation, Oral Surg Oral Med Oral Pathol, 1992. 73: p. 682-9.

552. Loo, WT, Jin, LJ, Chow, LW, Cheung, MN, Wang, M, Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients., Expert Opin Investig Drugs, 2010. 19 Suppl 1 (): p. S91-100., https://pubmed.ncbi.nlm.nih.gov/20374035/

553. Malik, IA, Moid, I, Haq, S, Sabih, M, A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis., J Pain Symptom Manage, 1997. 14 (2)(2): p. 82-7., https://pubmed.ncbi.nlm.nih.gov/9262037/

554. Baysal, E, Sari, D, Vural, F, Çağırgan, S, Saydam, G, Töbü, M, et.al. The Effect of Cryotherapy on the Prevention of Oral Mucositis and on the Oral pH Value in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation., Semin Oncol Nurs, 2021. 37 (3)(3): p. 151146., https://pubmed.ncbi.nlm.nih.gov/34001407/

555. Marchesi, F, Tendas, A, Giannarelli, D, Viggiani, C, Gumenyuk, S, Renzi, D, et.al. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study., Bone Marrow Transplant, 2017. 52 (1)(1): p. 154-156., https://pubmed.ncbi.nlm.nih.gov/27526285/

556. Walladbegi, J, Henriksson, R, Tavelin, B, Svanberg, A, Larfors, G, Jädersten, M, et.al. Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial., Bone Marrow Transplant, 2022. 57 (2)(2): p. 191-197., https://pubmed.ncbi.nlm.nih.gov/34728786/

557. Baydar, M, Dikilitas, M, Sevinc, A, Aydogdu, I, Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy., J Natl Med Assoc, 2005. 97 (8)(8): p. 1161-4., https://pubmed.ncbi.nlm.nih.gov/16173332/

558. Cascinu, S, Fedeli, A, Fedeli, SL, Catalano, G, Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis., Eur J Cancer B Oral Oncol, 1994. 30B (4)(4): p. 234-6., https://pubmed.ncbi.nlm.nih.gov/7950836/

559. Mahood, DJ, Dose, AM, Loprinzi, CL, Veeder, MH, Athmann, LM, Therneau, TM, et.al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy., J Clin Oncol, 1991. 9 (3)(3): p. 449-52., https://pubmed.ncbi.nlm.nih.gov/1999715/

560. Nikoletti, S, Hyde, S, Shaw, T, Myers, H, Kristjanson, LJ, Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil., J Clin Nurs, 2005. 14 (6)(6): p. 750-3., https://pubmed.ncbi.nlm.nih.gov/15946283/

561. Papadeas, E, Naxakis, S, Riga, M, Kalofonos, Ch, Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study., Eur J Oncol Nurs, 2007. 11 (1)(1): p. 60-5., https://pubmed.ncbi.nlm.nih.gov/16829196/

562. Farrington, M, Cullen, L, Dawson, C, Cryotherapy is a simple nursing intervention for oral mucositis., ORL Head Neck Nurs, 2014. 32 (2)(2): p. 13-5., https://pubmed.ncbi.nlm.nih.gov/24937908/

563. Karagözoğlu, S, Filiz Ulusoy, M, Chemotherapy: the effect of oral cryotherapy on the development of mucositis., J Clin Nurs, 2005. 14 (6)(6): p. 754-65., https://pubmed.ncbi.nlm.nih.gov/15946284/

564. Dreicer, R, Propert, KJ, Kuzel, T, Kirkwood, JM, O'Dwyer, PJ, Loehrer, PJ, A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study., Am J Clin Oncol, 1997. 20 (3)(3): p. 251-3., https://pubmed.ncbi.nlm.nih.gov/9167747/

565. Edelman, MJ, Gandara, DR, Perez, EA, Lau, D, Lauder, I, Turrell, C, et.al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy., Invest New Drugs, 1998. 16 (1)(1): p. 69-75., https://pubmed.ncbi.nlm.nih.gov/9740546/

566. Gandara, DR, Edelman, MJ, Crowley, JJ, Lau, DH, Livingston, RB, Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study., Cancer Chemother Pharmacol, 1997. 41 (1)(1): p. 75-8., https://pubmed.ncbi.nlm.nih.gov/9443617/

567. Askarifar, M, Lakdizaji, S, Ramzi, M, Rahmani, A, Jabbarzadeh, F, The Effects of Oral Cryotherapy on Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Transplantation of Blood Stem Cells: A Clinical Trial., Iran Red Crescent Med J, 2016. 18 (4)(4): p. e24775., https://pubmed.ncbi.nlm.nih.gov/27257512/

568. Gori, E, Arpinati, M, Bonifazi, F, Errico, A, Mega, A, Alberani, F, et.al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group., Bone Marrow Transplant, 2007. 39 (6)(6): p. 347-52., https://pubmed.ncbi.nlm.nih.gov/17277790/

569. Lilleby, K, Garcia, P, Gooley, T, McDonnnell, P, Taber, R, Holmberg, L, et.al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation., Bone Marrow Transplant, 2006. 37 (11)(11): p. 1031-5., https://pubmed.ncbi.nlm.nih.gov/16633359/

570. Salvador, P, Azusano, C, Wang, L, Howell, D, A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients., J Pain Symptom Manage, 2012. 44 (1)(1): p. 64-73., https://pubmed.ncbi.nlm.nih.gov/22672917/

571. Svanberg, A, Birgegård, G, Ohrn, K, Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial., Support Care Cancer, 2007. 15 (10)(10): p. 1155-61., https://pubmed.ncbi.nlm.nih.gov/17393189/

572. Svanberg, A, Ohrn, K, Birgegård, G, Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial., J Clin Nurs, 2010. 19 (15-16)(15-16): p. 2146-51., https://pubmed.ncbi.nlm.nih.gov/20659194/

573. Aisa, Y, Mori, T, Kudo, M, Yashima, T, Kondo, S, Yokoyama, A, et.al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients., Support Care Cancer, 2005. 13 (4)(4): p. 266-9., https://pubmed.ncbi.nlm.nih.gov/15668755/

574. Batlle, M, Morgades, M, Vives, S, Ferrà, C, Oriol, A, Sancho, JM, et.al. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma., Eur J Haematol, 2014. 93 (6)(6): p. 487-91., https://pubmed.ncbi.nlm.nih.gov/24889275/

575. Bhatt, V., Vendrell, N., Nau, K., Crumb, D., Roy, V., Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation, J Oncol Pharm Pract, 2010. 16: p. 195-204.

576. Chen, J, Seabrook, J, Fulford, A, Rajakumar, I, Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant., J Oncol Pharm Pract, 2017. 23 (2)(2): p. 116-120., https://pubmed.ncbi.nlm.nih.gov/26684614/

577. de Paula Eduardo, F, Bezinelli, LM, da Graça Lopes, RM, Nascimento Sobrinho, JJ, Hamerschlak, N, Correa, L, Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study., Hematol Oncol, 2015. 33 (3)(3): p. 152-8., https://pubmed.ncbi.nlm.nih.gov/24519448/

578. Dumontet, C, Sonnet, A, Bastion, Y, Salles, G, Espinouse, D, Coiffier, B, Prevention of high dose L-PAM-induced mucositis by cryotherapy., Bone Marrow Transplant, 1994. 14 (3)(3): p. 492-4., https://pubmed.ncbi.nlm.nih.gov/7994283/

579. Mori, T, Aisa, Y, Yamazaki, R, Mihara, A, Ikeda, Y, Okamoto, S, Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis., Bone Marrow Transplant, 2006. 38 (9)(9): p. 637-8., https://pubmed.ncbi.nlm.nih.gov/16953203/

580. Ohbayashi, Y, Imataki, O, Ohnishi, H, Iwasaki, A, Ogawa, T, Inagaki, N, et.al. Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation., Ann Hematol, 2008. 87 (10)(10): p. 837-45., https://pubmed.ncbi.nlm.nih.gov/18553082/

581. Sato, A, Saisho-Hattori, T, Koizumi, Y, Minegishi, M, Iinuma, K, Imaizumi, M, Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy., Tohoku J Exp Med, 2006. 210 (4)(4): p. 315-20., https://pubmed.ncbi.nlm.nih.gov/17146197/

582. Vokurka, S, Bystricka, E, Scudlova, J, Mazur, E, Visokaiova, M, Vasilieva, E, et.al. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation., Eur J Oncol Nurs, 2011. 15 (5)(5): p. 508-12., https://pubmed.ncbi.nlm.nih.gov/21310656/

583. Vokurka, S, Svoboda, T, Jungova, A, Karas, M, Koza, V, Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT., Bone Marrow Transplant, 2012. 47 (5)(5): p. 739-41., https://pubmed.ncbi.nlm.nih.gov/21785473/

584. Vokurka, S, Chvojkova, I, Svoboda, T, Brandejsova, R, Jungova, A, Bystricka, E, et.al. The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation., Eur J Oncol Nurs, 2014. 18 (2)(2): p. 228-9., https://pubmed.ncbi.nlm.nih.gov/24290034/

585. Erden, Y, Ipekcoban, G, Comparison of efficacy of cryotherapy and chlorhexidine to oral nutrition transition time in chemotherapy-induced oral mucositis., Eur J Cancer Care (Engl), 2017. 26 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/27132630/

586. Ferreira, B., da Motta Silveira, F. M., de Orange, F. A., Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial, Support Care Cancer, 2016. 24: p. 1035-42.

587. Hodgson, B. D., Margolis, D. M., Salzman, D. E., Eastwood, D., Tarima, S., Williams, L. D., et.al. Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients, Support Care Cancer, 2012. 20: p. 1405-15.

588. Khouri, V. Y., Stracieri, A. B., Rodrigues, M. C., Moraes, D. A., Pieroni, F., Simoes, B. P., et.al. Use of therapeutic laser for prevention and treatment of oral mucositis, Braz Dent J, 2009. 20: p. 215-20.

589. Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., et.al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy, Cancer, 2014. 120: p. 1453-61.

590. Migliorati, C., Hewson, I., Lalla, R. V., Antunes, H. S., Estilo, C. L., Hodgson, B., et.al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 333-41.

591. Silva, G. B., Mendonca, E. F., Bariani, C., Antunes, H. S., Silva, M. A., The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial, Photomed Laser Surg, 2011. 29: p. 27-31.

592. Silva, L. C., Sacono, N. T., Freire Mdo, C., Costa, L. R., Batista, A. C., Silva, G. B., The Impact of Low-Level Laser Therapy on Oral Mucositis and Quality of Life in Patients Undergoing Hematopoietic Stem Cell Transplantation Using the Oral Health Impact Profile and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation Questionnaires, Photomed Laser Surg, 2015. 33: p. 357-63.

593. da Silva, BM, Prosdócimo, ML, Gasparini, LR, da Silva, BM, de Araujo, MR, Amenábar, JM, Most used photobiomodulation dosimetry parameters to treat oral mucositis after preconditioning for hematopoietic stem cell transplantation: systematic review and meta-analysis., Support Care Cancer, 2022. 30 (5)(5): p. 3721-3732., https://pubmed.ncbi.nlm.nih.gov/35013780/

594. Hodgson, BD, Margolis, DM, Salzman, DE, Eastwood, D, Tarima, S, Williams, LD, et.al. Amelioration of oral mucositis pain by NASA near-infrared light-emitting diodes in bone marrow transplant patients., Support Care Cancer, 2012. 20 (7)(7): p. 1405-15., https://pubmed.ncbi.nlm.nih.gov/21725826/

595. van Zaanen, H. C., van der Lelie, H., Timmer, J. G., Furst, P., Sauerwein, H. P., Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity, Cancer, 1994. 74: p. 2879-84.

596. Schloerb, PR, Skikne, BS, Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study., JPEN J Parenter Enteral Nutr, 1999. 23 (3)(3): p. 117-22., https://pubmed.ncbi.nlm.nih.gov/10338217/

597. Blijlevens, N. M., Donnelly, J. P., Naber, A. H., Schattenberg, A. V., DePauw, B. E., A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients, Support Care Cancer, 2005. 13: p. 790-6.

598. Piccirillo, N., De Matteis, S., Laurenti, L., Chiusolo, P., Sora, F., Pittiruti, M., et.al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis, Haematologica, 2003. 88: p. 192-200.

599. Attal, M., Huguet, F., Rubie, H., Charlet, J. P., Schlaifer, D., Huynh, A., et.al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial, Blood, 1993. 82: p. 732-6.

600. van der Jagt, RH, Pari, G, McDiarmid, SA, Boisvert, DM, Huebsch, LB, Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation., Bone Marrow Transplant, 1994. 13 (2)(2): p. 203-7., https://pubmed.ncbi.nlm.nih.gov/8205090/

601. Ferrà, C, de Sanjosé, S, Lastra, CF, Martí, F, Mariño, EL, Sureda, A, et.al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications., Bone Marrow Transplant, 1997. 20 (12)(12): p. 1075-80., https://pubmed.ncbi.nlm.nih.gov/9466281/

602. Lockhart, PB, Brennan, MT, Kent, ML, Packman, CH, Norton, HJ, Fox, PC, et.al. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation., Bone Marrow Transplant, 2005. 35 (7)(7): p. 713-20., https://pubmed.ncbi.nlm.nih.gov/15696181/

603. Fox, P. C., Atkinson, J. C., Macynski, A. A., Wolff, A., Kung, D. S., Valdez, I. H., et.al. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia), Arch Intern Med, 1991. 151: p. 1149-52.

604. de Lima Dantas, JB, Freire, TFC, Sanches, ACB, Julião, ELD, Medrado, ARAP, Martins, GB, Action of Matricaria recutita (chamomile) in the management of radiochemotherapy oral mucositis: A systematic review., Phytother Res, 2022. 36 (3)(3): p. 1115-1125., https://pubmed.ncbi.nlm.nih.gov/35129844/

605. Hosseinjani, H, Hadjibabaie, M, Gholami, K, Javadi, M, Radfar, M, Jahangard-Rafsanjani, Z, et.al. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial., Hematol Oncol, 2017. 35 (1)(1): p. 106-112., https://pubmed.ncbi.nlm.nih.gov/26310513/

606. Harman, M, Ovayolu, N, Ovayolu, O, The effect of three different solutions on preventing oral mucositis in cancer patients undergoing stem cell transplantation: a non-randomized controlled trial: A Turkish study - NON-RANDOMISED TRIAL., J Pak Med Assoc, 2019. 69 (6)(6): p. 811-816., https://pubmed.ncbi.nlm.nih.gov/31189287/

607. Nicolatou-Galitis, O., Sarri, T., Bowen, J., Di Palma, M., Kouloulias, V. E., Niscola, P., et.al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 3179-89.

608. Tavakoli Ardakani, M, Ghassemi, S, Mehdizadeh, M, Mojab, F, Salamzadeh, J, Ghassemi, S, et.al. Evaluating the effect of Matricaria recutita and Mentha piperita herbal mouthwash on management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: A randomized, double blind, placebo controlled clinical trial., Complement Ther Med, 2016. 29 (): p. 29-34., https://pubmed.ncbi.nlm.nih.gov/27912953/

609. Garavito, AA, Cardona, AF, Reveiz, L, Ospina, E, Yepes, A, Ospina, V, Colchicine mouth washings to improve oral mucositis in patients with hematological malignancies: a clinical trial., Palliat Support Care, 2008. 6 (4)(4): p. 371-6., https://pubmed.ncbi.nlm.nih.gov/19006592/

610. Hamidieh, AA, Sherafatmand, M, Mansouri, A, Hadjibabaie, M, Ashouri, A, Jahangard-Rafsanjani, Z, et.al. Calcitriol for Oral Mucositis Prevention in Patients With Fanconi Anemia Undergoing Hematopoietic SCT: A Double-Blind, Randomized, Placebo-Controlled Trial., Am J Ther, 2016. 23 (6)(6): p. e1700-e1708., https://pubmed.ncbi.nlm.nih.gov/26164019/

611. Papas, A. S., Clark, R. E., Martuscelli, G., O'Loughlin, K. T., Johansen, E., Miller, K. B., A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation, Bone Marrow Transplant, 2003. 31: p. 705-12.

612. Svanberg, A., Ohrn, K., Birgegard, G., Caphosol((R)) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study, Eur J Oncol Nurs, 2015. 19: p. 50-3.

613. Wasko-Grabowska, A, Rzepecki, P, Oborska, S, Barzal, J, Mlot, B, Gawronski, K, et.al. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience., J BUON, 2012. 17 (2)(2): p. 363-8., https://pubmed.ncbi.nlm.nih.gov/22740219/

614. Waśko-Grabowska, A, Rzepecki, P, Oborska, S, Barzał, J, Gawroński, K, Młot, B, et.al. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience., Transplant Proc, 2011. 43 (8)(8): p. 3111-3., https://pubmed.ncbi.nlm.nih.gov/21996239/

615. Markiewicz, M, Dzierzak-Mietla, M, Frankiewicz, A, Zielinska, P, Koclega, A, Kruszelnicka, M, et.al. Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation., Support Care Cancer, 2012. 20 (9)(9): p. 2223-9., https://pubmed.ncbi.nlm.nih.gov/22736463/

616. Yuen, KY, Woo, PC, Tai, JW, Lie, AK, Luk, J, Liang, R, Effects of clarithromycin on oral mucositis in bone marrow transplant recipients., Haematologica, 2001. 86 (5)(5): p. 554-5., https://pubmed.ncbi.nlm.nih.gov/11410428/

617. Morishita, T, Tsushita, N, Imai, K, Sakai, T, Miyao, K, Sakemura, R, et.al. The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation., Intern Med, 2016. 55 (24)(24): p. 3561-3569., https://pubmed.ncbi.nlm.nih.gov/27980254/

618. Anderson, PM, Ramsay, NK, Shu, XO, Rydholm, N, Rogosheske, J, Nicklow, R, et.al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation., Bone Marrow Transplant, 1998. 22 (4)(4): p. 339-44., https://pubmed.ncbi.nlm.nih.gov/9722068/

619. Aquino, VM, Harvey, AR, Garvin, JH, Godder, KT, Nieder, ML, Adams, RH, et.al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study., Bone Marrow Transplant, 2005. 36 (7)(7): p. 611-6., https://pubmed.ncbi.nlm.nih.gov/16086046/

620. Plevová, P, Blazek, B, Intravenous immunoglobulin as prophylaxis of chemotherapy-induced oral mucositis., J Natl Cancer Inst, 1997. 89 (4)(4): p. 326-7., https://pubmed.ncbi.nlm.nih.gov/9048841/

621. Braga, FT, Santos, AC, Bueno, PC, Silveira, RC, Santos, CB, Bastos, JK, et.al. Use of Chamomilla recutita in the Prevention and Treatment of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized, Controlled, Phase II Clinical Trial., Cancer Nurs 38 (4)(4): p. 322-9., https://pubmed.ncbi.nlm.nih.gov/25232958/

622. Pourdeghatkar, F., Motaghi, Matin, Darbandi, Bahram, Baghersalimi, A., Comparative effect of chamomile mouthwash and topical mouth rinse in prevention of chemotherapy-induced oral mucositis in Iranian pediatric patients with acute lymphoblastic leukemia, 2017/09/01. 9: p. 84 - 88.

623. Moslehi, A, Taghizadeh-Ghehi, M, Gholami, K, Hadjibabaie, M, Jahangard-Rafsanjani, Z, Sarayani, A, et.al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial., Bone Marrow Transplant, 2014. 49 (6)(6): p. 818-23., https://pubmed.ncbi.nlm.nih.gov/24614837/

624. Ahmed, T, Engelking, C, Szalyga, J, Helson, L, Coombe, N, Cook, P, et.al. Propantheline prevention of mucositis from etoposide., Bone Marrow Transplant, 1993. 12 (2)(2): p. 131-2., https://pubmed.ncbi.nlm.nih.gov/8401358/

625. Oblon, DJ, Paul, SR, Oblon, MB, Malik, S, Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation., Bone Marrow Transplant, 1997. 20 (11)(11): p. 961-3., https://pubmed.ncbi.nlm.nih.gov/9422475/

626. Oberbaum, M, Yaniv, I, Ben-Gal, Y, Stein, J, Ben-Zvi, N, Freedman, LS, et.al. A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation., Cancer, 2001. 92 (3)(3): p. 684-90., https://pubmed.ncbi.nlm.nih.gov/11505416/

627. Mansouri, A, Hadjibabaie, M, Iravani, M, Shamshiri, AR, Hayatshahi, A, Javadi, MR, et.al. The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study., Hematol Oncol, 2012. 30 (1)(1): p. 22-6., https://pubmed.ncbi.nlm.nih.gov/21692101/

628. Hayashi, H, Kobayashi, R, Suzuki, A, Ishihara, M, Nakamura, N, Kitagawa, J, et.al. Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation., Anticancer Res, 2014. 34 (12)(12): p. 7271-7., https://pubmed.ncbi.nlm.nih.gov/25503160/

629. Seto, B. G., Kim, M., Wolinsky, L., Mito, R. S., Champlin, R., Oral mucositis in patients undergoing bone marrow transplantation, Oral Surg Oral Med Oral Pathol, 1985. 60: p. 493-7.

630. Cerchietti, L. C., Navigante, A. H., Korte, M. W., Cohen, A. M., Quiroga, P. N., Villaamil, E. C., et.al. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study, Pain, 2003. 105: p. 265-73.

631. Cunha, C. B., Eduardo, F. P., Zezell, D. M., Bezinelli, L. M., Shitara, P. P., Correa, L., Effect of irradiation with red and infrared laser in the treatment of oral mucositis: a pilot study with patients undergoing chemotherapy with 5-FU, Lasers Med Sci, 2012. 27: p. 1233-40.

632. Freitas, A. C., Campos, L., Brandao, T. B., Cristofaro, M., Eduardo Fde, P., Luiz, A. C., et.al. Chemotherapy-induced oral mucositis: effect of LED and laser phototherapy treatment protocols, Photomed Laser Surg, 2014. 32: p. 81-7.

633. Ottaviani, G., Gobbo, M., Sturnega, M., Martinelli, V., Mano, M., Zanconati, F., et.al. Effect of class IV laser therapy on chemotherapy-induced oral mucositis: a clinical and experimental study, Am J Pathol, 2013. 183: p. 1747-57.

634. Vayne-Bossert, P, Escher, M, de Vautibault, CG, Dulguerov, P, Allal, A, Desmeules, J, et.al. Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study., J Palliat Med, 2010. 13 (2)(2): p. 125-8., https://pubmed.ncbi.nlm.nih.gov/19827964/

635. Sarvizadeh, M, Hemati, S, Meidani, M, Ashouri, M, Roayaei, M, Shahsanai, A, Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer., Adv Biomed Res, 2015. 4 (): p. 44., https://pubmed.ncbi.nlm.nih.gov/25789270/

636. Coda, B. A., O'Sullivan, B., Donaldson, G., Bohl, S., Chapman, C. R., Shen, D. D., Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation, Pain, 1997. 72: p. 333-46.

637. Collins, J. J., Geake, J., Grier, H. E., Houck, C. S., Thaler, H. T., Weinstein, H. J., et.al. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone, J Pediatr, 1996. 129: p. 722-8.

638. Hill, H. F., Chapman, C. R., Kornell, J. A., Sullivan, K. M., Saeger, L. C., Benedetti, C., Self-administration of morphine in bone marrow transplant patients reduces drug requirement, Pain, 1990. 40: p. 121-9.

639. Hill, H. F., Jacobson, R. C., Coda, B. A., Mackie, A. M., A computer-based system for controlling plasma opioid concentration according to patient need for analgesia, Clin Pharmacokinet, 1991. 20: p. 319-30.

640. Hill, H. F., Mackie, A. M., Coda, B. A., Iverson, K., Chapman, C. R., Patient-controlled analgesic administration. A comparison of steady-state morphine infusions with bolus doses, Cancer, 1991. 67: p. 873-82.

641. Hill, H. F., Coda, B. A., Mackie, A. M., Iverson, K., Patient-controlled analgesic infusions: alfentanil versus morphine, Pain, 1992. 49: p. 301-10.

642. Mackie, A. M., Coda, B. C., Hill, H. F., Adolescents use patient-controlled analgesia effectively for relief from prolonged oropharyngeal mucositis pain, Pain, 1991. 46: p. 265-9.

643. Pillitteri, L. C., Clark, R. E., Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis, Bone Marrow Transplant, 1998. 22: p. 495-8.

644. Epstein, J. B., Truelove, E. L., Oien, H., Allison, C., Le, N. D., Epstein, M. S., Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy, Oral Oncol, 2001. 37: p. 632-7.

645. Epstein, J. B., Epstein, J. D., Epstein, M. S., Oien, H., Truelove, E. L., Doxepin rinse for management of mucositis pain in patients with cancer: one week follow-up of topical therapy, Spec Care Dentist, 2008. 28: p. 73-7.

646. Leenstra, J. L., Miller, R. C., Qin, R., Martenson, J. A., Dornfeld, K. J., Bearden, J. D., et.al. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]), J Clin Oncol, 2014. 32: p. 1571-7.

647. Loprinzi, C. L., Ghosh, C., Camoriano, J., Sloan, J., Steen, P. D., Michalak, J. C., et.al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy, J Clin Oncol, 1997. 15: p. 1235-8.

648. Chiara, S., Nobile, M. T., Vincenti, M., Gozza, A., Pastrone, I., Rosso, M., et.al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study, Anticancer Res, 2001. 21: p. 3707-10.

649. Raeessi, M. A., Raeessi, N., Panahi, Y., Gharaie, H., Davoudi, S. M., Saadat, A., et.al. "Coffee plus honey" versus "topical steroid" in the treatment of chemotherapy-induced oral mucositis: a randomised controlled trial, BMC Complement Altern Med, 2014. 14: p. 293.

650. Clarkson, J. E., Worthington, H. V., Furness, S., McCabe, M., Khalid, T., Meyer, S., Interventions for treating oral mucositis for patients with cancer receiving treatment, Cochrane Database Syst Rev, 2010. p. CD001973.

651. Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A. M., Littlewood, A., et.al. Interventions for preventing oral mucositis for patients with cancer receiving treatment, Cochrane Database Syst Rev, 2011. p. CD000978.

652. Ibrahim, E. M., al-Mulhim, F. A., Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients, Med Oncol, 1997. 14: p. 47-51.

653. Hejna, M., Kostler, W. J., Raderer, M., Steger, G. G., Brodowicz, T., Scheithauer, W., et.al. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial, Eur J Cancer, 2001. 37: p. 1994-2002.

654. Raber-Durlacher, J. E., von Bultzingslowen, I., Logan, R. M., Bowen, J., Al-Azri, A. R., Everaus, H., et.al. Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients, Support Care Cancer, 2013. 21: p. 343-55.

655. Nagaoka, H, Momo, K, Hamano, J, Miyaji, T, Oyamada, S, Kawaguchi, T, et.al. Effects of an Indomethacin Oral Spray on Pain Due to Oral Mucositis in Cancer Patients Treated With Radiotherapy and Chemotherapy: A Double-Blind, Randomized, Placebo-Controlled Trial (JORTC-PAL04)., J Pain Symptom Manage, 2021. 62 (3)(3): p. 537-544., https://pubmed.ncbi.nlm.nih.gov/33516927/

656. Hata, H, Takada, S, Sato, J, Yoshikawa, K, Imamachi, K, Edo, M, et.al. Analgesic effects of indomethacin spray on drug-induced oral mucositis pain in patients with cancer: A single-arm cross-sectional study., Spec Care Dentist, 2021. 41 (4)(4): p. 498-504., https://pubmed.ncbi.nlm.nih.gov/33735535/

657. Cabrera-Jaime, S, Martínez, C, Ferro-García, T, Giner-Boya, P, Icart-Isern, T, Estrada-Masllorens, JM, et.al. Efficacy of Plantago major, chlorhexidine 0.12% and sodium bicarbonate 5% solution in the treatment of oral mucositis in cancer patients with solid tumour: A feasibility randomised triple-blind phase III clinical trial., Eur J Oncol Nurs, 2018. 32 (): p. 40-47., https://pubmed.ncbi.nlm.nih.gov/29353631/

658. Dodd, M. J., Dibble, S. L., Miaskowski, C., MacPhail, L., Greenspan, D., Paul, S. M., et.al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2000. 90: p. 39-47.

659. Wang, L, Huang, XE, Ji, ZQ, Liu, MY, Qian, T, Li, L, Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis., Asian Pac J Cancer Prev, 2016. 17 (1)(1): p. 413-8., https://pubmed.ncbi.nlm.nih.gov/26838248/

660. LeVeque, FG, Parzuchowski, JB, Farinacci, GC, Redding, SW, Rodu, B, Johnson, JT, et.al. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy., J Clin Oncol, 1992. 10 (12)(12): p. 1963-8., https://pubmed.ncbi.nlm.nih.gov/1453210/

661. Carnel, SB, Blakeslee, DB, Oswald, SG, Barnes, M, Treatment of radiation- and chemotherapy-induced stomatitis., Otolaryngol Head Neck Surg, 1990. 102 (4)(4): p. 326-30., https://pubmed.ncbi.nlm.nih.gov/2113258/

662. Münstedt, K, Momm, F, Hübner, J, Honey in the management of side effects of radiotherapy- or radio/chemotherapy-induced oral mucositis. A systematic review., Complement Ther Clin Pract, 2019. 34 (): p. 145-152., https://pubmed.ncbi.nlm.nih.gov/30712719/

663. Eduardo, F. P., Bezinelli, L., Luiz, A. C., Correa, L., Vogel, C., Eduardo, C. P., Severity of oral mucositis in patients undergoing hematopoietic cell transplantation and an oral laser phototherapy protocol: a survey of 30 patients, Photomed Laser Surg, 2009. 27: p. 137-44.

664. Genot-Klastersky, M. T., Klastersky, J., Awada, F., Awada, A., Crombez, P., Martinez, M. D., et.al. The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies, Support Care Cancer, 2008. 16: p. 1381-7.

665. Antunes, H. S., de Azevedo, A. M., da Silva Bouzas, L. F., Adao, C. A., Pinheiro, C. T., Mayhe, R., et.al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial, Blood, 2007. 109: p. 2250-5.

666. Sonis, ST, Clairmont, F, Lockhart, PB, Connolly, SF, Benzydamine HCL in the management of chemotherapy-induced mucositis. I. Pilot study., J Oral Med, 1985. 40 (2)(2): p. 67-71., https://pubmed.ncbi.nlm.nih.gov/3858465/

667. Schubert, MM, Newton, RE, The use of benzydamine HCl for the management of cancer therapy-induced mucositis: preliminary report of a multicentre study., Int J Tissue React, 1987. 9 (2)(2): p. 99-103., https://pubmed.ncbi.nlm.nih.gov/3610519/

668. Lever, SA, Dupuis, LL, Chan, HS, Comparative evaluation of benzydamine oral rinse in children with antineoplastic-induced stomatitis., Drug Intell Clin Pharm, 1987. 21 (4)(4): p. 359-61., https://pubmed.ncbi.nlm.nih.gov/3569039/

669. Raphael, MF, den Boer, AM, Kollen, WJ, Mekelenkamp, H, Abbink, FC, Kaspers, GJ, et.al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? : Results from a prospective multicenter double blind randomized controlled trial., Support Care Cancer, 2014. 22 (1)(1): p. 3-6., https://pubmed.ncbi.nlm.nih.gov/24197056/

670. Turhal, N. S., Erdal, S., Karacay, S., Efficacy of treatment to relieve mucositis-induced discomfort, Support Care Cancer, 2000. 8: p. 55-8.

671. Rymes, N, Glick, L, Holmes, JA, Topical mesalazine in the treatment of chemotherapy and radiotherapy-induced oral mucositis., Bone Marrow Transplant, 1996. 18 (2)(2): p. 484., https://pubmed.ncbi.nlm.nih.gov/8864473/

672. Pretnar, J., Glazar, D., Mlakar, U., Modic, M., Prostaglandin E2 in the treatment of oral mucositis due to radiochemotherapy in patients with haematological malignancies, Bone Marrow Transplant, 1989. 4 Suppl 3: p. 106.

673. National Institutes of Health, National Cancer Institute, 1. CTCAE 4.03 Common Terminology Criteria for Adverse Events (CTCAE), 2010.

674. Flaherty, KT, Robert, C, Hersey, P, Nathan, P, Garbe, C, Milhem, M, et.al. Improved survival with MEK inhibition in BRAF-mutated melanoma., N Engl J Med, 2012. 367 (2)(2): p. 107-14., https://pubmed.ncbi.nlm.nih.gov/22663011/

675. Larkin, J, Ascierto, PA, Dréno, B, Atkinson, V, Liszkay, G, Maio, M, et.al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma., N Engl J Med, 2014. 371 (20)(20): p. 1867-76., https://pubmed.ncbi.nlm.nih.gov/25265494/

676. Dummer, R, Ascierto, PA, Gogas, HJ, Arance, A, Mandala, M, Liszkay, G, et.al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol, 2018. 19 (5)(5): p. 603-615., https://pubmed.ncbi.nlm.nih.gov/29573941/

677. Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., et.al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, Lancet Oncol, 2014. 15: p. 569-79.

678. Azim, H. A., Jr., Agbor-Tarh, D., Bradbury, I., Dinh, P., Baselga, J., Di Cosimo, S., et.al. Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial, J Clin Oncol, 2013. 31: p. 4504-11.

679. Potthoff, Karin M., Hassel, Jessica C., Wollenberg, Andreas, Hofheinz, Ralf-Dieter, Therapie und Prophylaxe EGFR-Inhibitorinduzierter Hautreaktionen, Arzneimitteltherapie, 2010. 28: p. 191-198.

680. Rosen, A. C., Wu, S., Damse, A., Sherman, E., Lacouture, M. E., Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis, J Clin Endocrinol Metab, 2012. 97: p. 1125-33.

681. Yang, James Chih-Hsin, Schuler, Martin H., Yamamoto, Nobuyuki, O'Byrne, Kenneth John, Hirsh, Vera, Mok, Tony, et.al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations., Journal of Clinical Oncology, 2012. 30: p. LBA7500.

682. Lacouture, M. E., Schadendorf, D., Chu, C. Y., Uttenreuther-Fischer, M., Stammberger, U., O'Brien, D., et.al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker, Expert Rev Anticancer Ther, 2013. 13: p. 721-8.

683. Gogas, H, Dréno, B, Larkin, J, Demidov, L, Stroyakovskiy, D, Eroglu, Z, et.al. Cobimetinib plus atezolizumab in BRAF, Ann Oncol, 2021. 32 (3)(3): p. 384-394., https://pubmed.ncbi.nlm.nih.gov/33309774/

684. Dummer, R, Schadendorf, D, Ascierto, PA, Arance, A, Dutriaux, C, Di Giacomo, AM, et.al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial., Lancet Oncol, 2017. 18 (4)(4): p. 435-445., https://pubmed.ncbi.nlm.nih.gov/28284557/

685. Arrieta, Oscar, Vega-González, María Teresa, López-Macías, Diego, Martínez-Hernández, Jorge Negueb, Bacon-Fonseca, Ludwing, Macedo-Pérez, Eleazar Omar, et.al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients, Lung Cancer, 2015. 88: p. 282-288.

686. Jatoi, A., Dakhil, S. R., Sloan, J. A., Kugler, J. W., Rowland, K. M., Jr., Schaefer, P. L., et.al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB), Supportive Care in Cancer, 2011. 19: p. 1601-7.

687. Jatoi, A., Rowland, K., Sloan, J. A., Gross, H. M., Fishkin, P. A., Kahanic, S. P., et.al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB), Cancer, 2008. 113: p. 847-53.

688. Scope, A., Agero, A. L., Dusza, S. W., Myskowski, P. L., Lieb, J. A., Saltz, L., et.al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption, Journal of Clinical Oncology, 2007. 25: p. 5390-6.

689. Yamada, M., Iihara, H., Fujii, H., Ishihara, M., Matsuhashi, N., Takahashi, T., et.al. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients, Anticancer Res, 2015. 35: p. 6175-81.

690. Deplanque, G, Gervais, R, Vergnenegre, A, Falchero, L, Souquet, PJ, Chavaillon, JM, et.al. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial., J Am Acad Dermatol, 2016. 74 (6)(6): p. 1077-85., https://pubmed.ncbi.nlm.nih.gov/26946985/

691. Melosky, B, Anderson, H, Burkes, RL, Chu, Q, Hao, D, Ho, V, et.al. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer., J Clin Oncol, 2016. 34 (8)(8): p. 810-5., https://pubmed.ncbi.nlm.nih.gov/26573073/

692. Amitay-Laish, I, Prag-Naveh, H, Ollech, A, Davidovici, B, Leshem, YA, Snast, I, et.al. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial., Dermatology, 2021. 237 (6)(6): p. 988-994., https://pubmed.ncbi.nlm.nih.gov/33378750/

693. Nishino, K, Fujiwara, Y, Ohe, Y, Saito, R, Miyauchi, E, Kobayashi, T, et.al. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512)., Support Care Cancer, 2021. 29 (5)(5): p. 2327-2334., https://pubmed.ncbi.nlm.nih.gov/, 32918131/

694. Lacouture, M. E., Mitchell, E. P., Piperdi, B., Pillai, M. V., Shearer, H., Iannotti, N., et.al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer, Journal of Clinical Oncology, 2010. 28: p. 1351-7.

695. Jatoi, A., Thrower, A., Sloan, J. A., Flynn, P. J., Wentworth-Hartung, N. L., Dakhil, S. R., et.al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4), Oncologist, 2010. 15: p. 1016-22.

696. Kobayashi, Y., Komatsu, Y., Yuki, S., Fukushima, H., Sasaki, T., Iwanaga, I., et.al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP, Future Oncol, 2015. 11: p. 617-27.

697. Gaiser, MR, Lorenzen, S, Merx, K, Trojan, J, Ocvirk, J, Ettrich, TJ, et.al. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score., Cancer Med, 2019. 8 (9)(9): p. 4169-4175., https://pubmed.ncbi.nlm.nih.gov/31199595/

698. Hofheinz, RD, Lorenzen, S, Trojan, J, Ocvirk, J, Ettrich, TJ, Al-Batran, SE, et.al. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity., Ann Oncol, 2018. 29 (4)(4): p. 1010-1015., https://pubmed.ncbi.nlm.nih.gov/29360920/

699. Chayahara, N, Mukohara, T, Tachihara, M, Fujishima, Y, Fukunaga, A, Washio, K, et.al. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE)., Oncologist, 2019. 24 (7)(7): p. 885-e413., https://pubmed.ncbi.nlm.nih.gov/30890624/

700. Wang, Y., Yang, Y., Xu, J., Yu, J., Liu, X., Gao, R., et.al. Randomized double-blind trial of prophylactic topical Evozac((R)) Calming Skin Spray for gefitinib-associated acne-like eruption, Onco Targets Ther, 2014. 7: p. 1261-6.

701. Wohlrab, J., Bangemann, N., Kleine-Tebbe, A., Thill, M., Kummel, S., Grischke, E. M., et.al. Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer, Breast Cancer (Dove Med Press), 2014. 6: p. 115-22.

702. Walon, L., Gilbeau, C., Lachapelle, J. M., [Acneiform eruptions induced by cetuximab], Ann Dermatol Venereol, 2003. 130: p. 443-6.

703. Matheis, P., Socinski, M. A., Burkhart, C., Warren, S., Thomas, N. E., Treatment of gefitinib-associated folliculitis, J Am Acad Dermatol, 2006. 55: p. 710-3.

704. DeWitt, C. A., Siroy, A. E., Stone, S. P., Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy, J Am Acad Dermatol, 2007. 56: p. 500-5.

705. de Noronha e Menezes, N. M., Lima, R., Moreira, A., Varela, P., Barroso, A., Baptista, A., et.al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients, Eur J Dermatol, 2009. 19: p. 248-51.

706. Bachet, J. B., Peuvrel, L., Bachmeyer, C., Reguiai, Z., Gourraud, P. A., Bouche, O., et.al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review, Oncologist, 2012. 17: p. 555-68.

707. Lacouture, Mario E., Anadkat, Milan J., Bensadoun, René-Jean, Bryce, Jane, Chan, Alexandre, Epstein, Joel B., et.al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities, Supportive Care in Cancer, 2011. 19: p. 1079-95.

708. Wehler, T. C., Graf, C., Mohler, M., Herzog, J., Berger, M. R., Gockel, I., et.al. Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective, J Cancer Res Clin Oncol, 2013. 139: p. 1667-72.

709. Gerber, P. A., Meller, S., Eames, T., Buhren, B. A., Schrumpf, H., Hetzer, S., et.al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients, Eur J Med Res, 2012. 17: p. 4.

710. Melosky, B., Burkes, R., Rayson, D., Alcindor, T., Shear, N., Lacouture, M., Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations, Curr Oncol, 2009. 16: p. 16-26.

711. Scope, A., Lieb, J. A., Dusza, S. W., Phelan, D. L., Myskowski, P. L., Saltz, L., et.al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption, J Am Acad Dermatol, 2009. 61: p. 614-20.

712. Choi, EK, Kim, IR, Chang, O, Kang, D, Nam, SJ, Lee, JE, et.al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients., Psychooncology, 2014. 23 (10)(10): p. 1103-10., https://pubmed.ncbi.nlm.nih.gov/24664939/

713. Dorr, VJ, A practitioner's guide to cancer-related alopecia., Semin Oncol, 1998. 25 (5)(5): p. 562-70., https://pubmed.ncbi.nlm.nih.gov/9783595/

714. Hussein, AM, Chemotherapy-induced alopecia: new developments., South Med J, 1993. 86 (5)(5): p. 489-96., https://pubmed.ncbi.nlm.nih.gov/8488392/

715. McGarvey, EL, Baum, LD, Pinkerton, RC, Rogers, LM, Psychological sequelae and alopecia among women with cancer., Cancer Pract, 2001. 9 (6)(6): p. 283-9., https://pubmed.ncbi.nlm.nih.gov/11879330/

716. Mulders, M, Vingerhoets, A, Breed, W, The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians., Eur J Oncol Nurs, 2008. 12 (2)(2): p. 97-102., https://pubmed.ncbi.nlm.nih.gov/18242139/

717. Lemieux, J, Maunsell, E, Provencher, L, Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review., Psychooncology, 2008. 17 (4)(4): p. 317-28., https://pubmed.ncbi.nlm.nih.gov/17721909/

718. Hesketh, PJ, Batchelor, D, Golant, M, Lyman, GH, Rhodes, N, Yardley, D, Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches., Support Care Cancer, 2004. 12 (8)(8): p. 543-9., https://pubmed.ncbi.nlm.nih.gov/15221580/

719. van den Hurk, CJ, Mols, F, Vingerhoets, AJ, Breed, WP, Impact of alopecia and scalp cooling on the well-being of breast cancer patients., Psychooncology, 2010. 19 (7)(7): p. 701-9., https://pubmed.ncbi.nlm.nih.gov/19637250/

720. Elder, D., Lever's histopathology of the skinElenitsas R., Johnson B.L., Murphy G.F. , Editor. 2004, Lippincott Williams & Wilkins: Philadelphia. 9th ed: p. p.1229.

721. Paus, R, Haslam, IS, Sharov, AA, Botchkarev, VA, Pathobiology of chemotherapy-induced hair loss., Lancet Oncol, 2013. 14 (2)(2): p. e50-9., https://pubmed.ncbi.nlm.nih.gov/23369683/

722. Chon, SY, Champion, RW, Geddes, ER, Rashid, RM, Chemotherapy-induced alopecia., J Am Acad Dermatol, 2012. 67 (1)(1): p. e37-47., https://pubmed.ncbi.nlm.nih.gov/22178150/

723. Yun, SJ, Kim, SJ, Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation., Dermatology, 2007. 215 (1)(1): p. 36-40., https://pubmed.ncbi.nlm.nih.gov/17587837/

724. Kanti, V, Nuwayhid, R, Lindner, J, Hillmann, K, Stroux, A, Bangemann, N, et.al. Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study., Br J Dermatol, 2014. 170 (3)(3): p. 643-50., https://pubmed.ncbi.nlm.nih.gov/24641211/

725. Kluger, N, Jacot, W, Frouin, E, Rigau, V, Poujol, S, Dereure, O, et.al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients., Ann Oncol, 2012. 23 (11)(11): p. 2879-2884., https://pubmed.ncbi.nlm.nih.gov/22571858/

726. Tosti, A, Palamaras, I, Miteva, M, Misciali, C, Docetaxel and permanent alopecia., J Am Acad Dermatol, 2013. 68 (5)(5): p. e151., https://pubmed.ncbi.nlm.nih.gov/23602186/

727. Miteva, M, Misciali, C, Fanti, PA, Vincenzi, C, Romanelli, P, Tosti, A, Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases., Am J Dermatopathol, 2011. 33 (4)(4): p. 345-50., https://pubmed.ncbi.nlm.nih.gov/21430504/

728. Freites-Martinez, A, Chan, D, Sibaud, V, Shapiro, J, Fabbrocini, G, Tosti, A, et.al. Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia., JAMA Dermatol, 2019. 155 (6)(6): p. 724-728., https://pubmed.ncbi.nlm.nih.gov/30840033/

729. Kang, D, Kim, IR, Choi, EK, Im, YH, Park, YH, Ahn, JS, et.al. Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study., Oncologist, 2019. 24 (3)(3): p. 414-420., https://pubmed.ncbi.nlm.nih.gov/30120165/

730. Prevezas, C, Matard, B, Pinquier, L, Reygagne, P, Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer., Br J Dermatol, 2009. 160 (4)(4): p. 883-5., https://pubmed.ncbi.nlm.nih.gov/19222453/

731. Kluetz, PG, Chingos, DT, Basch, EM, Mitchell, SA, Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)., Am Soc Clin Oncol Educ Book, 2016. 35 (): p. 67-73., https://pubmed.ncbi.nlm.nih.gov/27249687/

732. Cho, J, Choi, EK, Kim, IR, Im, YH, Park, YH, Lee, S, et.al. Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients., Ann Oncol, 2014. 25 (2)(2): p. 346-51., https://pubmed.ncbi.nlm.nih.gov/24379161/

733. Fehr, MK, Welter, J, Sell, W, Jung, R, Felberbaum, R, Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients., Curr Oncol, 2016. 23 (6)(6): p. e576-e582., https://pubmed.ncbi.nlm.nih.gov/28050147/

734. Trüeb, RM, Chemotherapy-induced alopecia., Semin Cutan Med Surg, 2009. 28 (1)(1): p. 11-4., https://pubmed.ncbi.nlm.nih.gov/19341937/

735. Belum, V. R., Marulanda, K., Ensslin, C., Gorcey, L., Parikh, T., Wu, S., et.al. Alopecia in patients treated with molecularly targeted anticancer therapies, Ann Oncol, 2015. 26(12): p. 2496 - 502.

736. Betticher, D. C., Delmore, G., Breitenstein, U., Anchisi, S., Zimmerli-Schwab, B., Muller, A., et.al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment, Support Care Cancer, 2013. 21: p. 2565-73.

737. Edelstyn, G. A., MacDonald, M., MacRae, K. D., Doxorubicin-induced hair loss and possible modification by scalp cooling, Lancet, 1977. 2: p. 253-4.

738. Giaccone, G., Di Giulio, F., Morandini, M. P., Calciati, A., Scalp hypothermia in the prevention of doxorubicin-induced hair loss, Cancer Nurs, 1988. 11: p. 170-3.

739. Kargar, M., Sarvestani, R. S., Khojasteh, H. N., Heidari, M. T., Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy, Journal of Advanced Nursing, 2011. 67: p. 2473-7.

740. Kennedy, M., Packard, R., Grant, M., Padilla, G., Presant, C., Chillar, R., The effects of using Chemocap on occurrence of chemotherapy-induced alopecia, Oncol Nurs Forum, 1983. 10: p. 19-24.

741. Lovejoy, N. C., Preventing hair loss during adriamycin therapy, Cancer Nurs, 1979. 2: p. 117-21.

742. Macduff, C., Mackenzie, T., Hutcheon, A., Melville, L., Archibald, H., The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel, European Journal of Cancer Care, 2003. 12: p. 154-61.

743. Mols, F., van den Hurk, C. J., Vingerhoets, A. J., Breed, W. P., Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations, Support Care Cancer, 2009. 17: p. 181-9.

744. Parker, R., The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia, Oncol Nurs Forum, 1987. 14: p. 49-53.

745. Peck, H. J., Mitchell, H., Stewart, A. L., Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer, Eur J Oncol Nurs, 2000. 4: p. 246-8.

746. Robinson, M. H., Jones, A. C., Durrant, K. D., Effectiveness of scalp cooling in reducing alopecia caused by epirubicin treatment of advanced breast cancer, Cancer Treatment Reports, 1987. 71: p. 913-4.

747. Satterwhite, B., Zimm, S., The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss, Cancer, 1984. 54: p. 34-7.

748. Shin, H., Jo, S. J., Kim do, H., Kwon, O., Myung, S. K., Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis, Int J Cancer, 2015. 136: p. E442-54.

749. van den Hurk, C. J., Breed, W. P., Nortier, J. W., Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia, Support Care Cancer, 2012. 20: p. 3255-60.

750. Villani, C., Inghirami, P., Pietrangeli, D., Tomao, S., Pucci, G., Prevention by hypothermic cap of antiblastic induced-alopecia, Eur J Gynaecol Oncol, 1986. 7: p. 15-7.

751. Shen, XF, Ru, LX, Yao, XB, Efficacy of scalp cooling for prevention of chemotherapy induced alopecia: a systematic review and meta-analysis., Eur Rev Med Pharmacol Sci, 2021. 25 (16)(16): p. 5090-5103., https://pubmed.ncbi.nlm.nih.gov/34486683/

752. Komen, MMC, van den Hurk, CJG, Nortier, JWR, van der Ploeg, T, Nieboer, P, van der Hoeven, JJM, et.al. Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy., Support Care Cancer, 2019. 27 (5)(5): p. 1919-1925., https://pubmed.ncbi.nlm.nih.gov/30206728/

753. Grevelman, E. G., Breed, W. P., Prevention of chemotherapy-induced hair loss by scalp cooling, Annals of Oncology, 2005. 16: p. 352-8.

754. van den Hurk, Corina, Dercksen, Martin W, Nortier, J. W. R., Breed, Wim, Learning from best scalp cooling practices in a registry: Differences in results from n>7000 patients with solid tumors.Wolters Kluwer, Journal of Clinical Oncology, 2019. 37(15_suppl): p. 11610 - 11610., https://doi.org/10.1200/JCO.2019.37.15_suppl.11610

755. Smetanay, K, Junio, P, Feißt, M, Seitz, J, Hassel, JC, Mayer, L, et.al. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer., Breast Cancer Res Treat, 2019. 173 (1)(1): p. 135-143., https://pubmed.ncbi.nlm.nih.gov/30255454/

756. Nangia, J, Wang, T, Osborne, C, Niravath, P, Otte, K, Papish, S, et.al. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial., JAMA, 2017. 317 (6)(6): p. 596-605., https://pubmed.ncbi.nlm.nih.gov/28196254/

757. Bajpai, J, Kagwade, S, Chandrasekharan, A, Dandekar, S, Kanan, S, Kembhavi, Y, et.al. "Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia"., Breast, 2020. 49 (): p. 187-193., https://pubmed.ncbi.nlm.nih.gov/31865282/

758. Dunnill, C, Ibraheem, K, Peake, M, Ioannou, M, Palmer, M, Smith, A, et.al. Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake., PLoS One, 2020. 15 (10)(10): p. e0240454., https://pubmed.ncbi.nlm.nih.gov/33057448/

759. Brook, TS, Seetsen, T, Dercksen, MW, van Riel, A, Derleyn, VA, van den Bosch, J, et.al. Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy., Oncologist, 2024. 29 (10)(10): p. e1386-e1395., https://pubmed.ncbi.nlm.nih.gov/38869252/

760. Rugo, HS, Melin, SA, Voigt, J, Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis., Breast Cancer Res Treat, 2017. 163 (2)(2): p. 199-205., https://pubmed.ncbi.nlm.nih.gov/28275922/

761. Witman, G, Cadman, E, Chen, M, Misuse of scalp hypothermia., Cancer Treat Rep, 1981. 65 (5-6)(5-6): p. 507-8., https://pubmed.ncbi.nlm.nih.gov/7237471/

762. Lemieux, J, Desbiens, C, Hogue, JC, Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up., Breast Cancer Res Treat, 2011. 128 (2)(2): p. 563-6., https://pubmed.ncbi.nlm.nih.gov/21431870/

763. Gardani, G., Cerrone, R., Biella, C., Galbiati, B., Proserpio, E., Casiraghi, M., et.al. A case-control study of Panicum Miliaceum in the treatment of cancer chemotherapy-induced alopecia, Minerva Medica, 2007. 98: p. 661-4.

764. Yu, F, Li, Y, Zou, J, Jiang, L, Wang, C, Tang, Y, et.al. The Chinese herb Xiaoaiping protects against breast cancer chemotherapy-induced alopecia and other side effects: a randomized controlled trial., J Int Med Res, 2019. 47 (6)(6): p. 2607-2614., https://pubmed.ncbi.nlm.nih.gov/31099281/

765. Granai, C. O., Frederickson, H., Gajewski, W., Goodman, A., Goldstein, A., Baden, H., The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies, European Journal of Gynaecological Oncology, 1991. 12: p. 129-32.

766. Hidalgo, M., Rinaldi, D., Medina, G., Griffin, T., Turner, J., Von Hoff, D. D., A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia, Anticancer Drugs, 1999. 10: p. 393-5.

767. Rodriguez, R., Machiavelli, M., Leone, B., Romero, A., Cuevas, M. A., Langhi, M., et.al. Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia, Annals of Oncology, 1994. 5: p. 769-70.

768. Duvic, M., Lemak, N. A., Valero, V., Hymes, S. R., Farmer, K. L., Hortobagyi, G. N., et.al. A randomized trial of minoxidil in chemotherapy-induced alopecia, J Am Acad Dermatol, 1996. 35: p. 74-8.

769. Hackbarth, M., Haas, N., Fotopoulou, C., Lichtenegger, W., Sehouli, J., Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study, Support Care Cancer, 2008. 16: p. 267-73.

770. McGarvey, E. L., Leon-Verdin, M., Baum, L. D., Bloomfield, K., Brenin, D. R., Koopman, C., et.al. An evaluation of a computer-imaging program to prepare women for chemotherapy-related alopecia, Psycho-Oncology, 2010. 19: p. 756-66.

771. Borsellino, M, Young, MM, Anticipatory coping: taking control of hair loss., Clin J Oncol Nurs, 2011. 15 (3)(3): p. 311-5., https://pubmed.ncbi.nlm.nih.gov/21624866/

772. Zannini, L, Verderame, F, Cucchiara, G, Zinna, B, Alba, A, Ferrara, M, 'My wig has been my journey's companion': perceived effects of an aesthetic care programme for Italian women suffering from chemotherapy-induced alopecia., Eur J Cancer Care (Engl), 2012. 21 (5)(5): p. 650-60., https://pubmed.ncbi.nlm.nih.gov/22339814/

773. Trusson, D, Quincey, K, Breast Cancer and Hair Loss: Experiential Similarities and Differences in Men's and Women's Narratives., Cancer Nurs 44 (1)(1): p. 62-70., https://pubmed.ncbi.nlm.nih.gov/31567492/

774. Burgdorf, W. H., Gilmore, W. A., Ganick, R. G., Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia, Ann Intern Med, 1982. 97: p. 61-2.

775. Baack, B. R., Burgdorf, W. H., Chemotherapy-induced acral erythema, J Am Acad Dermatol, 1991. 24: p. 457-61.

776. Jucgla, A., Sais, G., Navarro, M., Peyri, J., Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur, Arch Dermatol, 1995. 131: p. 364-5.

777. Rios-Buceta, L., Buezo, G. F., Penas, P. F., Dauden, E., Fernandez-Herrera, J., Garcia-Diez, A., Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur, Acta Derm Venereol, 1997. 77: p. 80-1.

778. Beldner, M., Jacobson, M., Burges, G. E., Dewaay, D., Maize, J. C., Jr., Chaudhary, U. B., Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib, Oncologist, 2007. 12: p. 1178-82.

779. Nagore, E., Insa, A., Sanmartin, O., Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management, Am J Clin Dermatol, 2000. 1: p. 225-34.

780. Abushullaih, S., Saad, E. D., Munsell, M., Hoff, P. M., Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience, Cancer Invest, 2002. 20: p. 3-10.

781. Banfield, G. K., Crate, I. D., Griffiths, C. L., Long-term sequelae of Palmar-Plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy, J R Soc Med, 1995. 88: p. 356P-357P.

782. Degen, A., Alter, M., Schenck, F., Satzger, I., Volker, B., Kapp, A., et.al. The hand-foot-syndrome associated with medical tumor therapy - classification and management, J Dtsch Dermatol Ges, 2010. 8: p. 652-61.

783. Lassere, Y., Hoff, P., Management of hand-foot syndrome in patients treated with capecitabine (Xeloda), Eur J Oncol Nurs, 2004. 8 Suppl 1: p. S31-40.

784. Yap, YS, Kwok, LL, Syn, N, Chay, WY, Chia, JWK, Tham, CK, et.al. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial., JAMA Oncol, 2017. 3 (11)(11): p. 1538-1545., https://pubmed.ncbi.nlm.nih.gov/28715540/

785. Strumberg, D., Awada, A., Hirte, H., Clark, J. W., Seeber, S., Piccart, P., et.al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?, Eur J Cancer, 2006. 42: p. 548-56.

786. Azad, N. S., Aragon-Ching, J. B., Dahut, W. L., Gutierrez, M., Figg, W. D., Jain, L., et.al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy, Clin Cancer Res, 2009. 15: p. 1411-6.

787. Heo, Y. S., Chang, H. M., Kim, T. W., Ryu, M. H., Ahn, J. H., Kim, S. B., et.al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, J Clin Pharmacol, 2004. 44: p. 1166-72.

788. Abuhelwa, AY, Badaoui, S, Yuen, HY, McKinnon, RA, Ruanglertboon, W, Shankaran, K, et.al. A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma., Cancer Chemother Pharmacol, 2022. 89 (4)(4): p. 479-485., https://pubmed.ncbi.nlm.nih.gov/35226112/

789. Chu, D., Lacouture, M. E., Fillos, T., Wu, S., Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis, Acta Oncol, 2008. 47: p. 176-86.

790. Lee, W. J., Lee, J. L., Chang, S. E., Lee, M. W., Kang, Y. K., Choi, J. H., et.al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib, Br J Dermatol, 2009. 161: p. 1045-51.

791. Rosenbaum, S. E., Wu, S., Newman, M. A., West, D. P., Kuzel, T., Lacouture, M. E., Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib (Structured abstract), Supportive Care in Cancer, 2008. 16: p. 557-566.

792. Belum, V. R., Wu, S., Lacouture, M. E., Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis, Invest New Drugs, 2013. 31: p. 1078-86.

793. Belum, V. R., Serna-Tamayo, C., Wu, S., Lacouture, M. E., Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis, Clin Exp Dermatol, 2015.

794. Wardley, A. M., Pivot, X., Morales-Vasquez, F., Zetina, L. M., de Fatima Dias Gaui, M., Reyes, D. O., et.al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer, J Clin Oncol, 2010. 28: p. 976-83.

795. Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., Scambia, G., Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome), Ann Oncol, 2007. 18: p. 1159-64.

796. Sehouli, J., Oskay-Ozcelik, G., Kuhne, J., Stengel, D., Hindenburg, H. J., Klare, P., et.al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial, Ann Oncol, 2006. 17: p. 957-61.

797. Strauss, H. G., Hemsen, A., Karbe, I., Lautenschlager, C., Persing, M., Thomssen, C., Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer, Anticancer Drugs, 2008. 19: p. 541-5.

798. Gressett, S. M., Stanford, B. L., Hardwicke, F., Management of hand-foot syndrome induced by capecitabine, Journal of Oncology Pharmacy Practice, 2006. 12: p. 131-41.

799. Levy, E., Piedbois, P., Buyse, M., Pignon, J. P., Rougier, P., Ryan, L., et.al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors, J Clin Oncol, 1998. 16: p. 3537-41.

800. Yen-Revollo, J. L., Goldberg, R. M., McLeod, H. L., Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?, Clin Cancer Res, 2008. 14: p. 8-13.

801. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et.al. Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 2015. 372: p. 30-9.

802. Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et.al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 2014. 371: p. 1877-88.

803. Hofheinz, R. D., Gencer, D., Schulz, H., Stahl, M., Hegewisch-Becker, S., Loeffler, L. M., et.al. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group, J Clin Oncol, 2015. 33: p. 2444-9.

804. Ren, Z., Zhu, K., Kang, H., Lu, M., Qu, Z., Lu, L., et.al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma, J Clin Oncol, 2015. 33: p. 894-900.

805. Wolf, S. L., Qin, R., Menon, S. P., Rowland, K. M., Jr., Thomas, S., Delaune, R., et.al. Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5, J Clin Oncol, 2010. 28: p. 5182-7.

806. Lee, YS, Jung, YK, Kim, JH, Cho, SB, Kim, DY, Kim, MY, et.al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study., Eur J Cancer, 2020. 140 (): p. 19-27., https://pubmed.ncbi.nlm.nih.gov/33039810/

807. Mangili, G., Petrone, M., Gentile, C., De Marzi, P., Vigano, R., Rabaiotti, E., Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling, Gynecologic Oncology, 2008. 108: p. 332-5.

808. McCarthy, A. L., Shaban, R. Z., Gillespie, K., Vick, J., Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial, Support Care Cancer, 2014. 22: p. 1375-83.

809. Scotte, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., et.al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot, Cancer, 2008. 112: p. 1625-31.

810. Scotte, F., Tourani, J. M., Banu, E., Peyromaure, M., Levy, E., Marsan, S., et.al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand, J Clin Oncol, 2005. 23: p. 4424-9.

811. Lademann, J., Martschick, A., Kluschke, F., Richter, H., Fluhr, J. W., Patzelt, A., et.al. Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy, Skin Pharmacol Physiol, 2014. 27: p. 66-70.

812. Chen, M., Zhang, L., Wang, Q., Shen, J., Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review, PLoS One, 2013. 8: p. e72245.

813. Jo, S. J., Shin, H., Jo, S., Kwon, O., Myung, S. K., Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis, Clin Exp Dermatol, 2015. 40: p. 260-70.

814. Zhou, Y., Peng, L., Li, Y., Chen, L., Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis, Biomed Rep, 2013. 1: p. 873-878.

815. Watanabe, K, Ishibe, A, Watanabe, J, Ota, M, Fujii, S, Ichikawa, Y, et.al. The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102)., Indian J Gastroenterol, 2020. 39 (2)(2): p. 204-210., https://pubmed.ncbi.nlm.nih.gov/32406009/

816. von Gruenigen, V., Frasure, H., Fusco, N., DeBernardo, R., Eldermire, E., Eaton, S., et.al. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients, Cancer, 2010. 116: p. 4735-43.

817. Chalermchai, T., Tantiphlachiva, K., Suwanrusme, H., Voravud, N., Sriuranpong, V., Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia, Asia-Pacific Journal of Clinical Oncology, 2010. 6: p. 155-60.

818. Fang, XH, Wu, Q, Han, XM, Cao, TH, Liu, LJ, al., et, High dose pyridoxine for the prevention of hand-foot syndrome caused by capecitabine., Oncology, 2010. 30: p. 1081-1082.

819. Kang, Y. K., Lee, S. S., Yoon, D. H., Lee, S. Y., Chun, Y. J., Kim, M. S., et.al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study, J Clin Oncol, 2010. 28: p. 3824-9.

820. Corrie, P. G., Bulusu, R., Wilson, C. B., Armstrong, G., Bond, S., Hardy, R., et.al. A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications, Br J Cancer, 2012. 107: p. 585-7.

821. Braik, T., Yim, B., Evans, A. T., Kassem, M., Mullane, M., Lad, T., et.al. Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy, J Community Support Oncol, 2014. 12: p. 65-70.

822. Mortimer, J.E., Lauman, M.K., Tan, B., Dempsey, C.L., Shillington, A.C., Hutchins, K.S., Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine., Journal of Oncology Pharmacy Practice, 2003. 9: p. 161-166.

823. Yoshimoto, N., Yamashita, T., Fujita, T., Hayashi, H., Tsunoda, N., Kimura, M., et.al. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer, Breast Cancer, 2010. 17: p. 298-302.

824. Ota, M., Tatsumi, K., Suwa, H., Watanabe, J., Watanabe, K., Osada, S., et.al. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study, Hepatogastroenterology, 2014. 61: p. 1008-13.

825. Templeton, A. J., Ribi, K., Surber, C., Sun, H., Hsu Schmitz, S. F., Beyeler, M., et.al. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08), Breast, 2014. 23: p. 244-9.

826. Lacouture, ME, Sibaud, V, Gerber, PA, van den Hurk, C, Fernández-Peñas, P, Santini, D, et.al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines, Ann Oncol, 2021. 32 (2)(2): p. 157-170., https://pubmed.ncbi.nlm.nih.gov/33248228/

827. Zhang, R. X., Wu, X. J., Lu, S. X., Pan, Z. Z., Wan, D. S., Chen, G., The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study, J Cancer Res Clin Oncol, 2011. 137: p. 953-7.

828. Zhang, R. X., Wu, X. J., Wan, D. S., Lu, Z. H., Kong, L. H., Pan, Z. Z., et.al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial, Ann Oncol, 2012. 23: p. 1348-53.

829. Kohne, C. H., De Greve, J., Hartmann, J. T., Lang, I., Vergauwe, P., Becker, K., et.al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015, Ann Oncol, 2008. 19: p. 920-6.

830. Elyasi, S, Shojaee, FSR, Allahyari, A, Karimi, G, Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial., Phytother Res, 2017. 31 (9)(9): p. 1323-1329., https://pubmed.ncbi.nlm.nih.gov/28635153/

831. Shinohara, N., Nonomura, N., Eto, M., Kimura, G., Minami, H., Tokunaga, S., et.al. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma, Ann Oncol, 2014. 25: p. 472-6.

832. Charalambous, A, Tsitsi, T, Astras, G, Paikousis, L, Filippou, E, A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD)., Eur J Oncol Nurs, 2021. 50 (): p. 101866., https://pubmed.ncbi.nlm.nih.gov/33227569/

833. Meadows, K. L., Rushing, C., Honeycutt, W., Latta, K., Howard, L., Arrowood, C. A., et.al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study, Support Care Cancer, 2015. 23: p. 1311-9.

834. Rodríguez-Garzotto, A, Iglesias-Docampo, L, Díaz-García, CV, Ruppen, I, Ximénez-Embún, P, Gómez, C, et.al. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies., Ther Adv Med Oncol, 2022. 14 (): p. 17588359221086911., https://pubmed.ncbi.nlm.nih.gov/35356259/

835. Robert, C., Sibaud, V., Mateus, C., Verschoore, M., Charles, C., Lanoy, E., et.al. Nail toxicities induced by systemic anticancer treatments, Lancet Oncol, 2015. 16: p. e181-9.

836. Rafi, L., Friedrich, M., Tilgen, W., Reichrath, J., Severe nail changes due to Docetaxel treatment, Eur J Dermatol, 2003. 13: p. 610-1.

837. Woo, I. S., Shim, K. H., Kim, G. Y., Lee, M. A., Kang, J. H., Hong, Y. S., et.al. Nail changes during docetaxel containing combination chemotherapy, Korean J Intern Med, 2004. 19: p. 132-3.

838. Lau, C. P., Hui, P., Chan, T. C., Docetaxel-induced nail toxicity: a case of severe onycholysis and topic review, Chin Med J (Engl), 2011. 124: p. 2559-60.

839. Akoglu, G., Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes, Indian J Pharmacol, 2014. 46: p. 225-7.

840. Hong, J., Park, S. H., Choi, S. J., Lee, S. H., Lee, K. C., Lee, J. I., et.al. Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer, Jpn J Clin Oncol, 2007. 37: p. 424-8.

841. Yorulmaz, A, Dogan, M, Artuz, F, Zengin, N, Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation., Cutan Ocul Toxicol, 2017. 36 (2)(2): p. 135-139., https://pubmed.ncbi.nlm.nih.gov/27086693/

842. Garden, B. C., Wu, S., Lacouture, M. E., The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis, J Am Acad Dermatol, 2012. 67: p. 400-8.

843. Mortimer, J., Jung, J., Yuan, Y., Kruper, L., Stewart, D., Chung, S., et.al. Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy, Breast Cancer Res Treat, 2014. 148: p. 563-70.

844. Ishiguro, H., Takashima, S., Yoshimura, K., Yano, I., Yamamoto, T., Niimi, M., et.al. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients, Supportive Care in Cancer, 2012. 20: p. 2017-24.

845. Floersheim, G. L., [Treatment of brittle fingernails with biotin], Z Hautkr, 1989. 64: p. 41-8.

846. Scheinfeld, N., Dahdah, M. J., Scher, R., Vitamins and minerals: their role in nail health and disease, J Drugs Dermatol, 2007. 6: p. 782-7.

847. Capriotti, KD, Anadkat, M, Choi, J, Kaffenberger, B, McLellan, B, Barone, S, et.al. A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia., Invest New Drugs, 2019. 37 (6)(6): p. 1247-1256., https://pubmed.ncbi.nlm.nih.gov/31240513/

848. Ensslin, C. J., Rosen, A. C., Wu, S., Lacouture, M. E., Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis, J Am Acad Dermatol, 2013. 69: p. 708-20.

849. Gandhi, M., Oishi, K., Zubal, B., Lacouture, M. E., Unanticipated toxicities from anticancer therapies: survivors' perspectives, Support Care Cancer, 2010. 18: p. 1461-8.

850. Rosen, A. C., Case, E. C., Dusza, S. W., Balagula, Y., Gordon, J., West, D. P., et.al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic, Am J Clin Dermatol, 2013. 14: p. 327-33.

851. Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., et.al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life, Cancer, 2010. 116: p. 3916-23.

852. Potthoff, K., Hofheinz, R., Hassel, J. C., Volkenandt, M., Lordick, F., Hartmann, J. T., et.al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion, Ann Oncol, 2011. 22: p. 524-35.

853. Valentine, J., Belum, V. R., Duran, J., Ciccolini, K., Schindler, K., Wu, S., et.al. Incidence and risk of xerosis with targeted anticancer therapies, J Am Acad Dermatol, 2015. 72: p. 656-67.

854. Agero, A. L., Dusza, S. W., Benvenuto-Andrade, C., Busam, K. J., Myskowski, P., Halpern, A. C., Dermatologic side effects associated with the epidermal growth factor receptor inhibitors, J Am Acad Dermatol, 2006. 55: p. 657-70.

855. Lacouture, M. E., Lai, S. E., The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome, Br J Dermatol, 2006. 155: p. 852-4.

856. Osio, A., Mateus, C., Soria, J. C., Massard, C., Malka, D., Boige, V., et.al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors, Br J Dermatol, 2009. 161: p. 515-21.

857. Belum, VR, Benhuri, B, Postow, MA, Hellmann, MD, Lesokhin, AM, Segal, NH, et.al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor., Eur J Cancer, 2016. 60 (): p. 12-25., https://pubmed.ncbi.nlm.nih.gov/27043866/

858. Clabbers, JMK, Boers-Doets, CB, Gelderblom, H, Stijnen, T, Lacouture, ME, van der Hoeven, KJM, et.al. Xerosis and pruritus as major EGFRI-associated adverse events., Support Care Cancer, 2016. 24 (2)(2): p. 513-521., https://pubmed.ncbi.nlm.nih.gov/26111953/

859. Steinhoff, M., Neisius, U., Ikoma, A., Fartasch, M., Heyer, G., Skov, P. S., et.al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin, J Neurosci, 2003. 23: p. 6176-80.

860. Shim, J. H., Park, J. H., Lee, J. H., Lee, D. Y., Lee, J. H., Yang, J. M., Moisturizers are effective in the treatment of xerosis irrespectively from their particular formulation: results from a prospective, randomized, double-blind controlled trial, J Eur Acad Dermatol Venereol, 2015.

861. Santini, D., Vincenzi, B., Guida, F. M., Imperatori, M., Schiavon, G., Venditti, O., et.al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study, Lancet Oncol, 2012. 13: p. 1020-4.

862. Barrios, DM, Phillips, GS, Geisler, AN, Trelles, SR, Markova, A, Noor, SJ, et.al. IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies., Ann Oncol, 2021. 32 (6)(6): p. 736-745., https://pubmed.ncbi.nlm.nih.gov/, 33667669/

863. Gutzmer, R, Sibaud, V, Hassel, JC, IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy., Ann Oncol, 2021. 32 (6)(6): p. 696-697., https://pubmed.ncbi.nlm.nih.gov/33882330/

864. Hirotsu, KE, Neal, TM, Khodadoust, MS, Wang, JY, Rieger, KE, Strelo, J, et.al. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome., JAMA Dermatol, 2021. 157 (6)(6): p. 700-707., https://pubmed.ncbi.nlm.nih.gov/33881447/

865. Hassel, J.C., Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma., 2021. 39:15_suppl: p. 9527 - 9527., https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9527

866. Heinzerling, LM, Tomsitz, D, Anliker, MD, Is drug allergy less prevalent than previously assumed? A 5-year analysis., Br J Dermatol, 2012. 166 (1)(1): p. 107-14., https://pubmed.ncbi.nlm.nih.gov/21916887 /

867. Shi, VJ, Rodic, N, Gettinger, S, Leventhal, JS, Neckman, JP, Girardi, M, et.al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy., JAMA Dermatol, 2016. 152 (10)(10): p. 1128-1136., https://pubmed.ncbi.nlm.nih.gov/27411054 /

868. Kratzsch, D, Simon, JC, Ziemer, M, Lichen planus-like drug eruption on anti-PD-1 therapy., J Dtsch Dermatol Ges, 2017. 15 (12)(12): p. 1238-1240., https://pubmed.ncbi.nlm.nih.gov/29211335 /

869. Goldinger, SM, Stieger, P, Meier, B, Micaletto, S, Contassot, E, French, LE, et.al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy., Clin Cancer Res, 2016. 22 (16)(16): p. 4023-9., https://pubmed.ncbi.nlm.nih.gov/26957557/

870. Schaberg, KB, Novoa, RA, Wakelee, HA, Kim, J, Cheung, C, Srinivas, S, et.al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy., J Cutan Pathol, 2016. 43 (4)(4): p. 339-46., https://pubmed.ncbi.nlm.nih.gov/26762844 /

871. Hofmann, L, Forschner, A, Loquai, C, Goldinger, SM, Zimmer, L, Ugurel, S, et.al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy., Eur J Cancer, 2016. 60 (): p. 190-209., https://pubmed.ncbi.nlm.nih.gov/27085692 /

872. Reschke, R, Mockenhaupt, M, Simon, JC, Ziemer, M, Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions., J Dtsch Dermatol Ges, 2019. 17 (9)(9): p. 942-948., https://pubmed.ncbi.nlm.nih.gov/31210413 /

873. Czuczman, MS, Fayad, L, Delwail, V, Cartron, G, Jacobsen, E, Kuliczkowski, K, et.al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study., Blood, 2012. 119 (16)(16): p. 3698-704., https://pubmed.ncbi.nlm.nih.gov/22389254/

874. Kuten-Shorrer, M, Hochberg, EP, Woo, SB, Lichenoid mucosal reaction to rituximab., Oncologist, 2014. 19 (10)(10): p. e12-3., https://pubmed.ncbi.nlm.nih.gov/25170011 /

875. Wahiduzzaman, M, Pubalan, M, Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review., Dermatol Online J, 2008. 14 (12)(12): p. 14., https://pubmed.ncbi.nlm.nih.gov/19265627/

876. Asarch, A, Gottlieb, AB, Lee, J, Masterpol, KS, Scheinman, PL, Stadecker, MJ, et.al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists., J Am Acad Dermatol, 2009. 61 (1)(1): p. 104-11., https://pubmed.ncbi.nlm.nih.gov/19539844 /

877. De Simone, C, Caldarola, G, D'Agostino, M, Rotoli, M, Capizzi, R, Amerio, P, Lichenoid reaction induced by adalimumab., J Eur Acad Dermatol Venereol, 2008. 22 (5)(5): p. 626-7., https://pubmed.ncbi.nlm.nih.gov/18005023 /

878. Vergara, G, Silvestre, JF, Betlloch, I, Vela, P, Albares, MP, Pascual, JC, Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern., Arch Dermatol, 2002. 138 (9)(9): p. 1258-9., https://pubmed.ncbi.nlm.nih.gov/12225003/

879. Inoue, A, Sawada, Y, Yamaguchi, T, Ohmori, S, Omoto, D, Haruyama, S, et.al. Lichenoid drug eruption caused by adalimumab: a case report and literature review., Eur J Dermatol, 2017. 27 (1)(1): p. 69-70., https://pubmed.ncbi.nlm.nih.gov/27777187/

880. Doesch, J, Debus, D, Meyer, C, Papadopoulos, T, Schultz, ES, Ficker, JH, et.al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient., Lung Cancer, 2016. 95 (): p. 35-8., https://pubmed.ncbi.nlm.nih.gov/27040849/

881. Nühnen, VP, Schön, MP, Mössner, R, Stevens-Johnson-Syndrom/toxische epidermale Nekrolyse Overlap bei einem NSCLC-Patienten unter Afatinib-Behandlung., J Dtsch Dermatol Ges, 2018. 16 (2)(2): p. 198-201., https://pubmed.ncbi.nlm.nih.gov/29418110 /

882. Otsuka, T, Tanaka, A, Azukizawa, H, Sasaki, S, Ishijima, M, Matsuki, T, et.al. Successful treatment with gefitinib after Stevens-Johnson syndrome associated with afatinib therapy in a patient with adenocarcinoma of the lung., Int Cancer Conf J, 2017. 6 (1)(1): p. 38-41., https://pubmed.ncbi.nlm.nih.gov/31149467 /

883. Lin, WL, Lin, WC, Yang, JY, Chang, YC, Ho, HC, Yang, LC, et.al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer., J Clin Oncol, 2008. 26 (16)(16): p. 2779-80., https://pubmed.ncbi.nlm.nih.gov/18509187 /

884. Yoon, J, Oh, CW, Kim, CY, Stevens-johnson syndrome induced by vandetanib., Ann Dermatol, 2011. 23 (Suppl 3)(Suppl 3): p. S343-5., https://pubmed.ncbi.nlm.nih.gov/22346274/

885. Jackman, DM, Cioffredi, LA, Jacobs, L, Sharmeen, F, Morse, LK, Lucca, J, et.al. A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer., Oncotarget, 2015. 6 (6)(6): p. 4527-36., https://pubmed.ncbi.nlm.nih.gov/25784657 /

886. Ziemer, M, Fries, V, Paulmann, M, Mockenhaupt, M, Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics., J Dtsch Dermatol Ges, 2022. 20 (6)(6): p. 777-786., https://pubmed.ncbi.nlm.nih.gov/35711043 /

887. Ikeda, M, Fujita, T, Amoh, Y, Mii, S, Matsumoto, K, Iwamura, M, Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma., Urol Int, 2013. 91 (4)(4): p. 482-3., https://pubmed.ncbi.nlm.nih.gov/23969404 /

888. Lewin, J, Farley-Loftus, R, Pomeranz, MK, Erythema multiforme-like drug reaction to sorafenib., J Drugs Dermatol, 2011. 10 (12)(12): p. 1462-3., https://pubmed.ncbi.nlm.nih.gov/22134572 /

889. Pichard, DC, Cardones, AR, Chu, EY, Dahut, WL, Kong, HH, Sorafenib-Induced Eruption Mimicking Erythema Multiforme., JAMA Dermatol, 2016. 152 (2)(2): p. 227-8., https://pubmed.ncbi.nlm.nih.gov/26422655/

890. Lapresta, A, Dotor, A, González-Herrada, C, Toxic epidermal necrolysis induced by vemurafenib., Actas Dermosifiliogr, 2015. 106 (8)(8): p. 682-3., https://pubmed.ncbi.nlm.nih.gov/26051238 /

891. Sinha, R, Lecamwasam, K, Purshouse, K, Reed, J, Middleton, MR, Fearfield, L, Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma., Br J Dermatol, 2014. 170 (4)(4): p. 997-9., https://pubmed.ncbi.nlm.nih.gov/24359127/

892. Hsiao, LT, Chung, HM, Lin, JT, Chiou, TJ, Liu, JH, Fan, FS, et.al. Stevens-Johnson syndrome after treatment with STI571: a case report., Br J Haematol, 2002. 117 (3)(3): p. 620-2., https://pubmed.ncbi.nlm.nih.gov/12028031 /

893. Valeyrie, L, Bastuji-Garin, S, Revuz, J, Bachot, N, Wechsler, J, Berthaud, P, et.al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients., J Am Acad Dermatol, 2003. 48 (2)(2): p. 201-6., https://pubmed.ncbi.nlm.nih.gov/12582389 /

894. Yang, S, Wu, L, Li, X, Huang, J, Zhong, J, Chen, X, Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient., Mol Clin Oncol, 2018. 8 (3)(3): p. 457-459., https://pubmed.ncbi.nlm.nih.gov/29456853/

895. Fang, B, Song, Y, Ma, J, Zhao, RC, Severe epidermal necrolysis after bortezomib treatment for multiple myeloma., Acta Haematol, 2007. 118 (2)(2): p. 65-7., https://pubmed.ncbi.nlm.nih.gov/17505132 /

896. Lee, HH, Song, IH, Friedrich, M, Gauliard, A, Detert, J, Röwert, J, et.al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists., Br J Dermatol, 2007. 156 (3)(3): p. 486-91., https://pubmed.ncbi.nlm.nih.gov/17300238 /

897. Mounach, A, Rezqi, A, Nouijai, A, Ghozlani, I, Achemlal, L, Maghraoui, AE, et.al. Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease., Rheumatol Int, 2013. 33 (5)(5): p. 1351-3., https://pubmed.ncbi.nlm.nih.gov/22187054 /

898. de Groot, AC, Systemic allergic dermatitis (systemic contact dermatitis) from pharmaceutical drugs: A review., Contact Dermatitis, 2022. 86 (3)(3): p. 145-164., https://pubmed.ncbi.nlm.nih.gov/34837391 /

899. Häusermann, P, Harr, T, Bircher, AJ, Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?, Contact Dermatitis, 2004. 51 (5-6)(5-6): p. 297-310., https://pubmed.ncbi.nlm.nih.gov/15606657 /

900. Cohen, PR, Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid., Dermatol Online J, 2015. 21 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/26437156 /

901. Copps, B, Lacroix, JP, Sasseville, D, Symmetrical drug-related intertriginous and flexural exanthema secondary to epidermal growth factor receptor inhibitor gefitinib., JAAD Case Rep, 2020. 6 (3)(3): p. 172-175., https://pubmed.ncbi.nlm.nih.gov/32099886 /

902. Baykal, C, Erkek, E, Tutar, E, Yüce, K, Ayhan, A, Cutaneous fixed drug eruption to paclitaxel; a case report., Eur J Gynaecol Oncol, 2000. 21 (2)(2): p. 190-1., https://pubmed.ncbi.nlm.nih.gov/10843484 /

903. Young, PC, Montemarano, AD, Lee, N, Sau, P, Weiss, RB, James, WD, Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption., J Am Acad Dermatol, 1996. 34 (2 Pt 1)(2 Pt 1): p. 313-4., https://pubmed.ncbi.nlm.nih.gov/8642105 /

904. Del Rosario, M, Tsai, H, Dasanu, CA, Fixed Drug Eruption Late in the Course of Capecitabine Therapy., Conn Med, 2016. 80 (4)(4): p. 223-5., https://pubmed.ncbi.nlm.nih.gov/27265926 /

905. Nikolaou, V, Sibaud, V, Fattore, D, Sollena, P, Ortiz-Brugués, A, Giacchero, D, et.al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group., J Am Acad Dermatol, 2021. 84 (5)(5): p. 1310-1320., https://pubmed.ncbi.nlm.nih.gov/33279646 /

906. Phillips, GS, Wu, J, Hellmann, MD, Postow, MA, Rizvi, NA, Freites-Martinez, A, et.al. Treatment Outcomes of Immune-Related Cutaneous Adverse Events., J Clin Oncol, 2019. 37 (30)(30): p. 2746-2758., https://pubmed.ncbi.nlm.nih.gov/31216228 /

907. Constantinou, A, Kotecha, D, Laouris, P, de Paula, B, A closer look at chemotherapy-induced flagellate dermatitis., Skin Health Dis, 2022. 2 (1)(1): p. e92., https://pubmed.ncbi.nlm.nih.gov/35665202 /

908. Vennepureddy, A, Siddique, MN, Odaimi, M, Terjanian, T, Bleomycin-induced flagellate erythema in a patient with Hodgkin's lymphoma - A case report and review of literature., J Oncol Pharm Pract, 2016. 22 (3)(3): p. 556-60., https://pubmed.ncbi.nlm.nih.gov/25855241 /

909. Changal, KH, Raina, H, Changal, QH, Raina, M, Bleomycin-induced Flagellate Erythema: A Rare and Unique Drug Rash., West Indian Med J, 2014. 63 (7)(7): p. 807-9., https://pubmed.ncbi.nlm.nih.gov/25867573 /

910. Lim, D, Aussedat, M, Maillet-Lebel, N, Marcoux, D, Flagellate Dermatitis in a Child Most Likely Secondary to Doxorubicin., Pediatr Dermatol, 2017. 34 (5)(5): p. e257-e259., https://pubmed.ncbi.nlm.nih.gov/28804924/

911. Vadeboncoeur, S, Côté, B, Flagellate Pattern of Toxic Erythema of Chemotherapy Due to Doxorubicin: A Case Report., J Cutan Med Surg, 2016. 20 (5)(5): p. 481-3., https://pubmed.ncbi.nlm.nih.gov/27068228 /

912. Cohen, PR, Trastuzumab-Associated Flagellate Erythema: Report in a Woman with Metastatic Breast Cancer and Review of Antineoplastic Therapy-Induced Flagellate Dermatoses., Dermatol Ther (Heidelb), 2015. 5 (4)(4): p. 253-264., https://pubmed.ncbi.nlm.nih.gov/26506993 /

913. Mahmoud, BH, Eide, MJ, Bendamustine-induced "flagellate dermatitis"., Dermatol Online J, 2012. 18 (11)(11): p. 12., https://pubmed.ncbi.nlm.nih.gov/23217953 /

914. Yokoyama, WM, Contact hypersensitivity: not just T cells!, Nat Immunol, 2006. 7 (5)(5): p. 437-9., https://pubmed.ncbi.nlm.nih.gov/16622426/

915. Brauer, J, Votava, HJ, Meehan, S, Soter, NA, Lichenoid drug eruption., Dermatol Online J, 2009. 15 (8)(8): p. 13., https://pubmed.ncbi.nlm.nih.gov/19891921 /

916. Yawalkar, N, Pichler, WJ, [Mechanisms of cutaneous drug reactions]., J Dtsch Dermatol Ges, 2004. 2 (12)(12): p. 1013-23; quiz 1024-6., https://pubmed.ncbi.nlm.nih.gov/16285316/

917. Meller, S, Gilliet, M, Homey, B, Chemokines in the pathogenesis of lichenoid tissue reactions., J Invest Dermatol, 2009. 129 (2)(2): p. 315-9., https://pubmed.ncbi.nlm.nih.gov/18719608 /

918. Wakade, DV, Carlos, G, Hwang, SJ, Chou, S, Hui, R, Fernandez-Peñas, P, PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases., Melanoma Res, 2016. 26 (4)(4): p. 421-4., https://pubmed.ncbi.nlm.nih.gov/27135655 /

919. Lage, D, Juliano, PB, Metze, K, de Souza, EM, Cintra, ML, Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study., Int J Dermatol, 2012. 51 (10)(10): p. 1199-205., https://pubmed.ncbi.nlm.nih.gov/22416968/

920. Van den Haute, V, Antoine, JL, Lachapelle, JM, Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples., Dermatologica, 1989. 179 (1)(1): p. 10-3., https://pubmed.ncbi.nlm.nih.gov/2527767 /

921. Oliver, GF, Winkelmann, RK, Muller, SA, Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases., J Am Acad Dermatol, 1989. 21 (2 Pt 1)(2 Pt 1): p. 284-92., https://pubmed.ncbi.nlm.nih.gov/2768578 /

922. Kawsar, A, Edwards, C, Patel, P, Heywood, RM, Gupta, A, Mann, J, et.al. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study., Br J Dermatol, 2022. 187 (6)(6): p. 981-987., https://pubmed.ncbi.nlm.nih.gov/35976170/

923. Barbaud, A, Drug patch testing in systemic cutaneous drug allergy., Toxicology, 2005. 209 (2)(2): p. 209-16., https://pubmed.ncbi.nlm.nih.gov/15767038/

924. Dréno, B, Ribas, A, Larkin, J, Ascierto, PA, Hauschild, A, Thomas, L, et.al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study., Ann Oncol, 2017. 28 (5)(5): p. 1137-1144., https://pubmed.ncbi.nlm.nih.gov/28444112 /

925. Neha, R, Beulah, E, Anusha, B, Vasista, S, Stephy, C, Subeesh, V, Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database., Curr Rev Clin Exp Pharmacol, 2021. 16 (2)(2): p. 168-173., https://pubmed.ncbi.nlm.nih.gov/32598268/

926. Brégeon, B, Bernier, C, Josselin, N, Peuvrel, L, Le Moigne, M, Saint-Jean, M, et.al. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases., J Am Acad Dermatol, 2019. 80 (2)(2): p. 558-562., https://pubmed.ncbi.nlm.nih.gov/30081108 /

927. Imafuku, K, Yoshino, K, Ishiwata, K, Otobe, S, Tsuboi, S, Ohara, K, et.al. Severe rash associated with vemurafenib administration following nivolumab therapy., J Eur Acad Dermatol Venereol, 2016. 30 (10)(10): p. e84-e86., https://pubmed.ncbi.nlm.nih.gov/26372833 /

928. Peuvrel, L, Quéreux, G, Saint-Jean, M, Brocard, A, Nguyen, JM, Khammari, A, et.al. Profile of vemurafenib-induced severe skin toxicities., J Eur Acad Dermatol Venereol, 2016. 30 (2)(2): p. 250-7., https://pubmed.ncbi.nlm.nih.gov/26524690 /

929. Torres-Navarro, I, de Unamuno-Bustos, B, Botella-Estrada, R, Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs)., J Eur Acad Dermatol Venereol, 2021. 35 (3)(3): p. 607-614., https://pubmed.ncbi.nlm.nih.gov/32846030/

930. Goldman, J, Duval-Modeste, AB, Lambert, A, Contentin, N, Courville, P, Musette, P, et.al. [Imatinib-induced DRESS]., Ann Dermatol Venereol, 2008. 135 (5)(5): p. 393-6., https://pubmed.ncbi.nlm.nih.gov/18457727 /

931. Le Nouail, P, Viseux, V, Chaby, G, Billet, A, Denoeux, JP, Lok, C, [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy]., Ann Dermatol Venereol, 2006. 133 (8-9 Pt 1)(8-9 Pt 1): p. 686-8., https://pubmed.ncbi.nlm.nih.gov/17053739 /

932. Kumar, M, Mandal, PK, Dolai, TK, Bhattacharrya, M, Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction., Indian Dermatol Online J, 2014. 5 (Suppl 2)(Suppl 2): p. S120-2., https://pubmed.ncbi.nlm.nih.gov/25593801/

933. Saidi, W, Lahouel, I, Laarif, M, Aounallah, A, A new case of imatinib-induced drug reaction with eosinophilia and systemic symptoms., Indian J Dermatol Venereol Leprol, 2017. 83 (2)(2): p. 224-226., https://pubmed.ncbi.nlm.nih.gov/28164890 /

934. Ben-Ami, E, Castells, MC, Connell, NT, Rutherford, AE, Thornton, KA, Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors: a patient with dermatofibrosarcoma protuberans and successful desensitization management., Anticancer Drugs, 2018. 29 (9)(9): p. 919-923., https://pubmed.ncbi.nlm.nih.gov/30096127 /

935. Vatel, O, Aumont, C, Mathy, V, Petit, M, Feriel, J, Sloma, I, et.al. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia., Leuk Lymphoma, 2017. 58 (2)(2): p. 473-474., https://pubmed.ncbi.nlm.nih.gov/27389710/

936. Kim, DK, Lee, SW, Nam, HS, Jeon, DS, Park, NR, Nam, YH, et.al. A Case of Sorafenib-induced DRESS Syndrome in Hepatocelluar Carcinoma., Korean J Gastroenterol, 2016. 67 (6)(6): p. 337-340., https://pubmed.ncbi.nlm.nih.gov/27312836 /

937. Rahmani, H, Mohebbi, N, Sajjadi-Jazi, SM, DRESS Syndrome Induced by Sorafenib in a Patient With Medullary Thyroid Cancer: A Case Report., Hosp Pharm, 2021. 56 (6)(6): p. 646-649., https://pubmed.ncbi.nlm.nih.gov/34732916 /

938. Salame, N, Chow, ML, Ochoa, MT, Compoginis, G, Crew, AB, Sorafenib Toxicity Mimicking Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome., J Drugs Dermatol, 2019. 18 (5)(5): p. 468-469., https://pubmed.ncbi.nlm.nih.gov/31141856 /

939. Huang, J, Meng, L, Yang, B, Sun, S, Luo, Z, Chen, H, Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System., Sci Rep, 2020. 10 (1)(1): p. 4803., https://pubmed.ncbi.nlm.nih.gov/32179761/

940. Marigliano, B, Rosa, F, Internullo, M, Scuro, L, Tavanti, A, Del Vecchio, LR, et.al. When Autoimmunity 'DRESSes up': A Case after Certolizumab Therapy., Eur J Case Rep Intern Med, 2022. 9 (7)(7): p. 003451., https://pubmed.ncbi.nlm.nih.gov/36051169 /

941. Morrisroe, K, Wong, M, Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis., Rheumatology (Oxford), 2015. 54 (11)(11): p. 2113-4., https://pubmed.ncbi.nlm.nih.gov/26224305 /

942. Brockow, K, Ardern-Jones, MR, Mockenhaupt, M, Aberer, W, Barbaud, A, Caubet, JC, et.al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity., Allergy, 2019. 74 (1)(1): p. 14-27., https://pubmed.ncbi.nlm.nih.gov/30028512 /

943. Descamps, V, Valance, A, Edlinger, C, Fillet, AM, Grossin, M, Lebrun-Vignes, B, et.al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms., Arch Dermatol, 2001. 137 (3)(3): p. 301-4., https://pubmed.ncbi.nlm.nih.gov/11255328 /

944. Kardaun, SH, Mockenhaupt, M, Roujeau, JC, Comments on: DRESS syndrome., J Am Acad Dermatol, 2014. 71 (5)(5): p. 1000-1000.e2., https://pubmed.ncbi.nlm.nih.gov/25437959 /

945. Kardaun, SH, Sidoroff, A, Valeyrie-Allanore, L, Halevy, S, Davidovici, BB, Mockenhaupt, M, et.al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?, Br J Dermatol, 2007. 156 (3)(3): p. 609-11., https://pubmed.ncbi.nlm.nih.gov/17300272/

946. Chen, YC, Chiu, HC, Chu, CY, Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases., Arch Dermatol, 2010. 146 (12)(12): p. 1373-9., https://pubmed.ncbi.nlm.nih.gov/20713773/

947. Phillips, EJ, Bigliardi, P, Bircher, AJ, Broyles, A, Chang, YS, Chung, WH, et.al. Controversies in drug allergy: Testing for delayed reactions., J Allergy Clin Immunol, 2019. 143 (1)(1): p. 66-73., https://pubmed.ncbi.nlm.nih.gov/30573342 /

948. Ros, J, Muñoz-Couselo, E, DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem., BMJ Case Rep, 2018. 2018 ():, https://pubmed.ncbi.nlm.nih.gov/30275021 /

949. Bellón, T, Lerma, V, González-Valle, O, González Herrada, C, de Abajo, FJ, Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds., Br J Dermatol, 2016. 174 (3)(3): p. 621-4., https://pubmed.ncbi.nlm.nih.gov/26412570/

950. Lin, CF, Liu, SY, Lo, TK, Lee, JY, Su, PL, Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report., Thorac Cancer, 2022. 13 (3)(3): p. 494-496., https://pubmed.ncbi.nlm.nih.gov/34918465 /

951. Kohlmann, J, Reschke, R, Mockenhaupt, M, Ziemer, M, Severe skin eruption with features of drug reaction with eosinophilia and systemic symptoms (DRESS) during vemurafenib treatment of melanoma., J Eur Acad Dermatol Venereol, 2022. 36 (3)(3): p. e242-e244., https://pubmed.ncbi.nlm.nih.gov/34704628 /

952. Uhara, H, Kiyohara, Y, Tsuda, A, Takata, M, Yamazaki, N, Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan., Clin Transl Oncol, 2018. 20 (2)(2): p. 169-175., https://pubmed.ncbi.nlm.nih.gov/28674996 /

953. Harding, JJ, Pulitzer, M, Chapman, PB, Vemurafenib sensitivity skin reaction after ipilimumab., N Engl J Med, 2012. 366 (9)(9): p. 866-8., https://pubmed.ncbi.nlm.nih.gov/22375995/

954. Tahseen, AI, Patel, NB, Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma., JAAD Case Rep, 2018. 4 (9)(9): p. 930-933., https://pubmed.ncbi.nlm.nih.gov/30320198 /

955. Jeudy, G, Dalac-Rat, S, Bonniaud, B, Hervieu, A, Petrella, T, Collet, E, et.al. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis., Br J Dermatol, 2015. 172 (5)(5): p. 1454-5., https://pubmed.ncbi.nlm.nih.gov/25384395 /

956. Luherne, C, Darrigade, AS, Dutriaux, C, Prey, S, Milpied, B, Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!, JAAD Case Rep, 2019. 5 (5)(5): p. 422-423., https://pubmed.ncbi.nlm.nih.gov/31061867 /

957. Sidoroff, A, Acute generalized exanthematous pustulosis., Chem Immunol Allergy, 2012. 97 (): p. 139-48., https://pubmed.ncbi.nlm.nih.gov/, 22613859/

958. Roujeau, JC, Bioulac-Sage, P, Bourseau, C, Guillaume, JC, Bernard, P, Lok, C, et.al. Acute generalized exanthematous pustulosis. Analysis of 63 cases., Arch Dermatol, 1991. 127 (9)(9): p. 1333-8., https://pubmed.ncbi.nlm.nih.gov/1832534 /

959. Hotz, C, Valeyrie-Allanore, L, Haddad, C, Bouvresse, S, Ortonne, N, Duong, TA, et.al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients., Br J Dermatol, 2013. 169 (6)(6): p. 1223-32., https://pubmed.ncbi.nlm.nih.gov/23855377/

960. Beylot, C, Bioulac, P, Doutre, MS, [Acute generalized exanthematic pustuloses (four cases) (author's transl)]., Ann Dermatol Venereol, 1980. 107 (1-2)(1-2): p. 37-48., https://pubmed.ncbi.nlm.nih.gov/6989310 /

961. Baker, H, Ryan, TJ, Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases., Br J Dermatol, 1968. 80 (12)(12): p. 771-93., https://pubmed.ncbi.nlm.nih.gov/4236712 /

962. Sidoroff, A, Halevy, S, Bavinck, JN, Vaillant, L, Roujeau, JC, Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern., J Cutan Pathol, 2001. 28 (3)(3): p. 113-9., https://pubmed.ncbi.nlm.nih.gov/11168761 /

963. Chang, SL, Huang, YH, Yang, CH, Hu, S, Hong, HS, Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia., Acta Derm Venereol, 2008. 88 (4)(4): p. 363-5., https://pubmed.ncbi.nlm.nih.gov/18709306 /

964. Halevy, S, Ghislain, PD, Mockenhaupt, M, Fagot, JP, Bouwes Bavinck, JN, Sidoroff, A, et.al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel., J Am Acad Dermatol, 2008. 58 (1)(1): p. 25-32., https://pubmed.ncbi.nlm.nih.gov/17919772 /

965. Britschgi, M, Pichler, WJ, Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells., Curr Opin Allergy Clin Immunol, 2002. 2 (4)(4): p. 325-31., https://pubmed.ncbi.nlm.nih.gov/12130947 /

966. Britschgi, M, Steiner, UC, Schmid, S, Depta, JP, Senti, G, Bircher, A, et.al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis., J Clin Invest, 2001. 107 (11)(11): p. 1433-41., https://pubmed.ncbi.nlm.nih.gov/11390425/

967. Schmid, S, Kuechler, PC, Britschgi, M, Steiner, UC, Yawalkar, N, Limat, A, et.al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation., Am J Pathol, 2002. 161 (6)(6): p. 2079-86., https://pubmed.ncbi.nlm.nih.gov/12466124 /

968. Schlapbach, C, Zawodniak, A, Irla, N, Adam, J, Hunger, RE, Yerly, D, et.al. NKp46+ cells express granulysin in multiple cutaneous adverse drug reactions., Allergy, 2011. 66 (11)(11): p. 1469-76., https://pubmed.ncbi.nlm.nih.gov/21819408 /

969. Kabashima, R, Sugita, K, Sawada, Y, Hino, R, Nakamura, M, Tokura, Y, Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis., J Eur Acad Dermatol Venereol, 2011. 25 (4)(4): p. 485-8., https://pubmed.ncbi.nlm.nih.gov/20569282 /

970. Wolkenstein, P, Chosidow, O, Fléchet, ML, Robbiola, O, Paul, M, Dumé, L, et.al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis., Contact Dermatitis, 1996. 35 (4)(4): p. 234-6., https://pubmed.ncbi.nlm.nih.gov/8957644 /

971. Barbaud, A, Collet, E, Milpied, B, Assier, H, Staumont, D, Avenel-Audran, M, et.al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions., Br J Dermatol, 2013. 168 (3)(3): p. 555-62., https://pubmed.ncbi.nlm.nih.gov/23136927 /

972. Vallejo-Yagüe, E, Martinez-De la Torre, A, Mohamad, OS, Sabu, S, Burden, AM, Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients., J Clin Med, 2022. 11 (2)(2):, https://pubmed.ncbi.nlm.nih.gov/35054090/

973. Mockenhaupt, Maja, Roujeau, Jean-Claude, Epidermal Necrolysis (Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis), in Fitzpatrick's Dermatology, 9e, Kang, SewonAmagai, MasayukiBruckner, Anna L.Enk, Alexander H.Margolis, David J.McMichael, Amy J. and Orringer, Jeffrey S., Editors. 2019, McGraw-Hill Education: New York, NY., accessmedicine.mhmedical.com/content.aspx?aid=1162814448

974. Naegele, D, Sekula, P, Paulmann, M, Mockenhaupt, M, Incidence of Epidermal Necrolysis: Results of the German Registry., J Invest Dermatol, 2020. 140 (12)(12): p. 2525-2527., https://pubmed.ncbi.nlm.nih.gov/32353449 /

975. Rzany, B, Hering, O, Mockenhaupt, M, Schröder, W, Goerttler, E, Ring, J, et.al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis., Br J Dermatol, 1996. 135 (1)(1): p. 6-11., https://pubmed.ncbi.nlm.nih.gov/8776350/

976. Mirjana Ziemer, Maja Mockenhaupt, Severe Drug-Induced Skin Reactions: Clinical Pattern, Diagnostics and Therapy2011, IntechOpen: Rijeka. p. Ch. 6., https://doi.org/10.5772/22335

977. White, KD, Abe, R, Ardern-Jones, M, Beachkofsky, T, Bouchard, C, Carleton, B, et.al. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation., J Allergy Clin Immunol Pract, 2018. 6 (1)(1): p. 38-69., https://pubmed.ncbi.nlm.nih.gov/29310768 /

978. Chung, WH, Hung, SI, Yang, JY, Su, SC, Huang, SP, Wei, CY, et.al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis., Nat Med, 2008. 14 (12)(12): p. 1343-50., https://pubmed.ncbi.nlm.nih.gov/19029983 /

979. Mockenhaupt, M, Viboud, C, Dunant, A, Naldi, L, Halevy, S, Bouwes Bavinck, JN, et.al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study., J Invest Dermatol, 2008. 128 (1)(1): p. 35-44., https://pubmed.ncbi.nlm.nih.gov/17805350/

980. Lin, MS, Dai, YS, Pwu, RF, Chen, YH, Chang, NC, Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study., Intern Med J, 2005. 35 (3)(3): p. 188-90., https://pubmed.ncbi.nlm.nih.gov/15737140 /

981. Grünwald, P, Mockenhaupt, M, Panzer, R, Emmert, S, Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment., J Dtsch Dermatol Ges, 2020. 18 (6)(6): p. 547-553., https://pubmed.ncbi.nlm.nih.gov/32469468/

982. Bolognia, JL, Cooper, DL, Glusac, EJ, Toxic erythema of chemotherapy: a useful clinical term., J Am Acad Dermatol, 2008. 59 (3)(3): p. 524-9., https://pubmed.ncbi.nlm.nih.gov/18694683 /

983. Hunjan, MK, Nowsheen, S, Ramos-Rodriguez, AJ, Hashmi, SK, Bridges, AG, Lehman, JS, et.al. Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation., Hematol Oncol Stem Cell Ther, 2019. 12 (1)(1): p. 19-25., https://pubmed.ncbi.nlm.nih.gov/30248313 /

984. Repass, TS, Wetter, DA, Camilleri, MJ, Toxic erythema of chemotherapy., Am J Hematol, 2012. 87 (9)(9): p. 923., https://pubmed.ncbi.nlm.nih.gov/22072527 /

985. Waltzer, JF, Flowers, FP, Bullous variant of chemotherapy-induced acral erythema., Arch Dermatol, 1993. 129 (1)(1): p. 43-5., https://pubmed.ncbi.nlm.nih.gov/8420487/

986. Huang, V, Anadkat, M, Dermatologic manifestations of cytotoxic therapy., Dermatol Ther, 2011. 24 (4)(4): p. 401-10., https://pubmed.ncbi.nlm.nih.gov/21910798 /

987. Inokuchi, M, Ishikawa, S, Furukawa, H, Takamura, H, Ninomiya, I, Kitagawa, H, et.al. Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: A case report., Oncol Lett, 2014. 7 (2)(2): p. 444-448., https://pubmed.ncbi.nlm.nih.gov/, 24396465/

988. Richards, KN, Ivan, D, Rashid, RM, Chon, SY, Paclitaxel-induced acral erythema., Arch Dermatol, 2012. 148 (11)(11): p. 1333-4., https://pubmed.ncbi.nlm.nih.gov/23165853 /

989. Zils, K, Wilhelm, M, Reeh, T, Bielack, S, Bullous variant of acral erythema in a child after high-dose methotrexate., Pediatr Hematol Oncol, 2012. 29 (4)(4): p. 378-9., https://pubmed.ncbi.nlm.nih.gov/22568802/

990. Chun, YS, Chang, SN, Oh, D, Park, WH, A case of cutaneous reaction to chemotherapeutic agents showing epidermal dysmaturation., J Am Acad Dermatol, 2000. 43 (2 Pt 2)(2 Pt 2): p. 358-60., https://pubmed.ncbi.nlm.nih.gov/10901723 /

991. Zhang, B, Bolognia, J, Marks, P, Podoltsev, N, Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia., Cancer Chemother Pharmacol, 2014. 74 (2)(2): p. 303-7., https://pubmed.ncbi.nlm.nih.gov/24908437 /

992. Tezer, H, Kuskonmaz, B, Kara, A, Devrim, I, Tuncer, M, Cengiz, AB, et.al. Intravenous immunoglobulin in the treatment of severe methotrexate-induced acral erythema., J Pediatr Hematol Oncol, 2008. 30 (5)(5): p. 391-3., https://pubmed.ncbi.nlm.nih.gov/18458576 /

993. Andersen, KE, Hjorth, N, Menné, T, The baboon syndrome: systemically-induced allergic contact dermatitis., Contact Dermatitis, 1984. 10 (2)(2): p. 97-100., https://pubmed.ncbi.nlm.nih.gov/6232098 /

994. Wolf, R, Tüzün, Y, Baboon syndrome and toxic erythema of chemotherapy: Fold (intertriginous) dermatoses., Clin Dermatol, 2015. 33 (4)(4): p. 462-5., https://pubmed.ncbi.nlm.nih.gov/26051062/

995. Anderson, HJ, Lee, JB, A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption., Medicina (Kaunas), 2021. 57 (9)(9):, https://pubmed.ncbi.nlm.nih.gov/34577848 /

996. Arnold, AW, Hausermann, P, Bach, S, Bircher, AJ, Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media., Dermatology, 2007. 214 (1)(1): p. 89-93., https://pubmed.ncbi.nlm.nih.gov/17191055 /

997. Magnolo, N, Metze, D, Ständer, S, Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema)., J Dtsch Dermatol Ges, 2017. 15 (6)(6): p. 657-659., https://pubmed.ncbi.nlm.nih.gov/28591434 /

998. Tan, SC, Tan, JW, Symmetrical drug-related intertriginous and flexural exanthema., Curr Opin Allergy Clin Immunol, 2011. 11 (4)(4): p. 313-8., https://pubmed.ncbi.nlm.nih.gov/21659857 /

999. Nespoulous, L, Matei, I, Charissoux, A, Bédane, C, Assikar, S, Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature., Contact Dermatitis, 2018. 79 (6)(6): p. 378-380., https://pubmed.ncbi.nlm.nih.gov/30062790 /

1000. McClatchy, J, Yap, T, Nirenberg, A, Scardamaglia, L, Fixed drug eruptions - the common and novel culprits since 2000., J Dtsch Dermatol Ges, 2022. 20 (10)(10): p. 1289-1302., https://pubmed.ncbi.nlm.nih.gov/36210056 /

1001. Hofmann, GA, Weber, B, Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences., J Dtsch Dermatol Ges, 2021. 19 (1)(1): p. 19-29., https://pubmed.ncbi.nlm.nih.gov/33491908 /

1002. Lembo, S, Raimondo, A, Conti, V, Venturini, M, Photosensitivity and cancer immune-targeted therapies., Photodermatol Photoimmunol Photomed, 2020. 36 (3)(3): p. 172-178., https://pubmed.ncbi.nlm.nih.gov/31978248/

1003. Sibaud, V, Anticancer treatments and photosensitivity., J Eur Acad Dermatol Venereol, 2022. 36 Suppl 6 (Suppl 6)(Suppl 6): p. 51-58., https://pubmed.ncbi.nlm.nih.gov/35738806 /

1004. Moore, DE, Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management., Drug Saf, 2002. 25 (5)(5): p. 345-72., https://pubmed.ncbi.nlm.nih.gov/12020173 /

1005. Blakely, KM, Drucker, AM, Rosen, CF, Drug-Induced Photosensitivity-An Update: Culprit Drugs, Prevention and Management., Drug Saf, 2019. 42 (7)(7): p. 827-847., https://pubmed.ncbi.nlm.nih.gov/30888626 /

1006. Dubakiene, R, Kupriene, M, Scientific problems of photosensitivity., Medicina (Kaunas), 2006. 42 (8)(8): p. 619-24., https://pubmed.ncbi.nlm.nih.gov/16963827 /

1007. Ferguson, J, Photosensitivity due to drugs., Photodermatol Photoimmunol Photomed, 2002. 18 (5)(5): p. 262-9., https://pubmed.ncbi.nlm.nih.gov/12390668 /

1008. Kato, Y, Otsuka, A, Miyachi, Y, Kabashima, K, Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma., J Eur Acad Dermatol Venereol, 2016. 30 (10)(10): p. e89-e91., https://pubmed.ncbi.nlm.nih.gov/26388113 /

1009. Ohtsuka, M, Miura, T, Mori, T, Ishikawa, M, Yamamoto, T, Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma., JAMA Dermatol, 2015. 151 (7)(7): p. 797-9., https://pubmed.ncbi.nlm.nih.gov/25875052 /

1010. Voudouri, D, Nikolaou, V, Laschos, K, Charpidou, A, Soupos, N, Triantafyllopoulou, I, et.al. Anti-PD1/PDL1 induced psoriasis., Curr Probl Cancer, 2017. 41 (6)(6): p. 407-412., https://pubmed.ncbi.nlm.nih.gov/29096940 /

1011. Totonchy, MB, Ezaldein, HH, Ko, CJ, Choi, JN, Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma., JAMA Dermatol, 2016. 152 (5)(5): p. 590-2., https://pubmed.ncbi.nlm.nih.gov/26675815/

1012. Bonigen, J, Raynaud-Donzel, C, Hureaux, J, Kramkimel, N, Blom, A, Jeudy, G, et.al. Anti-PD1-induced psoriasis: a study of 21 patients., J Eur Acad Dermatol Venereol, 2017. 31 (5)(5): p. e254-e257., https://pubmed.ncbi.nlm.nih.gov/27739129 /

1013. Ludwig, C, Goh, V, Rajkumar, J, Au, J, Tsoukas, M, Drug eruptions associated with tumor therapy: Great imitators., Clin Dermatol, 2020. 38 (2)(2): p. 208-215., https://pubmed.ncbi.nlm.nih.gov/32513400 /

1014. Yamamoto, T, Flagellate erythema induced by cisplatin., Clin Exp Dermatol, 2016. 41 (5)(5): p. 562-3., https://pubmed.ncbi.nlm.nih.gov/26931175 /

1015. Ziemer, M, Goetze, S, Juhasz, K, Elsner, P, Flagellate dermatitis as a bleomycin-specific adverse effect of cytostatic therapy: a clinical-histopathologic correlation., Am J Clin Dermatol, 2011. 12 (1)(1): p. 68-76., https://pubmed.ncbi.nlm.nih.gov/21067249/

1016. Wick, W, Hertenstein, A, Platten, M, Neurological sequelae of cancer immunotherapies and targeted therapies., Lancet Oncol, 2016. 17 (12)(12): p. e529-e541., https://pubmed.ncbi.nlm.nih.gov/27924751 /

1017. Alessi, I, Caroleo, AM, de Palma, L, Mastronuzzi, A, Pro, S, Colafati, GS, et.al. Short and Long-Term Toxicity in Pediatric Cancer Treatment: Central Nervous System Damage., Cancers (Basel), 2022. 14 (6)(6):, https://pubmed.ncbi.nlm.nih.gov/35326692/

1018. Bhojwani, D, Bansal, R, Wayne, AS, Managing therapy-associated neurotoxicity in children with ALL., Hematology Am Soc Hematol Educ Program, 2021. 2021 (1)(1): p. 376-383., https://pubmed.ncbi.nlm.nih.gov/34889354/

1019. Schacht, J, Talaska, AE, Rybak, LP, Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention., Anat Rec (Hoboken), 2012. 295 (11)(11): p. 1837-50., https://pubmed.ncbi.nlm.nih.gov/23045231/

1020. Chovanec, M, Abu Zaid, M, Hanna, N, El-Kouri, N, Einhorn, LH, Albany, C, Long-term toxicity of cisplatin in germ-cell tumor survivors., Ann Oncol, 2017. 28 (11)(11): p. 2670-2679., https://pubmed.ncbi.nlm.nih.gov/29045502/

1021. Skalleberg, J, Solheim, O, Fosså, SD, Småstuen, MC, Osnes, T, Gundersen, POM, et.al. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer., Gynecol Oncol, 2017. 145 (1)(1): p. 148-153., https://pubmed.ncbi.nlm.nih.gov/28202195/

1022. Moke, DJ, Luo, C, Millstein, J, Knight, KR, Rassekh, SR, Brooks, B, et.al. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study., Lancet Child Adolesc Health, 2021. 5 (4)(4): p. 274-283., https://pubmed.ncbi.nlm.nih.gov/33581749/

1023. Dillard, LK, Lopez-Perez, L, Martinez, RX, Fullerton, AM, Chadha, S, McMahon, CM, Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis., Cancer Epidemiol, 2022. 79 (): p. 102203., https://pubmed.ncbi.nlm.nih.gov/35724557/

1024. Strebel, S, Mader, L, Sláma, T, Waespe, N, Weiss, A, Parfitt, R, et.al. Severity of hearing loss after platinum chemotherapy in childhood cancer survivors., Pediatr Blood Cancer, 2022. 69 (9)(9): p. e29755., https://pubmed.ncbi.nlm.nih.gov/35723448/

1025. Paken, J, Govender, CD, Pillay, M, Ayele, BT, Sewram, V, Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa., BMC Cancer, 2021. 21 (1)(1): p. 822., https://pubmed.ncbi.nlm.nih.gov/34271863/

1026. Frisina, RD, Wheeler, HE, Fossa, SD, Kerns, SL, Fung, C, Sesso, HD, et.al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer., J Clin Oncol, 2016. 34 (23)(23): p. 2712-20., https://pubmed.ncbi.nlm.nih.gov/27354478/

1027. Haugnes, HS, Stenklev, NC, Brydøy, M, Dahl, O, Wilsgaard, T, Laukli, E, et.al. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study., Acta Oncol, 2018. 57 (8)(8): p. 1075-1083., https://pubmed.ncbi.nlm.nih.gov/29384420/

1028. Beyea, JA, Lau, C, Cooke, B, Hall, S, Nathan, PC, Gupta, S, Long-Term Incidence and Predictors of Significant Hearing Loss Requiring Hearing Assistive Devices Among Childhood Cancer Survivors: A Population-Based Study., J Clin Oncol, 2020. 38 (23)(23): p. 2639-2646., https://pubmed.ncbi.nlm.nih.gov/32463737/

1029. Hellberg, V, Wallin, I, Eriksson, S, Hernlund, E, Jerremalm, E, Berndtsson, M, et.al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity., J Natl Cancer Inst, 2009. 101 (1)(1): p. 37-47., https://pubmed.ncbi.nlm.nih.gov/19116379/

1030. Grossman, SA, Wharam, M, Sheidler, V, Kleinberg, L, Zeltzman, M, Yue, N, et.al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma., J Clin Oncol, 1997. 15 (7)(7): p. 2596-603., https://pubmed.ncbi.nlm.nih.gov/9215830/

1031. Camet, ML, Spence, A, Hayashi, SS, Wu, N, Henry, J, Sauerburger, K, et.al. Cisplatin Ototoxicity: Examination of the Impact of Dosing, Infusion Times, and Schedules In Pediatric Cancer Patients., Front Oncol, 2021. 11 (): p. 673080., https://pubmed.ncbi.nlm.nih.gov/34262862/

1032. Landier, W, Ototoxicity and cancer therapy., Cancer, 2016. 122 (11)(11): p. 1647-58., https://pubmed.ncbi.nlm.nih.gov/26859792/

1033. van As, JW, van den Berg, H, van Dalen, EC, Different infusion durations for preventing platinum-induced hearing loss in children with cancer., Cochrane Database Syst Rev, 2016. (8)(8): p. CD010885., https://pubmed.ncbi.nlm.nih.gov/27498707/

1034. Meijer, AJM, Li, KH, Brooks, B, Clemens, E, Ross, CJ, Rassekh, SR, et.al. The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments., Cancer, 2022. 128 (1)(1): p. 169-179., https://pubmed.ncbi.nlm.nih.gov/34490624/

1035. Jordan, B, Margulies, A, Cardoso, F, Cavaletti, G, Haugnes, HS, Jahn, P, et.al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up., Ann Oncol, 2020. 31 (10)(10): p. 1306-1319., https://pubmed.ncbi.nlm.nih.gov/32739407/

1036. Kros, CJ, Steyger, PS, Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies., Cold Spring Harb Perspect Med, 2019. 9 (11)(11):, https://pubmed.ncbi.nlm.nih.gov/30559254/

1037. Drögemöller, BI, Brooks, B, Critchley, C, Monzon, JG, Wright, GEB, Liu, G, et.al. Further Investigation of the Role of , Clin Cancer Res, 2018. 24 (8)(8): p. 1866-1871., https://pubmed.ncbi.nlm.nih.gov/29358504/

1038. Langer, T, Clemens, E, Broer, L, Maier, L, Uitterlinden, AG, de Vries, ACH, et.al. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study., Eur J Cancer, 2020. 138 (): p. 212-224., https://pubmed.ncbi.nlm.nih.gov/32905960/

1039. Zhang, X, Trendowski, MR, Wilkinson, E, Shahbazi, M, Dinh, PC, Shuey, MM, et.al. Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy., Cancer Med, 2022. 11 (14)(14): p. 2801-2816., https://pubmed.ncbi.nlm.nih.gov/35322580/

1040. Meijer, Annelot J. M., van den Heuvel-Eibrink, Marry M., Brooks, Beth, am Zehnhoff-Dinnesen, Antoinette G., Knight, Kristin R., Freyer, David R., et.al. Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report, 2021. 7(10): p. 1550 - 1558., https://doi.org/10.1001/jamaoncol.2021.2697

1041. Freyer, DR, Brock, P, Knight, K, Reaman, G, Cabral, S, Robinson, PD, et.al. Interventions for cisplatin-induced hearing loss in children and adolescents with cancer., Lancet Child Adolesc Health, 2019. 3 (8)(8): p. 578-584., https://pubmed.ncbi.nlm.nih.gov/31160205/

1042. Fetoni, AR, Brigato, F, De Corso, E, Lucidi, D, Sergi, B, Scarano, E, et.al. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity., Eur Arch Otorhinolaryngol, 2022. 279 (10)(10): p. 4677-4686., https://pubmed.ncbi.nlm.nih.gov/35024956/

1043. Brock, PR, Bellman, SC, Yeomans, EC, Pinkerton, CR, Pritchard, J, Cisplatin ototoxicity in children: a practical grading system., Med Pediatr Oncol, 1991. 19 (4)(4): p. 295-300., https://pubmed.ncbi.nlm.nih.gov/2056973 /

1044. American Speech-Language-Hearing Association, Audiologic management of individuals receiving cochleotoxic drug therapyASHA, 1994.

1045. Schmidt, CM, Bartholomäus, E, Deuster, D, Heinecke, A, Dinnesen, AG, [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy]., HNO, 2007. 55 (4)(4): p. 299-306., https://pubmed.ncbi.nlm.nih.gov/16437215 /

1046. Chang, KW, Chinosornvatana, N, Practical grading system for evaluating cisplatin ototoxicity in children., J Clin Oncol, 2010. 28 (10)(10): p. 1788-95., https://pubmed.ncbi.nlm.nih.gov/20194861 /

1047. Theunissen, EA, Dreschler, WA, Latenstein, MN, Rasch, CR, van der Baan, S, de Boer, JP, et.al. A new grading system for ototoxicity in adults., Ann Otol Rhinol Laryngol, 2014. 123 (10)(10): p. 711-8., https://pubmed.ncbi.nlm.nih.gov/24820112/

1048. Brock, PR, New insights into cisplatin ototoxicity., Cancer, 2022. 128 (1)(1): p. 43-46., https://pubmed.ncbi.nlm.nih.gov/34490622/

1049. Ardeshirrouhanifard, S, Fossa, SD, Huddart, R, Monahan, PO, Fung, C, Song, Y, et.al. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments., Ear Hear, 2022. 43 (3)(3): p. 794-807., https://pubmed.ncbi.nlm.nih.gov/35067571/

1050. Foster, T, Ionescu, C, Walker, D, Jones, M, Wagle, S, Kovacevic, B, et.al. Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices., Ther Deliv, 2021. 12 (10)(10): p. 723-737., https://pubmed.ncbi.nlm.nih.gov/34697955/

1051. Komaki, R, Lee, JS, Milas, L, Lee, HK, Fossella, FV, Herbst, RS, et.al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial., Int J Radiat Oncol Biol Phys, 2004. 58 (5)(5): p. 1369-77., https://pubmed.ncbi.nlm.nih.gov/15050312/

1052. Marina, N, Chang, KW, Malogolowkin, M, London, WB, Frazier, AL, Womer, RB, et.al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study., Cancer, 2005. 104 (4)(4): p. 841-7., https://pubmed.ncbi.nlm.nih.gov/15999362/

1053. Gallegos-Castorena, S, Martínez-Avalos, A, Mohar-Betancourt, A, Guerrero-Avendaño, G, Zapata-Tarrés, M, Medina-Sansón, A, Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin., Pediatr Hematol Oncol, 2007. 24 (6)(6): p. 403-8., https://pubmed.ncbi.nlm.nih.gov/17710657/

1054. Fouladi, M, Chintagumpala, M, Ashley, D, Kellie, S, Gururangan, S, Hassall, T, et.al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma., J Clin Oncol, 2008. 26 (22)(22): p. 3749-55., https://pubmed.ncbi.nlm.nih.gov/18669462/

1055. Katzenstein, HM, Chang, KW, Krailo, M, Chen, Z, Finegold, MJ, Rowland, J, et.al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group., Cancer, 2009. 115 (24)(24): p. 5828-35., https://pubmed.ncbi.nlm.nih.gov/19813275/

1056. Gurney, JG, Bass, JK, Onar-Thomas, A, Huang, J, Chintagumpala, M, Bouffet, E, et.al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma., Neuro Oncol, 2014. 16 (6)(6): p. 848-55., https://pubmed.ncbi.nlm.nih.gov/24414535/

1057. Villani, V, Zucchella, C, Cristalli, G, Galiè, E, Bianco, F, Giannarelli, D, et.al. Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial., Head Neck, 2016. 38 Suppl 1 (): p. E2118-21., https://pubmed.ncbi.nlm.nih.gov/26849799/

1058. Paredes, J, Hong, WK, Felder, TB, Dimery, IW, Choksi, AJ, Newman, RA, et.al. Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck., J Clin Oncol, 1988. 6 (6)(6): p. 955-62., https://pubmed.ncbi.nlm.nih.gov/2836565/

1059. Verma, S, Stewart, DJ, Maroun, JA, Nair, RC, A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram., Am J Clin Oncol, 1990. 13 (2)(2): p. 119-24., https://pubmed.ncbi.nlm.nih.gov/2180271/

1060. Wang, J, Tian, KY, Fang, Y, Chang, HM, Han, YN, Chen, FQ, Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression., Int J Immunopathol Pharmacol, 2021. 35 (): p. 20587384211034086., https://pubmed.ncbi.nlm.nih.gov/34344210/

1061. Gandara, D. R., Nahhas, W. A., Adelson, M. D., Lichtman, S. M., Podczaski, E. S., Yanovich, S., et.al. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities, J Clin Oncol, 1995. 13: p. 490-6.

1062. Riga, MG, Chelis, L, Kakolyris, S, Papadopoulos, S, Stathakidou, S, Chamalidou, E, et.al. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy., Am J Clin Oncol, 2013. 36 (1)(1): p. 1-6., https://pubmed.ncbi.nlm.nih.gov/22134515/

1063. Yoo, J, Hamilton, SJ, Angel, D, Fung, K, Franklin, J, Parnes, LS, et.al. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients., Laryngoscope, 2014. 124 (3)(3): p. E87-94., https://pubmed.ncbi.nlm.nih.gov/23946126/

1064. Sarafraz, Z, Ahmadi, A, Daneshi, A, Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial., Int Tinnitus J, 2018. 22 (1)(1): p. 40-45., https://pubmed.ncbi.nlm.nih.gov/29993216/

1065. Wang, W, Chen, E, Ding, X, Lu, P, Chen, J, Ma, P, et.al. N-acetylcysteine protect inner hair cells from cisplatin by alleviated celluar oxidative stress and apoptosis., Toxicol In Vitro, 2022. 81 (): p. 105354., https://pubmed.ncbi.nlm.nih.gov/35346799/

1066. Sena, LS, Sasso, GRS, Sanches, JM, Franco, PC, Azevedo, MF, Oliani, SM, et.al. Pharmacological treatment with annexin A1-derived peptide protects against cisplatin-induced hearing loss., Toxicol Lett, 2022. 363 (): p. 27-35., https://pubmed.ncbi.nlm.nih.gov/35561849/

1067. Péus, D, Sellathurai, S, Newcomb, N, Tschopp, K, Radeloff, A, The Otoprotective Effect of Ear Cryotherapy: Systematic Review and Future Perspectives., Audiol Res, 2022. 12 (4)(4): p. 377-387., https://pubmed.ncbi.nlm.nih.gov/35892664/

1068. Orgel, E, Villaluna, D, Krailo, MD, Esbenshade, A, Sung, L, Freyer, DR, Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431., Lancet Oncol, 2022. 23 (5)(5): p. 570-572., https://pubmed.ncbi.nlm.nih.gov/35489339/

1069. Chen, CH, Huang, CY, Lin, HH, Wang, MC, Chang, CY, Cheng, YF, Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis., JAMA Netw Open, 2021. 4 (8)(8): p. e2118895., https://pubmed.ncbi.nlm.nih.gov/34338793/

1070. Brock, PR, Maibach, R, Childs, M, Rajput, K, Roebuck, D, Sullivan, MJ, et.al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss., N Engl J Med, 2018. 378 (25)(25): p. 2376-2385., https://pubmed.ncbi.nlm.nih.gov/29924955/

1071. Freyer, DR, Chen, L, Krailo, MD, Knight, K, Villaluna, D, Bliss, B, et.al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial., Lancet Oncol, 2017. 18 (1)(1): p. 63-74., https://pubmed.ncbi.nlm.nih.gov/27914822/

1072. Moreno, I, Belinchon, A, Evaluating the Efficacy of Intratympanic Dexamethasone in Protecting Against Irreversible Hearing Loss in Patients on Cisplatin-Based Cancer Treatment: A Randomized Controlled Phase IIIB Clinical Trial., Ear Hear, 2022. 43 (2)(2): p. 676-684., https://pubmed.ncbi.nlm.nih.gov/34483247/

1073. Marshak, T, Steiner, M, Kaminer, M, Levy, L, Shupak, A, Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone: A Randomized Controlled Study., Otolaryngol Head Neck Surg, 2014. 150 (6)(6): p. 983-90., https://pubmed.ncbi.nlm.nih.gov/24618499/

1074. Lu, W, Ni, K, Li, Z, Xiao, L, Li, Y, Jiang, Y, et.al. Salubrinal Protects Against Cisplatin-Induced Cochlear Hair Cell Endoplasmic Reticulum Stress by Regulating Eukaryotic Translation Initiation Factor 2α Signalling., Front Mol Neurosci, 2022. 15 (): p. 916458., https://pubmed.ncbi.nlm.nih.gov/35706425/

1075. Febles, NK, Bauer, MA, Ding, B, Zhu, X, Gallant, ND, Frisina, RD, A combinatorial approach to protect sensory tissue against cisplatin-induced ototoxicity., Hear Res, 2022. 415 (): p. 108430., https://pubmed.ncbi.nlm.nih.gov/35051751/

1076. Lanvers-Kaminsky, C, Ciarimboli, G, Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin., Pharmacogenomics, 2017. 18 (18)(18): p. 1683-1695., https://pubmed.ncbi.nlm.nih.gov/29173064/

1077. Tyler, RS, Owen, RL, Bridges, J, Gander, PE, Perreau, A, Mancini, PC, Tinnitus Suppression in Cochlear Implant Patients Using a Sound Therapy App., Am J Audiol, 2018. 27 (3)(3): p. 316-323., https://pubmed.ncbi.nlm.nih.gov/30105356/

1078. Renovanz, Mirjam, Rieger, Johannes, Tabatabai, Ghazaleh, Tumortherapieassoziierte neurologische Symptome, 2021. 92(12): p. 1305 - 1314., https://doi.org/10.1007/s00115-021-01223-9

1079. Morris, PG, Correa, DD, Yahalom, J, Raizer, JJ, Schiff, D, Grant, B, et.al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome., J Clin Oncol, 2013. 31 (31)(31): p. 3971-9., https://pubmed.ncbi.nlm.nih.gov/24101038/

1080. Roth, P, Winklhofer, S, Müller, AMS, Dummer, R, Mair, MJ, Gramatzki, D, et.al. Neurological complications of cancer immunotherapy., Cancer Treat Rev, 2021. 97 (): p. 102189., https://pubmed.ncbi.nlm.nih.gov/33872978/

1081. Mocquot, P, Mossazadeh, Y, Lapierre, L, Pineau, F, Despas, F, The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials., J Clin Pharm Ther, 2022. 47 (9)(9): p. 1337-1351., https://pubmed.ncbi.nlm.nih.gov/35906791/

1082. Ide, Y, Yanagisawa, R, Kubota, N, Sakashita, K, Tozuka, M, Nakamura, T, et.al. Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy., Pediatr Blood Cancer, 2019. 66 (12)(12): p. e27996., https://pubmed.ncbi.nlm.nih.gov/31535455/

1083. Rieger, C, Fiegl, M, Tischer, J, Ostermann, H, Schiel, X, Incidence and severity of ifosfamide-induced encephalopathy., Anticancer Drugs, 2004. 15 (4)(4): p. 347-50., https://pubmed.ncbi.nlm.nih.gov/15057138/

1084. David, KA, Picus, J, Evaluating risk factors for the development of ifosfamide encephalopathy., Am J Clin Oncol, 2005. 28 (3)(3): p. 277-80., https://pubmed.ncbi.nlm.nih.gov/15923801/

1085. Szabatura, AH, Cirrone, F, Harris, C, McDonnell, AM, Feng, Y, Voit, D, et.al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center., J Oncol Pharm Pract, 2015. 21 (3)(3): p. 188-93., https://pubmed.ncbi.nlm.nih.gov/24664476/

1086. Vazirian, F, Samadi, S, Rahimi, H, Sadeghi, M, Mohammadpour, AH, Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review., Cancer Chemother Pharmacol, 2022. 90 (1)(1): p. 1-6., https://pubmed.ncbi.nlm.nih.gov/35635561/

1087. Lee Brink, A, Bowe, C, Dains, JE, Risk Factors for Ifosfamide-Related Encephalopathy in Adult Cancer Patients: An Integrative Review., J Adv Pract Oncol, 2020. 11 (4)(4): p. 368-380., https://pubmed.ncbi.nlm.nih.gov/33604097/

1088. Howell, JE, Szabatura, AH, Hatfield Seung, A, Nesbit, SA, Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant., J Oncol Pharm Pract, 2008. 14 (3)(3): p. 157-62., https://pubmed.ncbi.nlm.nih.gov/18719071/

1089. Jarkowski, A, Miller, A, Hecke, T, Blustein, L, Wong, M, The Risk of Neurotoxicity with Concomitant Use of Aprepitant and Ifosfamide.Journal of Hematology Oncology Pharmacy, 2011. 1 (2): p. 16 - 21.

1090. Küpfer, A, Aeschlimann, C, Wermuth, B, Cerny, T, Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue., Lancet, 1994. 343 (8900)(8900): p. 763-4., https://pubmed.ncbi.nlm.nih.gov/7510815/

1091. Pelgrims, J, De Vos, F, Van den Brande, J, Schrijvers, D, Prové, A, Vermorken, JB, Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature., Br J Cancer, 2000. 82 (2)(2): p. 291-4., https://pubmed.ncbi.nlm.nih.gov/10646879/

1092. Buesa, JM, García-Teijido, P, Losa, R, Fra, J, Treatment of ifosfamide encephalopathy with intravenous thiamin., Clin Cancer Res, 2003. 9 (12)(12): p. 4636-7., https://pubmed.ncbi.nlm.nih.gov/14555540/

1093. Kasper, B, Harter, C, Meissner, J, Bellos, F, Krasniqi, F, Ho, AD, et.al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?, Support Care Cancer, 2004. 12 (3)(3): p. 205-7., https://pubmed.ncbi.nlm.nih.gov/14727169/

1094. Richards, A, Marshall, H, McQuary, A, Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity., J Oncol Pharm Pract, 2011. 17 (4)(4): p. 372-80., https://pubmed.ncbi.nlm.nih.gov/20861178/

1095. Kettle, JK, Grauer, D, Folker, TL, O'Neal, N, Henry, DW, Williams, CB, Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy., Pharmacotherapy, 2010. 30 (8)(8): p. 812-7., https://pubmed.ncbi.nlm.nih.gov/20653357/

1096. McDonnell, AM, Rybak, I, Wadleigh, M, Fisher, DC, Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy., J Oncol Pharm Pract, 2012. 18 (4)(4): p. 436-9., https://pubmed.ncbi.nlm.nih.gov/22235061/

1097. Snyder, M, Gangadhara, S, Brohl, AS, Ludlow, S, Nanjappa, S, Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue., Cancer Control, 2017. 24 (5)(5): p. 1073274817729070., https://pubmed.ncbi.nlm.nih.gov/28975823/

1098. Abahssain, H, Moukafih, B, Essangri, H, Mrabti, H, Meddah, B, Guessous, F, et.al. Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?, J Oncol Pharm Pract, 2021. 27 (1)(1): p. 143-149., https://pubmed.ncbi.nlm.nih.gov/33153383/

1099. Chain, G, Kalia, M, Kestenbaum, K, Pappas, L, Sechser-Perl, A, Campino, GA, et.al. A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature., BMC Pediatr, 2022. 22 (1)(1): p. 76., https://pubmed.ncbi.nlm.nih.gov/35109795/

1100. Feinsilber, D, Leoni, RJ, Siripala, D, Leuck, J, Mears, KA, Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies., Cureus, 2018. 10 (1)(1): p. e2040., https://pubmed.ncbi.nlm.nih.gov/29541561/

1101. Mateos, MK, Marshall, GM, Barbaro, PM, Quinn, MCJ, George, C, Mayoh, C, et.al. Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia., Haematologica, 2022. 107 (3)(3): p. 635-643., https://pubmed.ncbi.nlm.nih.gov/33567813/

1102. Rijmenams, I, Moechars, D, Uyttebroeck, A, Radwan, A, Blommaert, J, Deprez, S, et.al. Age- and Intravenous Methotrexate-Associated Leukoencephalopathy and Its Neurological Impact in Pediatric Patients with Lymphoblastic Leukemia., Cancers (Basel), 2021. 13 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/33923795/

1103. Hussain, F, Rehman, J, Chaudhry, QU, Mahmood, SK, Ghafoor, T, Methotrexate-induced Leukoencephalopathy: A Rare but Life-threatening Toxicity., J Coll Physicians Surg Pak, 2022. 32 (4)(4): p. S44-S46., https://pubmed.ncbi.nlm.nih.gov/35633009/

1104. Śliwa-Tytko, P, Kaczmarska, A, Lejman, M, Zawitkowska, J, Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy., Int J Mol Sci, 2022. 23 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/35628334/

1105. Bernini, JC, Fort, DW, Griener, JC, Kane, BJ, Chappell, WB, Kamen, BA, Aminophylline for methotrexate-induced neurotoxicity., Lancet, 1995. 345 (8949)(8949): p. 544-7., https://pubmed.ncbi.nlm.nih.gov/7776773/

1106. Razi, W, Haque, AU, Sadiq, H, Ullah, R, Jabbar, N, Mirza, S, Safety and Efficacy of Aminophylline in Intrathecal Methotrexate-related Neurological Toxicity in Large Pediatric Oncology Centre., J Coll Physicians Surg Pak, 2021. 30 (4)(4): p. 481-484., https://pubmed.ncbi.nlm.nih.gov/33866741/

1107. Drachtman, RA, Cole, PD, Golden, CB, James, SJ, Melnyk, S, Aisner, J, et.al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity., Pediatr Hematol Oncol, 2002. 19 (5)(5): p. 319-27., https://pubmed.ncbi.nlm.nih.gov/12078863/

1108. Afshar, M, Birnbaum, D, Golden, C, Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity., Pediatr Neurol, 2014. 50 (6)(6): p. 625-9., https://pubmed.ncbi.nlm.nih.gov/24742799/

1109. Shuper, A, Stark, B, Kornreich, L, Cohen, IJ, Aviner, S, Steinmetz, A, et.al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity., J Child Neurol, 2000. 15 (9)(9): p. 573-80., https://pubmed.ncbi.nlm.nih.gov/11019787/

1110. Cohen, IJ, Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system., J Pediatr Hematol Oncol, 2004. 26 (3)(3): p. 156-63., https://pubmed.ncbi.nlm.nih.gov/15125607/

1111. Paul, S, Short, NJ, Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management., Curr Oncol Rep, 2022. 24 (4)(4): p. 427-436., https://pubmed.ncbi.nlm.nih.gov/35141858/

1112. Cohen, IJ, Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue., Cancer Chemother Pharmacol, 2017. 79 (6)(6): p. 1057-1065., https://pubmed.ncbi.nlm.nih.gov/28455583/

1113. Vezmar, S, Schüsseler, P, Becker, A, Bode, U, Jaehde, U, Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity., Pediatr Blood Cancer, 2009. 52 (1)(1): p. 26-32., https://pubmed.ncbi.nlm.nih.gov/19006245/

1114. Herrlinger, U, Küker, W, Uhl, M, Blaicher, HP, Karnath, HO, Kanz, L, et.al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report., Ann Neurol, 2005. 57 (6)(6): p. 843-7., https://pubmed.ncbi.nlm.nih.gov/15929034/

1115. Juergens, A, Pels, H, Rogowski, S, Fliessbach, K, Glasmacher, A, Engert, A, et.al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma., Ann Neurol, 2010. 67 (2)(2): p. 182-9., https://pubmed.ncbi.nlm.nih.gov/20225195/

1116. Gibson, EM, Nagaraja, S, Ocampo, A, Tam, LT, Wood, LS, Pallegar, PN, et.al. Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment., Cell, 2019. 176 (1-2)(1-2): p. 43-55.e13., https://pubmed.ncbi.nlm.nih.gov/30528430/

1117. Bhojwani, D, Sabin, ND, Pei, D, Yang, JJ, Khan, RB, Panetta, JC, et.al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia., J Clin Oncol, 2014. 32 (9)(9): p. 949-59., https://pubmed.ncbi.nlm.nih.gov/24550419/

1118. Verduin, M, Zindler, JD, Martinussen, HM, Jansen, RL, Croes, S, Hendriks, LE, et.al. Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors., Oncologist, 2017. 22 (2)(2): p. 222-235., https://pubmed.ncbi.nlm.nih.gov/28167569/

1119. Kaur, G, Ashraf, I, Peck, MM, Maram, R, Mohamed, A, Ochoa Crespo, D, et.al. Chemotherapy and Immunosuppressant Therapy-Induced Posterior Reversible Encephalopathy Syndrome., Cureus, 2020. 12 (10)(10): p. e11163., https://pubmed.ncbi.nlm.nih.gov/33251070/

1120. How, J, Blattner, M, Fowler, S, Wang-Gillam, A, Schindler, SE, Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature., Neurologist, 2016. 21 (6)(6): p. 112-117., https://pubmed.ncbi.nlm.nih.gov/27801773/

1121. Jennane, S, Mahtat, EM, Ababou, M, El Maaroufi, H, Doghmi, K, Posterior Reversible Encephalopathy Syndrome Secondary to R-CHOP Chemotherapy Regimen., Cureus, 2022. 14 (5)(5): p. e24988., https://pubmed.ncbi.nlm.nih.gov/35719806/

1122. Roy, S, Gandhi, AK, Jana, M, Julka, PK, Recurrent posterior reversible encephalopathy syndrome after chemotherapy in hematologic malignancy-posterior reversible encephalopathy syndrome can strike twice!!!, J Cancer Res Ther, 2014. 10 (2)(2): p. 393-6., https://pubmed.ncbi.nlm.nih.gov/25022403/

1123. Floeter, AE, Patel, A, Tran, M, Chamberlain, MC, Hendrie, PC, Gopal, AK, et.al. Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy., Clin Lymphoma Myeloma Leuk, 2017. 17 (4)(4): p. 225-230., https://pubmed.ncbi.nlm.nih.gov/28169156/

1124. Hun, M, Xie, M, She, Z, Abdirahman, AS, Li, C, Wu, F, et.al. Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size., Front Pediatr, 2021. 9 (): p. 678890., https://pubmed.ncbi.nlm.nih.gov/34277519/

1125. Herzig, RH, Hines, JD, Herzig, GP, Wolff, SN, Cassileth, PA, Lazarus, HM, et.al. Cerebellar toxicity with high-dose cytosine arabinoside., J Clin Oncol, 1987. 5 (6)(6): p. 927-32., https://pubmed.ncbi.nlm.nih.gov/3585447/

1126. Jolson, HM, Bosco, L, Bufton, MG, Gerstman, BB, Rinsler, SS, Williams, E, et.al. Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine., J Natl Cancer Inst, 1992. 84 (7)(7): p. 500-5., https://pubmed.ncbi.nlm.nih.gov/1545440/

1127. Feldman, EJ, Alberts, DS, Arlin, Z, Ahmed, T, Mittelman, A, Baskind, P, et.al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia., J Clin Oncol, 1993. 11 (10)(10): p. 2002-9., https://pubmed.ncbi.nlm.nih.gov/8410125/

1128. Low, M, Lee, D, Coutsouvelis, J, Patil, S, Opat, S, Walker, P, et.al. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia., Intern Med J, 2013. 43 (3)(3): p. 294-7., https://pubmed.ncbi.nlm.nih.gov/22757980/

1129. Taillibert, S, Le Rhun, E, Chamberlain, MC, Chemotherapy-Related Neurotoxicity., Curr Neurol Neurosci Rep, 2016. 16 (9)(9): p. 81., https://pubmed.ncbi.nlm.nih.gov/27443648/

1130. Malhotra, P, Mahi, S, Lal, V, Kumari, S, Jain, S, Varma, S, Cytarabine-induced neurotoxicity responding to methyl prednisolone., Am J Hematol, 2004. 77 (4)(4): p. 416., https://pubmed.ncbi.nlm.nih.gov/15551283/

1131. Tran, PN, Kong, XT, Cytarabine Induced Acute Cerebellar Syndrome during Hyper-CVAD Treatment for B-Cell Acute Lymphoblastic Leukemia., Case Rep Neurol, 2017. 9 (1)(1): p. 114-120., https://pubmed.ncbi.nlm.nih.gov/28559835/

1132. Dotson, JL, Jamil, MO, Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series., Int J Hematol, 2018. 108 (5)(5): p. 554-557., https://pubmed.ncbi.nlm.nih.gov/29946854/

1133. Smith, GA, Damon, LE, Rugo, HS, Ries, CA, Linker, CA, High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency., J Clin Oncol, 1997. 15 (2)(2): p. 833-9., https://pubmed.ncbi.nlm.nih.gov/9053511/

1134. Grossman, SA, Finkelstein, DM, Ruckdeschel, JC, Trump, DL, Moynihan, T, Ettinger, DS, Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group., J Clin Oncol, 1993. 11 (3)(3): p. 561-9., https://pubmed.ncbi.nlm.nih.gov/8445432/

1135. Chamberlain, MC, Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series., J Neurooncol, 2012. 109 (1)(1): p. 143-8., https://pubmed.ncbi.nlm.nih.gov/22539243/

1136. Cachia, D, Kamiya-Matsuoka, C, Pinnix, CC, Chi, L, Kantarjian, HM, Cortes, JE, et.al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience., J Neurooncol, 2015. 122 (2)(2): p. 391-8., https://pubmed.ncbi.nlm.nih.gov/25666482/

1137. Mrugala, MM, Kim, B, Sharma, A, Johnson, N, Graham, C, Kurland, BF, et.al. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer., Clin Breast Cancer, 2019. 19 (5)(5): p. 311-316., https://pubmed.ncbi.nlm.nih.gov/31175053/

1138. Bidikian, AH, Bazarbachi, A, Hourani, R, El-Cheikh, J, Abou Dalle, I, Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature., Curr Res Transl Med, 2021. 69 (3)(3): p. 103296., https://pubmed.ncbi.nlm.nih.gov/34139603/

1139. Palmisciano, P, Watanabe, G, Conching, A, Ogasawara, C, Vojnic, M, D'Amico, RS, Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials., J Neurooncol, 2022. 160 (1)(1): p. 79-100., https://pubmed.ncbi.nlm.nih.gov/35999434/

1140. Graber, JJ, Nolan, CP, Myelopathies in patients with cancer., Arch Neurol, 2010. 67 (3)(3): p. 298-304., https://pubmed.ncbi.nlm.nih.gov/20212227/

1141. Dornbos, D, Elder, JB, Otero, JJ, Baiocchi, RA, Slone, HW, Puduvalli, VK, et.al. Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation., World Neurosurg, 2019. 128 (): p. 381-384., https://pubmed.ncbi.nlm.nih.gov/31128312/

1142. Di Francia, R, Crisci, S, De Monaco, A, Cafiero, C, Re, A, Iaccarino, G, et.al. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers., Cancers (Basel), 2021. 13 (5)(5):, https://pubmed.ncbi.nlm.nih.gov/33669053/

1143. Tariq, H, Gilbert, A, Sharkey, FE, Intrathecal Methotrexate-Induced Necrotizing Myelopathy: A Case Report and Review of Histologic Features., Clin Med Insights Pathol, 2018. 11 (): p. 1179555718809071., https://pubmed.ncbi.nlm.nih.gov/30450009/

1144. Ackermann, R, Semmler, A, Maurer, GD, Hattingen, E, Fornoff, F, Steinbach, JP, et.al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites., J Neurooncol, 2010. 97 (3)(3): p. 425-7., https://pubmed.ncbi.nlm.nih.gov/19821069/

1145. Iglseder, S, Nowosielski, M, Bsteh, G, Muigg, A, Heugenhauser, J, Mayer, E, et.al. Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification., Strahlenther Onkol, 2022. 198 (5)(5): p. 475-483., https://pubmed.ncbi.nlm.nih.gov/35267049/

1146. Tan, CS, Koralnik, IJ, Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis., Lancet Neurol, 2010. 9 (4)(4): p. 425-37., https://pubmed.ncbi.nlm.nih.gov/20298966/

1147. Focosi, D, Tuccori, M, Maggi, F, Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab., Rev Med Virol, 2019. 29 (6)(6): p. e2077., https://pubmed.ncbi.nlm.nih.gov/31369199/

1148. Joly, M, Conte, C, Cazanave, C, Le Moing, V, Tattevin, P, Delobel, P, et.al. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions., Brain, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35779271/

1149. Mayr, P, Lutz, M, Schmutz, M, Hoeppner, J, Liesche-Starnecker, F, Schlegel, J, et.al. Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication., Front Oncol, 2022. 12 (): p. 905103., https://pubmed.ncbi.nlm.nih.gov/36003787/

1150. Bernard-Valnet, R, Koralnik, IJ, Du Pasquier, R, Advances in Treatment of Progressive Multifocal Leukoencephalopathy., Ann Neurol, 2021. 90 (6)(6): p. 865-873., https://pubmed.ncbi.nlm.nih.gov/34405435/

1151. Lambert, N, El Moussaoui, M, Maquet, P, Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors., Eur J Neurol, 2021. 28 (11)(11): p. 3814-3819., https://pubmed.ncbi.nlm.nih.gov/34251719/

1152. Roos-Weil, D, Weiss, N, Guihot, A, Uzunov, M, Bellanger, A, Eymard, B, et.al. Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?, J Neurol, 2021. 268 (7)(7): p. 2458-2465., https://pubmed.ncbi.nlm.nih.gov/33515299/

1153. Volk, T, Warnatz, K, Marks, R, Urbach, H, Schluh, G, Strohmeier, V, et.al. Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patients., J Neurol, 2022. 269 (2)(2): p. 973-981., https://pubmed.ncbi.nlm.nih.gov/34196768/

1154. Hopfner, F, Möhn, N, Eiz-Vesper, B, Maecker-Kolhoff, B, Gottlieb, J, Blasczyk, R, et.al. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy., Neurol Neuroimmunol Neuroinflamm, 2021. 8 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/34001660/

1155. Durand, B, Zairi, F, Boulanger, T, Bonneterre, J, Mortier, L, Le Rhun, E, Chemical meningitis related to intra-CSF liposomal cytarabine., CNS Oncol, 2017. 6 (4)(4): p. 261-267., https://pubmed.ncbi.nlm.nih.gov/29057672/

1156. Glantz, MJ, Jaeckle, KA, Chamberlain, MC, Phuphanich, S, Recht, L, Swinnen, LJ, et.al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors., Clin Cancer Res, 1999. 5 (11)(11): p. 3394-402., https://pubmed.ncbi.nlm.nih.gov/10589750/

1157. Jaeckle, KA, Batchelor, T, O'Day, SJ, Phuphanich, S, New, P, Lesser, G, et.al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis., J Neurooncol, 2002. 57 (3)(3): p. 231-9., https://pubmed.ncbi.nlm.nih.gov/12125986/

1158. Le Rhun, E, Taillibert, S, Zairi, F, Kotecki, N, Devos, P, Mailliez, A, et.al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer., J Neurooncol, 2013. 113 (1)(1): p. 83-92., https://pubmed.ncbi.nlm.nih.gov/23456656/

1159. Strik H, Cell count and staining, in Cerebrospinal fluid in clinical neurology, 2015, Springer Basel; Deisenhammer F, Sellebjerg F, Teunissen CE et al. (Eds).: Basel. p. 81 - 100.

1160. Verstappen, CC, Heimans, JJ, Hoekman, K, Postma, TJ, Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management., Drugs, 2003. 63 (15)(15): p. 1549-63., https://pubmed.ncbi.nlm.nih.gov/12887262/

1161. Ray, J, Mahmood, A, Dogar, M, Guo, J, Nwamaghinna, F, Salciccioli, L, et.al. Simultaneous Cardiotoxicity and Neurotoxicity Associated with 5-fluorouracil Containing Chemotherapy: A Case Report and Literature Review., Am J Med Case Rep, 2020. 8 (3)(3): p. 73-75., https://pubmed.ncbi.nlm.nih.gov/32149185/

1162. Seidel, C, Hentschel, B, Simon, M, Schnell, O, Heese, O, Tatagiba, M, et.al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network., J Neurol, 2013. 260 (3)(3): p. 847-55., https://pubmed.ncbi.nlm.nih.gov/23104124/

1163. Kaptein, FHJ, Stals, MAM, Kapteijn, MY, Cannegieter, SC, Dirven, L, van Duinen, SG, et.al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma., J Thromb Haemost, 2022. 20 (7)(7): p. 1665-1673., https://pubmed.ncbi.nlm.nih.gov/35460331/

1164. Herrmann, J, Common Vascular Toxicities of Cancer Therapies., Cardiol Clin, 2019. 37 (4)(4): p. 365-384., https://pubmed.ncbi.nlm.nih.gov/31587779/

1165. Gilron, I, Baron, R, Jensen, T, Neuropathic pain: principles of diagnosis and treatment., Mayo Clin Proc, 2015. 90 (4)(4): p. 532-45., https://pubmed.ncbi.nlm.nih.gov/25841257/

1166. Tan, AC, McCrary, JM, Park, SB, Trinh, T, Goldstein, D, Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade., Support Care Cancer, 2019. 27 (12)(12): p. 4771-4777., https://pubmed.ncbi.nlm.nih.gov/30972648/

1167. Cavaletti, G, Bogliun, G, Marzorati, L, Zincone, A, Piatti, M, Colombo, N, et.al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale., Neurology, 2003. 61 (9)(9): p. 1297-300., https://pubmed.ncbi.nlm.nih.gov/14610145/

1168. Cavaletti, G, Jann, S, Pace, A, Plasmati, R, Siciliano, G, Briani, C, et.al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity., J Peripher Nerv Syst, 2006. 11 (2)(2): p. 135-41., https://pubmed.ncbi.nlm.nih.gov/16787511/

1169. Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology., J Natl Cancer Inst, 1993. 85 (5)(5): p. 365-76., https://pubmed.ncbi.nlm.nih.gov/8433390/

1170. Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et.al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20, Eur J Cancer, 2005. 41: p. 1135-9.

1171. Cavaletti, G, Cornblath, DR, Merkies, ISJ, Postma, TJ, Rossi, E, Frigeni, B, et.al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings., Ann Oncol, 2013. 24 (2)(2): p. 454-462., https://pubmed.ncbi.nlm.nih.gov/22910842/

1172. Cavaletti, G., Frigeni, B., Lanzani, F., Piatti, M., Rota, S., Briani, C., et.al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale, J Peripher Nerv Syst, 2007. 12: p. 210-5.

1173. Postma, TJ, Aaronson, NK, Heimans, JJ, Muller, MJ, Hildebrand, JG, Delattre, JY, et.al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20., Eur J Cancer, 2005. 41 (8)(8): p. 1135-9., https://pubmed.ncbi.nlm.nih.gov/15911236/

1174. Calhoun, EA, Welshman, EE, Chang, CH, Lurain, JR, Fishman, DA, Hunt, TL, et.al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy., Int J Gynecol Cancer 13 (6)(6): p. 741-8., https://pubmed.ncbi.nlm.nih.gov/14675309/

1175. Huang, HQ, Brady, MF, Cella, D, Fleming, G, Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study., Int J Gynecol Cancer 17 (2)(2): p. 387-93., https://pubmed.ncbi.nlm.nih.gov/17362317/

1176. Cella, D, Peterman, A, Hudgens, S, Webster, K, Socinski, MA, Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)., Cancer, 2003. 98 (4)(4): p. 822-31., https://pubmed.ncbi.nlm.nih.gov/12910528/

1177. Kautio, AL, Haanpää, M, Kautiainen, H, Leminen, A, Kalso, E, Saarto, T, Oxaliplatin scale and National Cancer Institute-Common Toxicity Criteria in the assessment of chemotherapy-induced peripheral neuropathy., Anticancer Res, 2011. 31 (10)(10): p. 3493-6., https://pubmed.ncbi.nlm.nih.gov/21965767/

1178. Burgess, J, Ferdousi, M, Gosal, D, Boon, C, Matsumoto, K, Marshall, A, et.al. Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment., Oncol Ther, 2021. 9 (2)(2): p. 385-450., https://pubmed.ncbi.nlm.nih.gov/34655433/

1179. Cavaletti, G, Marmiroli, P, Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity., Expert Opin Pharmacother, 2018. 19 (2)(2): p. 113-121., https://pubmed.ncbi.nlm.nih.gov/29219629/

1180. Gewandter, JS, Freeman, R, Kitt, RA, Cavaletti, G, Gauthier, LR, McDermott, MP, et.al. Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations., Neurology, 2017. 89 (8)(8): p. 859-869., https://pubmed.ncbi.nlm.nih.gov/28747442/

1181. Jordan, K, Feyer, P, Höller, U, Link, H, Wörmann, B, Jahn, F, Supportive Treatments for Patients with Cancer., Dtsch Arztebl Int, 2017. 114 (27-28)(27-28): p. 481-487., https://pubmed.ncbi.nlm.nih.gov/28764837/

1182. Park, SB, Goldstein, D, Krishnan, AV, Lin, CS, Friedlander, ML, Cassidy, J, et.al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis., CA Cancer J Clin, 2013. 63 (6)(6): p. 419-37., https://pubmed.ncbi.nlm.nih.gov/24590861/

1183. Kandula, T, Farrar, MA, Kiernan, MC, Krishnan, AV, Goldstein, D, Horvath, L, et.al. Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer., Clin Neurophysiol, 2017. 128 (7)(7): p. 1166-1175., https://pubmed.ncbi.nlm.nih.gov/28511129/

1184. Kandula, T, Park, SB, Cohn, RJ, Krishnan, AV, Farrar, MA, Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge., Cancer Treat Rev, 2016. 50 (): p. 118-128., https://pubmed.ncbi.nlm.nih.gov/27664395/

1185. Miltenburg, NC, Boogerd, W, Chemotherapy-induced neuropathy: A comprehensive survey., Cancer Treat Rev, 2014. 40 (7)(7): p. 872-82., https://pubmed.ncbi.nlm.nih.gov/24830939/

1186. Staff, NP, Grisold, A, Grisold, W, Windebank, AJ, Chemotherapy-induced peripheral neuropathy: A current review., Ann Neurol, 2017. 81 (6)(6): p. 772-781., https://pubmed.ncbi.nlm.nih.gov/28486769/

1187. Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., et.al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis, Pain, 2014. 155: p. 2461-70.

1188. Hershman, DL, Till, C, Wright, JD, Awad, D, Ramsey, SD, Barlow, WE, et.al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials., J Clin Oncol, 2016. 34 (25)(25): p. 3014-22., https://pubmed.ncbi.nlm.nih.gov/27325863/

1189. Molassiotis, A, Cheng, HL, Leung, KT, Li, YC, Wong, KH, Au, JSK, et.al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy., Brain Behav, 2019. 9 (6)(6): p. e01312., https://pubmed.ncbi.nlm.nih.gov/31063261/

1190. Johnson, C, Pankratz, VS, Velazquez, AI, Aakre, JA, Loprinzi, CL, Staff, NP, et.al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients., J Neurol Sci, 2015. 349 (1-2)(1-2): p. 124-8., https://pubmed.ncbi.nlm.nih.gov/25586538/

1191. Loprinzi, CL, Lacchetti, C, Bleeker, J, Cavaletti, G, Chauhan, C, Hertz, DL, et.al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update., J Clin Oncol, 2020. 38 (28)(28): p. 3325-3348., https://pubmed.ncbi.nlm.nih.gov/32663120/

1192. Maihöfner, C, Diel, I, Tesch, H, Quandel, T, Baron, R, Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin., Support Care Cancer, 2021. 29 (8)(8): p. 4223-4238., https://pubmed.ncbi.nlm.nih.gov/33624117/

1193. Kus, T., Aktas, G., Alpak, G., Kalender, M. E., Sevinc, A., Kul, S., et.al. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study, Support Care Cancer, 2015.

1194. Beutler, A. S., Kulkarni, A. A., Kanwar, R., Klein, C. J., Therneau, T. M., Qin, R., et.al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy, Ann Neurol, 2014. 76: p. 727-37.

1195. Dispenzieri, A., Kyle, R. A., Neurological aspects of multiple myeloma and related disorders, Best Pract Res Clin Haematol, 2005. 18: p. 673-88.

1196. Silberman, J., Lonial, S., Review of peripheral neuropathy in plasma cell disorders, Hematol Oncol, 2008. 26: p. 55-65.

1197. Kleckner, IR, Kamen, C, Gewandter, JS, Mohile, NA, Heckler, CE, Culakova, E, et.al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial., Support Care Cancer, 2018. 26 (4)(4): p. 1019-1028., https://pubmed.ncbi.nlm.nih.gov/29243164/

1198. Bland, KA, Kirkham, AA, Bovard, J, Shenkier, T, Zucker, D, McKenzie, DC, et.al. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial., Clin Breast Cancer, 2019. 19 (6)(6): p. 411-422., https://pubmed.ncbi.nlm.nih.gov/31601479/

1199. Greenlee, H, Crew, KD, Capodice, J, Awad, D, Buono, D, Shi, Z, et.al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer., Breast Cancer Res Treat, 2016. 156 (3)(3): p. 453-464., https://pubmed.ncbi.nlm.nih.gov/27013473/

1200. Chan, YT, Wang, N, Tam, CW, Tan, HY, Lu, Y, So, TH, et.al. Systematic Review with Meta-Analysis: Effectiveness and Safety of Acupuncture as Adjuvant Therapy for Side Effects Management in Drug Therapy-Receiving Breast Cancer Patients., Evid Based Complement Alternat Med, 2021. 2021 (): p. 9949777., https://pubmed.ncbi.nlm.nih.gov/34675990/

1201. Beijers, AJM, Bonhof, CS, Mols, F, Ophorst, J, de Vos-Geelen, J, Jacobs, EMG, et.al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy., Ann Oncol, 2020. 31 (1)(1): p. 131-136., https://pubmed.ncbi.nlm.nih.gov/31912787/

1202. Kanbayashi, Y, Sakaguchi, K, Ishikawa, T, Ouchi, Y, Nakatsukasa, K, Tabuchi, Y, et.al. Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial., Breast, 2020. 49 (): p. 219-224., https://pubmed.ncbi.nlm.nih.gov/31901783/

1203. Chitkumarn, P, Rahong, T, Achariyapota, V, Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial., Support Care Cancer, 2022. 30 (6)(6): p. 4835-4843., https://pubmed.ncbi.nlm.nih.gov/35147758/

1204. Tsuyuki, S, Senda, N, Kanng, Y, Yamaguchi, A, Yoshibayashi, H, Kikawa, Y, et.al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group., Breast Cancer Res Treat, 2016. 160 (1)(1): p. 61-67., https://pubmed.ncbi.nlm.nih.gov/27620884/

1205. Hanai, A, Ishiguro, H, Sozu, T, Tsuda, M, Yano, I, Nakagawa, T, et.al. Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial., J Natl Cancer Inst, 2018. 110 (2)(2): p. 141-148., https://pubmed.ncbi.nlm.nih.gov/29924336/

1206. Kotani, H, Terada, M, Mori, M, Horisawa, N, Sugino, K, Kataoka, A, et.al. Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial., BMC Cancer, 2021. 21 (1)(1): p. 548., https://pubmed.ncbi.nlm.nih.gov/33985457/

1207. Coolbrandt, A, Vancoille, K, Dejaeger, E, Peeters, H, Laenen, A, Neven, P, et.al. Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer., Breast Cancer Res Treat, 2022. 192 (2)(2): p. 293-301., https://pubmed.ncbi.nlm.nih.gov/34982322/

1208. Sundar, R, Bandla, A, Tan, SS, Liao, LD, Kumarakulasinghe, NB, Jeyasekharan, AD, et.al. Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study., Front Oncol, 2016. 6 (): p. 274., https://pubmed.ncbi.nlm.nih.gov/28119855/

1209. Griffiths, C, Kwon, N, Beaumont, JL, Paice, JA, Cold therapy to prevent paclitaxel-induced peripheral neuropathy., Support Care Cancer, 2018. 26 (10)(10): p. 3461-3469., https://pubmed.ncbi.nlm.nih.gov/29681015/

1210. Rosenbaek, F, Holm, HS, Hjelmborg, JVB, Ewertz, M, Jensen, JD, Effect of cryotherapy on dose of adjuvant paclitaxel in early-stage breast cancer., Support Care Cancer, 2020. 28 (8)(8): p. 3763-3769., https://pubmed.ncbi.nlm.nih.gov/31828491/

1211. Shigematsu, H, Hirata, T, Nishina, M, Yasui, D, Ozaki, S, Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients., Support Care Cancer, 2020. 28 (10)(10): p. 5005-5011., https://pubmed.ncbi.nlm.nih.gov/32036471/

1212. Michel, L., Romar, P., Feisst, M., Hamberger, D., Schwarz, D., Kurre, E., et.al. Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial, Annals of Oncology, 2022. 33: p. S713-S742.

1213. Afonseca, S. O., Cruz, F. M., Cubero Dde, I., Lera, A. T., Schindler, F., Okawara, M., et.al. Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial, Sao Paulo Med J, 2013. 131: p. 35-8.

1214. Argyriou, A. A., Chroni, E., Polychronopoulos, P., Iconomou, G., Koutras, A., Makatsoris, T., et.al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy, Neurology, 2006. 67: p. 2253-5.

1215. Bodnar, L., Wcislo, G., Gasowska-Bodnar, A., Synowiec, A., Szarlej-Wcislo, K., Szczylik, C., Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study, Eur J Cancer, 2008. 44: p. 2608-14.

1216. Bogliun, G., Marzorati, L., Marzola, M., Miceli, M.D., Cantù, M.G., Cavaletti, G., Neurotoxicity of cisplatin +/? reduced glutathione in the first?line treatment of advanced ovarian cancer, International Journal of Gynecological Cancer, 1996. 08/1996: p. 415 - 419.

1217. Cascinu, S., Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Oncology, 2002. 20: p. 3478-3483.

1218. Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M., Catalano, G., Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial, J Clin Oncol, 1995. 13: p. 26-32.

1219. Chay, W. Y., Tan, S. H., Lo, Y. L., Ong, S. Y., Ng, H. C., Gao, F., et.al. Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy, Asia Pac J Clin Oncol, 2010. 6: p. 270-7.

1220. Colombo, N., Bini, S., Miceli, D., Bogliun, G., Marzorati, L., Cavaletti, G., et.al. Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma, Int J Gynecol Cancer, 1995. 5: p. 81-86.

1221. De Vos, F. Y., Bos, A. M., Schaapveld, M., de Swart, C. A., de Graaf, H., van der Zee, A. G., et.al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma, Gynecol Oncol, 2005. 97: p. 60-7.

1222. Dong M, ; Xing PY, ; Liu P,; et al., Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity, Zhonghua Zhong Liu Za Zhi, 2010. 32: p. 208–211.

1223. Gamelin, L., Boisdron-Celle, M., Delva, R., Guerin-Meyer, V., Ifrah, N., Morel, A., et.al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer, Clin Cancer Res, 2004. 10: p. 4055-61.

1224. Gelmon, K., Eisenhauer, E., Bryce, C., Tolcher, A., Mayer, L., Tomlinson, E., et.al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer, J Clin Oncol, 1999. 17: p. 3038-47.

1225. Grothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., et.al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7, J Clin Oncol, 2011. 29: p. 421-7.

1226. Hilpert, F., Stahle, A., Tome, O., Burges, A., Rossner, D., Spathe, K., et.al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group, Support Care Cancer, 2005. 13: p. 797-805.

1227. Hovestadt, A., van der Burg, M. E., Verbiest, H. B., van Putten, W. L., Vecht, C. J., The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo, J Neurol, 1992. 239: p. 143-6.

1228. Ishibashi, K., Okada, N., Miyazaki, T., Sano, M., Ishida, H., Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study, Int J Clin Oncol, 2010. 15: p. 82-7.

1229. Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., et.al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer, J Clin Oncol, 1996. 14: p. 2101-12.

1230. Koeppen, S., Verstappen, C. C., Korte, R., Scheulen, M. E., Strumberg, D., Postma, T. J., et.al. Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma, J Cancer Res Clin Oncol, 2004. 130: p. 153-60.

1231. Kottschade, L. A., Sloan, J. A., Mazurczak, M. A., Johnson, D. B., Murphy, B. P., Rowland, K. M., et.al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial, Support Care Cancer, 2011. 19: p. 1769-77.

1232. Leal, A. D., Qin, R., Atherton, P. J., Haluska, P., Behrens, R. J., Tiber, C. H., et.al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study, Cancer, 2014. 120: p. 1890-7.

1233. Leong, S. S., Tan, E. H., Fong, K. W., Wilder-Smith, E., Ong, Y. K., Tai, B. C., et.al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer, J Clin Oncol, 2003. 21: p. 1767-74.

1234. Lin, P. C., Lee, M. Y., Wang, W. S., Yen, C. C., Chao, T. C., Hsiao, L. T., et.al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data, Support Care Cancer, 2006. 14: p. 484-7.

1235. Loprinzi, C. L., Qin, R., Dakhil, S. R., Fehrenbacher, L., Flynn, K. A., Atherton, P., et.al. Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance), J Clin Oncol, 2014. 32: p. 997-1005.

1236. Milla, P., Airoldi, M., Weber, G., Drescher, A., Jaehde, U., Cattel, L., Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity, Anticancer Drugs, 2009. 20: p. 396-402.

1237. Pace, A., Giannarelli, D., Galie, E., Savarese, A., Carpano, S., Della Giulia, M., et.al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial, Neurology, 2010. 74: p. 762-6.

1238. Pace, A., Savarese, A., Picardo, M., Maresca, V., Pacetti, U., Del Monte, G., et.al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy, J Clin Oncol, 2003. 21: p. 927-31.

1239. Schmidinger, M., Budinsky, A. C., Wenzel, C., Piribauer, M., Brix, R., Kautzky, M., et.al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer, Wien Klin Wochenschr, 2000. 112: p. 617-23.

1240. Smyth, J. F., Bowman, A., Perren, T., Wilkinson, P., Prescott, R. J., Quinn, K. J., et.al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial, Ann Oncol, 1997. 8: p. 569-73.

1241. van der Hoop, R. G., Vecht, C. J., van der Burg, M. E., Elderson, A., Boogerd, W., Heimans, J. J., et.al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer, N Engl J Med, 1990. 322: p. 89-94.

1242. van Gerven, J. M., Hovestadt, A., Moll, J. W., Rodenburg, C. J., Splinter, T. A., van Oosterom, A. T., et.al. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial, J Neurol, 1994. 241: p. 432-5.

1243. van Kooten, B., van Diemen, H. A., Groenhout, K. M., Huijgens, P. C., Ossenkoppele, G. J., Nauta, J. J., et.al. A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy, Arch Neurol, 1992. 49: p. 1027-31.

1244. von Delius, S., Eckel, F., Wagenpfeil, S., Mayr, M., Stock, K., Kullmann, F., et.al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study, Invest New Drugs, 2007. 25: p. 173-80.

1245. Hershman, DL, Unger, JM, Crew, KD, Till, C, Greenlee, H, Minasian, LM, et.al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)., J Natl Cancer Inst, 2018. 110 (6)(6): p. 669-676., https://pubmed.ncbi.nlm.nih.gov/29361042/

1246. Guo, Y, Jones, D, Palmer, JL, Forman, A, Dakhil, SR, Velasco, MR, et.al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial., Support Care Cancer, 2014. 22 (5)(5): p. 1223-31., https://pubmed.ncbi.nlm.nih.gov/24362907/

1247. Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et.al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline, J Clin Oncol, 2014.

1248. Jordan, B, Jahn, F, Beckmann, J, Unverzagt, S, Müller-Tidow, C, Jordan, K, Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review., Oncology, 2016. 90 (6)(6): p. 299-306., https://pubmed.ncbi.nlm.nih.gov/27169552/

1249. Han, CH, Khwaounjoo, P, Kilfoyle, DH, Hill, A, McKeage, MJ, Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients., BMC Cancer, 2013. 13 (): p. 495., https://pubmed.ncbi.nlm.nih.gov/24156389/

1250. Glimelius, B, Manojlovic, N, Pfeiffer, P, Mosidze, B, Kurteva, G, Karlberg, M, et.al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx, Acta Oncol, 2018. 57 (3)(3): p. 393-402., https://pubmed.ncbi.nlm.nih.gov/29140155/

1251. Aghili, M, Darzikolaee, NM, Babaei, M, Ghalehtaki, R, Farhan, F, Razavi, SZE, et.al. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial., J Gastrointest Cancer, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35426033/

1252. Rokhsareh, S, Haghighi, S, Tavakoli-Ardakani, M, Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial., J Oncol Pharm Pract, 2021. (): p. 10781552211052646., https://pubmed.ncbi.nlm.nih.gov/34738855/

1253. Yehia, R, Saleh, S, El Abhar, H, Saad, AS, Schaalan, M, L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways., Toxicol Appl Pharmacol, 2019. 365 (): p. 41-50., https://pubmed.ncbi.nlm.nih.gov/30592963/

1254. Zhu, Y, Yang, J, Jiao, S, Ji, T, Ganglioside-monosialic acid (GM1) prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors., World J Surg Oncol, 2013. 11 (): p. 19., https://pubmed.ncbi.nlm.nih.gov/23351188/

1255. Su, Y, Huang, J, Wang, S, Unger, JM, Arias-Fuenzalida, J, Shi, Y, et.al. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial., J Natl Cancer Inst, 2020. 112 (1)(1): p. 55-62., https://pubmed.ncbi.nlm.nih.gov/31093677/

1256. Wang, DS, Wang, ZQ, Chen, G, Peng, JW, Wang, W, Deng, YH, et.al. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer., Cancer Med, 2020. 9 (1)(1): p. 151-159., https://pubmed.ncbi.nlm.nih.gov/31724334/

1257. Kuriyama, A, Endo, K, Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis., Support Care Cancer, 2018. 26 (4)(4): p. 1051-1059., https://pubmed.ncbi.nlm.nih.gov/(29280005/

1258. El-Fatatry, BM, Ibrahim, OM, Hussien, FZ, Mostafa, TM, Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study., Int J Colorectal Dis, 2018. 33 (12)(12): p. 1675-1683., https://pubmed.ncbi.nlm.nih.gov/29931409/

1259. de Andrade, DC, Jacobsen Teixeira, M, Galhardoni, R, Ferreira, KSL, Braz Mileno, P, Scisci, N, et.al. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial., Oncologist, 2017. 22 (10)(10): p. 1154-e105., https://pubmed.ncbi.nlm.nih.gov/28652279/

1260. Aghili, M, Zare, M, Mousavi, N, Ghalehtaki, R, Sotoudeh, S, Kalaghchi, B, et.al. Efficacy of gabapentin for the prevention of paclitaxel induced peripheral neuropathy: A randomized placebo controlled clinical trial., Breast J, 2019. 25 (2)(2): p. 226-231., https://pubmed.ncbi.nlm.nih.gov/30773731/

1261. Alberti, P, Canta, A, Chiorazzi, A, Fumagalli, G, Meregalli, C, Monza, L, et.al. Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity., Neuropharmacology, 2020. 164 (): p. 107905., https://pubmed.ncbi.nlm.nih.gov/31811874/

1262. Zimmerman, C, Atherton, PJ, Pachman, D, Seisler, D, Wagner-Johnston, N, Dakhil, S, et.al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy., Support Care Cancer, 2016. 24 (3)(3): p. 1071-8., https://pubmed.ncbi.nlm.nih.gov/26248652/

1263. Huang, H, He, M, Liu, L, Huang, L, Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis., Contemp Oncol (Pozn), 2016. 20 (3)(3): p. 237-41., https://pubmed.ncbi.nlm.nih.gov/27647988/

1264. Chen, J, Shan, H, Yang, W, Zhang, J, Dai, H, Ye, Z, Vitamin E for the Prevention of Chemotherapy-Induced Peripheral Neuropathy: A meta-Analysis., Front Pharmacol, 2021. 12 (): p. 684550., https://pubmed.ncbi.nlm.nih.gov/34054560/

1265. Miao, H, Li, R, Chen, D, Hu, J, Chen, Y, Xu, C, et.al. Protective Effects of Vitamin E on Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Randomized Controlled Trials., Ann Nutr Metab, 2021. 77 (3)(3): p. 127-137., https://pubmed.ncbi.nlm.nih.gov/34148036/

1266. Wang, XS, Shi, Q, Bhadkamkar, NA, Cleeland, CS, Garcia-Gonzalez, A, Aguilar, JR, et.al. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial., J Pain Symptom Manage, 2019. 58 (4)(4): p. 662-671., https://pubmed.ncbi.nlm.nih.gov/31254639/

1267. Pachman, DR, Dockter, T, Zekan, PJ, Fruth, B, Ruddy, KJ, Ta, LE, et.al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I., Support Care Cancer, 2017. 25 (11)(11): p. 3407-3416., https://pubmed.ncbi.nlm.nih.gov/28551844/

1268. Campone, M, Berton-Rigaud, D, Joly-Lobbedez, F, Baurain, JF, Rolland, F, Stenzl, A, et.al. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy., Oncologist, 2013. 18 (11)(11): p. 1190-1., https://pubmed.ncbi.nlm.nih.gov/24105751/

1269. Shinde, SS, Seisler, D, Soori, G, Atherton, PJ, Pachman, DR, Lafky, J, et.al. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial., Support Care Cancer, 2016. 24 (2)(2): p. 547-553., https://pubmed.ncbi.nlm.nih.gov/26155765/

1270. Mezzanotte, JN, Grimm, M, Shinde, NV, Nolan, T, Worthen-Chaudhari, L, Williams, NO, et.al. Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy., Curr Treat Options Oncol, 2022. 23 (1)(1): p. 29-42., https://pubmed.ncbi.nlm.nih.gov/35167004/

1271. Schloss, JM, Colosimo, M, Airey, C, Masci, P, Linnane, AW, Vitetta, L, A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN)., Support Care Cancer, 2017. 25 (1)(1): p. 195-204., https://pubmed.ncbi.nlm.nih.gov/27612466/

1272. Kneis, S, Wehrle, A, Müller, J, Maurer, C, Ihorst, G, Gollhofer, A, et.al. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial., BMC Cancer, 2019. 19 (1)(1): p. 414., https://pubmed.ncbi.nlm.nih.gov/31046719/

1273. Zimmer, P, Trebing, S, Timmers-Trebing, U, Schenk, A, Paust, R, Bloch, W, et.al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial., Support Care Cancer, 2018. 26 (2)(2): p. 615-624., https://pubmed.ncbi.nlm.nih.gov/28963591/

1274. Dhawan, S, Andrews, R, Kumar, L, Wadhwa, S, Shukla, G, A Randomized Controlled Trial to Assess the Effectiveness of Muscle Strengthening and Balancing Exercises on Chemotherapy-Induced Peripheral Neuropathic Pain and Quality of Life Among Cancer Patients., Cancer Nurs, 2020. 43 (4)(4): p. 269-280., https://pubmed.ncbi.nlm.nih.gov/30888982/

1275. Streckmann, F, Lehmann, HC, Balke, M, Schenk, A, Oberste, M, Heller, A, et.al. Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial., Support Care Cancer, 2019. 27 (7)(7): p. 2471-2478., https://pubmed.ncbi.nlm.nih.gov/30382392/

1276. Park, SB, Tamburin, S, Schenone, A, Kleckner, IR, Velasco, R, Alberti, P, et.al. Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion., Expert Rev Neurother, 2022. 22 (1)(1): p. 65-76., https://pubmed.ncbi.nlm.nih.gov/34894974/

1277. Miaskowski, C, Mastick, J, Paul, SM, Topp, K, Smoot, B, Abrams, G, et.al. Chemotherapy-Induced Neuropathy in Cancer Survivors., J Pain Symptom Manage, 2017. 54 (2)(2): p. 204-218.e2., https://pubmed.ncbi.nlm.nih.gov/28063866/

1278. Guo, S, Han, W, Wang, P, Wang, X, Fang, X, Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis., J Cancer Surviv, 2022. ():, https://pubmed.ncbi.nlm.nih.gov/35149899/

1279. Lee, KM, Jung, D, Hwang, H, Son, KL, Kim, TY, Im, SA, et.al. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer., J Psychosom Res, 2018. 108 (): p. 14-19., https://pubmed.ncbi.nlm.nih.gov/29602320/

1280. Smith, E. M., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., et.al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, JAMA, 2013. 309: p. 1359-67.

1281. Avan, R, Janbabaei, G, Hendouei, N, Alipour, A, Borhani, S, Tabrizi, N, et.al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: A randomized clinical trial., J Res Med Sci, 2018. 23 (): p. 52., https://pubmed.ncbi.nlm.nih.gov/30057636/

1282. Salehifar, E, Janbabaei, G, Hendouei, N, Alipour, A, Tabrizi, N, Avan, R, Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial., Clin Drug Investig, 2020. 40 (3)(3): p. 249-257., https://pubmed.ncbi.nlm.nih.gov/31925721/

1283. Farshchian, N, Alavi, A, Heydarheydari, S, Moradian, N, Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy., Cancer Chemother Pharmacol, 2018. 82 (5)(5): p. 787-793., https://pubmed.ncbi.nlm.nih.gov/30105459/

1284. Hirayama, Y, Ishitani, K, Sato, Y, Iyama, S, Takada, K, Murase, K, et.al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial., Int J Clin Oncol, 2015. 20 (5)(5): p. 866-71., https://pubmed.ncbi.nlm.nih.gov/25762165/

1285. Matsuoka, H, Iwase, S, Miyaji, T, Kawaguchi, T, Ariyoshi, K, Oyamada, S, et.al. Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)., J Pain Symptom Manage, 2019. 58 (4)(4): p. 645-653., https://pubmed.ncbi.nlm.nih.gov/31254640/

1286. Durand, J. P., Deplanque, G., Montheil, V., Gornet, J. M., Scotte, F., Mir, O., et.al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial, Ann Oncol, 2012. 23: p. 200-5.

1287. Kautio, A. L., Haanpaa, M., Saarto, T., Kalso, E., Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms, J Pain Symptom Manage, 2008. 35: p. 31-9.

1288. Hammack, JE, Michalak, JC, Loprinzi, CL, Sloan, JA, Novotny, PJ, Soori, GS, et.al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy., Pain, 2002. 98 (1-2)(1-2): p. 195-203., https://pubmed.ncbi.nlm.nih.gov/12098632/

1289. Rao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., et.al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3), Cancer, 2007. 110: p. 2110-8.

1290. Magnowska, M, Iżycka, N, Kapoła-Czyż, J, Romała, A, Lorek, J, Spaczyński, M, et.al. Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy., Ginekol Pol, 2018. 89 (4)(4): p. 200-4., https://pubmed.ncbi.nlm.nih.gov/29781075/

1291. Mishra, S., Bhatnagar, S., Goyal, G. N., Rana, S. P., Upadhya, S. P., A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study, Am J Hosp Palliat Care, 2012. 29: p. 177-82.

1292. Hincker, A, Frey, K, Rao, L, Wagner-Johnston, N, Ben Abdallah, A, Tan, B, et.al. Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study., Pain, 2019. 160 (8)(8): p. 1835-1846., https://pubmed.ncbi.nlm.nih.gov/31335651/

1293. Rao, R. D., Flynn, P. J., Sloan, J. A., Wong, G. Y., Novotny, P., Johnson, D. B., et.al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3, Cancer, 2008. 112: p. 2802-8.

1294. Intravooth, T, Staack, AM, Juerges, K, Stockinger, J, Steinhoff, BJ, Antiepileptic drugs-induced hyponatremia: Review and analysis of 560 hospitalized patients., Epilepsy Res, 2018. 143 (): p. 7-10., https://pubmed.ncbi.nlm.nih.gov/29631131/

1295. Cartoni, C., Brunetti, G. A., Federico, V., Efficace, F., Grammatico, S., Tendas, A., et.al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma, Support Care Cancer, 2012. 20: p. 2621-6.

1296. Garassino, M. C., Piva, S., La Verde, N., Spagnoletti, I., Iorno, V., Carbone, C., et.al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients, PLoS One, 2013. 8: p. e59981.

1297. Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., et.al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis, Lancet Neurol, 2015.

1298. Chaparro, L. E., Wiffen, P. J., Moore, R. A., Gilron, I., Combination pharmacotherapy for the treatment of neuropathic pain in adults, Cochrane Database Syst Rev, 2012. 7: p. Cd008943.

1299. Ho, T. W., Backonja, M., Ma, J., Leibensperger, H., Froman, S., Polydefkis, M., Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies, Pain, 2009. 141: p. 19-24.

1300. Hermanns, K., Junker, U., Nolte, T., Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study, Expert Opin Pharmacother, 2012. 13: p. 299-311.

1301. Nalamachu, S., Ruck, D., Nalamasu, R., Fasbinder, S., Bansal, R., Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain, J Opioid Manag, 2013. 9: p. 43-9.

1302. Lazzari, M., Sabato, A. F., Caldarulo, C., Casali, M., Gafforio, P., Marcassa, C., et.al. Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis, Curr Med Res Opin, 2014. 30: p. 555-64.

1303. Raptis, E., Vadalouca, A., Stavropoulou, E., Argyra, E., Melemeni, A., Siafaka, I., Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study, Pain Pract, 2014. 14: p. 32-42.

1304. Nagashima, M, Ooshiro, M, Moriyama, A, Sugishita, Y, Kadoya, K, Sato, A, et.al. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients., Support Care Cancer, 2014. 22 (6)(6): p. 1579-84., https://pubmed.ncbi.nlm.nih.gov/24452412/

1305. McNicol, ED, Ferguson, MC, Schumann, R, Methadone for neuropathic pain in adults., Cochrane Database Syst Rev, 2017. 5 (): p. CD012499., https://pubmed.ncbi.nlm.nih.gov/28514508/

1306. Dworkin, R. H., O'Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., et.al. Pharmacologic management of neuropathic pain: evidence-based recommendations, Pain, 2007. 132: p. 237-51.

1307. Stamer, UM, Lehnen, K, Höthker, F, Bayerer, B, Wolf, S, Hoeft, A, et.al. Impact of CYP2D6 genotype on postoperative tramadol analgesia., Pain, 2003. 105 (1-2)(1-2): p. 231-8., https://pubmed.ncbi.nlm.nih.gov/14499440/

1308. Niesters, M., Proto, P. L., Aarts, L., Sarton, E. Y., Drewes, A. M., Dahan, A., Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy, Br J Anaesth, 2014. 113: p. 148-56.

1309. Sommer, C, Klose, P, Welsch, P, Petzke, F, Häuser, W, Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration., Eur J Pain, 2020. 24 (1)(1): p. 3-18., https://pubmed.ncbi.nlm.nih.gov/31705717/

1310. Moulin, D., Boulanger, A., Clark, A. J., Clarke, H., Dao, T., Finley, G. A., et.al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society, Pain Res Manag, 2014. 19: p. 328-35.

1311. Schlereth, T, Guideline "diagnosis and non interventional therapy of neuropathic pain" of the German Society of Neurology (deutsche Gesellschaft für Neurologie)., Neurol Res Pract, 2020. 2 (): p. 16., https://pubmed.ncbi.nlm.nih.gov/33324922/

1312. Blanton, HL, Brelsfoard, J, DeTurk, N, Pruitt, K, Narasimhan, M, Morgan, DJ, et.al. Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain., Drugs, 2019. 79 (9)(9): p. 969-995., https://pubmed.ncbi.nlm.nih.gov/31127530/

1313. Barton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., et.al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA, Support Care Cancer, 2011. 19: p. 833-41.

1314. Gewandter, JS, Mohile, SG, Heckler, CE, Ryan, JL, Kirshner, JJ, Flynn, PJ, et.al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors., Support Care Cancer, 2014. 22 (7)(7): p. 1807-14., https://pubmed.ncbi.nlm.nih.gov/24531792/

1315. Filipczak-Bryniarska, I, Krzyzewski, RM, Kucharz, J, Michalowska-Kaczmarczyk, A, Kleja, J, Woron, J, et.al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience., Med Oncol, 2017. 34 (9)(9): p. 162., https://pubmed.ncbi.nlm.nih.gov/28819738/

1316. Anand, P, Elsafa, E, Privitera, R, Naidoo, K, Yiangou, Y, Donatien, P, et.al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification., J Pain Res, 2019. 12 (): p. 2039-2052., https://pubmed.ncbi.nlm.nih.gov/31308732/

1317. van Nooten, F, Treur, M, Pantiri, K, Stoker, M, Charokopou, M, Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis., Clin Ther, 2017. 39 (4)(4): p. 787-803.e18., https://pubmed.ncbi.nlm.nih.gov/28365034/

1318. Haanpää, M, Cruccu, G, Nurmikko, TJ, McBride, WT, Docu Axelarad, A, Bosilkov, A, et.al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain., Eur J Pain, 2016. 20 (2)(2): p. 316-28., https://pubmed.ncbi.nlm.nih.gov/26581442/

1319. Maihöfner, CG, Heskamp, ML, Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study., Eur J Pain, 2014. 18 (5)(5): p. 671-9., https://pubmed.ncbi.nlm.nih.gov/24259265/

1320. I. Vinik, Aaron, Perrot, Serge, Vinik, Etta, Pazdera, Ladislav, Stoker, Malcolm, Snijder, Robert, et.al. Repeat treatment with capsaicin 8% patch (179mg capsaicin cutaneous patch): Effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial, 2019/12/24. 2(12): p. 388-401., http://cmro.in/index.php/jcmro/article/view/242

1321. Vinik, AI, Perrot, S, Vinik, EJ, Pazdera, L, Jacobs, H, Stoker, M, et.al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study., BMC Neurol, 2016. 16 (1)(1): p. 251., https://pubmed.ncbi.nlm.nih.gov/27919222/

1322. Gálvez, R, Navez, ML, Moyle, G, Maihöfner, C, Stoker, M, Ernault, E, et.al. Capsaicin 8% Patch Repeat Treatment in Nondiabetic Peripheral Neuropathic Pain: A 52-Week, Open-Label, Single-Arm, Safety Study., Clin J Pain, 2017. 33 (10)(10): p. 921-931., https://pubmed.ncbi.nlm.nih.gov/28872473/

1323. Freynhagen, R, Argoff, C, Eerdekens, M, Engelen, S, Perrot, S, Progressive Response to Repeat Application of Capsaicin 179 mg (8% w/w) Cutaneous Patch in Peripheral Neuropathic Pain: Comprehensive New Analysis and Clinical Implications., Pain Med, 2021. 22 (10)(10): p. 2324-2336., https://pubmed.ncbi.nlm.nih.gov/33871648/

1324. Dupoiron, D, Jubier-Hamon, S, Seegers, V, Bienfait, F, Pluchon, YM, Lebrec, N, et.al. Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch., J Pain Res, 2022. 15 (): p. 241-255., https://pubmed.ncbi.nlm.nih.gov/35136354/

1325. Bienfait, F, Julienne, A, Jubier-Hamon, S, Seegers, V, Delorme, T, Jaoul, V, et.al. Correction: Bienfait et al. Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center. , Cancers (Basel), 2023. 15 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/37509412/

1326. Lux, MP, Flöther, L, Frömter, C, Rack, B, Veselinovic, K, Heine, M, et.al. Topical treatment of chemotherapy-induced peripheral neuropathy (CIPN) with high-concentration (179 mg) capsaicin patch in breast cancer patients - results of the QUCIP study., Front Oncol, 2024. 14 (): p. 1452099., https://pubmed.ncbi.nlm.nih.gov/39309732/

1327. Kern, K. U., Nalamachu, S., Brasseur, L., Zakrzewska, J. M., Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?, J Pain Res, 2013. 6: p. 261-80.

1328. Binder, A, Baron, R, The Pharmacological Therapy of Chronic Neuropathic Pain., Dtsch Arztebl Int, 2016. 113 (37)(37): p. 616-625., https://pubmed.ncbi.nlm.nih.gov/27697147/

1329. Fallon, M. T., Storey, D. J., Krishan, A., Weir, C. J., Mitchell, R., Fleetwood-Walker, S. M., et.al. Cancer treatment-related neuropathic pain: proof of concept study with menthol-a TRPM8 agonist, Support Care Cancer, 2015.

1330. Coleman, R, Hadji, P, Body, JJ, Santini, D, Chow, E, Terpos, E, et.al. Bone health in cancer: ESMO Clinical Practice Guidelines., Ann Oncol, 2020. 31 (12)(12): p. 1650-1663., https://pubmed.ncbi.nlm.nih.gov/32801018/

1331. Saad, F., Lipton, A., Cook, R., Chen, Y. M., Smith, M., Coleman, R., Pathologic fractures correlate with reduced survival in patients with malignant bone disease, Cancer, 2007. 110: p. 1860-7.

1332. Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., et.al. Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin Proc, 2003. 78: p. 21-33.

1333. Heindel, W, Gübitz, R, Vieth, V, Weckesser, M, Schober, O, Schäfers, M, The diagnostic imaging of bone metastases., Dtsch Arztebl Int, 2014. 111 (44)(44): p. 741-7., https://pubmed.ncbi.nlm.nih.gov/25412631/

1334. Kloth, J.K., Wolf, M., Rehnitz, C., Lehner, B., Wiedenhöfer, B., Weber, M.-A., Radiologische Diagnostik spinaler Tumoren, Der Orthopäde, 2012. 41: p. 595-607.

1335. Rodallec, M. H., Feydy, A., Larousserie, F., Anract, P., Campagna, R., Babinet, A., et.al. Diagnostic imaging of solitary tumors of the spine: what to do and say, Radiographics, 2008. 28: p. 1019-41.

1336. Uddandam, R., Kovilapu, U., Jain, N. K., Grewal, D. S., Bhattacharjee, S., Maheshwari, S., A Comparative Study of MRI and Bone Scan in Early Detection of Vertebral Metastases, J. Evid. Based Med. Healthc., 2020. 7(24): p. 1143-1148.

1337. Vogler, J. B., 3rd, Murphy, W. A., Bone marrow imaging, Radiology, 1988. 168: p. 679-93.

1338. Broski, SM, Young, JR, Kendi, AT, Subramaniam, RM, Skeletal Metastasis Evaluation: Value and Impact of PET/Computed Tomography on Diagnosis, Management and Prognosis., PET Clin, 2019. 14 (1)(1): p. 103-120., https://pubmed.ncbi.nlm.nih.gov/30420213/

1339. Attal, M., Harousseau, J. L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., et.al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, 2006. 108: p. 3289-3294.

1340. Aviles, A., Nambo, M. J., Neri, N., Castaneda, C., Cleto, S., Huerta-Guzman, J., Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma, Medical Oncology (Northwood, London, England), 2007. 24: p. 227-230.

1341. Aviles, A., Neri, N., Huerta-Guzman, J., Nambo, M. J., Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation, Current Oncology, 2013. 20: p. e13-20.

1342. Berenson, J. R., Lichtenstein, A., Porter, L., Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events, Journal of Clinical Oncology, 1998. 16: p. 593-602.

1343. Body, J. J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., et.al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases, Ann Oncol, 2003. 14: p. 1399-405.

1344. Conte, P. F., Latreille, J., Mauriac, L., Calabresi, F., Santos, R., Campos, D., et.al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group, J Clin Oncol, 1996. 14: p. 2552-9.

1345. Daragon, A., Humez, C., Michot, C. X. L. L., Treatment of multiple myeloma with etidronate results of a multicentre double-blind study, European Journal of Medicine, 1993. 2: p. 449-452.

1346. Garcia-Sanz, R., Oriol, A., Moreno, M. J., de la Rubia, J., Payer, A. R., Hernandez, M. T., et.al. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial, Haematologica, 2015. 100: p. 1207-13.

1347. Heras, P., Kritikos, K., Hatzopoulos, A., Georgopoulou, A. P., Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer, Eur J Cancer Care (Engl), 2009. 18: p. 653-6.

1348. Hultborn, R., Gundersen, S., Ryden, S., Holmberg, E., Carstensen, J., Wallgren, U. B., et.al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study, Anticancer Res, 1999. 19: p. 3383-92.

1349. Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., et.al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial, J Clin Oncol, 2005. 23: p. 3314-21.

1350. Kristensen, B., Ejlertsen, B., Groenvold, M., Hein, S., Loft, H., Mouridsen, H. T., Oral clodronate in breast cancer patients with bone metastases: a randomized study, J Intern Med, 1999. 246: p. 67-74.

1351. Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J. J., et.al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy, Clin Cancer Res, 2008. 14: p. 6690-6.

1352. Menssen, H. D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., et.al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption in patients with advanced multiple myeloma, Journal of Clinical Oncology, 2002. 20 (9): p. 2353-2359.

1353. Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., et.al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma, Cancer, 2008. 113: p. 1588-1595.

1354. Pan, Y., Jin, H., Chen, W., Yu, Z., Ye, T., Zheng, Y., et.al. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer, Int Urol Nephrol, 2014. 46: p. 2319-26.

1355. Paterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., Ashley, S., Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer, J Clin Oncol, 1993. 11: p. 59-65.

1356. Robertson, A. G., Reed, N. S., Ralston, S. H., Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study, Journal of Clinical Oncology, 1995. 13: p. 2427-30.

1357. Saad, Fred, Eastham, James, Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer, Urology, 2010. 76: p. 1175-81.

1358. Smith, Matthew R., Halabi, Susan, Ryan, Charles J., Hussain, Arif, Vogelzang, Nicholas, Stadler, Walter, et.al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), Journal of Clinical Oncology, 2014. 32: p. 1143-50.

1359. Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., et.al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, 2010. 28: p. 5132-9.

1360. Tubiana-Hulin, M., Beuzeboc, P., Mauriac, L., Barbet, N., Frenay, M., Monnier, A., et.al. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases], Bull Cancer, 2001. 88: p. 701-7.

1361. Ueno, Satoru, Mizokami, Atsushi, Fukagai, Takashi, Fujimoto, Naohiro, Oh-Oka, Hitoshi, Kondo, Yukihiro, et.al. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study, Anticancer Research, 2013. 33: p. 3837-44.

1362. van Holten-Verzantvoort, A. T., Kroon, H. M., Bijvoet, O. L., Cleton, F. J., Beex, L. V., Blijham, G., et.al. Palliative pamidronate treatment in patients with bone metastases from breast cancer, J Clin Oncol, 1993. 11: p. 491-8.

1363. Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., et.al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies, Br J Cancer, 2004. 90: p. 1133-7.

1364. Dearnaley, David P., Sydes, Matthew R., Mason, Malcolm D., Stott, Mark, Powell, Christopher S., Robinson, Anne C. R., et.al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial), Journal of the National Cancer Institute, 2003. 95: p. 1300-11.

1365. Hirai, F., Murakami, H., Yamamoto, N., Yamanaka, T., Okamoto, I., Sawa, T., Randomized Phase II Trial of Zoledronic Acid in Combination With Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients With Bone Metastases – Result of a West Japan Oncology Group Study, European Journal of Cancer, 2011. Suppl 47:

1366. Scagliotti, G. V., Kosmidis, P., Marinis, F., Schreurs, A. J., Albert, I., Engel-Riedel, W., et.al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study, Annals of Oncology, 2012. p. 2082-7.

1367. Zaghloul, Mohamed S., Boutrus, Rimoun, El-Hossieny, Hisham, Kader, Yasser Abdel, El-Attar, Inas, Nazmy, Mohamed, A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer, International Journal of Clinical Oncology, 2010. 15: p. 382-9.

1368. Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., et.al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 2011. 29: p. 1125-32.

1369. Broom, R. J., Hinder, V., Sharples, K., Proctor, J., Duffey, S., Pollard, S., et.al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: A randomized first-line phase II trial, Clinical genitourinary cancer, 2015. p. 50-8.

1370. Small, EJ, Smith, MR, Seaman, JJ, Petrone, S, Kowalski, MO, Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer., J Clin Oncol, 2003. 21 (23)(23): p. 4277-84., https://pubmed.ncbi.nlm.nih.gov/14581438/

1371. Fizazi, K., Lipton, A., Mariette, X., Body, J. J., Rahim, Y., Gralow, J. R., et.al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 2009. 27: p. 1564-71.

1372. Raje, N, Terpos, E, Willenbacher, W, Shimizu, K, García-Sanz, R, Durie, B, et.al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study., Lancet Oncol, 2018. 19 (3)(3): p. 370-381., https://pubmed.ncbi.nlm.nih.gov/29429912/

1373. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., et.al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 2011. 377: p. 813-22.

1374. Sun, L, Yu, S, Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis., Am J Clin Oncol, 2013. 36 (4)(4): p. 399-403., https://pubmed.ncbi.nlm.nih.gov/22772430/

1375. Chen, F, Pu, F, Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials., Oncol Res Treat, 2016. 39 (7-8)(7-8): p. 453-9., https://pubmed.ncbi.nlm.nih.gov/27487236/

1376. Terpos, E, Raje, N, Croucher, P, Garcia-Sanz, R, Leleu, X, Pasteiner, W, et.al. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study., Blood Adv, 2021. 5 (3)(3): p. 725-736., https://pubmed.ncbi.nlm.nih.gov/33560384/

1377. Scagliotti, GV, Hirsh, V, Siena, S, Henry, DH, Woll, PJ, Manegold, C, et.al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study., J Thorac Oncol, 2012. 7 (12)(12): p. 1823-1829., https://pubmed.ncbi.nlm.nih.gov/23154554/

1378. Black, DM, Abrahamsen, B, Bouxsein, ML, Einhorn, T, Napoli, N, Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management., Endocr Rev, 2019. 40 (2)(2): p. 333-368., https://pubmed.ncbi.nlm.nih.gov/30169557/

1379. Himelstein, Andrew Louis, Qin, Rui, Novotny, Paul J., Seisler, Drew K., Khatcheressian, James L., Roberts, John D., et.al. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer., J Clin Oncol, 2015. 33:

1380. Himelstein, AL, Foster, JC, Khatcheressian, JL, Roberts, JD, Seisler, DK, Novotny, PJ, et.al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial., JAMA, 2017. 317 (1)(1): p. 48-58., https://pubmed.ncbi.nlm.nih.gov/28030702/

1381. Amadori, D., Aglietta, M., Alessi, B., Gianni, L., Ibrahim, T., Farina, G., et.al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial, Lancet Oncol, 2013. 14: p. 663-70.

1382. Hortobagyi, Gabriel N., Lipton, Allan, Chew, Helen K., Gradishar, William John, Sauter, Nicholas P., Mohanlal, Ramon W., et.al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial., J Clin Oncol, 2014. 32:5s:

1383. Ibrahim, M. F., Mazzarello, S., Shorr, R., Vandermeer, L., Jacobs, C., Hilton, J., et.al. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis, Ann Oncol, 2015. 26: p. 2205-13.

1384. Hortobagyi, GN, Van Poznak, C, Harker, WG, Gradishar, WJ, Chew, H, Dakhil, SR, et.al. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial., JAMA Oncol, 2017. 3 (7)(7): p. 906-912., https://pubmed.ncbi.nlm.nih.gov/28125763/

1385. Clemons, M, Ong, M, Stober, C, Ernst, S, Booth, C, Canil, C, et.al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer., Eur J Cancer, 2021. 142 (): p. 132-140., https://pubmed.ncbi.nlm.nih.gov/33023785 /

1386. Fizazi, Karim, Bosserman, Linda, Gao, Guozhi, Skacel, Tomas, Markus, Richard, Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial, Journal of Urology, 2009. 182: p. 509-15; discussion 515-6.

1387. Templeton, Arnoud J., Stalder, Lukas, Bernhard, Juerg, Brauchli, Peter, Gillessen, Silke, Hayoz, Stefanie, et.al. Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)., J Clin Oncol, 2014. 32:5s:

1388. Dachverband Osteologie e.V. (DVO), Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und bei Männern ab dem 50.Lebensjahr, Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V., 2023.

1389. Tsourdi, E, Langdahl, B, Cohen-Solal, M, Aubry-Rozier, B, Eriksen, EF, Guañabens, N, et.al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS., Bone, 2017. 105 (): p. 11-17., https://pubmed.ncbi.nlm.nih.gov/28789921 /

1390. McClung, MR, Wagman, RB, Miller, PD, Wang, A, Lewiecki, EM, Observations following discontinuation of long-term denosumab therapy., Osteoporos Int, 2017. 28 (5)(5): p. 1723-1732., https://pubmed.ncbi.nlm.nih.gov/28144701 /

1391. Cummings, SR, Ferrari, S, Eastell, R, Gilchrist, N, Jensen, JB, McClung, M, et.al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension., J Bone Miner Res, 2018. 33 (2)(2): p. 190-198., https://pubmed.ncbi.nlm.nih.gov/29105841 /

1392. Tripto-Shkolnik, L, Fund, N, Rouach, V, Chodick, G, Shalev, V, Goldshtein, I, Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider., Bone, 2020. 130 (): p. 115150., https://pubmed.ncbi.nlm.nih.gov/31715340 /

1393. Bone, HG, Bolognese, MA, Yuen, CK, Kendler, DL, Miller, PD, Yang, YC, et.al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass., J Clin Endocrinol Metab, 2011. 96 (4)(4): p. 972-80., https://pubmed.ncbi.nlm.nih.gov/21289258 /

1394. Gonzalez-Rodriguez, E, Aubry-Rozier, B, Stoll, D, Zaman, K, Lamy, O, Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors., Breast Cancer Res Treat, 2020. 179 (1)(1): p. 153-159., https://pubmed.ncbi.nlm.nih.gov/31598815 /

1395. Anastasilakis, AD, Papapoulos, SE, Polyzos, SA, Appelman-Dijkstra, NM, Makras, P, Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial., J Bone Miner Res, 2019. 34 (12)(12): p. 2220-2228., https://pubmed.ncbi.nlm.nih.gov/31433518 /

1396. Guañabens, N, Moro-Álvarez, MJ, Casado, E, Blanch-Rubió, J, Gómez-Alonso, C, Díaz-Guerra, GM, et.al. The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment., Endocrine, 2019. 64 (3)(3): p. 441-455., https://pubmed.ncbi.nlm.nih.gov/30963388 /

1397. Kondo, H, Okimoto, N, Yoshioka, T, Akahoshi, S, Fuse, Y, Ogawa, T, et.al. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment., J Bone Miner Metab, 2020. 38 (6)(6): p. 894-902., https://pubmed.ncbi.nlm.nih.gov/32656645 /

1398. Makras, P, Appelman-Dijkstra, NM, Papapoulos, SE, van Wissen, S, Winter, EM, Polyzos, SA, et.al. The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation., J Clin Endocrinol Metab, 2021. 106 (10)(10): p. e4155-e4162., https://pubmed.ncbi.nlm.nih.gov/33978745/

1399. Tsourdi, E, Zillikens, MC, Meier, C, Body, JJ, Gonzalez Rodriguez, E, Anastasilakis, AD, et.al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS., J Clin Endocrinol Metab, 2021. 106: p. 264 - 281., https://pubmed.ncbi.nlm.nih.gov/33103722 /

1400. Dimopoulos, M. A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., et.al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid, Ann Oncol, 2009. 20: p. 117-20.

1401. Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., et.al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Ann Oncol, 2009. 20: p. 137-45.

1402. Kyrgidis, Athanassios, Tzellos, Thrasivoulos-George, Toulis, Konstantinos, Arora, Amit, Kouvelas, Dimitrios, Triaridis, Stefanos, An evidence-based review of risk-reductive strategies for osteonecrosis of the jaws among cancer patients, Current Clinical Pharmacology, 2013. 8: p. 124-34.

1403. Mücke, T, Deppe, H, Hein, J, Wolff, KD, Mitchell, DA, Kesting, MR, et.al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years., J Craniomaxillofac Surg, 2016. 44 (10)(10): p. 1689-1693., https://pubmed.ncbi.nlm.nih.gov/27555374 /

1404. Schiegnitz, E., Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)AWMF, AWMF-Register-Nr. 007-091, 2018.

1405. Ikesue, H, Mouri, M, Tomita, H, Hirabatake, M, Ikemura, M, Muroi, N, et.al. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases., Support Care Cancer, 2021. 29 (8)(8): p. 4763-4772., https://pubmed.ncbi.nlm.nih.gov/33527228 /

1406. Saad, F, Brown, JE, Van Poznak, C, Ibrahim, T, Stemmer, SM, Stopeck, AT, et.al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases., Ann Oncol, 2012. 23 (5)(5): p. 1341-1347., https://pubmed.ncbi.nlm.nih.gov/21986094 /

1407. Vahtsevanos, K, Kyrgidis, A, Verrou, E, Katodritou, E, Triaridis, S, Andreadis, CG, et.al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw., J Clin Oncol, 2009. 27 (32)(32): p. 5356-62., https://pubmed.ncbi.nlm.nih.gov/19805682 /

1408. Kyrgidis, A., Triaridis, S., Kontos, K., Patrikidou, A., Andreadis, C., Constantinidis, J., et.al. Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires, Anticancer Res, 2012. 32: p. 3527-34.

1409. Yarom, N, Shapiro, CL, Peterson, DE, Van Poznak, CH, Bohlke, K, Ruggiero, SL, et.al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline., J Clin Oncol, 2019. 37 (25)(25): p. 2270-2290., https://pubmed.ncbi.nlm.nih.gov/31329513/

1410. Leithner, A., Maurer-Ertl, W., Windhager, R., Biopsy of bone and soft tissue tumours: hints and hazards, Recent Results Cancer Res, 2009. 179: p. 3-10.

1411. Cappellari, A, Trovarelli, G, Crimì, A, Pala, E, Angelini, A, Berizzi, A, et.al. New concepts in the surgical treatment of actual and impending pathological fractures in metastatic disease., Injury, 2023. 54 Suppl 1 (): p. S31-S35., https://pubmed.ncbi.nlm.nih.gov/33213863 /

1412. Leithner, A., Friesenbichler, J., Andreou, D., Maurer-Ertl, W., Tunn, P. U., [Bone metastases treatment strategies], Orthopade, 2012. 41: p. 863-71; quiz 872.

1413. Mirels, H., Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989, Clin Orthop Relat Res, 2003. p. S4-13.

1414. Howard, EL, Shepherd, KL, Cribb, G, Cool, P, The validity of the Mirels score for predicting impending pathological fractures of the lower limb., Bone Joint J, 2018. 100-B (8)(8): p. 1100-1105., https://pubmed.ncbi.nlm.nih.gov/30062934 /

1415. Damron, TA, Nazarian, A, Entezari, V, Brown, C, Grant, W, Calderon, N, et.al. CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions., Clin Orthop Relat Res, 2016. 474 (3)(3): p. 643-51., https://pubmed.ncbi.nlm.nih.gov/26169800/

1416. Fisher, C. G., DiPaola, C. P., Ryken, T. C., Bilsky, M. H., Shaffrey, C. I., Berven, S. H., et.al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group, Spine (Phila Pa 1976), 2010. 35: p. E1221-9.

1417. Forsberg, J. A., Wedin, R., Bauer, H. C., Hansen, B. H., Laitinen, M., Trovik, C. S., et.al. External validation of the Bayesian Estimated Tools for Survival (BETS) models in patients with surgically treated skeletal metastases, BMC Cancer, 2012. 12: p. 493.

1418. Tokuhashi, Y., Matsuzaki, H., Toriyama, S., Kawano, H., Ohsaka, S., Scoring system for the preoperative evaluation of metastatic spine tumor prognosis, Spine (Phila Pa 1976), 1990. 15: p. 1110-3.

1419. Tomita, K., Kawahara, N., Kobayashi, T., Yoshida, A., Murakami, H., Akamaru, T., Surgical strategy for spinal metastases, Spine (Phila Pa 1976), 2001. 26: p. 298-306.

1420. Ratasvuori, M., Wedin, R., Hansen, B. H., Keller, J., Trovik, C., Zaikova, O., et.al. Prognostic role of en-bloc resection and late onset of bone metastasis in patients with bone-seeking carcinomas of the kidney, breast, lung, and prostate: SSG study on 672 operated skeletal metastases, J Surg Oncol, 2014. 110: p. 360-5.

1421. Wedin, R., Bauer, H. C., Rutqvist, L. E., Surgical treatment for skeletal breast cancer metastases: a population-based study of 641 patients, Cancer, 2001. 92: p. 257-62.

1422. Gainor, B. J., Buchert, P., Fracture healing in metastatic bone disease, Clin Orthop Relat Res, 1983. p. 297-302.

1423. Meynard, P, Seguineau, A, Laumonerie, P, Fabre, T, Foltran, D, Niglis, L, et.al. Surgical management of proximal femoral metastasis: Fixation or hip replacement? A 309 case series., Orthop Traumatol Surg Res, 2020. 106 (6)(6): p. 1013-1023., https://pubmed.ncbi.nlm.nih.gov/32778439 /

1424. Bullmann, V., Liljenqvist, U., Operative Behandlung von Wirbelsäulenmetastasen. Orthopädie und Unfallchirurgie up2date, 2010. 5: p. 279-293.

1425. Delank KS, Wendtner, C., Behandlung von Wirbelsäulenmetastasen., Dt. Ärzteblatt, 2014. 1: p. 1-11.

1426. Druschel, C., Disch, A. C., Pumberger, M., Schwabe, P., Melcher, I., Haas, N. P., et.al. [Solitary spinal metastases. Is aggressive surgical management justified?], Orthopade, 2013. 42: p. 709-24.

1427. Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schechtman, K., Tillman, J. B., et.al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial, Lancet Oncol, 2011. 12: p. 225-35.

1428. Eck, J. C., Nachtigall, D., Humphreys, S. C., Hodges, S. D., Comparison of vertebroplasty and balloon kyphoplasty for treatment of vertebral compression fractures: a meta-analysis of the literature, Spine J, 2008. 8: p. 488-97.

1429. Beall, DP, Chambers, MR, Thomas, S, Amburgy, J, Webb, JR, Goodman, BS, et.al. Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures: The EVOLVE Trial., Neurosurgery, 2019. 84 (1)(1): p. 169-178., https://pubmed.ncbi.nlm.nih.gov/29547939/

1430. Health Quality Ontario, Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review., Ont Health Technol Assess Ser, 2016. 16 (11)(11): p. 1-202., https://pubmed.ncbi.nlm.nih.gov/27298655/

1431. Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366: p. 643-8.

1432. Rades, D., Huttenlocher, S., Dunst, J., Bajrovic, A., Karstens, J. H., Rudat, V., et.al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression, J Clin Oncol, 2010. 28: p. 3597-604.

1433. George, R, Jeba, J, Ramkumar, G, Chacko, AG, Tharyan, P, Interventions for the treatment of metastatic extradural spinal cord compression in adults., Cochrane Database Syst Rev, 2015. 2015 (9)(9): p. CD006716., https://pubmed.ncbi.nlm.nih.gov/26337716 /

1434. Drost, L, Ganesh, V, Wan, BA, Raman, S, Chan, S, Christakis, M, et.al. Efficacy of postoperative radiation treatment for bone metastases in the extremities., Radiother Oncol, 2017. 124 (1)(1): p. 45-48., https://pubmed.ncbi.nlm.nih.gov/28545958/

1435. Itshayek, E., Yamada, J., Bilsky, M., Schmidt, M., Shaffrey, C., Gerszten, P., et.al. Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review, Int J Oncol, 2010. 36: p. 533-44.

1436. Ghogawala, Z., Mansfield, F. L., Borges, L. F., Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression, Spine (Phila Pa 1976), 2001. 26: p. 818-24.

1437. Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., Lutz, S., Update on the systematic review of palliative radiotherapy trials for bone metastases, Clin Oncol (R Coll Radiol), 2012. 24: p. 112-24.

1438. Chow, E., Wu, J. S., Hoskin, P., Coia, L. R., Bentzen, S. M., Blitzer, P. H., International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases, Radiother Oncol, 2002. 64: p. 275-80.

1439. Rich, SE, Chow, R, Raman, S, Liang Zeng, K, Lutz, S, Lam, H, et.al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases., Radiother Oncol, 2018. 126 (3)(3): p. 547-557., https://pubmed.ncbi.nlm.nih.gov/29397209/

1440. Koswig, S., Buchali, A., Bohmer, D., Schlenger, L., Budach, V., [Palliative radiotherapy of bone metastases. A retrospective analysis of 176 patients], Strahlenther Onkol, 1999. 175: p. 509-14.

1441. Dennis, K., Makhani, L., Zeng, L., Lam, H., Chow, E., Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials, Radiother Oncol, 2013. 106: p. 5-14.

1442. Hoskin, PJ, Hopkins, K, Misra, V, Holt, T, McMenemin, R, Dubois, D, et.al. Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial., JAMA, 2019. 322 (21)(21): p. 2084-2094., https://pubmed.ncbi.nlm.nih.gov/31794625/

1443. Rades, D., Huttenlocher, S., Bajrovic, A., Karstens, J. H., Adamietz, I. A., Kazic, N., et.al. Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors, Int J Radiat Oncol Biol Phys, 2011. 81: p. e861-8.

1444. Chow, E., van der Linden, Y. M., Roos, D., Hartsell, W. F., Hoskin, P., Wu, J. S., et.al. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial, Lancet Oncol, 2014. 15: p. 164-71.

1445. Hoskin, P., Sundar, S., Reczko, K., Forsyth, S., Mithal, N., Sizer, B., et.al. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer, J Natl Cancer Inst, 2015. 107:

1446. Lutz, S., Berk, L., Chang, E., Chow, E., Hahn, C., Hoskin, P., et.al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, Int J Radiat Oncol Biol Phys, 2011. 79: p. 965-76.

1447. Agarwal, K. K., Singla, S., Arora, G., Bal, C., (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study, Eur J Nucl Med Mol Imaging, 2015. 42: p. 79-88.

1448. Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fossa, S. D., et.al. Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 2013. 369: p. 213-23.

1449. Roque, I. Figuls M., Martinez-Zapata, M. J., Scott-Brown, M., Alonso-Coello, P., Radioisotopes for metastatic bone pain, Cochrane Database Syst Rev, 2011. p. CD003347.

1450. Sartor, O., Coleman, R., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., et.al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, Lancet Oncol, 2014. 15: p. 738-46.

1451. Handkiewicz-Junak, D, Poeppel, TD, Bodei, L, Aktolun, C, Ezziddin, S, Giammarile, F, et.al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides., Eur J Nucl Med Mol Imaging, 2018. 45 (5)(5): p. 846-859., https://pubmed.ncbi.nlm.nih.gov/29453701/

1452. Shah, HJ, Ruppell, E, Bokhari, R, Aland, P, Lele, VR, Ge, C, et.al. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review., Eur J Radiol Open, 2023. 10 (): p. 100477., https://pubmed.ncbi.nlm.nih.gov/36785643/

1453. Khan, N. F., Mant, D., Carpenter, L., Forman, D., Rose, P. W., Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study, Br J Cancer, 2011. 105 Suppl 1: p. S29-37.

1454. Mincey, B. A., Duh, M. S., Thomas, S. K., Moyneur, E., Marynchencko, M., Boyce, S. P., et.al. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors, Clin Breast Cancer, 2006. 7: p. 127-32.

1455. Goldvaser, Hadar, Barnes, Tristan A, Šeruga, Boštjan, Cescon, David W, Ocaña, Alberto, Ribnikar, Domen, et.al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis, JNCI: Journal of the National Cancer Institute, 2018. 110(1): p. 31-39.

1456. Qian, X, Li, Z, Ruan, G, Tu, C, Ding, W, Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials., Breast Cancer Res Treat, 2020. 179 (2)(2): p. 275-285., https://pubmed.ncbi.nlm.nih.gov/31606823/

1457. Shahinian, V. B., Kuo, Y. F., Freeman, J. L., Goodwin, J. S., Risk of fracture after androgen deprivation for prostate cancer, N Engl J Med, 2005. 352: p. 154-64.

1458. Skolarus, T. A., Caram, M. V., Shahinian, V. B., Androgen-deprivation-associated bone disease, Curr Opin Urol, 2014. 24: p. 601-7.

1459. Skolarus, T. A., Wolf, A. M., Erb, N. L., Brooks, D. D., Rivers, B. M., Underwood, W., 3rd, et.al. American Cancer Society prostate cancer survivorship care guidelines, CA Cancer J Clin, 2014. 64: p. 225-49.

1460. Morote, J., Morin, J. P., Orsola, A., Abascal, J. M., Salvador, C., Trilla, E., et.al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer, Urology, 2007. 69: p. 500-4.

1461. Higano, C. S., Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?, Nat Clin Pract Urol, 2008. 5: p. 24-34.

1462. Alibhai, S. M., Duong-Hua, M., Cheung, A. M., Sutradhar, R., Warde, P., Fleshner, N. E., et.al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men, J Urol, 2010. 184: p. 918-23.

1463. Bienz, M., Saad, F., Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review, Bonekey Rep, 2015. 4: p. 716.

1464. Todenhofer, T., Stenzl, A., Hofbauer, L. C., Rachner, T. D., Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies, Int J Endocrinol, 2015. 2015: p. 838202.

1465. Shao, Y. H., Moore, D. F., Shih, W., Lin, Y., Jang, T. L., Lu-Yao, G. L., Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications, BJU Int, 2013. 111: p. 745-52.

1466. Elliott, S. P., Jarosek, S. L., Alanee, S. R., Konety, B. R., Dusenbery, K. E., Virnig, B. A., Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture, Cancer, 2011. 117: p. 4557-65.

1467. Rief, H., Bischof, M., Bruckner, T., Welzel, T., Askoxylakis, V., Rieken, S., et.al. The stability of osseous metastases of the spine in lung cancer--a retrospective analysis of 338 cases, Radiat Oncol, 2013. 8: p. 200.

1468. Edwards, B. J., Gradishar, W. J., Smith, M. E., Pacheco, J. A., Holbrook, J., McKoy, J. M., et.al. Elevated incidence of fractures in women with invasive breast cancer, Osteoporos Int, 2015.

1469. Waning, D. L., Guise, T. A., Cancer-associated muscle weakness: What's bone got to do with it?, Bonekey Rep, 2015. 4: p. 691.

1470. Hadji, P., Cancer Treatment-Induced Bone Loss in women with breast cancer, Bonekey Rep, 2015. 4: p. 692.

1471. Svejme, O., Ahlborg, H. G., Nilsson, J. A., Karlsson, M. K., Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women, BJOG, 2012. 119: p. 810-6.

1472. Haller-Kikkatalo, K., Uibo, R., Kurg, A., Salumets, A., The prevalence and phenotypic characteristics of spontaneous premature ovarian failure: a general population registry-based study, Hum Reprod, 2015. 30: p. 1229-38.

1473. Viswanathan, M, Reddy, S, Berkman, N, Cullen, K, Middleton, JC, Nicholson, WK, et.al. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force., JAMA, 2018. 319 (24)(24): p. 2532-2551., https://pubmed.ncbi.nlm.nih.gov/29946734/

1474. Cavalier, E, Rozet, E, Gadisseur, R, Carlisi, A, Monge, M, Chapelle, JP, et.al. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs., Osteoporos Int, 2010. 21 (6)(6): p. 1047-51., https://pubmed.ncbi.nlm.nih.gov/19756833/

1475. Zhao, R, Feng, F, Wang, X, Exercise interventions and prevention of fall-related fractures in older people: a meta-analysis of randomized controlled trials., Int J Epidemiol, 2017. 46 (1)(1): p. 149-161., https://pubmed.ncbi.nlm.nih.gov/27477031/

1476. Vestergaard, P, Mosekilde, L, Fracture risk associated with smoking: a meta-analysis., J Intern Med, 2003. 254 (6)(6): p. 572-83., https://pubmed.ncbi.nlm.nih.gov/14641798/

1477. Wu, ZJ, Zhao, P, Liu, B, Yuan, ZC, Effect of Cigarette Smoking on Risk of Hip Fracture in Men: A Meta-Analysis of 14 Prospective Cohort Studies., PLoS One, 2016. 11 (12)(12): p. e0168990., https://pubmed.ncbi.nlm.nih.gov/28036356/

1478. Liang, J, Meng, WD, Yang, JM, Li, SL, Zhong, MN, Hou, XX, et.al. The association between liver cirrhosis and fracture risk: A systematic review and meta-analysis., Clin Endocrinol (Oxf), 2018. 89 (4)(4): p. 408-413., https://pubmed.ncbi.nlm.nih.gov/29885255/

1479. Zhang, X, Yu, Z, Yu, M, Qu, X, Alcohol consumption and hip fracture risk., Osteoporos Int, 2015. 26 (2)(2): p. 531-42., https://pubmed.ncbi.nlm.nih.gov/25266483/

1480. Johansson, H, Kanis, JA, Odén, A, McCloskey, E, Chapurlat, RD, Christiansen, C, et.al. A meta-analysis of the association of fracture risk and body mass index in women., J Bone Miner Res, 2014. 29 (1)(1): p. 223-33., https://pubmed.ncbi.nlm.nih.gov/23775829/

1481. De Laet, C, Kanis, JA, Odén, A, Johanson, H, Johnell, O, Delmas, P, et.al. Body mass index as a predictor of fracture risk: a meta-analysis., Osteoporos Int, 2005. 16 (11)(11): p. 1330-8., https://pubmed.ncbi.nlm.nih.gov/15928804/

1482. Cumming, RG, Cummings, SR, Nevitt, MC, Scott, J, Ensrud, KE, Vogt, TM, et.al. Calcium intake and fracture risk: results from the study of osteoporotic fractures., Am J Epidemiol, 1997. 145 (10)(10): p. 926-34., https://pubmed.ncbi.nlm.nih.gov/9149664/

1483. Ensrud, KE, Duong, T, Cauley, JA, Heaney, RP, Wolf, RL, Harris, E, et.al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group., Ann Intern Med, 2000. 132 (5)(5): p. 345-53., https://pubmed.ncbi.nlm.nih.gov/10691584/

1484. Howe, T. E., Shea, B., Dawson, L. J., Downie, F., Murray, A., Ross, C., et.al. Exercise for preventing and treating osteoporosis in postmenopausal women, Cochrane Database Syst Rev, 2011. p. CD000333.

1485. Kemmler, W., Haberle, L., von Stengel, S., Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis, Osteoporos Int, 2013. 24: p. 1937-50.

1486. Linhares, DG, Borba-Pinheiro, CJ, Castro, JBP, Santos, AOBD, Santos, LLD, Cordeiro, LS, et.al. Effects of Multicomponent Exercise Training on the Health of Older Women with Osteoporosis: A Systematic Review and Meta-Analysis., Int J Environ Res Public Health, 2022. 19 (21)(21):, https://pubmed.ncbi.nlm.nih.gov/36361073/

1487. Tian, L., Lu, H. J., Lin, L., Hu, Y., Effects of aerobic exercise on cancer-related fatigue: a meta-analysis of randomized controlled trials, Support Care Cancer, 2015.

1488. Teleni, L., Chan, R. J., Chan, A., Isenring, E. A., Vela, I., Inder, W., et.al. Exercise improves quality of life in ADT-treated prostate cancer: systematic review of RCTs, Endocr Relat Cancer, 2015.

1489. Dieli-Conwright, C. M., Orozco, B. Z., Exercise after breast cancer treatment: current perspectives, Breast Cancer (Dove Med Press), 2015. 7: p. 353-62.

1490. Loughney, L., West, M. A., Kemp, G. J., Grocott, M. P., Jack, S., Exercise intervention in people with cancer undergoing adjuvant cancer treatment following surgery: A systematic review, Eur J Surg Oncol, 2015.

1491. Groeneveldt, L., Mein, G., Garrod, R., Jewell, A. P., Van Someren, K., Stephens, R., et.al. A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors, BMC Cancer, 2013. 13: p. 31.

1492. Fornusek, CP, Kilbreath, SL, Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analyses., J Cancer Surviv, 2017. 11 (5)(5): p. 525-541., https://pubmed.ncbi.nlm.nih.gov/28639157 /

1493. Saarto, T, Sievänen, H, Kellokumpu-Lehtinen, P, Nikander, R, Vehmanen, L, Huovinen, R, et.al. Effect of supervised and home exercise training on bone mineral density among breast cancer patients. A 12-month randomised controlled trial., Osteoporos Int, 2012. 23 (5)(5): p. 1601-12., https://pubmed.ncbi.nlm.nih.gov/21892676 /

1494. Thomas, GA, Cartmel, B, Harrigan, M, Fiellin, M, Capozza, S, Zhou, Y, et.al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors., Obesity (Silver Spring), 2017. 25 (2)(2): p. 346-351., https://pubmed.ncbi.nlm.nih.gov/28026901 /

1495. de Paulo, TRS, Winters-Stone, KM, Viezel, J, Rossi, FE, Simões, RR, Tosello, G, et.al. Effects of resistance plus aerobic training on body composition and metabolic markers in older breast cancer survivors undergoing aromatase inhibitor therapy., Exp Gerontol, 2018. 111 (): p. 210-217., https://pubmed.ncbi.nlm.nih.gov/30077574 /

1496. Peppone, LJ, Ling, M, Huston, AJ, Reid, ME, Janelsins, MC, Puzas, JE, et.al. The effects of high-dose calcitriol and individualized exercise on bone metabolism in breast cancer survivors on hormonal therapy: a phase II feasibility trial., Support Care Cancer, 2018. 26 (8)(8): p. 2675-2683., https://pubmed.ncbi.nlm.nih.gov/29470705/

1497. James, EG, Leveille, SG, Hausdorff, JM, Barton, B, Cote, S, Karabulut, M, et.al. Coordination Impairments Are Associated With Falling Among Older Adults., Exp Aging Res, 2017. 43 (5)(5): p. 430-439., https://pubmed.ncbi.nlm.nih.gov/29072539 /

1498. Kemmler, W., Engelke, K., von Stengel, S., Long-Term Exercise and Bone Mineral Density Changes in Postmenopausal Women-Are There Periods of Reduced Effectiveness?, J Bone Miner Res, 2015.

1499. Liu, C, Kuang, X, Li, K, Guo, X, Deng, Q, Li, D, Effects of combined calcium and vitamin D supplementation on osteoporosis in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials., Food Funct, 2020. 11 (12)(12): p. 10817-10827., https://pubmed.ncbi.nlm.nih.gov/33237064/

1500. Gupta, D., Vashi, P. G., Trukova, K., Lis, C. G., Lammersfeld, C. A., Prevalence of serum vitamin D deficiency and insufficiency in cancer: Review of the epidemiological literature, Exp Ther Med, 2011. 2: p. 181-193.

1501. Maier, G. S., Horas, K., Kurth, A. A., Lazovic, D., Seeger, J. B., Maus, U., Prevalence of Vitamin D Deficiency in Patients with Bone Metastases and Multiple Myeloma, Anticancer Res, 2015. 35: p. 6281-5.

1502. Bischoff-Ferrari, HA, Freystätter, G, Vellas, B, Dawson-Hughes, B, Kressig, RW, Kanis, JA, et.al. Effects of vitamin D, omega-3 fatty acids, and a simple home strength exercise program on fall prevention: the DO-HEALTH randomized clinical trial., Am J Clin Nutr, 2022. 115 (5)(5): p. 1311-1321., https://pubmed.ncbi.nlm.nih.gov/35136915/

1503. Dawson-Hughes, B, Dallal, GE, Krall, EA, Sadowski, L, Sahyoun, N, Tannenbaum, S, A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women., N Engl J Med, 1990. 323 (13)(13): p. 878-83., https://pubmed.ncbi.nlm.nih.gov/2203964/

1504. Reid, IR, Ames, RW, Evans, MC, Gamble, GD, Sharpe, SJ, Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial., Am J Med, 1995. 98 (4)(4): p. 331-5., https://pubmed.ncbi.nlm.nih.gov/7709944/

1505. Yang, C, Shi, X, Xia, H, Yang, X, Liu, H, Pan, D, et.al. The Evidence and Controversy Between Dietary Calcium Intake and Calcium Supplementation and the Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Cohort Studies and Randomized Controlled Trials., J Am Coll Nutr, 2020. 39 (4)(4): p. 352-370., https://pubmed.ncbi.nlm.nih.gov/31625814/

1506. Inoue-Choi, M., Greenlee, H., Oppeneer, S. J., Robien, K., The association between postdiagnosis dietary supplement use and total mortality differs by diet quality among older female cancer survivors, Cancer Epidemiol Biomarkers Prev, 2014. 23: p. 865-75.

1507. Deghan Manshadi, S., Ishiguro, L., Sohn, K. J., Medline, A., Renlund, R., Croxford, R., et.al. Folic acid supplementation promotes mammary tumor progression in a rat model, PLoS One, 2014. 9: p. e84635.

1508. Eisen, A, Somerfield, MR, Accordino, MK, Blanchette, PS, Clemons, MJ, Dhesy-Thind, S, et.al. Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update., J Clin Oncol, 2022. 40 (7)(7): p. 787-800., https://pubmed.ncbi.nlm.nih.gov/35041467/

1509. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe,, AWMF), S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, AWMF Registernummer: 032-045OL, 2021 (abgerufen am: 01.09.2024)., http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/

1510. Ellis, G. K., Bone, H. G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J., et.al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer, J Clin Oncol, 2008. 26: p. 4875-82.

1511. Lester, J. E., Dodwell, D., Purohit, O. P., Gutcher, S. A., Ellis, S. P., Thorpe, R., et.al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer, Clin Cancer Res, 2008. 14: p. 6336-42.

1512. Van Poznak, C., Hannon, R. A., Mackey, J. R., Campone, M., Apffelstaedt, J. P., Clack, G., et.al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial, J Clin Oncol, 2010. 28: p. 967-75.

1513. Sestak, I., Singh, S., Cuzick, J., Blake, G. M., Patel, R., Gossiel, F., et.al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial, Lancet Oncol, 2014. 15: p. 1460-8.

1514. Wilson, C, Bell, R, Hinsley, S, Marshall, H, Brown, J, Cameron, D, et.al. Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study., Eur J Cancer, 2018. 94 (): p. 70-78., https://pubmed.ncbi.nlm.nih.gov/29544162 /

1515. Livi, L, Scotti, V, Desideri, I, Saieva, C, Cecchini, S, Francolini, G, et.al. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial., Eur J Cancer, 2019. 108 (): p. 100-110., https://pubmed.ncbi.nlm.nih.gov/30648627 /

1516. Santa-Maria, CA, Bardia, A, Blackford, AL, Snyder, C, Connolly, RM, Fetting, JH, et.al. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial., Breast Cancer Res Treat, 2018. 171 (1)(1): p. 121-129., https://pubmed.ncbi.nlm.nih.gov/29752687 /

1517. Sestak, I, Blake, GM, Patel, R, Coleman, RE, Cuzick, J, Eastell, R, Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia., Bone, 2019. 124 (): p. 83-88., https://pubmed.ncbi.nlm.nih.gov/31028957 /

1518. Monda, V, Lupoli, GA, Messina, G, Peluso, R, Panico, A, Villano, I, et.al. Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole., Front Pharmacol, 2017. 8 (): p. 632., https://pubmed.ncbi.nlm.nih.gov/28955236/

1519. Waqas, K, Lima Ferreira, J, Tsourdi, E, Body, JJ, Hadji, P, Zillikens, MC, Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer., J Bone Oncol, 2021. 28 (): p. 100355., https://pubmed.ncbi.nlm.nih.gov/33948427 /

1520. Bouxsein, ML, Eastell, R, Lui, LY, Wu, LA, de Papp, AE, Grauer, A, et.al. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials., J Bone Miner Res, 2019. 34 (4)(4): p. 632-642., https://pubmed.ncbi.nlm.nih.gov/30674078 /

1521. Pineda-Moncusí, M, Garcia-Giralt, N, Diez-Perez, A, Servitja, S, Tusquets, I, Prieto-Alhambra, D, et.al. Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates., J Bone Miner Res, 2020. 35 (2)(2): p. 291-297., https://pubmed.ncbi.nlm.nih.gov/31596961 /

1522. Coleman, R, Hall, A, Albanell, J, Hanby, A, Bell, R, Cameron, D, et.al. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial., Lancet Oncol, 2017. 18 (11)(11): p. 1543-1552., https://pubmed.ncbi.nlm.nih.gov/29037984 /

1523. Serpa Neto, A., Tobias-Machado, M., Esteves, M. A., Senra, M. D., Wroclawski, M. L., Fonseca, F. L., et.al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis, Prostate Cancer Prostatic Dis, 2012. 15: p. 36-44.

1524. James, ND, Sydes, MR, Clarke, NW, Mason, MD, Dearnaley, DP, Spears, MR, et.al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial., Lancet, 2016. 387 (10024)(10024): p. 1163-77., https://pubmed.ncbi.nlm.nih.gov/26719232/

1525. Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., et.al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 2009. 361: p. 756-65.

1526. Smith, M. R., Egerdie, B., Hernandez Toriz, N., Feldman, R., Tammela, T. L., Saad, F., et.al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 2009. 361: p. 745-55.

1527. Smith, M. R., Saad, F., Egerdie, B., Szwedowski, M., Tammela, T. L., Ke, C., et.al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer, J Urol, 2009. 182: p. 2670-5.

1528. Hadji, P, Aapro, MS, Body, JJ, Gnant, M, Brandi, ML, Reginster, JY, et.al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG., J Bone Oncol, 2017. 7 (): p. 1-12., https://pubmed.ncbi.nlm.nih.gov/28413771 /

1529. Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., et.al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 2015. 386: p. 433-43.

1530. Bone, HG, Wagman, RB, Brandi, ML, Brown, JP, Chapurlat, R, Cummings, SR, et.al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension., Lancet Diabetes Endocrinol, 2017. 5 (7)(7): p. 513-523., https://pubmed.ncbi.nlm.nih.gov/28546097 /

1531. Nakatsukasa, K, Koyama, H, Ouchi, Y, Sakaguchi, K, Fujita, Y, Matsuda, T, et.al. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer., J Bone Miner Metab, 2019. 37 (2)(2): p. 301-306., https://pubmed.ncbi.nlm.nih.gov/29520506 /

1532. Nakatsukasa, K, Koyama, H, Ouchi, Y, Sakaguchi, K, Fujita, Y, Matsuda, T, et.al. Effect of denosumab administration on low bone mineral density (T-score -1.0 to -2.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer., J Bone Miner Metab, 2018. 36 (6)(6): p. 716-722., https://pubmed.ncbi.nlm.nih.gov/29116414/

1533. Nakamura, Y., Soma, T., Izumi, K., Sakai, Y., Ushijima, H., Kudo, S., et.al. Screening of chronic radiation proctitis and colorectal cancer using periodic total colonoscopy after external beam radiation therapy for prostate cancer, Jpn J Clin Oncol, 2021. 51(8): p. 1298-1302.

1534. Cheng, Y. K., Qin, Q. Y., Huang, X. Y., Lan, P., Wang, L., Gao, X., et.al. Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial, Cancer Med, 2020. 9(3): p. 912-919.

1535. Jhingran, Anuja, Complications of Radiation Oncology, in Principles of Gynecologic Oncology Surgery, 2018, Elsevier. p. 318 - 329.

1536. Mallick, S., Madan, R., Julka, P. K., Rath, G. K., Radiation Induced Cystitis and Proctitis - Prediction, Assessment and Management, Asian Pac J Cancer Prev, 2015. 16(14): p. 5589-94.

1537. Nakamura, K., Konishi, K., Komatsu, T., Ishiba, R., Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities, Int J Urol, 2019. 26(10): p. 950-954.

1538. Garg, A. K., Mai, W. Y., McGary, J. E., Grant, W. H., 3rd, Butler, E. B., Teh, B. S., Radiation proctopathy in the treatment of prostate cancer, Int J Radiat Oncol Biol Phys, 2006. 66(5): p. 1294-305.

1539. Jackson, A., Marks, L. B., Bentzen, S. M., Eisbruch, A., Yorke, E. D., Ten Haken, R. K., et.al. The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome, Int J Radiat Oncol Biol Phys, 2010. 76: p. S155-60.

1540. Wortel, R. C., Incrocci, L., Pos, F. J., van der Heide, U. A., Lebesque, J. V., Aluwini, S., et.al. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts, Int J Radiat Oncol Biol Phys, 2016. 95(2): p. 680-9.

1541. Borghetti, P., Spiazzi, L., Cozzaglio, C., Pedretti, S., Caraffini, B., Triggiani, L., et.al. Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further, Radiol Med, 2018. 123(1): p. 63-70.

1542. Lawrie, T. A., Green, J. T., Beresford, M., Wedlake, L., Burden, S., Davidson, S. E., et.al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers, Cochrane Database Syst Rev, 2018. 1(1): p. Cd012529.

1543. Mansha, M. A., Sadaf, T., Waheed, A., Munawar, A., Rashid, A., Chaudry, S. J., Long-Term Toxicity and Efficacy of Intensity-Modulated Radiation Therapy in Cervical Cancers: Experience of a Cancer Hospital in Pakistan, JCO Glob Oncol, 2020. 6: p. 1639-1646.

1544. Ferini, G., Pergolizzi, S., A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy, In Vivo, 2021. 35(3): p. 1379-1391.

1545. Kouloulias, V. E., Kouvaris, J. R., Pissakas, G., Kokakis, J. D., Antypas, C., Mallas, E., et.al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity, Strahlenther Onkol, 2004. 180: p. 557-62.

1546. Simone, N. L., Menard, C., Soule, B. P., Albert, P. S., Guion, P., Smith, S., et.al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score, Int J Radiat Oncol Biol Phys, 2008. 70: p. 90-5.

1547. Singh, A. K., Menard, C., Guion, P., Simone, N. L., Smith, S., Crouse, N. S., et.al. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study, Int J Radiat Oncol Biol Phys, 2006. 65: p. 1008-13.

1548. Koukourakis, M. I., Kyrgias, G., Panteliadou, M., Papadopoulou, A., Tsiarkatsi, M., Papachristou, E., et.al. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy, Am J Clin Oncol, 2013. 36(4): p. 338-43.

1549. Ben-Josef, E., Han, S., Tobi, M., Shaw, L. M., Bonner, H. S., Vargas, B. J., et.al. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury, Int J Radiat Oncol Biol Phys, 2002. 53(5): p. 1160-4.

1550. Kouloulias, V. E., Kouvaris, J. R., Pissakas, G., Mallas, E., Antypas, C., Kokakis, J. D., et.al. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application, Int J Radiat Oncol Biol Phys, 2005. 62: p. 486-93.

1551. Montana, G. S., Anscher, M. S., Mansbach, C. M., 2nd, Daly, N., Delannes, M., Carke-Pearson, D., et.al. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial, Cancer, 1992. 69(11): p. 2826-30.

1552. Myerson, R., Zobeiri, I., Birnbaum, E., Dietz, D., Fleshman, J., Kodner, I., et.al. Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma, Semin Oncol, 2002. 29(6 Suppl 19): p. 29-33.

1553. Kouloulias, VE, Kouvaris, JR, Kokakis, JD, Kostakopoulos, A, Mallas, E, Metafa, A, et.al. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis., Int J Radiat Oncol Biol Phys, 2004. 59 (4)(4): p. 1148-56., https://pubmed.ncbi.nlm.nih.gov/15234050/

1554. Koukourakis, M. I., Kyrias, G., Kakolyris, S., Kouroussis, C., Frangiadaki, C., Giatromanolaki, A., et.al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study, J Clin Oncol, 2000. 18(11): p. 2226-33.

1555. Kouvaris, J., Kouloulias, V., Malas, E., Antypas, C., Kokakis, J., Michopoulos, S., et.al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy, Strahlenther Onkol, 2003. 179(3): p. 167-74.

1556. Freund, U., Scholmerich, J., Siems, H., Kluge, F., Schafer, H. E., Wannenmacher, M., [Unwanted side-effects in using mesalazine (5-aminosalicylic acid) during radiotherapy], Strahlenther Onkol, 1987. 163: p. 678-80.

1557. Sanguineti, G., Franzone, P., Marcenaro, M., Foppiano, F., Vitale, V., Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study, Strahlenther Onkol, 2003. 179: p. 464-70.

1558. Kilic, D., Egehan, I., Ozenirler, S., Dursun, A., Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy, Radiother Oncol, 2000. 57: p. 125-9.

1559. Martenson, J. A., Jr., Hyland, G., Moertel, C. G., Mailliard, J. A., O'Fallon, J. R., Collins, R. T., et.al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial, Int J Radiat Oncol Biol Phys, 1996. 35: p. 299-303.

1560. Kilic, D, Ozenirler, S, Egehan, I, Dursun, A, Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy., Ann Pharmacother, 2001. 35 (7-8)(7-8): p. 806-10., https://pubmed.ncbi.nlm.nih.gov/11485124/

1561. Martenson, JA, Bollinger, JW, Sloan, JA, Novotny, PJ, Urias, RE, Michalak, JC, et.al. Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: A North Central Cancer Treatment Group phase III double-blind placebo-controlled trial., J Clin Oncol, 2000. 18 (6)(6): p. 1239-45., https://pubmed.ncbi.nlm.nih.gov/10715293/

1562. Jahraus, C. D., Bettenhausen, D., Malik, U., Sellitti, M., St Clair, W. H., Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients, Int J Radiat Oncol Biol Phys, 2005. 63(5): p. 1483-7.

1563. Hille, A., Schmidberger, H., Hermann, R. M., Christiansen, H., Saile, B., Pradier, O., et.al. A phase III randomized, placebo-controlled, double-blind study of misoprostol rectal suppositories to prevent acute radiation proctitis in patients with prostate cancer, Int J Radiat Oncol Biol Phys, 2005. 63: p. 1488-93.

1564. Khan, A. M., Birk, J. W., Anderson, J. C., Georgsson, M., Park, T. L., Smith, C. J., et.al. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients, Am J Gastroenterol, 2000. 95: p. 1961-6.

1565. Kertesz, T., Herrmann, M. K., Zapf, A., Christiansen, H., Hermann, R. M., Pradier, O., et.al. Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study, Strahlenther Onkol, 2009. 185: p. 596-602.

1566. O'Brien, P. C., Franklin, C. I., Dear, K. B., Hamilton, C. C., Poulsen, M., Joseph, D. J., et.al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis, Radiother Oncol, 1997. 45: p. 117-23.

1567. Henriksson, R., Franzen, L., Littbrand, B., Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer, J Clin Oncol, 1992. 10: p. 969-75.

1568. Kneebone, A., Mameghan, H., Bolin, T., Berry, M., Turner, S., Kearsley, J., et.al. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial, Int J Radiat Oncol Biol Phys, 2004. 60(4): p. 1088-97.

1569. Saei, S., Sahebnasagh, A., Ghasemi, A., Akbari, J., Alipour, A., Lashkardoost, H., et.al. Efficacy of sucralfate ointment in the prevention of acute proctitis in cancer patients: A randomized controlled clinical trial, Caspian J Intern Med, 2020. 11(4): p. 410-418.

1570. Henriksson, R., Franzén, L., Littbrand, B., Prevention and therapy of radiation-induced bowel discomfort, Scand J Gastroenterol Suppl, 1992. 191: p. 7-11.

1571. Henriksson, R., Franzén, L., Littbrand, B., Prevention of irradiation-induced bowel discomfort by sucralfate: a double-blind, placebo-controlled study when treating localized pelvic cancer, Am J Med, 1991. 91(2a): p. 151s-157s.

1572. Henriksson, R., Arevärn, M., Franzén, L., Persson, H., Stendahl, U., Beneficial effects of sucralphate in radiation induced diarrhea. An open randomized study in gynecological cancer patients, Eur J Gynaecol Oncol, 1990. 11(4): p. 299-302.

1573. Fuccio, L., Guido, A., Laterza, L., Eusebi, L. H., Busutti, L., Bunkheila, F., et.al. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer, Aliment Pharmacol Ther, 2011. 34: p. 628-37.

1574. Maggio, A., Magli, A., Rancati, T., Fiorino, C., Valvo, F., Fellin, G., et.al. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study, Int J Radiat Oncol Biol Phys, 2014. 89: p. 518-24.

1575. Qin, S. B., Gao, X. S., Li, H. Z., Liu, C. X., Hou, D. L., Nian, W. D., et.al. Intra-rectal use of epinephrine in radiotherapy of prostate cancer, Cancer Manag Res, 2019. 11: p. 4847-4854.

1576. Sahebnasagh, A., Ghasemi, A., Akbari, J., Alipour, A., Lashkardoost, H., Ala, S., et.al. Prevention of acute radiation-induced Proctitis by Aloe vera: a prospective randomized, double-blind, placebo controlled clinical trial in Pelvic Cancer patients, BMC Complement Med Ther, 2020. 20(1): p. 146.

1577. Chopra, S, Krishnatry, R, Dora, T, Kannan, S, Thomas, B, Sonawone, S, et.al. Predictors of late bowel toxicity using three different methods of contouring in patients undergoing post-operative radiation for cervical cancer., Br J Radiol, 2015. 88 (1055)(1055): p. 20150054., https://pubmed.ncbi.nlm.nih.gov/26394195/

1578. Naik, A, Gurjar, OP, Bagdare, P, Gupta, KL, Bhandari, V, Kausar, M, et.al. Dosimetric comparison between intensity modulated radiotherapy and three dimensional conformal radiotherapy planning in patients with locally advanced cervical carcinomaNovin Medical Radiation Institute, 2016. 14(3): p. 189.

1579. Viani, GA, Viana, BS, Martin, JE, Rossi, BT, Zuliani, G, Stefano, EJ, Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial., Cancer, 2016. 122 (13)(13): p. 2004-11., https://pubmed.ncbi.nlm.nih.gov/27028170/

1580. D'Agostino, GR, Mancosu, P, Di Brina, L, Franzese, C, Pasini, L, Iftode, C, et.al. Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study., Am J Clin Oncol, 2020. 43 (9)(9): p. 628-635., https://pubmed.ncbi.nlm.nih.gov/32889832/

1581. Rastogi, M, Nanda, SS, Gandhi, AK, Dalela, D, Khurana, R, Mishra, SP, et.al. Pelvic bone anatomy vs implanted gold seed marker registration for image-guided intensity modulated radiotherapy for prostate carcinoma: Comparative analysis of inter-fraction motion and toxicities., J Egypt Natl Canc Inst, 2017. 29 (4)(4): p. 185-190., https://pubmed.ncbi.nlm.nih.gov/29129577/

1582. Te Velde, BL, Westhuyzen, J, Awad, N, Wood, M, Shakespeare, TP, Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion., J Med Imaging Radiat Oncol, 2019. 63 (6)(6): p. 836-841., https://pubmed.ncbi.nlm.nih.gov/31520465 /

1583. Prada, PJ, Gonzalez, H, Menéndez, C, Llaneza, A, Fernández, J, Santamarta, E, et.al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients., Brachytherapy, 2009. 8 (2)(2): p. 210-217., https://pubmed.ncbi.nlm.nih.gov/19213607 /

1584. Hamstra, DA, Mariados, N, Sylvester, J, Shah, D, Karsh, L, Hudes, R, et.al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial., Int J Radiat Oncol Biol Phys, 2017. 97 (5)(5): p. 976-985., https://pubmed.ncbi.nlm.nih.gov/28209443/

1585. Müller, AC, Mischinger, J, Klotz, T, Gagel, B, Habl, G, Hatiboglu, G, et.al. Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients., Radiol Oncol, 2016. 50 (3)(3): p. 329-36., https://pubmed.ncbi.nlm.nih.gov/27679550/

1586. Kim, A, Karotki, A, Presutti, J, Gonzales, G, Wong, S, Chu, W, The effect of prone and supine treatment positions for the pre-operative treatment of rectal cancer on organ-at-risk sparing and setup reproducibility using volumetric modulated arc therapy., Radiat Oncol, 2017. 12 (1)(1): p. 180., https://pubmed.ncbi.nlm.nih.gov/29202879/

1587. Yang, Y, Cai, S, Zhao, T, Peng, Q, Qian, J, Tian, Y, Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy., Transl Cancer Res, 2020. 9 (2)(2): p. 491-499., https://pubmed.ncbi.nlm.nih.gov/35117393/

1588. Siddiqui, F, Shi, C, Papanikolaou, N, Fuss, M, Image-guidance protocol comparison: supine and prone set-up accuracy for pelvic radiation therapy., Acta Oncol, 2008. 47 (7)(7): p. 1344-50., https://pubmed.ncbi.nlm.nih.gov/18663650/

1589. Kószó, R, Varga, L, Fodor, E, Kahán, Z, Cserháti, A, Hideghéty, K, et.al. Prone Positioning on a Belly Board Decreases Rectal and Bowel Doses in Pelvic Intensity-Modulated Radiation Therapy (IMRT) for Prostate Cancer., Pathol Oncol Res, 2019. 25 (3)(3): p. 995-1002., https://pubmed.ncbi.nlm.nih.gov/29882196/

1590. Frøseth, TC, Strickert, T, Solli, KS, Salvesen, Ø, Frykholm, G, Reidunsdatter, RJ, A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients., Radiat Oncol, 2015. 10 (): p. 217., https://pubmed.ncbi.nlm.nih.gov/26508131/

1591. Wiesendanger-Wittmer, EM, Sijtsema, NM, Muijs, CT, Beukema, JC, Systematic review of the role of a belly board device in radiotherapy delivery in patients with pelvic malignancies., Radiother Oncol, 2012. 102 (3)(3): p. 325-34., https://pubmed.ncbi.nlm.nih.gov/22364650/

1592. Gonzalez, VJ, Hullett, CR, Burt, L, Rassiah-Szegedi, P, Sarkar, V, Tward, JD, et.al. Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy., Adv Radiat Oncol, 2017. 2 (2)(2): p. 235-243., https://pubmed.ncbi.nlm.nih.gov/28740937/

1593. Mullaney, LM, O'Shea, E, Dunne, MT, Finn, MA, Thirion, PG, Cleary, LA, et.al. A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy., Pract Radiat Oncol, 2014. 4 (5)(5): p. e203-e212., https://pubmed.ncbi.nlm.nih.gov/25194106 /

1594. Chitapanarux, I., Chitapanarux, T., Traisathit, P., Kudumpee, S., Tharavichitkul, E., Lorvidhaya, V., Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients, Radiat Oncol, 2010. 5: p. 31.

1595. Linn, Y. H., Thu, K. K., Win, N. H. H., Effect of Probiotics for the Prevention of Acute Radiation-Induced Diarrhoea Among Cervical Cancer Patients: a Randomized Double-Blind Placebo-Controlled Study, Probiotics Antimicrob Proteins, 2019. 11(2): p. 638-647.

1596. Nascimento, M., Aguilar-Nascimento, J. E., Caporossi, C., Castro-Barcellos, H. M., Motta, R. T., Efficacy of synbiotics to reduce acute radiation proctitis symptoms and improve quality of life: a randomized, double-blind, placebo-controlled pilot trial, Int J Radiat Oncol Biol Phys, 2014. 90(2): p. 289-95.

1597. Nascimento, M., Caporossi, C., Eduardo Aguilar-Nascimento, J., Michelon Castro-Barcellos, H., Teixeira Motta, R., Reis Lima, S., Efficacy of Synbiotics to Reduce Symptoms and Rectal Inflammatory Response in Acute Radiation Proctitis: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial, Nutr Cancer, 2020. 72(4): p. 602-609.

1598. Sasidharan, B. K., Ramadass, B., Viswanathan, P. N., Samuel, P., Gowri, M., Pugazhendhi, S., et.al. A phase 2 randomized controlled trial of oral resistant starch supplements in the prevention of acute radiation proctitis in patients treated for cervical cancer, J Cancer Res Ther, 2019. 15(6): p. 1383-1391.

1599. Saadipoor, A., Razzaghdoust, A., Simforoosh, N., Mahdavi, A., Bakhshandeh, M., Moghadam, M., et.al. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy, Phytother Res, 2019. 33(2): p. 370-378.

1600. Hejazi, J, Rastmanesh, R, Taleban, FA, Molana, SH, Ehtejab, G, A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer, 2013. 5(10): p. 320 - 4.

1601. Ahmad, IU, Forman, JD, Sarkar, FH, Hillman, GG, Heath, E, Vaishampayan, U, et.al. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer., Nutr Cancer, 2010. 62 (7)(7): p. 996-1000., https://pubmed.ncbi.nlm.nih.gov/20924975/

1602. López, E Arregui, Serrano, C Bueno, Linán, M Rodríguez, Cabezas, S García, Eito, A Palacios, Sofía, Complejo Hospitalario Reina, et.al. Steady diet as prophylaxis of acute diarrhea in preoperative pelvic radiotherapy of rectal adenocarcinoma, 2012. 17: p. S111.

1603. Dale, P. S., Tamhankar, C. P., George, D., Daftary, G. V., Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects, Cancer Chemother Pharmacol, 2001. 47 Suppl: p. S29-34.

1604. Vernia, P., Fracasso, P. L., Casale, V., Villotti, G., Marcheggiano, A., Stigliano, V., et.al. Topical butyrate for acute radiation proctitis: randomised, crossover trial, Lancet, 2000. 356: p. 1232-5.

1605. Hille, A., Herrmann, M. K., Kertesz, T., Christiansen, H., Hermann, R. M., Pradier, O., et.al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation, Strahlenther Onkol, 2008. 184(12): p. 686-92.

1606. Sahebnasagh, A., Ghasemi, A., Akbari, J., Alipour, A., Lashkardoost, H., Ala, S., et.al. Successful Treatment of Acute Radiation Proctitis with Aloe Vera: A Preliminary Randomized Controlled Clinical Trial, J Altern Complement Med, 2017. 23(11): p. 858-865.

1607. Wang, L., Zhang, Z. Z., Tu, X. H., Zou, Z. D., Liu, J. H., Wang, Y., Safety and efficacy of Qingre Buyi Decoction in the treatment of acute radiation proctitis: a prospective, randomized and controlled trial, Chin J Integr Med, 2009. 15(4): p. 272-8.

1608. Andreyev, H. J., Muls, A. C., Norton, C., Ralph, C., Watson, L., Shaw, C., et.al. Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease, Frontline Gastroenterol, 2015. 6: p. 53-72.

1609. Goldner, G., Potter, R., Kranz, A., Bluhm, A., Dorr, W., Healing of late endoscopic changes in the rectum between 12 and 65 months after external beam radiotherapy, Strahlenther Onkol, 2011. 187: p. 202-5.

1610. Cavcic, J., Turcic, J., Martinac, P., Jelincic, Z., Zupancic, B., Panijan-Pezerovic, R., et.al. Metronidazole in the treatment of chronic radiation proctitis: clinical trial, Croat Med J, 2000. 41: p. 314-8.

1611. Sahakitrungruang, C., Patiwongpaisarn, A., Kanjanasilp, P., Malakorn, S., Atittharnsakul, P., A randomized controlled trial comparing colonic irrigation and oral antibiotics administration versus 4% formalin application for treatment of hemorrhagic radiation proctitis, Dis Colon Rectum, 2012. 55: p. 1053-8.

1612. Pui, W. C., Chieng, T. H., Siow, S. L., Nik Abdullah, N. A., Sagap, I., A Randomized Controlled Trial of Novel Treatment for Hemorrhagic Radiation Proctitis, Asian Pac J Cancer Prev, 2020. 21(10): p. 2927-2934.

1613. Kochhar, R., Patel, F., Dhar, A., Sharma, S. C., Ayyagari, S., Aggarwal, R., et.al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate, Dig Dis Sci, 1991. 36: p. 103-7.

1614. Chruscielewska-Kiliszek, M. R., Regula, J., Polkowski, M., Rupinski, M., Kraszewska, E., Pachlewski, J., et.al. Sucralfate or placebo following argon plasma coagulation for chronic radiation proctitis: a randomized double blind trial, Colorectal Dis, 2013. 15(1): p. e48-55.

1615. Nelamangala Ramakrishnaiah, V. P., Javali, T. D., Dharanipragada, K., Reddy, K. S., Krishnamachari, S., Formalin dab, the effective way of treating haemorrhagic radiation proctitis: a randomized trial from a tertiary care hospital in South India, Colorectal Dis, 2012. 14(7): p. 876-82.

1616. Wu, C., Guan, L., Yao, L., Huang, J., Mesalazine suppository for the treatment of refractory ulcerative chronic radiation proctitis, Exp Ther Med, 2018. 16(3): p. 2319-2324.

1617. Seo, E. H., Kim, T. O., Kim, T. G., Joo, H. R., Park, J., Park, S. H., et.al. The efficacy of the combination therapy with oral and topical mesalazine for patients with the first episode of radiation proctitis, Dig Dis Sci, 2011. 56(9): p. 2672-7.

1618. Clavo, B., Ceballos, D., Gutierrez, D., Rovira, G., Suarez, G., Lopez, L., et.al. Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy, J Pain Symptom Manage, 2013. 46(1): p. 106-12.

1619. Rougier, Ph, Zimmermann, P, Pignon, JP, Kac, J, Crespon, B, Zrihen, E, Rectites radiques: efficacite comparee de deux types de corticoïdes administres localement, 1992. 21(2): p. 91 - 93.

1620. Pinto, A., Fidalgo, P., Cravo, M., Midoes, J., Chaves, P., Rosa, J., et.al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial, Dis Colon Rectum, 1999. 42: p. 788-95; discussion 795-6.

1621. Talley, N. A., Chen, F., King, D., Jones, M., Talley, N. J., Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial, Dis Colon Rectum, 1997. 40: p. 1046-50.

1622. al-Sabbagh, R., Sinicrope, F. A., Sellin, J. H., Shen, Y., Roubein, L., Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis, Am J Gastroenterol, 1996. 91(9): p. 1814-6.

1623. Chautems, R. C., Delgadillo, X., Rubbia-Brandt, L., Deleaval, J. P., Marti, M. C., Roche, B., Formaldehyde application for haemorrhagic radiation-induced proctitis: a clinical and histological study, Colorectal Dis, 2003. 5(1): p. 24-8.

1624. de Parades, V., Etienney, I., Bauer, P., Bourguignon, J., Meary, N., Mory, B., et.al. Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis--an effective but not risk-free procedure: a prospective study of 33 patients, Dis Colon Rectum, 2005. 48(8): p. 1535-41.

1625. Yeoh, E., Tam, W., Schoeman, M., Moore, J., Thomas, M., Botten, R., et.al. Argon plasma coagulation therapy versus topical formalin for intractable rectal bleeding and anorectal dysfunction after radiation therapy for prostate carcinoma, Int J Radiat Oncol Biol Phys, 2013. 87(5): p. 954-9.

1626. Furtado, F. S., Furtado, G. B., Oliveira, A. T., Oliveira, F. A. A., Pinho, C. S., Sampaio, J. P. A., et.al. Endorectal formalin instillation or argon plasma coagulation for hemorrhagic radiation proctopathy therapy: a prospective and randomized clinical trial, Gastrointest Endosc, 2021. 93(6): p. 1393-1400.

1627. Clarke, R. E., Tenorio, L. M., Hussey, J. R., Toklu, A. S., Cone, D. L., Hinojosa, J. G., et.al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up, Int J Radiat Oncol Biol Phys, 2008. 72: p. 134-143.

1628. Glover, M., Smerdon, G. R., Andreyev, H. J., Benton, B. E., Bothma, P., Firth, O., et.al. Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial, Lancet Oncol, 2016. 17(2): p. 224-233.

1629. Alpuim Costa, D., Amaro, C. E., Nunes, A., Cardoso, J. S., Daniel, P. M., Rosa, I., et.al. Hyperbaric oxygen therapy as a complementary treatment for radiation proctitis: Useless or useful? - A literature review, World J Gastroenterol, 2021. 27(27): p. 4413-4428.

1630. Mathieu, D., Marroni, A., Kot, J., Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment, Diving Hyperb Med, 2017. 47(1): p. 24-32.

1631. Bennett, M. H., Feldmeier, J., Hampson, N. B., Smee, R., Milross, C., Hyperbaric oxygen therapy for late radiation tissue injury, Cochrane Database Syst Rev, 2016. 4(4): p. Cd005005.

1632. Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., et.al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy, Cancer, 2020. 126(19): p. 4423-4431.

1633. Ehrenpreis, E. D., Jani, A., Levitsky, J., Ahn, J., Hong, J., A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy, Dis Colon Rectum, 2005. 48: p. 1-8.

1634. Kennedy, M., Bruninga, K., Mutlu, E. A., Losurdo, J., Choudhary, S., Keshavarzian, A., Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C, Am J Gastroenterol, 2001. 96: p. 1080-4.

1635. Gothard, L., Cornes, P., Brooker, S., Earl, J., Glees, J., Hall, E., et.al. Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy, Radiother Oncol, 2005. 75(3): p. 334-41.

1636. Venkitaraman, R., Price, A., Coffey, J., Norman, A. R., James, F. V., Huddart, R. A., et.al. Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial, Clin Oncol (R Coll Radiol), 2008. 20(4): p. 288-92.

1637. Zhong, Q. H., Liu, Z. Z., Yuan, Z. X., Ma, T. H., Huang, X. Y., Wang, H. M., et.al. Efficacy and complications of argon plasma coagulation for hemorrhagic chronic radiation proctitis, World J Gastroenterol, 2019. 25(13): p. 1618-1627.

1638. Montes de Oca Megías, E, Morera Pérez, M, Noa Pedroso, G, Piñol Jiménez, F, Armenteros Torres, M, Short and long term response to argon plasma therapy for hemorrhagic radiation proctitis., Rev Esp Enferm Dig, 2019. 111 (11)(11): p. 852-857., https://pubmed.ncbi.nlm.nih.gov/31595754/

1639. Sultania, S., Sarkar, R., Das, K., Dhali, G. K., Argon plasma coagulation is an effective treatment for chronic radiation proctitis in gynaecological malignancy: an observational study, Colorectal Dis, 2019. 21(4): p. 465-471.

1640. Weiner, J., Schwartz, D., Martinez, M., Safdieh, J., Aytaman, A., Schreiber, D., Long-term results on the efficacy of argon plasma coagulation for patients with chronic radiation proctitis after conventionally fractionated, dose-escalated radiation therapy for prostate cancer, Pract Radiat Oncol, 2017. 7(1): p. e35-e42.

1641. Dees, J., Meijssen, M. A., Kuipers, E. J., Argon plasma coagulation for radiation proctitis, Scand J Gastroenterol Suppl, 2006. p. 175-8.

1642. Siow, S. L., Mahendran, H. A., Seo, C. J., Complication and remission rates after endoscopic argon plasma coagulation in the treatment of haemorrhagic radiation proctitis, Int J Colorectal Dis, 2017. 32(1): p. 131-134.

1643. Sato, Y., Takayama, T., Sagawa, T., Hirakawa, M., Ohnuma, H., Miyanishi, K., et.al. Argon plasma coagulation treatment of hemorrhagic radiation proctopathy: the optimal settings for application and long-term outcome, Gastrointest Endosc, 2011. 73(3): p. 543-9.

1644. Alfadhli, A. A., Alazmi, W. M., Ponich, T., Howard, J. M., Prokopiw, I., Alaqeel, A., et.al. Efficacy of argon plasma coagulation compared to topical formalin application for chronic radiation proctopathy, Can J Gastroenterol, 2008. 22(2): p. 129-32.

1645. Alvaro-Villegas, J. C., Sobrino-Cossío, S., Tenorio-Téllez, L. C., de la Mora-Levy, J. G., Hernández-Guerrero, A., Alonso-Lárraga, J. O., et.al. Argon plasma coagulation and hyperbaric oxygen therapy in chronic radiation proctopathy, effectiveness and impact on tissue toxicity, Rev Esp Enferm Dig, 2011. 103(11): p. 576-81.

1646. Zhou, C., Adler, D. C., Becker, L., Chen, Y., Tsai, T. H., Figueiredo, M., et.al. Effective treatment of chronic radiation proctitis using radiofrequency ablation, Therap Adv Gastroenterol, 2009. 2: p. 149-156.

1647. Nikfarjam, M., Faulx, A., Laughinghouse, M., Marks, J. M., Feasibility of radiofrequency ablation for the treatment of chronic radiation proctitis, Surg Innov, 2010. 17: p. 92-4.

1648. Rustagi, T, Corbett, FS, Mashimo, H, Treatment of chronic radiation proctopathy with radiofrequency ablation (with video)., Gastrointest Endosc, 2015. 81 (2)(2): p. 428-36., https://pubmed.ncbi.nlm.nih.gov/24973172/

1649. Kantsevoy, S. V., Cruz-Correa, M. R., Vaughn, C. A., Jagannath, S. B., Pasricha, P. J., Kalloo, A. N., Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study, Gastrointest Endosc, 2003. 57: p. 403-6.

1650. Hou, J. K., Abudayyeh, S., Shaib, Y., Treatment of chronic radiation proctitis with cryoablation, Gastrointest Endosc, 2011. 73: p. 383-9.

1651. Dhaliwal, A., Saghir, S. M., Mashiana, H. S., Braseth, A., Dhindsa, B. S., Ramai, D., et.al. Endoscopic cryotherapy: Indications, techniques, and outcomes involving the gastrointestinal tract, World J Gastrointest Endosc, 2022. 14(1): p. 17-28.

1652. Lenz, L., Tafarel, J., Correia, L., Bonilha, D., Santos, M., Rodrigues, R., et.al. Comparative study of bipolar eletrocoagulation versus argon plasma coagulation for rectal bleeding due to chronic radiation coloproctopathy, Endoscopy, 2011. 43(8): p. 697-701.

1653. Jensen, D. M., Machicado, G. A., Cheng, S., Jensen, M. E., Jutabha, R., A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia, Gastrointest Endosc, 1997. 45(1): p. 20-5.

1654. Anseline, P. F., Lavery, I. C., Fazio, V. W., Jagelman, D. G., Weakley, F. L., Radiation injury of the rectum: evaluation of surgical treatment, Ann Surg, 1981. 194: p. 716-24.

1655. Ayerdi, J., Moinuddeen, K., Loving, A., Wiseman, J., Deshmukh, N., Diverting loop colostomy for the treatment of refractory gastrointestinal bleeding secondary to radiation proctitis, Mil Med, 2001. 166: p. 1091-3.

1656. Jao, S. W., Beart, R. W., Jr., Gunderson, L. L., Surgical treatment of radiation injuries of the colon and rectum, Am J Surg, 1986. 151: p. 272-7.

1657. Lucarotti, M. E., Mountford, R. A., Bartolo, D. C., Surgical management of intestinal radiation injury, Dis Colon Rectum, 1991. 34: p. 865-9.

1658. Pricolo, V. E., Shellito, P. C., Surgery for radiation injury to the large intestine. Variables influencing outcome, Dis Colon Rectum, 1994. 37: p. 675-84.

1659. Huang, X., Zhong, Q., Wang, H., Zhao, J., Kuang, Y., Guan, Q., et.al. Diverting colostomy is an effective procedure for ulcerative chronic radiation proctitis patients after pelvic malignancy radiation, BMC Surg, 2020. 20(1): p. 267.

1660. Ray, Dipankar, Chattopadhyay, Gautam, Chronic Radiation Proctitis: A Challenging and Enigmatic Problem, 2021. 41(4): p. 159 - 167.

1661. Sarin, A., Safar, B., Management of radiation proctitis, Gastroenterol Clin North Am, 2013. 42: p. 913-25.

1662. Turina, M., Mulhall, A. M., Mahid, S. S., Yashar, C., Galandiuk, S., Frequency and surgical management of chronic complications related to pelvic radiation, Arch Surg, 2008. 143(1): p. 46-52; discussion 52.

1663. McCrone, L. F., Neary, P. M., Larkin, J., McCormick, P., Mehigan, B., The surgical management of radiation proctopathy, Int J Colorectal Dis, 2017. 32(8): p. 1099-1108.

1664. Baughan, C. A., Canney, P. A., Buchanan, R. B., Pickering, R. M., A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis, Clin Oncol (R Coll Radiol), 1993. 5: p. 19-24.

1665. Resbeut, M., Marteau, P., Cowen, D., Richaud, P., Bourdin, S., Dubois, J. B., et.al. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis, Radiother Oncol, 1997. 44: p. 59-63.

1666. Miller, RC, Petereit, DG, Sloan, JA, Liu, H, Martenson, JA, Bearden, JD, et.al. N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy., Int J Radiat Oncol Biol Phys, 2016. 95 (4)(4): p. 1168-74., https://pubmed.ncbi.nlm.nih.gov/27354129/

1667. Athanassiou, H., Antonadou, D., Coliarakis, N., Kouveli, A., Synodinou, M., Paraskevaidis, M., et.al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial, Int J Radiat Oncol Biol Phys, 2003. 56: p. 1154-60.

1668. Katsanos, K. H., Briasoulis, E., Tsekeris, P., Batistatou, A., Bai, M., Tolis, C., et.al. Randomized phase II exploratory study of prophylactic amifostine in cancer patients who receive radical radiotherapy to the pelvis, J Exp Clin Cancer Res, 2010. 29: p. 68.

1669. Liu, T., Liu, Y., He, S., Zhang, Z., Kligerman, M. M., Use of radiation with or without WR-2721 in advanced rectal cancer, Cancer, 1992. 69: p. 2820-5.

1670. Chary, S., Thomson, D. H., A clinical trial evaluating cholestyramine to prevent diarrhea in patients maintained on low-fat diets during pelvic radiation therapy, Int J Radiat Oncol Biol Phys, 1984. 10: p. 1885-90.

1671. Kozelsky, T. F., Meyers, G. E., Sloan, J. A., Shanahan, T. G., Dick, S. J., Moore, R. L., et.al. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy, J Clin Oncol, 2003. 21: p. 1669-74.

1672. Vidal-Casariego, A., Calleja-Fernandez, A., de Urbina-Gonzalez, J. J., Cano-Rodriguez, I., Cordido, F., Ballesteros-Pomar, M. D., Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial, JPEN J Parenter Enteral Nutr, 2014. 38: p. 205-13.

1673. Zachariah, B., Gwede, C. K., James, J., Ajani, J., Chin, L. J., Donath, D., et.al. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315, J Natl Cancer Inst, 2010. 102: p. 547-56.

1674. Delia, P., Sansotta, G., Donato, V., Frosina, P., Messina, G., De Renzis, C., et.al. Use of probiotics for prevention of radiation-induced diarrhea, World J Gastroenterol, 2007. 13: p. 912-5.

1675. Giralt, J., Regadera, J. P., Verges, R., Romero, J., de la Fuente, I., Biete, A., et.al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial, Int J Radiat Oncol Biol Phys, 2008. 71: p. 1213-9.

1676. Salminen, E., Elomaa, I., Minkkinen, J., Vapaatalo, H., Salminen, S., Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures, Clin Radiol, 1988. 39: p. 435-7.

1677. Urbancsek, H., Kazar, T., Mezes, I., Neumann, K., Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea, Eur J Gastroenterol Hepatol, 2001. 13: p. 391-6.

1678. Picó-Monllor, JA, Mingot-Ascencao, JM, Search and Selection of Probiotics That Improve Mucositis Symptoms in Oncologic Patients. A Systematic Review., Nutrients, 2019. 11 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/31581434/

1679. Liu, MM, Li, ST, Shu, Y, Zhan, HQ, Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials., PLoS One, 2017. 12 (6)(6): p. e0178870., https://pubmed.ncbi.nlm.nih.gov/28575095/

1680. Castro, MG, Sanchez, PX, Glasberg, J, Horie, LM, Waitzberg, DL, P112 effects of probiotic in prevention of radiation-induced diarrhea, 2009. 2(4): p. 72 - 73.

1681. Jian, Y, Zhang, D, Liu, M, Wang, Y, Xu, ZX, The Impact of Gut Microbiota on Radiation-Induced Enteritis., Front Cell Infect Microbiol, 2021. 11 (): p. 586392., https://pubmed.ncbi.nlm.nih.gov/34395308/

1682. Rosli, D, Shahar, S, Manaf, ZA, Lau, HJ, Yusof, NYM, Haron, MR, et.al. Randomized Controlled Trial on the Effect of Partially Hydrolyzed Guar Gum Supplementation on Diarrhea Frequency and Gut Microbiome Count Among Pelvic Radiation Patients., JPEN J Parenter Enteral Nutr, 2021. 45 (2)(2): p. 277-286., https://pubmed.ncbi.nlm.nih.gov/32740950/

1683. Garcia-Peris, P, Velasco, C, Hernandez, M, Lozano, MA, Paron, L, de la Cuerda, C, et.al. Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial., Eur J Clin Nutr, 2016. 70 (2)(2): p. 170-4., https://pubmed.ncbi.nlm.nih.gov/26603881/

1684. Demers, M, Dagnault, A, Desjardins, J, A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation., Clin Nutr, 2014. 33 (5)(5): p. 761-7., https://pubmed.ncbi.nlm.nih.gov/24200199/

1685. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., et.al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), Lancet Oncol, 2008. 9: p. 105-16.

1686. Cetin, E., Ozturk, A. S., Orhun, H., Ulger, S., Role of triamcinolone in radiation enteritis management, World J Gastroenterol, 2014. 20: p. 4341-4.

1687. Hombrink, J., Frohlich, D., Glatzel, M., Krauss, A., Thiel, H. J., Meier, J., et.al. [Prevention of radiation-induced diarrhea by smectite. Results of a double-blind randomized, placebo-controlled multicenter study], Strahlenther Onkol, 2000. 176: p. 173-9.

1688. Hovdenak, N, Sørbye, H, Dahl, O, Sucralfate does not ameliorate acute radiation proctitis: randomised study and meta-analysis., Clin Oncol (R Coll Radiol), 2005. 17 (6)(6): p. 485-91., https://pubmed.ncbi.nlm.nih.gov/16149294/

1689. Wedlake, L, Shaw, C, McNair, H, Lalji, A, Mohammed, K, Klopper, T, et.al. Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy., Am J Clin Nutr, 2017. 106 (3)(3): p. 849-857., https://pubmed.ncbi.nlm.nih.gov/28679552/

1690. White, KL, Henson, CC, Hann, M, Eden, M, Burden, ST, Lal, S, et.al. Randomised clinical trial of a gastrointestinal care bundle to reduce symptoms in patients with pelvic cancer undergoing chemoradiotherapy., BMJ Open Gastroenterol, 2020. 7 (1)(1):, https://pubmed.ncbi.nlm.nih.gov/32771983/

1691. Yeoh, E. K., Horowitz, M., Russo, A., Muecke, T., Robb, T., Chatterton, B. E., Gastrointestinal function in chronic radiation enteritis--effects of loperamide-N-oxide, Gut, 1993. 34: p. 476-82.

1692. AkdÄ, Drug Safety Mail 2016-19- LoperamidArzneimittelkommission der deutschen Ärzteschaft, 2016.

1693. Yavuz, M. N., Yavuz, A. A., Aydin, F., Can, G., Kavgaci, H., The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study, International Journal of Radiation Oncology, Biology, Physics, 2002. 54: p. 195-202.

1694. Cao, DD, Xu, HL, Xu, M, Qian, XY, Yin, ZC, Ge, W, Therapeutic role of glutamine in management of radiation enteritis: a meta-analysis of 13 randomized controlled trials., Oncotarget, 2017. 8 (18)(18): p. 30595-30605., https://pubmed.ncbi.nlm.nih.gov/28427169/

1695. Dalsania, RM, Shah, KP, Stotsky-Himelfarb, E, Hoffe, S, Willingham, FF, Management of Long-Term Toxicity From Pelvic Radiation Therapy., Am Soc Clin Oncol Educ Book, 2021. 41 (): p. 1-11., https://pubmed.ncbi.nlm.nih.gov/33793314/

1696. Lefevre, J. H., Amiot, A., Joly, F., Bretagnol, F., Panis, Y., Risk of recurrence after surgery for chronic radiation enteritis, Br J Surg, 2011. 98: p. 1792-7.

1697. Regimbeau, J. M., Panis, Y., Gouzi, J. L., Fagniez, P. L., Operative and long term results after surgery for chronic radiation enteritis, Am J Surg, 2001. 182: p. 237-42.

1698. Zhang, L., Gong, J. F., Dong, J. N., Zhu, W. M., Li, N., Li, J. S., Effectiveness of a clinical pathway for inpatients undergoing ileal/ileocecal resection for chronic radiation enteritis with intestinal obstruction, Am Surg, 2015. 81: p. 252-8.

1699. Sharp, L., Finnila, K., Johansson, H., Abrahamsson, M., Hatschek, T., Bergenmar, M., No differences between Calendula cream and aqueous cream in the prevention of acute radiation skin reactions--results from a randomised blinded trial, Eur J Oncol Nurs, 2013. 17: p. 429-35.

1700. Behroozian, T, Milton, LT, Shear, NH, McKenzie, E, Razvi, Y, Karam, I, et.al. Radiation dermatitis assessment tools used in breast cancer: A systematic review of measurement properties., Support Care Cancer, 2021. 29 (5)(5): p. 2265-2278., https://pubmed.ncbi.nlm.nih.gov/33205325/

1701. Roy, I., Fortin, A., Larochelle, M., The impact of skin washing with water and soap during breast irradiation: a randomized study, Radiother Oncol, 2001. 58: p. 333-9.

1702. Westbury, C., Hines, F., Hawkes, E., Ashley, S., Brada, M., Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial, Radiother Oncol, 2000. 54: p. 109-16.

1703. Burch, S. E., Parker, S. A., Vann, A. M., Arazie, J. C., Measurement of 6-MV X-ray surface dose when topical agents are applied prior to external beam irradiation, Int J Radiat Oncol Biol Phys, 1997. 38: p. 447-51.

1704. Theberge, V., Harel, F., Dagnault, A., Use of axillary deodorant and effect on acute skin toxicity during radiotherapy for breast cancer: a prospective randomized noninferiority trial, Int J Radiat Oncol Biol Phys, 2009. 75: p. 1048-52.

1705. Graham, P. H., Graham, J. L., Use of deodorants during adjuvant breast radiotherapy: a survey of compliance with standard advice, impact on patients and a literature review on safety, J Med Imaging Radiat Oncol, 2009. 53: p. 569-73.

1706. Watson, L. C., Gies, D., Thompson, E., Thomas, B., Randomized control trial: evaluating aluminum-based antiperspirant use, axilla skin toxicity, and reported quality of life in women receiving external beam radiotherapy for treatment of Stage 0, I, and II breast cancer, Int J Radiat Oncol Biol Phys, 2012. 83: p. e29-34.

1707. Hemati, S., Asnaashari, O., Sarvizadeh, M., Motlagh, B. N., Akbari, M., Tajvidi, M., et.al. Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer, Support Care Cancer, 2012. 20: p. 1613-8.

1708. Alliance Pharma (Ireland) Ltd, Fachinformation Flammazine® Creme, 10 mg Sulfadiazin-Silber, 2019., https://www.fachinfo.de/static/lib/pdfjs/web/viewer.html?file=/fi/pdf/005730/flammazine-creme

1709. Pommier, P., Gomez, F., Sunyach, M. P., D'Hombres, A., Carrie, C., Montbarbon, X., Phase III randomized trial of Calendula officinalis compared with trolamine for the prevention of acute dermatitis during irradiation for breast cancer, J Clin Oncol, 2004. 22: p. 1447-53.

1710. Siddiquee, S, McGee, MA, Vincent, AD, Giles, E, Clothier, R, Carruthers, S, et.al. Efficacy of topical Calendula officinalis on prevalence of radiation-induced dermatitis: A randomised controlled trial., Australas J Dermatol, 2021. 62 (1)(1): p. e35-e40., https://pubmed.ncbi.nlm.nih.gov/32965030/

1711. Simões, FV, Santos, VO, Silva, RND, Silva, RCD, Effectiveness of skin protectors and calendula officinalis for prevention and treatment of radiodermatitis: an integrative review., Rev Bras Enferm, 2020. 73 (suppl 5)(suppl 5): p. e20190815., https://pubmed.ncbi.nlm.nih.gov/33084806/

1712. Hausen, Björn, Brinkmann, Jürgen, Dohn, Wolfgang, Lexikon der Kontaktallergeneecomed Fachverlag, Lexikon der Kontaktallergene, 2012. 6:

1713. Bostrom, A., Lindman, H., Swartling, C., Berne, B., Bergh, J., Potent corticosteroid cream (mometasone furoate) significantly reduces acute radiation dermatitis: results from a double-blind, randomized study, Radiother Oncol, 2001. 59: p. 257-65.

1714. Miller, R. C., Schwartz, D. J., Sloan, J. A., Griffin, P. C., Deming, R. L., Anders, J. C., et.al. Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4, Int J Radiat Oncol Biol Phys, 2011. 79: p. 1460-6.

1715. Neben-Wittich, M. A., Atherton, P. J., Schwartz, D. J., Sloan, J. A., Griffin, P. C., Deming, R. L., et.al. Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a Phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4), Int J Radiat Oncol Biol Phys, 2011. 81: p. 397-402.

1716. Omidvari, S., Saboori, H., Mohammadianpanah, M., Mosalaei, A., Ahmadloo, N., Mosleh-Shirazi, M. A., et.al. Topical betamethasone for prevention of radiation dermatitis, Indian J Dermatol Venereol Leprol, 2007. 73: p. 209.

1717. Schmuth, M., Wimmer, M. A., Hofer, S., Sztankay, A., Weinlich, G., Linder, D. M., et.al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study, Br J Dermatol, 2002. 146: p. 983-91.

1718. Shukla, P. N., Gairola, M., Mohanti, B. K., Rath, G. K., Prophylactic beclomethasone spray to the skin during postoperative radiotherapy of carcinoma breast: a prospective randomized study, Indian J Cancer, 2006. 43: p. 180-4.

1719. Sio, TT, Atherton, PJ, Birckhead, BJ, Schwartz, DJ, Sloan, JA, Seisler, DK, et.al. Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance])., Support Care Cancer, 2016. 24 (9)(9): p. 3847-55., https://pubmed.ncbi.nlm.nih.gov/27075674/

1720. Liao, Y, Feng, G, Dai, T, Long, F, Tang, J, Pu, Y, et.al. Randomized, self-controlled, prospective assessment of the efficacy of mometasone furoate local application in reducing acute radiation dermatitis in patients with head and neck squamous cell carcinomas., Medicine (Baltimore), 2019. 98 (52)(52): p. e18230., https://pubmed.ncbi.nlm.nih.gov/31876704/

1721. Ho, AY, Olm-Shipman, M, Zhang, Z, Siu, CT, Wilgucki, M, Phung, A, et.al. A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation., Int J Radiat Oncol Biol Phys, 2018. 101 (2)(2): p. 325-333., https://pubmed.ncbi.nlm.nih.gov/29726361/

1722. Ulff, E, Maroti, M, Serup, J, Nilsson, M, Falkmer, U, Prophylactic treatment with a potent corticosteroid cream ameliorates radiodermatitis, independent of radiation schedule: A randomized double blinded study., Radiother Oncol, 2017. 122 (1)(1): p. 50-53., https://pubmed.ncbi.nlm.nih.gov/27913066/

1723. Menon, A, Prem, SS, Kumari, R, Topical Betamethasone Valerate As a Prophylactic Agent to Prevent Acute Radiation Dermatitis in Head and Neck Malignancies: A Randomized, Open-Label, Phase 3 Trial., Int J Radiat Oncol Biol Phys, 2021. 109 (1)(1): p. 151-160., https://pubmed.ncbi.nlm.nih.gov/32853709/

1724. Meghrajani, CF, Co, HS, Arcillas, JG, Maaño, CC, Cupino, NA, A randomized, double-blind trial on the use of 1% hydrocortisone cream for the prevention of acute radiation dermatitis., Expert Rev Clin Pharmacol, 2016. 9 (3)(3): p. 483-91., https://pubmed.ncbi.nlm.nih.gov/26619355/

1725. Yokota, T, Zenda, S, Ota, I, Yamazaki, T, Yamaguchi, T, Ogawa, T, et.al. Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation., Int J Radiat Oncol Biol Phys, 2021. 111 (3)(3): p. 794-803., https://pubmed.ncbi.nlm.nih.gov/34102298/

1726. Robijns, J, Censabella, S, Claes, S, Pannekoeke, L, Bussé, L, Colson, D, et.al. Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients., Support Care Cancer, 2019. 27 (4)(4): p. 1245-1254., https://pubmed.ncbi.nlm.nih.gov/30270415/

1727. Robijns, J, Censabella, S, Claes, S, Pannekoeke, L, Bussé, L, Colson, D, et.al. Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo-controlled trial in breast cancer patients (TRANSDERMIS trial)., Lasers Surg Med, 2018. ():, https://pubmed.ncbi.nlm.nih.gov/, 29427390/

1728. Robijns, J, Lodewijckx, J, Puts, S, Vanmechelen, S, Van Bever, L, Claes, S, et.al. Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole-breast irradiation (LABRA trial)., Lasers Surg Med, 2022. 54 (3)(3): p. 374-383., https://pubmed.ncbi.nlm.nih.gov/34481420/

1729. Robijns, J, Lodewijckx, J, Claes, S, Van Bever, L, Pannekoeke, L, Censabella, S, et.al. Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial)., Radiother Oncol, 2021. 158 (): p. 268-275., https://pubmed.ncbi.nlm.nih.gov/, 33711412/

1730. Schmeel, LC, Koch, D, Stumpf, S, Leitzen, C, Simon, B, Schüller, H, et.al. Prophylactically applied Hydrofilm polyurethane film dressings reduce radiation dermatitis in adjuvant radiation therapy of breast cancer patients., Acta Oncol, 2018. 57 (7)(7): p. 908-915., https://pubmed.ncbi.nlm.nih.gov/29463159/

1731. Møller, PK, Olling, K, Berg, M, Habæk, I, Haislund, B, Iversen, AM, et.al. Breast cancer patients report reduced sensitivity and pain using a barrier film during radiotherapy - A Danish intra-patient randomized multicentre study., Tech Innov Patient Support Radiat Oncol, 2018. 7 (): p. 20-25., https://pubmed.ncbi.nlm.nih.gov/32095578/

1732. Herst, PM, Bennett, NC, Sutherland, AE, Peszynski, RI, Paterson, DB, Jasperse, ML, Prophylactic use of Mepitel Film prevents radiation-induced moist desquamation in an intra-patient randomised controlled clinical trial of 78 breast cancer patients., Radiother Oncol, 2014. 110 (1)(1): p. 137-43., https://pubmed.ncbi.nlm.nih.gov/24486117/

1733. Schmeel, LC, Koch, D, Schmeel, FC, Bücheler, B, Leitzen, C, Mahlmann, B, et.al. Hydrofilm Polyurethane Films Reduce Radiation Dermatitis Severity in Hypofractionated Whole-Breast Irradiation: An Objective, Intra-Patient Randomized Dual-Center Assessment., Polymers (Basel), 2019. 11 (12)(12):, https://pubmed.ncbi.nlm.nih.gov/31888185/

1734. Graham, P., Browne, L., Capp, A., Fox, C., Graham, J., Hollis, J., et.al. Randomized, paired comparison of No-Sting Barrier Film versus sorbolene cream (10% glycerine) skin care during postmastectomy irradiation, Int J Radiat Oncol Biol Phys, 2004. 58: p. 241-6.

1735. Graham, PH, Plant, N, Graham, JL, Browne, L, Borg, M, Capp, A, et.al. A paired, double-blind, randomized comparison of a moisturizing durable barrier cream to 10% glycerine cream in the prophylactic management of postmastectomy irradiation skin care: trans Tasman Radiation Oncology Group (TROG) 04.01., Int J Radiat Oncol Biol Phys, 2013. 86 (1)(1): p. 45-50., https://pubmed.ncbi.nlm.nih.gov/23414763/

1736. Chan, RJ, Blades, R, Jones, L, Downer, TR, Peet, SC, Button, E, et.al. A single-blind, randomised controlled trial of StrataXRT® - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer., Radiother Oncol, 2019. 139 (): p. 72-78., https://pubmed.ncbi.nlm.nih.gov/31445838/

1737. Rades, D, Narvaez, CA, Splettstößer, L, Dömer, C, Setter, C, Idel, C, et.al. A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN)., Radiother Oncol, 2019. 139 (): p. 79-82., https://pubmed.ncbi.nlm.nih.gov/31431372/

1738. Yan, J, Yuan, L, Wang, J, Li, S, Yao, M, Wang, K, et.al. Mepitel Film is superior to Biafine cream in managing acute radiation-induced skin reactions in head and neck cancer patients: a randomised intra-patient controlled clinical trial., J Med Radiat Sci, 2020. 67 (3)(3): p. 208-216., https://pubmed.ncbi.nlm.nih.gov/32475079/

1739. Niazi, T. M., Vuong, T., Azoulay, L., Marijnen, C., Bujko, K., Nasr, E., et.al. Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study, Int J Radiat Oncol Biol Phys, 2012. 84: p. e305-10.

1740. Vuong, T., Franco, E., Lehnert, S., Lambert, C., Portelance, L., Nasr, E., et.al. Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum, Int J Radiat Oncol Biol Phys, 2004. 59: p. 809-14.

1741. Schreck, U., Paulsen, F., Bamberg, M., Budach, W., Intraindividual comparison of two different skin care conceptions in patients undergoing radiotherapy of the head-and-neck region. Creme or powder?, Strahlenther Onkol, 2002. 178: p. 321-9.

1742. Hoopfer, D, Holloway, C, Gabos, Z, Alidrisi, M, Chafe, S, Krause, B, et.al. Three-Arm Randomized Phase III Trial: Quality Aloe and Placebo Cream Versus Powder as Skin Treatment During Breast Cancer Radiation Therapy., Clin Breast Cancer, 2015. 15 (3)(3): p. 181-90.e1-4., https://pubmed.ncbi.nlm.nih.gov/25619686/

1743. Liguori, V., Guillemin, C., Pesce, G. F., Mirimanoff, R. O., Bernier, J., Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy, Radiother Oncol, 1997. 42: p. 155-61.

1744. Pinnix, C., Perkins, G. H., Strom, E. A., Tereffe, W., Woodward, W., Oh, J. L., et.al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial, Int J Radiat Oncol Biol Phys, 2012. 83: p. 1089-94.

1745. Rahimi, A, Mohamad, O, Albuquerque, K, Kim, DWN, Chen, D, Thomas, K, et.al. Novel hyaluronan formulation for preventing acute skin reactions in breast during radiotherapy: a randomized clinical trial., Support Care Cancer, 2020. 28 (3)(3): p. 1481-1489., https://pubmed.ncbi.nlm.nih.gov/31273506/

1746. Abbas, H., Bensadoun, R. J., Trolamine emulsion for the prevention of radiation dermatitis in patients with squamous cell carcinoma of the head and neck, Support Care Cancer, 2012. 20: p. 185-90.

1747. Falkowski, S., Trouillas, P., Duroux, J. L., Bonnetblanc, J. M., Clavere, P., Radiodermatitis prevention with sucralfate in breast cancer: fundamental and clinical studies, Support Care Cancer, 2011. 19: p. 57-65.

1748. Fisher, J., Scott, C., Stevens, R., Marconi, B., Champion, L., Freedman, G. M., et.al. Randomized phase III study comparing Best Supportive Care to Biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: Radiation Therapy Oncology Group (RTOG) 97-13, Int J Radiat Oncol Biol Phys, 2000. 48: p. 1307-10.

1749. Haddad, P., Amouzgar-Hashemi, F., Samsami, S., Chinichian, S., Oghabian, M. A., Aloe vera for prevention of radiation-induced dermatitis: a self-controlled clinical trial, Curr Oncol, 2013. 20: p. e345-8.

1750. Heggie, S., Bryant, G. P., Tripcony, L., Keller, J., Rose, P., Glendenning, M., et.al. A Phase III study on the efficacy of topical aloe vera gel on irradiated breast tissue, Cancer Nurs, 2002. 25: p. 442-51.

1751. Kirova, Y. M., Fromantin, I., De Rycke, Y., Fourquet, A., Morvan, E., Padiglione, S., et.al. Can we decrease the skin reaction in breast cancer patients using hyaluronic acid during radiation therapy? Results of phase III randomised trial, Radiother Oncol, 2011. 100: p. 205-9.

1752. Lievens, Y., Haustermans, K., Van den Weyngaert, D., Van den Bogaert, W., Scalliet, P., Hutsebaut, L., et.al. Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial, Radiother Oncol, 1998. 47: p. 149-53.

1753. Maiche, A., Isokangas, O. P., Grohn, P., Skin protection by sucralfate cream during electron beam therapy, Acta Oncol, 1994. 33: p. 201-3.

1754. Olivotto, I. A., Kim-Sing, C., Bajdik, C. D., Trevisan, C. H., Ludgate, C. M., Weir, L. M., et.al. Effect of acetylsalicylic acid on radiation and cosmetic results after conservative surgery for early breast cancer: a randomized trial, Radiother Oncol, 1996. 41: p. 1-6.

1755. Olsen, D. L., Raub, W., Jr., Bradley, C., Johnson, M., Macias, J. L., Love, V., et.al. The effect of aloe vera gel/mild soap versus mild soap alone in preventing skin reactions in patients undergoing radiation therapy, Oncol Nurs Forum, 2001. 28: p. 543-7.

1756. Szumacher, E., Wighton, A., Franssen, E., Chow, E., Tsao, M., Ackerman, I., et.al. Phase II study assessing the effectiveness of Biafine cream as a prophylactic agent for radiation-induced acute skin toxicity to the breast in women undergoing radiotherapy with concomitant CMF chemotherapy, Int J Radiat Oncol Biol Phys, 2001. 51: p. 81-6.

1757. Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., et.al. Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial, Radiother Oncol, 2004. 73: p. 153-62.

1758. Williams, M. S., Burk, M., Loprinzi, C. L., Hill, M., Schomberg, P. J., Nearhood, K., et.al. Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity, Int J Radiat Oncol Biol Phys, 1996. 36: p. 345-9.

1759. Menêses, AG, Reis, PEDD, Guerra, ENS, Canto, GL, Ferreira, EB, Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis., Rev Lat Am Enfermagem, 2018. 26 (): p. e2929., https://pubmed.ncbi.nlm.nih.gov/29742271/

1760. Tungkasamit, T, Chakrabandhu, S, Samakgarn, V, Kunawongkrit, N, Jirawatwarakul, N, Chumachote, A, et.al. Reduction in severity of radiation-induced dermatitis in head and neck cancer patients treated with topical aloe vera gel: A randomized multicenter double-blind placebo-controlled trial., Eur J Oncol Nurs, 2022. 59 (): p. 102164., https://pubmed.ncbi.nlm.nih.gov/35767935/

1761. Evensen, JF, Bjordal, K, Jacobsen, AB, Løkkevik, E, Tausjø, JE, Effects of Na-sucrose octasulfate on skin and mucosa reactions during radiotherapy of head and neck cancers--a randomized prospective study., Acta Oncol, 2001. 40 (6)(6): p. 751-5., https://pubmed.ncbi.nlm.nih.gov/11765071/

1762. Becker-Schiebe, M., Mengs, U., Schaefer, M., Bulitta, M., Hoffmann, W., Topical use of a silymarin-based preparation to prevent radiodermatitis : results of a prospective study in breast cancer patients, Strahlenther Onkol, 2011. 187: p. 485-91.

1763. Leonardi, M. C., Gariboldi, S., Ivaldi, G. B., Ferrari, A., Serafini, F., Didier, F., et.al. A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis, Eur J Dermatol, 2008. 18: p. 317-21.

1764. Lokkevik, E., Skovlund, E., Reitan, J. B., Hannisdal, E., Tanum, G., Skin treatment with bepanthen cream versus no cream during radiotherapy--a randomized controlled trial, Acta Oncol, 1996. 35: p. 1021-6.

1765. Miko Enomoto, T., Johnson, T., Peterson, N., Homer, L., Walts, D., Johnson, N., Combination glutathione and anthocyanins as an alternative for skin care during external-beam radiation, Am J Surg, 2005. 189: p. 627-30; discussion 630-1.

1766. Pardo Masferrer, J., Murcia Mejia, M., Vidal Fernandez, M., Alvarado Astudillo, A., Hernandez Armenteros, M. L., Macias Hernandez, V., et.al. Prophylaxis with a cream containing urea reduces the incidence and severity of radio-induced dermatitis, Clin Transl Oncol, 2010. 12: p. 43-8.

1767. Primavera, G., Carrera, M., Berardesca, E., Pinnaro, P., Messina, M., Arcangeli, G., A double-blind, vehicle-controlled clinical study to evaluate the efficacy of MAS065D (XClair), a hyaluronic acid-based formulation, in the management of radiation-induced dermatitis, Cutan Ocul Toxicol, 2006. 25: p. 165-71.

1768. Rizza, L., D'Agostino, A., Girlando, A., Puglia, C., Evaluation of the effect of topical agents on radiation-induced skin disease by reflectance spectrophotometry, J Pharm Pharmacol, 2010. 62: p. 779-85.

1769. Roper, B., Kaisig, D., Auer, F., Mergen, E., Molls, M., Theta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. A new prophylactic agent in skin care?, Strahlenther Onkol, 2004. 180: p. 315-22.

1770. Geara, FB, Eid, T, Zouain, N, Thebian, R, Andraos, T, Chehab, C, et.al. Randomized, Prospective, Open-label Phase III Trial Comparing Mebo Ointment With Biafine Cream for the Management of Acute Dermatitis During Radiotherapy for Breast Cancer., Am J Clin Oncol, 2018. 41 (12)(12): p. 1257-1262., https://pubmed.ncbi.nlm.nih.gov/, 29889137/

1771. Ryan Wolf, J, Gewandter, JS, Bautista, J, Heckler, CE, Strasser, J, Dyk, P, et.al. Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial., Support Care Cancer, 2020. 28 (7)(7): p. 3303-3311., https://pubmed.ncbi.nlm.nih.gov/31758326/

1772. Aygenc, E., Celikkanat, S., Kaymakci, M., Aksaray, F., Ozdem, C., Prophylactic effect of pentoxifylline on radiotherapy complications: a clinical study, Otolaryngol Head Neck Surg, 2004. 130: p. 351-6.

1773. Gujral, M. S., Patnaik, P. M., Kaul, R., Parikh, H. K., Conradt, C., Tamhankar, C. P., et.al. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers, Cancer Chemother Pharmacol, 2001. 47 Suppl: p. S23-8.

1774. Martin, T., Uhder, K., Kurek, R., Roeddiger, S., Schneider, L., Vogt, H. G., et.al. Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial, Radiother Oncol, 2002. 65: p. 17-22.